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Abstract       
 
 
Multiple sclerosis (MS) is generally considered to be an autoimmune disease; it results in 
areas of focal demyelination known as plaques, where astrocytes are the main 
constituent and appear hypertrophic and stellate with increased expression of glial 
fibrillary acidic protein (GFAP). Although these reactive astrocytes can be beneficial for 
encapsulating areas of tissue necrosis within the glial scar, the pro-inflammatory 
cytokines and extracellular molecules they secrete are thought to be inhibitors of 
remyelination. Conversely, astrocytes can secrete anti-inflammatory cytokines in their 
less activated state and thereby can be beneficial for remyelination; although the 
mechanisms involved are not clearly understood. We have developed myelinating 
cultures of embryonic rat mixed spinal cord cells that are plated on neurosphere-
derived astrocyte monolayers, which allow us to manipulate their reactive state and 
determine any effects of these astrocytes on myelination. To identify any differences in 
gene expression profiles of several purified astrocyte phenotypes we carried out a 
microarray analysis using myelinating cultures plated on astrocytes on poly-L-lysine 
(PLL-astrocytes) or on tenascin C (TnC-astrocytes), untreated or treated with ciliary 
neurotrophic factor (CNTF) since it was previously shown that CNTF could stimulate 
myelination in these myelinating cultures and that TnC-astrocytes supported 
myelination less than PLL-astrocytes. The microarray analysis suggested CCL2, CCL7 and 
SERPINB2 as potential myelination regulators, which were validated by qRT-PCR but 
failed to affect axonal ensheathment in myelinating cultures. A metabolomics analysis 
was also carried out using untreated or CNTF-treated PLL- and TnC-astrocytes. A list of 
metabolites were associated with different astrocyte phenotypes and highlighted the 
importance of lipid metabolism, which might be crucial for stimulating myelination. 
These in vitro astrocyte phenotypes were compared with previously identified in vivo 
astrocyte reactivity markers, which suggested that PLL- and TnC-astrocytes could 
reflect in vivo astrocytes to some extent and that TnC-astrocytes might not be as 
“quiescent” as currently considered. It is possible that TnC-astrocytes suppress 
myelination by creating an extracellular matrix (ECM) rich environment, while CNTF 
dissolves the ECM and thus creates a more regenerative environment. Despite similar 
stimulatory effects of CNTF on mixed neural cells on PLL and TnC, CNTF appears to 
affect them via different mechanisms showing that distinct reactive astrocytes could 
react to the same stimulus in different ways as also presented in in vivo studies. 
 
 
 
xvii 
 
 
Author’s Declaration 
 
 
I declare that, except where explicit references is made to the contribution of others, 
that this dissertation is the result of my own work and has not been submitted for any 
other degree at the University of Glasgow or any other institution.  
 
Signature        ________________________ 
Printed name  _______________________ 
 
 
 
1 
 
Chapter 1 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
2 
 
1.1 Anatomy and function of the central nervous system 
with a specific focus on glial cells 
The central nervous system (CNS) consists of the brain and the spinal cord, which are 
both separated from the rest of the body by the blood-brain barrier (BBB) that regulates 
the diffusion of molecules between the two tissues (Bradbury, 1993; Engelhardt, 2003). 
The CNS is derived from neuroepithelium, which consists of stem-like progenitor cells 
that give rise to immature neurons, basal progenitors, and radial glia (Gotz and Huttner, 
2005). Radial glia cells not only can generate radial glia and immature neurons or basal 
progenitors through asymmetric cell divisions but also provide the progenitors that 
eventually differentiate into mature glial cells; namely, oligodendrocytes, ependymal 
cells, and astrocytes (Miyata et al., 2001; Noctor et al., 2001; Shimojo et al., 2011). 
Microglia, also a glial cell type, are not derived from neurepithelial cells unlike the rest 
of the CNS structures (Nayak et al., 2014).  
Glial cells are found nearly in one to one ratio to neurons in human brains despite 
regional differences presenting lower glia/neuron ratio in the cerebellum and grey 
matter of the cerebral cortex as opposed to the rest of brain where glial cells 
outnumber neurons by a ratio of 10 (Azevedo et al., 2009; Herculano-Houzel, 2014). 
Unlike neurons that provide electrical transmissions, which allow for both conscious and 
autonomic behaviours (Zoidi and Dermietzel, 2002; Burdakov, 2004); glial cells were 
considered as the structural “glue” in the extracellular matrix to physically support 
neural networks rather than play active roles in the CNS (Virchow, 1859). Glial cells 
have gained more importance lately with their vital roles shown in brain physiology, 
metabolism, development and neurological diseases (Barres, 2008). Glial cells consist of 
the following cell types: astrocytes, microglia, oligodendrocytes, and ependymal cells 
(Somjen, 1988). Ependymal cells take place at the interface between the brain 
parenchyma and ventricles and are suggested to regulate the flow of substances through 
both sides of the interface (Jimenez et al., 2014): while, other glial cells take part in 
various crucial cellular functions such as regulation of synapse formation (Ullian et al., 
2001) and synapse transmission (Fields and Stevens-Graham, 2002), providing neurons 
with metabolites as a source of energy (Wender et al., 2000; Magistretti, 2006; Lee et 
al., 2012), modulation of neuronal activity through the release of gliotransmistters 
(Volterra and Meldolesi, 2005), regulation of blood flow (Koehler et al., 2009) and many 
other developmental and homeostatic functions, some of which will be explained below 
in more detail.  
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1.1.1 Oligodendrocytes 
Oligodendrocyte (OL) progenitor cells (OPCs) in the spinal cord are initially generated 
from ventral neuroepithelial cells (NECs) that take place at a specific domain of the 
ventricular zone termed pMN (Sun et al., 1998; Takebayashi et al., 2002) and also from 
dorsal NECs (Fogarty et al., 2005). The proliferating OPCs migrate away from these sites 
of origin and populate the entire spinal cord before differentiating into mature OLs. 
OPC production in the brain occur from ventral to dorsal regions in three waves, which 
are initiated in ventral neuroepithelium, lateral and the caudal ganglionic eminences 
(LGE/CGE), and cortex, respectively (Kessaris et al., 2006, 2008). While the first OPCs 
generated in the ventral forebrain almost disappear during postnatal period and are 
replaced by progenitors migrating from LGE/CGE; the majority of OPCs in most regions 
of the postnatal and adult telencephalon consist of LGE/CGE-derived populations and 
the cortex-derived populations that primarily inhabit cortex (Kessaris et al., 2006). 
OLs go through several maturation stages, in which they show different morphology 
mostly in terms of their process numbers and expression profile (reviewed in Zhang, 
2001; in Barateiro et al., 2014, Fig 1.1). OPCs take place at the very early stages of 
differentiation with their increased proliferation and migration capacity (Grinspan et 
al., 1995; Miller et al., 1998). As the OPCs differentiate into preoligodendrocytes, they 
increase the number of their cell processes, which increase even more and become 
ramified in immature oligodendrocytes that develop into post-mitotic cells (Armstrong 
et al., 1992; Grinspan et al., 1995). In the final stages of OL development, mature 
oligodendrocytes present extensive secondary branching, and extend membranes that 
contain myelin proteins and enwrap the neuronal axons tightly to provide their 
insulating myelin sheath. In cell cultures, where they do not have contact with axons, 
leaflets of flattened membrane stay connected to soma, which can be seen in Fig 1.1 
(Gard et al., 1989).  
The main function of OLs is to produce myelin sheaths that wrap axons in several layers 
and thus support the axonal signal conduction (Fig 1.2). One OL can extend multiple 
processes to the same or different axons to generate the myelin segments known as 
internodes (Fig 1.2). This ensheathment not only protects the axons and hence the 
neurons from the external chemical/physical insults but also facilitates axonal 
conduction by restricting the membrane depolarisation to the areas in between the 
internodes (Sherman et al., 2005). Thus, these areas, called nodes of Ranvier, provide 
rapid and saltatory nerve conduction (Fig 1.2). Both the nodal and the paranodal 
proteins are important for forming the right axo-glial junctions in order to initiate the 
myelination (Poliak et al., 2003). The myelination also depends on the presence of the 
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Figure 1. 1 The major maturation stages of oligodendroglial cells.                          
The basic morphology and the markers known to be expressed along the differentiation stages in the 
oligodendrocyte lineage are presented in the figure. An example of a mature oligodendrocyte, purified from 
primary rat cortical astrocyte cultures, is shown in the image on the right, where the markers MBP and the O4 
antibody are shown in red and green, respectively. The cell nuclei are visualised by DAPI in blue. The 
schematic image was modified from Barateiro and Fernandes, 2014. CNPase: 2’,3’-cyclic nucleotide 3’-
phosphodiesterase; FABP: fatty-acid-binding proteins; GalC: galactocerebroside C; GPR17: G protein-coupled 
receptor; MAG: myelin associated glycoprotein; MBP: myelin basic protein; MOG: myelin oligodendrocyte 
glycoprotein; MRF: myelin gene regulatory factor; Nkx2.2: NK2 homeobox 2; PDGF-R: platelet-derived growth 
factor; PLP: proteolipid protein; PSA-NCAM: polysialic acid-neural cell adhesion molecule; zfp: zinc finger 
proteins.  
 
type of extracellular ligands on the axons and the secreted molecules in the 
environment. For example, the axonal ligands Jagged, PSA-NCAM, LINGO-1 have been 
shown to inhibit either OPC differentiation or myelination; while, some others such as 
neuregulin and Wnt signaling have shown controversial effects on axonal ensheathment 
(Reviewed in Emery, 2010). Several oligodendroglial transcription factors such as 
Olig1/2, Ascl1, Nkx2.2, Sox6/10, YY1, Tcf4, Id2/4, Hes5, and Myrf have also emerged as 
intrinsic regulators of OPC differentiation and/or myelination (Emery, 2010). 
Neuronal activity also appears to play a role in the capacity of OLs to myelinate axons. 
The presence of a crosstalk between neurons and OLs can regulate both the 
differentiation of OLs and myelination. For instance, active axons secrete adenosine, 
which then activates purinergic receptors on OPCs and promote their differentiation and 
myelination (Stevens et al., 2002). The crosstalk sometimes even includes astrocytes 
that for example can respond to axonal release of ATP by secreting the cytokine LIF, 
which in turn stimulates OLs to enhance myelination (Ishibashi et al., 2006). Moreover, 
the ionotropic glutamate receptors on OLs have been shown to respond to glutamate, 
exogenously added to the system, as well as to that released by neuronal activity 
(Yamazaki et al., 2007). Other types of neurotransmitter receptors are also present on   
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Figure 1. 2 The schematic of ensheathment of an axon by an oligodendrocyte.                                                                                              
An oligodendrocyte extends its processes that wrap the neighbouring axons in several layers. This 
membranious structure that encapsulates the oligodendrocyte (OL) cytoplasm has channels in between the 
layers that forms the myelin sheaths. Axons are myelinated intermittently forming internodes that can be seen 
above in the figure. The structures between the internodes are termed nodes of Ranvier and are also shown 
above in detail. The nodal and paranodal surface proteins contribute to the generation of healthy myelin 
sheaths. The figure was modified from Sherman and Brophy, 2005. AnkG: ankyrin G; Ax: axon; Caspr: 
contactin-associated protein; Nav channel: voltage-gated sodium channel; Nfasc: neurofascin 
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OLs such as ionotropic γ- aminobutyric acid (GABA) receptors that also initiate 
depolarisation in OLs upon activation (Gilbert et al., 1984; Berger et al., 1992; 
Yamazaki et al., 2010). The ion influx across the plasma membrane following the 
activation of such receptors is suggested to change the structure of the OL processes 
due to osmotic swelling. The tightness of the insulation, provided by myelin sheaths, 
might increase or decrease depending on those structural changes and thus facilitate or 
slow down the axonal conduction velocity, respectively (Karadottir et al., 2005; 
reviewed in Yamazaki et al., 2010). The conduction velocity might also be affected by 
the ability of OLs to dynamically and rapidly extend/retract their processes depending 
on the stimuli in the vicinity (Paez et al., 2007; Yamazaki et al., 2010). Consequently, 
OLs not only function in myelination but also appear to take part in the maintenance 
and regulation of it in later stages.  
In addition to playing a role in myelination, OLs have also been reported to participate 
in neuronal survival and development. Targeted ablation of OLs in mice using diphtheria 
toxin have resulted in symptoms such as spastic paralysis, motor deficits, tremor, and 
ataxia, which have been associated with severe axonal injury detected as the 
accumulation of non-phosphorylated neurofilaments and amyloid precursor proteins 
(Ghosh et al., 2011; Pohl et al., 2011; Oluich et al., 2012). Secondary immune reaction 
and demyelination have been ruled out as causes for axonal injury in these animal 
models, which has left the lack of OLs as the primary cause. In addition, studies with 
transgenic animals showing abnormal expression of an oligodendroglial myelin protein 
(PLP, proteolipid protein) have presented axon degeneration that has been linked to 
decreased axonal transport of the proteins from soma (Griffiths et al., 1998; Gotow et 
al., 1999; Edgar et al., 2004; Edgar et al., 2010). Axon injury and motor neuron cell loss 
has also been observed in spinal cord organotypic cultures that were treated with an 
inhibitor to an extracellular membrane channel (MCT1), which is expressed 
predominantly in OLs and is suggested to function in the transport of lactate mainly out 
of cells (Lee et al., 2012b). Because extracellular lactate is important for the neuronal 
energy supply (Wyss et al., 2011) and because conditional down-regulation of Mct1 in 
OLs has also lead to axon degeneration in mice, OLs are proposed to play role in the 
survival of neuronal cells (Lee et al., 2012b). The neurotrophins OLs produce also 
provide trophic support for both OLs and local neurons (Byravan et al., 1994; Dai et al., 
2001).  
Degeneration of OLs have been observed in some demyelinating diseases such as 
multiple sclerosis (MS), which presents symptoms such as numbness/tingling, weakness, 
spasticity, vertigo, and walking difficulties (Ozawa et al. 1994). Post-mortem tissue 
from MS patients and several animal models of MS have shown increased numbers of 
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early OL progenitors in the subventricular zone with the presence of certain progenitor 
markers and morphology that suggests that OPCs potentially migrate to the lesions to 
renew the lost OL numbers (Nait-Oumesmar et al., 2007; reviewed in Maki et al., 2013) 
and to provide remyelination (Prineas et al., 1993; Raine and Wu, 1993). Despite the 
presence of OPCs and pre-myelinating OLs in MS lesions, myelin repair is often 
insufficient or absent especially during chronic stages of the disease (Wolswijk, 1998; 
Chang et al., 2002), which is why studies are conducted to discover methods that 
provide a more regenerative environment allowing remyelination in these lesions 
(Huang et al., 2010; Rodgers et al., 2013). This and above-mentioned functions show 
how important OLs are and what a major role they play in the CNS. 
1.1.2 Microglia 
Microglia are the CNS-resident innate immune cells that constantly survey their local 
microenvironment with their dynamic processes and react rapidly to various 
pathologies. They constitute 10-15% of all glial cells in the CNS. Microglia were first 
considered to be of hematopoietic origin due to their phenotypic resemblance to 
peripheral monocytes/macrophages and dendritic cells (Hickey and Kimura, 1988; Eglitis 
and Mezey, 1997; Simard and Rivest 2004). Later it has been shown that they are 
derived from erythromyeloid progenitors cells in the yolk sac and migrate into the brain 
with the help of the circulatory system in early embryonic stages (Cuadros et al., 1993; 
Alliot et al., 1999; Schulz et al., Ginhoux et al., 2010; 2012; Kierdorf et al., 2013). 
During neonatal development, these microglial progenitors appear similar to 
macrophages morphologically but they eventually proliferate and differentiate into 
mature microglia with ramified processes. Their morphology presents differences mainly 
in terms of the length and number of their processes depending on their location in the 
adult brain showing that these cells are sensitive to their milieu (Lawson et al., 1990).  
Microglia play a role in neuronal survival, neuronal apoptosis, synaptogenesis, defence 
against pathogens and clearing all the metabolic products and the debris of dying cells. 
They secrete growth factors such as IGF-1, FGF, NGF, BDNF, which play roles in 
neuronal development, maintenance and function (Araujo et al., 1992; Yamagata et al., 
1995; Nakajima et al., 2001; Trang et al., 2011; Ueno et al., 2013). On the other hand, 
they can also stimulate the programmed cell death of neurons that show transient 
functions or are faulty due to defective differentiation or migration (Frade et al., 1998; 
Marin-Teva et al., 2004; Wakselman et al. 2008). In addition to that, microglia clean the 
resultant cellular debris through phagocytosis (Takahashi et al., 2005; Hristova et al., 
2010). Microglia also secrete factors that are important for synaptic function and 
plasticity (Roumier et al., 2004; Wake et al., 2009; Paolicelli et al., 2011; Ji et al., 
 
 
8 
 
2013). They can change their morphology and location in relation to synapses upon 
exposure to a sensory stimulus (Tremblay et al., 2010). In order to perform their 
functions, the resting (quiescent) microglia survey the CNS parenchyma and become 
activated upon encountering unhealthy cells, cellular debris, and any foreign antigens 
they cannot recognise such as those on pathogens (Garg et al., 2005; Morgan et al., 
2005; Esen and Kielian, 2006; Herber et al., 2006; Faustino et al., 2011). The change in 
their morphology after the activation starts with extension of microglial processes 
towards the target, which is followed by migration of their cell bodies and phagocytosis 
(Catalin et al., 2013). They can even surround the lesion sites in various CNS injuries to 
protect the healthy CNS from the injured tissue in the vicinity (Dibaj et al., 2010). 
Microglial dysfunction has been associated with some CNS diseases. For example, 
obsessive-compulsive disorder and Rett syndrome have been linked to mutations in 
some microglial transcriptions factors (Greer et al., 2002; Chen et al., 2010; Derecki et 
al., 2012). Other than that, functional microglia can sometimes exacerbate 
neurodegenerative conditions, where they initially play positive roles. They can 
phagocytose the toxic proteins that accumulate in patients with Alzheimer’s and 
Parkinson’s diseases but their production of pro-inflammatory cytokines at later stages 
can cause the pathology and hence the cognitive decline to progress (McGeer et al., 
1988; Hickman et al., 2008; Heneka et al., 2010; Stefanova et al., 2011; Vom Berg et 
al., 2012; Krabbe et al., 2013). Similarly, microglia clear the myelin debris during the 
demyelination in multiple sclerosis but they can later present antigens to the infiltrating 
T-cells from periphery and also produce reactive-oxygen species and pro-inflammatory 
cytokines, which would aggravate the disease (Boyle and McGeer, 1990; Hao et al., 
2010; reviewed in Ciccarelli et al., 2014). In addition, they can also secrete 
metalloproteinase proteins that would disrupt the blood brain barrier (BBB) integrity 
and elevate the inflammation (Yong et al., 1998; Maeda and Sobel, 1996).  
These detrimental roles of microglia have been associated with their “classically 
activated M1 state”, during which they are able to recognise harmful stimuli using 
various immune receptors such as toll-like receptors (TLRs), nucleotide-binding 
oligomerisation domains (NODs), CD68, Fcy, and many scavenger receptors; and react 
by secreting inflammatory cytokines such as TNFα, IL-6, IL-1β, IFNγ, and several 
chemokines (Ransohoff and Perry, 2009; Ransohoff and Brown, 2012; Boche et al., 
2013). If M1 response is not down-regulated once the pathological stimulus is eradicated 
and persists for longer than normal, chronic inflammation can lead to tissue destruction 
as mentioned above (Perry and Teeling, 2013). The pro-inflammatory M1 response is 
usually followed by “alternatively activated M2” response, where microglia express 
cytokines and receptors to inhibit inflammation and restore homeostasis (Martinez et 
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al., 2009, Varin and Gordon, 2009). Therefore, the dysregulation of the transition from 
M1 state to M2 state might be contributing to disease progress in multiple sclerosis by 
prolonging the detrimental effects of pro-inflammatory cytokines in the CNS (Tanner et 
al., 2011; Cherry et al., 2014). M2-promoting cytokines such as IL-33 and IL-10 have 
been shown to decrease demyelination levels and improve clinical scores in an animal 
model of MS (Yang et al., 2009; Jiang et al., 2012), which can be attributed to the 
production of neurotrophic mediators such as IGF1, PDGFα, TGFβ, and SPP1 that might 
support remyelination and regeneration as predicted from their up-regulation in M2 
microglia during recovery (Olah et al., 2012). Therefore, the equilibrium between the 
resting microglia and their polarised states, M1 and M2; and the spatial and temporal 
regulation of these phenotypes appears to be important for the amelioration of CNS 
pathologies.  
1.1.3 Astrocytes 
Astrocytes are the most abundant glial cells in the CNS. They are distinguished from 
other glial cells by their stellate morphology, which is mainly divided into two subtypes. 
Protoplasmic astrocytes reside in gray matter and they morphologically have several 
stem branches which branch further into many fine processes; whereas, fibrous 
astrocytes reside throughout all white matter and have long fiber-like processes (Cajal, 
1909). Astrocytes are found throughout the whole healthy CNS in a non-overlapping, 
highly well organized manner (Bush et al., 1999).   
Astrocytes originate from neuroectoderm like other CNS cells apart from microglia. 
Neuroepithelial cells generate radial glial cells, which differentiate first into neurons 
and later become gliogenic to produce astrocytes (McConnel et al., 1992; Cepko et al., 
1996). JAK-STAT signaling pathway, which is regulated by IL-6 family cytokines, is 
associated with the switch from the neurogenesis to astrogenesis in the progenitor cells 
(Barnabe-Heider et al., 2005; He et al., 2005). In mouse spinal cord, astrocyte 
progenitors appear between embryonic days (E) 13.5-15.5 in three subpopulations, VA1-
3 (ventral astrocytes 1-3), which show differential expression of transcription factors 
that regulate the astrogenesis (Hochstim et al., 2008). The functional importance of 
these astrocyte subpopulations is not clear. In the cerebral cortex, astrocyte production 
from radial glial cells begins around E18.5 in the cortical subventrical zone, from where 
astrocytes migrate to other brain regions (Hochstim et al., 2008). In the adult cortex, 
fibrous and protoplasmic astrocytes have been recently shown to be derived from 
separate lineages (Garcia-Marques and Lopez-Mascaraque, 2013). Moreover, an 
additional astrocyte subtype, named pial astrocytes due to their presence at the pial 
surface, has also been shown to present a different developmental origin, morphology, 
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location and thus has been suggested to have a distinct function (Garcia-Marques and 
Lopez-Mascaraque, 2013). Such regional astrocyte subtypes are suggested to have 
different roles during development and most likely in adulthood (Molofsky et al., 2014; 
reviewed in Bayraktar, et al., 2015).     
Despite the diverse functions of astrocytes (Section 1.2), there is one major 
immunostaining marker used in general for these cells. That marker is glial fibrillary 
acid protein (GFAP), which is an intermediate filament protein (Sofroniew and Vinters, 
2010). Other markers have been used for immunohistochemical detection of astrocytes 
such as glutamine synthetase and S100β; however unlike GFAP, they are also expressed 
in neural cells such as neurons or oligodendrocytes (Norenberg, 1979; Cammer, 1990; 
Wang and Walz, 2003; Goncalves et al., 2008). GFAP was first isolated from multiple 
sclerosis patients’ demyelinated plaques, where it was found in high concentrations 
(Eng et al., 1970). This led to the immunohistochemical association of GFAP with 
reactive astrocytes. GFAP expression is considered as a sensitive marker that labels 
most reactive astrocytes present in CNS injury sites although it does not label all non-
reactive astrocytes in healthy CNS tissue or distant from CNS lesions (Sofroniew and 
Vinters, 2010). GFAP might still be expressed in these astrocytes in low levels but the 
current immunohistochemical techniques might not be sensitive enough to detect any 
such expressions. 
Transcriptomic analyses recently carried out by comparing primary cultures of 
astrocytes, neurons, and oligodendrocytes in an attempt to detect cell type-specific 
transcriptional regulations have identified some other proteins highly expressed in 
astrocytes (Lovatt et al., 2007; Cahoy et al., 2008). For example, aldehyde 
dehydrogenase 1 L1 (Aldh1L1) enzyme has been proposed by Cahoy et al. (2008) as a 
more sensitive and reliable new immunohistochemical astrocyte marker. Their study has 
shown that Aldh1L1 is expressed specifically by astrocytes in the CNS, not being 
expressed in neurons, oligodendrocyets or in OPCs, and that it can label both astrocyte 
perikarya and processes throughout both grey and white matter unlike GFAP, which 
labels mainly thick main processes of astrocytes (Cahoy et al., 2008). In addition, all 
GFAP positive cells are also labelled with Adh1L1; whereas, the latter one potently 
labels many more astrocytes (Cahoy et al., 2008). These findings suggest that GFAP, the 
conventional, common marker for labelling astrocytes immunohistochemically, might be 
displaced with Adh1L1 in the near future.  
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1.2 Astrocytes and their roles in the CNS 
1.2.1 The functions of astrocytes in the healthy CNS 
1.2.1.1 Transport of ions and molecules into/out of cells 
Astrocytes are suggested to form astroglial networks via their expression of membrane 
proteins connexins (Cxs) to provide intercellular communication (Giaume, 2010). 
Astrocytes are connected to each other at the very distal tips of their processes via gap 
junctions that can be detected at an ultrastructural level (Ogata and Kosaka, 2002). 
Gap junction channels (GJCs), constructed from connexin monomers, constitute a direct 
pathway between the cytoplasm of two adjacent astrocytes and allow the transport of 
amino acids, metabolites, second messengers, and ions such as K+, Ca2+, and Na+ 
(Ransom and Ye, 2005; Tabernero et al., 2006; Ransom and Giaume, 2012). 
Hemichannels (HCs), another connexin-based channel type, do not take part in 
astroglial networks directly. Nevertheless, they regulate the transport between the cell 
cytoplasm and extracellular space, which in turn provides paracrine and/or autocrine 
signaling that could be considered as a form of cell-to-cell communication, as well. HCs, 
unlike GJCs, are generally closed at resting membrane potential and normal 
concentrations of the intra/extracellular cations. However, a change in these conditions 
and/or the presence of other signals such as pro-inflammatory agents can activate these 
channels to allow the transport of molecules such as glutamate, ATP, and glucose (Spray 
et al., 2006; Retamal et al., 2007; Orellana et al., 2009, 2012).  
Heterocellular coupling, provided by GJCs, has also been observed between astrocytes 
and other cells such as oligodendrocytes and neurons (Ransom and Kettenmann, 1990; 
Robinson et al., 1993; Venance et al., 1995; Maglione et al., 2010; Wasseff and Scherer, 
2011). However, these couplings appear to be more restricted and developmentally 
regulated (Froes et al., 1999; Alvarez-Maubecin et al., 2000; Bittman et al., 2002; 
Pakhotin and Verkhratsky, 2005). They have been detected in developing tissues but not 
in adult animals, where functional astrocyte-astrocyte and neuron-neuron couplings are 
present (Cotrina et al., 2001; Peters et al., 2009; Cruz et al., 2010). These 
heterocellular couplings might therefore be important primarily for development.   
Studies with knockout animals, where various connexin expressions are inhibited, 
suggest the importance of the communication between astrocytes, and between 
astrocytes and oligodendrocytes on myelin integrity. Myelin damage has been observed 
in Cx47, Cx43/Cx30, Cx30/Cx47 single/double knockout mice (Menichella et al., 2003; 
Odermatt et al., 2003; Lutz et al., 2009; Tress et al., 2012). Moreover, connexin 
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channels and hence connexin proteins have been demonstrated to play a role in the 
regulation of neuronal activity and survival (Barnett et al., 2001). For example, 
astroglial connexins decrease neuronal excitability by removing extracellular K+ and 
glutamate; while, they provide metabolic supply to neurons (Wallraff et al., 2006; 
Rouach et al., 2008; Froger et al. 2010; Pannasch et al., 2011). On the other hand, the 
elevation of connexin expression at lesion sites in CNS pathologies might also be 
associated with other (possibly protective) roles  (Nagy et al., 1996; Koulakoff et al., 
2008; Kuchibhotla et al., 2009; Mei et al., 2010; Karpuk et al., 2011).  
More recently, another membrane channel family, pannexins (Panxs), has been 
identified (Panchin et al., 2000) and has been shown to form HCs-like channels but not 
any GJCs (Giaume et al., 2013). Even though less has been revealed about currently 
known two pannexins, Panx1 and Panx2, they have been both shown to be expressed in 
astrocytes (Zappala et al., 2007; Iglesias et al., 2009) in addition to Panx1 expression 
also in microglia and oligodendrocytes (Domercq et al., 2010; Orellana et al., 2011a). 
Panx channels (PCs) can be activated by positive transmembrane voltages and by 
increased intracellular free Ca2+ concentrations similar to HCs (Bennet et al., 2003; 
Locovei et al., 2006; Kienitz et al., 2011; Ma et al., 2012b). Both HCs and PCs provide 
the release of precursor and signaling molecules (e.g., NAD+, ATP, adenosine, inositol 
triphosphate, glutamate), uptake of second messengers (e.g., cyclic-ADP-ribose, nitric 
oxide, Ca2+) and metabolites (e.g., glucose, glutathione, ascorbate, reviewed in Giaume 
et al., 2013). The opening/closing of these channels is also regulated by extracellular 
signals such as 1) integral membrane proteins (e.g., stomatin), 2) growth factors (EGF 
and FGF1/2), and 3) pro-inflammatory agents (e.g.,TNF-α, IL-1β, β-amyloid peptide) in 
vitro (Morita et al., 2007; Retamal et al., 2007; Garre et al., 2010; Orellana et al., 
2011b; Zhan et al., 2012) in addition to the 4) difference between intra/extracellular 
concentrations of mono/divalent cations, 5) pH, 6) mechanical stress, 7) protein 
kinases and phosphatases, and 8) oxidant and reducing agents (reviewed in Sarz et al., 
2010; Wang et al., 2013). Consequently, astrocytes appear to maintain water, pH, ion, 
and metabolite homeostasis in the CNS and to provide intercellular communication with 
each other and with neurons and other glial cells utilising their GJCs and elaborately 
controlled HCs, as explained above.  
1.2.1.2 Energy and metabolism 
Glucose enters the brain via cells lining the blood brain barrier. Unlike these endothelial 
cells, neurons and other glial cells can phosphorylate glucose efficiently and thus allow 
it to be trapped inside these cells. Astrocytes can perform several steps of reactions to 
transform glucose into glycogen, the principal source of stored energy in both the brain 
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and the body (Pellegri et al., 1996; Pfeiffer- Guglielmi et al., 2003). Astrocytes appear 
to utilise both i) oxidative aerobic reactions to produce high-yield energy and ii) 
anaerobic reactions to produce lactate, which presents increased levels upon glucose 
treatment in cultured astrocytes in aerobic conditions (Walz and Mukerji, 1988). In 
addition to that, astrocytes have been suggested to increase extracellular lactate levels 
to provide energy substrate for nearby neurons based on following pieces of evidence: 
1) Lactate transporters are present on neuronal membranes (Dringen et al., 1993), 2) 
Elevated neurotransmitter (glutamate) uptake causes glucose to be converted into 
lactate in cultured astrocytes (Pellerin and Magistretti, 1994), 3) Lactate levels increase 
in parallel with stimulated neuronal activity in different brain regions (reviewed in 
Figley and Stroman, 2011), 4) The cytoarchitectural arrangement of astrocytes is such 
that their processes surround both synapses and capillaries, which deliver glucose and 
oxygen to the brain (reviewed in Agulhon et al., 2008). As an alternative to this 
‘astrocyte-neuron lactate shuttle’ hypothesis, it has been proposed that energy 
demands in regions surrounding synapses could be met by mitochondria, recently-
discovered in astrocyte processes (Lovatt et al., 2007; Pardo et al., 2011; Derouiche et 
al., 2015). However, the fact that glucose and glutamate stimulate lactate production 
in astrocytes despite the presence of mitochondria in aerobic conditions still favours the 
initial hypothesis. 
Astrocytes are also proposed to be primary cellular sources of cholesterol in the CNS 
(reviewed in Pfrieger and Ungerer, 2011), which is surrounded by the blood- brain 
barrier that does not allow the transport of hepatic or dietary supply of cholesterol to 
enter inside. It is crucial for the cholesterol to be synthesised in the CNS since it is a 
major component of biological membranes and is a precursor to many signaling 
molecules such as steroid hormones. Astrocytic expression of several apolipoproteins, 
which can mediate the secretion of cholesterol, has strengthened the suggestion that 
astrocytes can provide cholesterol to other cells in the CNS (Boyles et al., 1985; Lin et 
al., 1986; Xu et al., 2006; Kurumada et al., 2007). Both in vitro and in vivo studies have 
revealed that neurons can take up lipoproteins via specific receptors (Rothe and Muller, 
1991; Narita et al., 1997; Sun et al., 1998; Liu et al., 2007). The neuron-specific 
knockout of one of these proteins has led to age-dependent loss of spines and synapses, 
and impairment of motor function and memory (May et al., 2004; Liu et al., 2010), 
emphasising the vital role of cholesterol uptake by neurons. Additionally, sterol 
synthesis has been detected at higher levels in astrocytes compared to in neurons of the 
developing rat brain (Nieweg et al., 2009. Therefore, in addition to their roles in 
providing energy for neurons, astrocytes also emerge as cholesterol-suppliers in the 
CNS. 
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1.2.1.3 Neuronal support and synapse formation/function 
Astrocytes do not create or transmit action potentials like neurons do even though they 
express potassium and sodium channels (Kang et al., 1998). However, they can 
contribute to neuronal signal transmission in various ways.  They can regulate the 
neuronal excitability by releasing gliotransmitters such as glutamate, purine, GABA and 
D-serine into the synaptic cleft upon being excited by changes in neuronal synaptic 
activity (Parpura et al., 1994; Bezzi et al., 1998; Mothet et al., 2000; Coco et al., 2003; 
reviewed in Halassa et al., 2007). The neurotransmitter released from the synapse can 
reach adjacent glial cells, stimulating increases in intracellular Ca2+ concentrations, 
which then leads to the secretion of gliotransmitters (Porter and McCarthy, 1996). 
These regulatory molecules then feed back to presynaptic nerve terminal to modulate 
synaptic neurotransmission (Araque et al., 1998). These observations have even given 
rise to the currently accepted ‘tripartite synapse’ hypothesis, where astrocytes form an 
active, integral regulatory component of the synapse (Fig 1.3, reviewed in Araque et 
al., 1999; in Halassa et al., 2007). It is predicted that processes of one astrocyte can 
contact with over 100,000 synapses (Bushong et al., 2002), which could explain how 
groups of pyramidal neurons within approximately 100 µm can be synchronously excited 
by glutamatergic gliotransmission (Guthrie et al., 1999; Fellin et al., 2004). Recently, 
microglia have also been shown to interact with neuronal synapses (Fig 1.3) using 
electron microscopy (Tremblay et al., 2010) and to play a role in synapse maturation, 
synaptic remodelling, and synaptic activity (reviewed in Ji et al., 2013), suggesting the 
complexity of crosstalk between neural cells.   
In addition to playing a role in synaptic signal transmission, astrocytes can also actively 
remove excitotoxic glutamate from the extracellular space and convert it to glutamine 
by increasing their levels of glutamate transporters and glutamine synthetase (Faden et 
al., 1989; Eng et al., 1997; Krum et al., 2002). Thereby, they prevent neuronal cell 
death in case of brain pathology. Moreover, astrocytes secrete molecules that might be 
required for the formation, function and pruning of developing synapses (Ullian et al., 
2001; Christopherson et al., 2005). Such growth factors and other molecules might also 
be functional in synaptic remodelling and pruning in healthy or diseased adult CNS 
(reviewed in Barres, 2008). 
Another way in which astrocytes contribute to the synaptic transmission is by supporting 
maintenance of fluid, ion, pH and transmitter homeostasis of the synaptic interstitial 
fluid. Astrocyte processes contain transporters for K+ uptake and aquaporin 4 water 
channels (Nielsen et al.; 1997; Rash et al., 1998; Amiry-Moghaddam et al., 2003; 
Solenov et al., 2004). These channels are especially clustered along processes that  
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Figure 1. 3 A schematic of interaction of an astrocyte and microglia with a neuronal 
synapse.                  
The schematic presents a model for the interaction of astrocytic and microglial ends with a neuronal synapse 
based on the evidence provided by electron microscopy using in vivo tissue. The astrocytic process enwraps 
the pre-synaptic and post-synaptic neuronal terminals, forming the “tripartite synapse”. Astrocytes clear K+ 
ions that accumulate after neuronal activity in the synaptic cleft using their K+ channels and remove the 
synaptic transmitter glutamate by the activity of plasma-membrane glutamate transporters. Neurotransmitters 
secreted from the pre-synaptic terminal can activate astrocytic metabotropic glutamate receptors, which in turn 
induces an  increase in intracellular Ca2+ levels and thereby triggers the release of gliotransmitters into the 
synaptic cleft. Microglia processes in proximity to neuronal synapses can secrete proteases that will modulate 
the stability of synaptic adhesion proteins, which in turn affects synaptic transmission, or remove complement-
tagged structures to provide synaptic pruning or remodelling. Microglia can also secrete cytokines and 
glutamate into the milieu and thus induce neurotransmission. They can release ectosomes (microvesicles) 
that directly interact with neuronal membranes and can play a role in signaling cascades. Locations of 
transporters and receptors in this schematic do not necessarily represent their exact spatial distribution. The 
image was modified from Halassa et al., 2007 and Ji et al., 2013. 
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contact blood vessels and function in regulation of fluid homeostasis in the healthy CNS 
(reviewed in Sofroniew and Vinters, 2010). Astrocyte processes also express high levels 
of transporters for neurotransmitters and thus maintain the transmitter homeostasis of 
the synaptic interstitial fluid (Steinhauser et al., 1994; Gundersen et al., 1996; 
Mennerick et al., 1996; Bergles and Jahr, 1997; Fujita et al., 1999). The harmful effects 
of accumulation of some small molecules like potassium or glutamate could be 
eliminated by the spreading of these molecules into the linked astrocytes via gap 
junctions (reviewed in Seifert et al., 2006; in Sofroniew and Vinters, 2010). 
Astrocytes support neuronal survival not only by removing excitotoxic molecules from 
the extracellular space but also by providing energy for neurons. They contact blood 
vessels with some of their processes while they also have contacts with neuronal cell 
body, axons and synapses. Such a positioning allows uptake of glucose from blood 
vessels and transfer energy metabolites to neurons, which might be established again 
via gap junctions (Rouach et al., 2008). In addition, astrocytes are main storage places 
for glycogen granules in the CNS and astrocytic glycogen accumulates the most in areas 
of high synaptic density (Phelps, 1972; Peters et al., 1991). The utilization of astrocytic 
glycogen by neurons maintains the neural activity during hypoglycemia and during high 
neuronal activity (Brown and Ransom, 2007; Suh et al., 2007). This is provided by 
astrocyte-neuron lactate shuttle that has been explained above.  
1.2.1.4 Blood-brain barrier integrity 
The blood-brain barrier (BBB) is a physical barrier consisting of mainly ependymal cells 
that regulate the transport of ions and molecules via their tight junctions, which render 
the necessity of membrane transporters (solute carriers) to provide the brain-blood 
traffic. Brain nutrients such as glucose and amino acids enter the brain through this 
barrier; whereas, potentially toxic and metabolic waste products are removed away 
from the brain into the blood to be decomposed. The BBB is present as three sites: 1) 
the middle layer of the meninges, which surrounds the brain and the spinal cord as a 
whole, 2) the choroid plexus epithelium, which separates brain parenchyma from 
ventricles, and 3) brain endothelium that is the barrier between the brain cells and the 
capillaries (Reviewed in Abbott et al., 2006). This endothelium is covered by enlarged 
astrocytes processes, named ‘end feet’, showing the close relationship of astrocytes 
with the BBB. Indeed, primary brain endothelial cells can form tight endothelial barriers 
with closer similarities to the BBB in vivo when co-cultured with astrocytes compared to 
when grown alone (Candela et al., 2010; Skinner et al., 2009). Moreover, several 
astrocytic growth factors such as TGFα and GDNF have been shown to stimulate the 
formation of tight junctions in cultured endothelial cells, as well (Abbott, 2002). 
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Lineage-specific inhibition of early postnatal astrogliosis in mouse cortex delays vessel 
growth and branching; while, the astrogliosis that is allowed to proceed in later stages 
can rescue these delays (Ma et al., 2012a). Therefore, it is clear that astrocytes are 
important for the development of a healthy BBB.   
Astrocytes not only transport water, ions and molecules between the CNS tissue and the 
BBB but also appear to control the dilation and contraction of the arteriols upon 
synaptic transmission. Glutamate released during signal transduction can activate the 
astrocytic Ca2+ signaling, which has been associated with the secretion of vasoactive 
cyclooxygenase that can dilate the arteriol and thus increase the local blood flow 
(Anderson and Nedergaard, 2003; Zonta et al., 2003). Consequently, astrocytes 
contribute to the homeostasis in the CNS by playing a role in the development, 
maintenance, and function of the BBB in addition to their other homeostatic roles, 
explained above.  
1.2.1.5 Crosstalk between astrocytes and other neural cells 
Astrocytes can communicate with other neural cells in the CNS and thereby alter their 
functions. An example for the crosstalk between astrocytes and other neural cells in the 
CNS is the tripartite synapse as explained above (Fig 1.3, Araque et al., 1999; Halassa et 
al., 2007). Neurotransmitters secreted into the pre-synaptic cleft can stimulate 
astrocytes to increase their intracellular Ca2+ levels, which would initiate the release of 
gliotransmitters into the synapse (Fig 1.3). Gliotransmitters can regulate the neuronal 
excitability in return (Parpura et al., 1994; Bezzi et al., 1998; Mothet et al., 2000; Coco 
et al., 2003; reviewed in Halassa et al., 2007). Heterocellular couplings, provided by 
gap junction channels, between astrocytes and other cells such as oligodendrocytes and 
neurons (Ransom and Kettenmann, 1990; Robinson et al., 1993; Venance et al., 1995; 
Maglione et al., 2010; Wasseff and Scherer, 2011) present another example for the 
crosstalk including astrocytes. The astrocytic crosstalk is sometimes more complex and 
takes part in the communication between two different cell types such as seen in 
responding to axonal release of ATP by secreting the cytokine LIF, which in turn 
stimulates oligodendrocytes to enhance myelination (Ishibashi et al., 2006).  
1.2.2 Astrocyte phenotypes and their reactivity 
Astrocytes are suggested to inhabit the CNS at various degrees of reactivity, which is 
likely to exist as a whole spectrum rather than a few different types (Sofroniew and 
Vinters, 2010; Nash et al., 2011a). Astrocytes have presented differences in 
morphology, proliferation rate, and secretion profile in various CNS pathologies 
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compared to in health. In healthy CNS tissue, there are few proliferating or newly 
generated astrocytes; whereas, actively dividing reactive astrocytes in human 
specimens have been particularly reported in association with infection and acute 
demyelinating lesions (Colodner et al., 2005). The source of these proliferating cells 
may be mature astrocytes that re-enter the cell cycle and/or progenitor cells in the 
local parenchyma or periventricular regions (Buffo et al., 2008; Gadea et al., 2008; 
Magnus et al., 2008; Carlen et al., 2009). These observations have divided astrocytes 
initially into quiescent and reactive astrocytes. Reactive astrocytes have been shown to 
play a role in reactive astrogliosis, which includes mainly four elements: i) astrocytes 
show molecular, cellular and functional changes in response to all forms and severities 
of CNS injury, ii) the type and level of changes the astrocytes undergo depend on the 
severity of the injury, iii) the changes in this process are moderated in a context-
specific manner by inter- and intracellular signalling molecules, iv) the changes the 
astrocytes go through in this process could be seen as gain or loss of function of their 
activities and these can affect the surrounding neural or non-neural cells positively or 
negatively (Reviewed in Sofroniew, 2009). Reactive astrogliosis has further been 
categorised as 1) mild, 2) severe diffuse and 3) severe with glial scar formation 
(reviewed in Sofroniew and Vinters, 2010), which will be explained below  
1.2.2.1 Mild astrogliosis 
Mild astrogliosis is also termed as isomorphic astrogliosis or as astrocyte activation. 
These activated astrocytes show a low level of increase in GFAP expression, cell 
hypertrophy, little or no cell proliferation (Wilhelmsson et al., 2006; reviewed in 
Sofroniew, 2009). This type of astrogliosis generally occurs due to mild non-penetrating, 
non-contusive trauma and due to diffuse innate activation that could be caused by viral 
or bacterial infections. It is also seen in sites distal to CNS lesions. The possible 
mechanisms causing this phenomenon are summarised in four elements by Malhotra and 
Shintka (2002): i) cytokines released in the injury site might diffuse into a large area, ii) 
activated astrocytes might migrate from the lesion to distant sites, iii) neuronal 
degeneration at the lesion might lead to fibre degeneration that will affect distal 
astrocytes or iv) direct astrocyte injury at the site of injury might release molecules 
that will be carried to distal astrocytes via gap junctions. Although the cell body and 
processes of the astrocytes enlarge, processes of neighbouring astrocytes still do not 
overlap with each other, maintaining the neatly ordered cell network organisation 
(Wilhelmsson et al., 2006).  Because there is little change in the organisation of the 
tissue architecture, activated astrocytes have the potential to return to their healthy 
appearance if the pathological mechanism is eliminated or reversed.  
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1.2.2.2 Severe diffuse reactive astrogliosis 
The reorganisation in tissue architecture is more severe, long-lasting and can spread 
around in a large area in severe diffuse reactive astrogliosis compared to that in mild 
astrogliosis (Sofroniew and Vinters, 2010). It is seen as explicit hypertrophy of the cell 
body and processes and astrocyte proliferation, which result in intermingling and 
overlapping of neighbouring astrocyte processes. The GFAP expression is up regulated to 
higher levels compared to that seen in mild astrogliosis. This glial reaction usually 
occurs in areas around severe focal lesions, infections or in areas responding to chronic 
neurodegenerative insults.  
1.2.2.3 Severe astrogliosis with glial scar formation 
Another severe reactive astrogliosis type presents up-regulation in GFAP expression, 
extensive astrocyte proliferation and hypertrophy of the cell body and processes to a 
higher extent such that astrocyte processes overlap with each other considerably and 
dense glial scars form (Fig 1.4). These glial scars consist of mostly astrocytes (reviewed 
in Silver and Miller, 2004) and they function as compact barriers along borders to severe 
tissue damage, necrosis, infection or autoimmune-stimulated inflammatory infiltration 
(Bush et al., 1999; Fisher, 2008; Herrmann et al., 2008; Voskuhl et al., 2009). This type 
of reactive astrogliosis occurs in cases of penetrating or contusive trauma, invasive 
infections, neoplasm, chronic degeneration and systemically triggered inflammatory 
challenges (Sofroniew and Vinters, 2010). The dense collagenous extracellular matrix, 
deposed in these areas, contain molecular cues that inhibit axonal and cellular 
migration, which can prevent or complicate the axonal regeneration in CNS lesions (in 
Silver and Miller, 2004). Nevertheless, these scars have been shown to protect neurons 
from the damages of inflammatory cells and infectious agents. In the study carried by 
Bush et al. (1999), the ablation of scar-forming reactive astrocytes in transgenic mice 
has led to increased outgrowth of nerve fibers in injured CNS parenchyma as expected 
but also has resulted in a prolonged increase in leukocyte infiltration, failure of BBB 
repair with the presence of vasogenic edema, and neuronal degeneration. Such 
observations have disproved the stereotyped views that reactive astrogliosis and glial 
scar formation are uniformly negative processes and that the total inhibition of them 
can be considered as a potential therapeutic strategy. 
1.2.2.4 Pros and cons of reactive astrocytes  
The beneficial roles of reactive astrocytes in protecting CNS cells and tissue have been 
summarized by Sofroniew and Vinters (2010) as 1) taking up potentially excitotoxic 
glutamate and converting it to non-toxic precursors (Rothstein et al., 1996),  
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Figure 1. 4 Schematic representation of a glial scar in a large spinal cord lesion following 
stab injury.                                         
Stab lesion disrupts the blood-brain barrier by penetrating the meninges and allows the invasion of fibroblasts 
and macrophages into the central nervious system. Astrocytes proliferate and undergo hypertrophy, which 
forms a dense network of reactive cells at the lesion site.  Axons are repelled by elevated levels of inhibitory 
molecules in the milieu such as sulphate proteoglycans of chondroitin and keratan, which are produced by 
reactive astrocytes. The glial scar forms a physical and chemical barrier to regenerating axons. Astrocytes 
around the lesion (seen on the right of the figure) are mildly-activated as opposed to highly reactive astrocytes 
at the lesion site and to relatively “quescient” astrocytes outside the lesion (seen on the left of the figure). The 
image was modified from Silver and Miller, 2004.  
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2) protecting from oxidative stress via glutathione production (Chen et al., 2001; Shih 
et al., 2003), 3) protecting neurons by releasing adenosine (Lin et al., 2008) and by 
degrading amyloid-beta peptides (Koistinaho et al., 2004), 4) protecting from NH4+ 
toxicity (Rao et al., 2005), 5) expediting the repair of the BBB (Bush et al., 1999), 6) 
reducing vasogenic edema after trauma, stroke or obstructive hydrocephalus (Bush et 
al., 1999; Zador et al., 2009), 7) stabilising extracellular fluid and ion balance (Zador et 
al., 2009), and 8) preventing the spread of inflammatory cells or infectious agents from 
CNS lesions into healthy CNS parenchyma by forming a glial barrier (Faulkner et al., 
2004; Myer et al., 2006; Okada et al., 2006; Li et al., 2008a).  
Reactive astrocytes also exhibit various detrimental effects upon being stimulated by 
specific signalling cascades. They can i) deteriorate inflammation via cytokine 
production (Brambilla et al., 2005; 2009), ii) produce reactive oxygen species at 
neurotoxic levels (Swanson et al., 2004; Hamby et al., 2006), iii) release excitotoxic 
glutamate (Takano et al., 2005), iv) disrupt the BBB function due to VEGF production 
(Argaw et al., 2009), v) initiate cytotoxic edema during trauma and stroke because of 
over activity of aquaporin 4 channels, vi) potentially contribute to the formation of 
seizure and chronic pain (Jansen et al., 2005; Tian et al., 2005; Milligan et al., 2009). 
The fact that reactive astrocytes can play both beneficial and detrimental roles in CNS 
lesions might be explained by their secreting pro- or anti-inflammatory cytokines 
depending on types of molecules that stimulate these astrocytes (Eddleston and Mucke, 
1993; John et al., 2003). Their stimulation by certain types of molecules might depend 
on particular time frames after the insult or on different locations in relation to lesions. 
The observations so far suggest that astrocytes would exhibit pro-inflammatory effects 
in or nearby CNS lesion shortly after the lesion has started to form; whereas, they would 
exhibit anti-inflammatory effects at later times and more distant locations from the 
lesions (reviewed in Sofroniew, 2005; 2009).  
Although astrocytes playing a role in each type of astrogliosis have been defined as 
reactive astrocytes in paragraphs above, it is important to mention that an attempt has 
also been made by others to distinguish between the terminology used to define 
astrocytes taking place in mild astrogliosis (isomorphic astrogliosis) and those in severe 
astrogliosis (anisomorphic astrogliosis, Liberto et al., 2004). Nash et al. (2011a) have 
recently defined mild astrogliosis as “astrocyte activation” and severe astrogliosis as 
“astrocyte reactivity”. So in terms of level of activation, quiescent astrocytes are 
followed by “activated astrocytes”, which are followed by “reactive astrocytes”. In 
order to eliminate confusion, these new terms will be used below when these two 
phenotypes will be required to be differentiated. Otherwise, astrocytes in any kind of 
reactive astrogliosis will be referred to as ‘reactive astrocytes’ in general.     
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1.2.2.5 Activation of astrocytes in astrogliosis 
Many intercellular signalling molecules can trigger reactive astrogliosis or can regulate 
some aspects of it. These molecules include large polypeptide growth factors and 
cytokines (John et al., 2003; Di Giorgio et al., 2007), mediators of innate immunity such 
as lipopolysaccharide and other Toll-like receptor ligands (Farina et al., 2007), 
neurotransmitters (Bekar et al., 2008), purines, reactive oxygen species (Swanson et al., 
2004), molecules related to hypoxia and glucose deprivation (Swanson et al., 2004), 
products associated with neurodegeneration and with systemic metabolic toxicity 
(Simpson et al., 2010; Norenberg et al., 2009 ), and regulators of cell proliferation. 
Such molecules can be produced and released by both other astrocytes and other cell 
types in the CNS such as neurons, oligodendrocyte lineage cells, microglia, pericytes 
and endothelia. For example, in response to injury, microglia become activated and 
release the cytokine IL-1β (Herx et al., 2000), which is an early and dominant injury 
signal (Auron, 1998). Since astrocyte activation is delayed in mice lacking IL-1β as well 
as in mice lacking IL-1 type 1 receptor, it could be concluded that microglial activation 
is necessary for the activation of astrocytes (Herx et al., 2000).  
Astrocytes have also been shown to react to other cytokines and growth factors. For 
instance, fibroblast growth factor (FGF), epidermal growth factor (EGF) and insulin-like 
growth factor-1 (IGF-1) increase the expression of glutamine transporters in astrocytes 
in vitro (Zelenaia et al., 2000; Suzuki et al., 2001), which might be a sign of astrocyte 
activation since the expression of these receptors is also increased in cultured 
traumatized astrocytes and in astrocytes obtained from traumatized rat cortex (Eng et 
al., 1979; Faden et al., 1989; Krum et al., 2002). Moreover, activated astrocytes up-
regulate the expression of glutamine synthetase, whose levels can be regulated also by 
cytokines, including nerve growth factor  (NGF) and FGF-2, which are downstream of IL-
1 stimulation (Loret et al., 1989; Kazazoglu et al., 1996). So the pro-inflammatory 
cytokine IL-1 secreted in the case of a brain injury could stimulate the production 
and/or secretion of growth factors, which then could up-regulate the expression of 
enzymes and transporters in reactive astrocytes as mentioned above to remove the 
potential exocytotoxic glutamate. In contrast to that, TGFβ, an anti-inflammatory 
cytokine that has been shown to be elevated in neurodegenerative diseases (Masliah et 
al., 2001; Pasquali et al., 2015), impairs astrocytic glutamine synthetase function in 
astroglial cultures and stimulates neurotoxicitiy in neuronal/astrocyte mixed cultures 
(Toru-Delbauffe et al., 1990; Chao et al., 1992), which might be associated with 
detrimental roles of highly reactive astrocytes as opposed to mildly activated beneficial 
astrocytes.  
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CNTF stands out as a well-known IL-6 family cytokine that has been demonstrated to 
activate astrocytes both in vitro and in vivo as observed by the increase in the 
astrocytic expression of reactivity markers such as GFAP, vimentin, and clusterin; 
cellular and nuclear hypertrophy; and cell proliferation (Winter et al., 1995; Levison et 
al., 1996; 1998; Hudgins and Levison, 1998). Like CNTF, pro-inflammatory cytokines 
such as TNFα and INFγ have also been shown to potentiate reactive astrogliosis (Yong et 
al., 1991; Balasingam et al., 1994; Corbin et al., 1996; reviewed in John et al., 2003). 
This could be especially important in inflammatory neurodegenerative diseases such as 
multiple sclerosis as will be explained below. 
1.2.3 Astrocytic roles on myelination in general 
Several studies have demonstrated that astrocytes can have promoting effects on 
myelination (Moore et al., 2011). In vitro studies, where conditioned medium was 
collected from primary astrocytes to treat other cultures, have shown that secreted 
astrocytic factors can act as mitogens for oligodendrocyte precursor cells, can protect 
oligodendrocytes against various kinds of stress and neurons from injury, and can 
support neuronal survival better than non-conditioned medium (Noble and Murray, 1984; 
Yoshida et al., 1995; Yamamuro et al., 2003; Zhu et al., 2006; Arai and Lo, 2010). 
Astrocytes can also secrete factors that increase the number of myelinated axons in 
response to axon firing (Ishibashi et al., 2006) and that influence the rate of axonal 
ensheathment in vitro (Watkins et al., 2008). In contrary to their stimulatory effects on 
myelination, astrocytes can generate an extracellular matrix inhibitory to the axonal 
outgrowth due to chondroitin sulphates they secrete (Canning et al., 1996; Filous et al., 
2010). The fact that whether astrocytes will behave in a positive or negative way in 
neuronal support and myelination could be related to the degree of the astrocyte 
reactivity; i.e., ‘activated astrocytes’ could be providing a stimulatory environment 
unlike ‘reactive astrocytes’ do (reviewed in Nash et al., 2011a; in Barnett and 
Linington, 2013). Additionally, the difference between levels and activities of 
stimulatory and inhibitory secreted astrocytic-factors could be important to determine 
the overall astrocytic effect in the microenvironment.    
Interestingly, rat spinal cords, where myelination was followed over a postnatal time 
period, have presented a direct ratio between the immunereactivity for myelin basic 
protein (MBP) and the number of GFAP positive astrocytes (Dziewulska et al., 1999). 
Moreover, transplantation of astrocytes into lesions has enhanced remyelination in rat 
spinal cords (Franklin et al., 1991). Knockout studies presented abnormal myelination, 
nonmyelinated axons in the optic nerve, and reduced myelin thickness in spinal cords of 
older (18-24 months of age as opposed to 2 months) GFAP null mice (Liedtke et al., 
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1996). Non-conservative mutations in GFAP gene have also been linked to a white 
matter brain disorder named Alexender disease (Brenner et al., 2001; Li et al., 2002). 
Therefore, the evidence for direct or indirect astrocytic roles on re/myelination has 
been established both at in vitro and in vivo studies.  
1.2.4 The effects of cytokine-activated astrocytes on 
neurogenesis, neuronal survival, and re/myelination  
Cytokine-activated astrocytes can promote neuronal survival potentially by secreting 
various neurotrophic and growth factors (GFs) into the vicinity of neurons. Neurotrophic 
factors (NFs) secreted by astrocytes in response to injury, disease, and activation of 
cytokine receptors include nerve GF (NGF), brain-derived NF (BDNF), activity dependent 
NF (ADNF), hepatocyte GF (HGF), ciliary NF (CNTF), leukemia inhibitory factor (LIF) and 
fibroblast GF-2  (FGF-2) (Schwartz et al., 1994; Rudge et al., 1995; Uchida et al., 1998; 
Dreyfus et al., 1999; Messersmith et al., 2000; Albrecht et al., 2002). For example, IL-
1β potently increases astrocytic expression of NGF, which then can promote neuronal 
survival (Friedman et al., 1990; Spranger et al., 1990). Primary rat astrocytes have also 
been shown to increase their expression of NGF in response to a fusion protein of IL-6 
and soluble IL-6 receptor (Marz et al., 1999). Activation by another cytokine, vasoactive 
intestinal peptide (VIP), promotes ADNF secretion from astrocytes, which has been 
shown to promote the survival of spinal cord neurons and cortical neurons (Gozes et al., 
1999). In addition, it protects rat cerebral cortical cultures from β-amyloid peptide 
neurotoxicity (Brenneman et al., 1996; Gozes et al., 1996). CNTF also activates 
astrocytes to promote neuronal survival. Cultured spinal cord astrocytes, activated with 
CNTF, support the survival of a significantly greater number of ventral spinal motor 
neurons and promote neurite outgrowth better than compared to unstimulated 
astrocytes (Albrecht et al., 2002). IL-1β can induce the production of astrocytic CNTF, 
which likely presents its above-mentioned effects by increasing the production of 
astrocytic neurotrophic factors such as FGF-2 (Herx et al., 2000; Liberto et al., 2004).  
Accumulating evidence show that cytokine-activated astrocytes can promote 
neurogenesis possibly by stimulating the differentiation of neural stem cells (NSCs), 
which are present in the subventricular zone and the dentate gyrus of the hippocampus 
in adult animals (Liberto et al., 2004). Because these multipotent cells can migrate 
beyond their sites of origin and can later differentiate into neurons and microglia, they 
carry the potential to enhance recovery from CNS injury and disease. FGF-2 and other 
factors, which can be secreted by cytokine-activated astrocytes (Albrecht et al., 2002), 
have been shown to stimulate NSCs to proliferate both in vitro and in vivo (Kuhn et al., 
1997). Moreover, co-culturing adult NSCs with primary hippocampal astrocytes increases 
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the number of newly formed neurons 10-fold (Song et al., 2002), which suggests that 
astrocyte-derived factors must be regulating neurogenesis.  
CNTF also plays a role in remyelination process of demyelinated CNS lesions. Mice 
infected with the A-59 strain of the mouse hepatitis virus (MHV-A59), another useful 
animal model for MS (Jordan et al., 1989, Messersmith et al., 2000), have presented IL-
1β production early during the course of infection, when demyelination takes place; 
whereas levels of CNTF have increased later, during the remyelination phase (Albrecht 
et al., 2003). In the same animal model, Cntf mRNA, but not Il-1β mRNA, has been 
found to be induced in remyelinating regions and to be present in cells exhibiting 
astrocytic features. It is suggested that the increase in IL-1β levels at early stages of the 
pathology stimulates the induction of CNTF mRNA and protein in astrocytes (Stockli et 
al., 1991; Guthrie et al., 1997; Dallner et al., 2002; Liberto et al., 2004), a phenomenon 
which appears to be important for remyelination stages (Herx et al., 2000).  Moreover, 
CNTF treatment elevates astrocytic levels of Fgf-2 mRNA significantly; whereas, IL-1β 
shows no effect (Albrecht et al., 2003). Since FGF-2 can enhance oligodendrocyte 
precursor cell (OPC) proliferation (Albrecht et al., 2003), it is likely that CNTF-
activated-astrocytic release of FGF-2 stimulates OPC proliferation (Redwine et al. 1997; 
Messersmith et al., 2000) and thus provides remyelination in demyelinated CNS lesions. 
Similarly, IL-1β  can stimulate the astrocytic production of another IL-6 family cytokine, 
LIF (Aloisi et al., 1994), which has been shown to promote survival and differentiation 
of oligodendrocytes and expression of mature myelin protein in different studies (Kahn 
and De Vellis, 1994; Mayer et al., 1994; Bugga et al., 1998). 
Above-mentioned beneficial effects of astrocytes on myelination could be associated 
with mild astrogliosis rather than more severe reactive astrogliosis types as discussed by 
several groups of investigators (reviewed in White and Jakeman, 2008; in Sofroniew and 
Vinters, 2010; in Nash et al., 2011a). Astrocytes can impede myelination probably 
depending on their activation phenotype (Moore et al., 2011). The word ‘phenotype’ 
here represents the change in their several properties such as morphology, and 
antigenic and physiological characteristics obtained after injury. As it is argued by Nash 
et al. (2011a), activated astrocytes could promote remyelination; whereas, reactive 
astrocytes could suppress remyelination after injury. 
Reactive astrocytes are functional in severe astrogliosis as mentioned above (Section 
1.2.2.3). Various pro-inflammatory cytokines can activate astrocytes in such CNS 
pathologies, where reactive astrocytes will in turn secrete other cytokines and/or 
chemokines (reviewed in John et al., 2003). One of the cytokines, secreted by reactive 
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astrocytes, with detrimental effects is tumor necrosis factor-α (TNFα), which induces 
myelin and oligodendrocyte damage in vitro (Selmaj et al., 1988). Its expression in MS 
plaques positively correlates with the extent of demyelination (Bitsch et al., 2000). 
Since one of the major targets for TNFα is the maturation of oligodendrocytes (Cammer 
and Zhang, 1999), the remyelination failure present in CNS lesions could be because 
TNFα prevents the differentiation of oligodendrocytes in these sites. Reactive 
astrocytes also secrete CXCL10 (Ransohoff et al., 1993), a chemokine that has also been 
shown to be expressed by reactive astrocytes around active MS lesions (Omari et al., 
2005; Carter et al., 2007). Cxcl10 mRNA expression increases significantly during peak 
disease and decreases during the recovery phases in animal models of MS (Godiska et 
al., 1995; Glabinski et al., 1997; Fife et al., 2001). In a very recent in vitro study, 
astrocytes with increased expression of Cxcl10 failed to promote myelination, which 
was reversed by the neutralisation of CXCL10 by using antibodies (Nash et al., 2011b). 
CXCL10 might express this effect by binding to its receptor CXCR3, expressed by 
oligodendrocytes. Therefore, reactive astrocytes appear also to be capable of initiating 
myelination-inhibiting crosstalk with other cells unlike their stimulatory roles, explained 
above.  
As seen above, astrocytes appear to play important roles not just in myelination in 
embryonic CNS tissues but also in remyelination in adult tissue after CNS injury in 
addition to their various functions stimulated following CNS damage. Their functions 
might be related to their ‘phenotype’ and hence it is important to test different 
phenotypes of astrocytes in follow-up studies to elucidate the molecular mechanisms 
how astrocytes play a role in myelination. Such studies might reveal novel treatments 
for MS patients, who currently lack a treatment that will reverse their disabilities.  
1.2.5 Astrocytes in multiple sclerosis 
Multiple sclerosis is an autoimmune, neurodegenerative disease, affecting the CNS. The 
highest prevalence for this disease has been detected so far in Scotland which ranges 
from 145 to 193 per 100 000 (Pugliatti et al., 2001). The initial symptoms of the disease 
often include weakness in one or more limbs, inflammation of the optic nerve, 
paraesthesiae (sensation of tingling, pricking, numbness), diplopia (double vision), 
vertigo, and bladder dysfunction (McAlpine et al., 1972). The age of onset of the disease 
may vary usually between 10 and 50 years (Noseworthy et al., 1983; Sindern et al., 
1992). The disease can have a progressive or a relapsing-remitting course, where 
periods of worsening neurologic functions (exacerbations) are followed by partial or 
complete recovery periods (remissions, Fig 1.5). The progressive subtype is named as 
primary progressive if the progression has been present from the onset; whereas, 
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secondary progressive MS shows progression after an initial period of relapsing-remitting 
course (Fig 1.5, reviewed in McDonnell and Hawkins, 1996). As the disease progresses, 
disabilities might accumulate and might produce immobility, lack of protective 
pharyngeal reflexes and bladder problems, making the patient more susceptible to 
infection. 
The main pathological mechanisms leading to an initiation or increase in the disease 
activity could be summarized as T-cell reactivity to a myelin antigen or another CNS 
antigen, disruptions in the BBB permeability and increase in the expression of cell 
adhesion molecules, which would affect the cell trafficking across the BBB (McFarland 
and Martin, 2007). Two major occurrences of MS are relapses and progression. Relapses 
are considered to be clinical presentation of acute inflammation and demyelination in 
the CNS; whereas, progression is considered to reflect the presence of axonal loss and 
neurodegeneration (Fitzner and Simons, 2010). The loss of myelin in MS can lead to 
severe loss of function as mentioned above and thus it is very important to find 
treatments to prevent the myelin damage from occurring in the first place or to find 
ways to facilitate the remyelination process. 
Astrocytes in MS plaques have been suggested to secrete cytokines that are either 
stimulatory or inhibitory for myelination. TNFα and INFγ not only can activate 
astrocytes but they can also be secreted by reactive astrocytes both in MS and 
experimental autoimmune encephalomyelitis (EAE), a mouse MS model, where 
demyelination is induced by myelin antigens, administered together with adjuvant that 
contains bacterial components (Traugott and Lebon, 1988; Tsukada et al., 1991; 
Villarroya et al., 1996; Meeuwsen et al., 2003). The level of TNFα expression in MS has 
been correlated with the extent of demyelination (Bitsch et al., 2000). Similarly, INFγ 
has been shown to suppress remyelination and to delay disease recovery in transgenic 
EAE mice, where INFγ expression was stimulated temporally in recovery stage in 
astrocytes (Lin et al., 2006b). On the other hand, another astrocytic-cytokine, LIF, 
decreases disease severity when exogenously administered in both chronic EAE and 
relapsing-remitting EAE mice (Aloisi et al., 1994; Butzkueven et al., 2002; Ishibashi et 
al., 2006). Promoting effects of LIF on the survival and maturation of oligodendrocytes 
also support the positive roles of LIF on remyelination (Khan and De Vellis, 1994; Mayer 
et al., 1994; Bugga et al., 1998).  
Reactive astrocytes have been observed both in acute and chronic plaques in MS with 
increased expressions of markers such as GFAP, vimentin, nestin, eNCAM, FGFR4, EGFR, 
NGF, bFGF, TnR, and CTGF (Holley et al., 2003). The failed axonal regeneration in MS 
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Figure 1. 5 Multiple sclerosis (MS) subtypes                                                                       
A) Secondary progressive MS. Iniitial relapsing-remitting MS that suddenly begins to present increased 
disability without periods of remission. B) Relapsing-remitting MS with many short attacks that tend to 
increase in duration and severity. These unpredictable attacks are followed by periods of remission. C) 
Progressive-relapsing MS. Slow and steady progression since onset with superimposed relapse and 
increasing disability. D) Primary progressive MS. Slow and steady progression from onset without relapses. E) 
Abrupt onset with good remission followed by long latent phase. F) Relapses of diminishing frequency and 
severity; slight residual disability only. Image was taken from Compston et al., 2006.  
 
lesions has been correlated with dense glial scars that consist primarily of enlarged and 
entangled reactive astrocytes and that surround non-regenerating fibers closely 
(reviewed in Silver and Miller, 2004). However, this glial scar has later gained attention 
also with its protective roles in lesions. Targeted depletion of the group of reactive 
astrocytes that proliferate immediately around the core of the lesion in mouse brains 
and spinal cords has resulted in increased levels of failure in BBB repair, inflammatory 
response and cellular degeneration (Bush et al., 1999; Faulkner et al., 2004). Therefore, 
the glial scar is now also considered as a protective barrier that separates the injury 
from healthy tissue and thus prevents the damage and the immune response from 
spreading around and invading the normal CNS. Nevertheless, astrocytes going through 
astrogliosis can still be seen as harmful due to their secretion of toxic factors and 
glutamate-mediated excitotoxicity in addition to taking part in compact glial scars 
(Bannerman et al., 2007; Cambron et al., 2012). The most recent opinion is that 
Educated at Aberdeen University, Charles Lumsden learned
the techniques of tissue culture and immunocytochemistry
(with Elvin Kabat, see below) in the United States during the
late 1940s after serving, amongst other places, in the Faroe Islands
with the Royal Army Medical Corps. He applied laboratory
methodologies to the study of demyelinating disease, publishing
the first papers on experimental autoimmune encephalomyelitis
from the United Kingdom. As Professor of Pathology in the
University of Leeds, Lumsden was vigorous in his defence of
pathology as the primary discipline of medicine. A shrewd but
shy man, who painted and played the violin with distinction, he
acquired the reputation for seldom changing his opinion since
his position was not often wrong.
McAlpine accumulated clinical records on 1072 cases of mul-
tiple sclerosis, of whom a proportion were consecutive examples
seen at onset, and these formed the basis for his clinical descrip-
tions and classification of the disease. In summarizing features of
the clinical course, McAlpine, Compston and Lumsden empha-
sized a number of special features – the symmetry of bilateral
lesions, paroxysmal manifestations of demyelination, the pre-
dictable evolution of individual lesions according to anatomical
principles, the variety of words used by patients to describe motor
and sensory symptoms, early disappearance of the abdominal
reflexes, the frequency of pupillary hippus (as distinct from the
Marcus Gunn pupil, which curiously was not mentioned despite
having been described in 1904), and occasional upper limb
wasting (illustrated by Oppenheim in his textbook, first pub-
lished in 1894) with absent tendon reflexes (also with Horner’s
syndrome in the case of patient WJ). Throughout, McAlpine
and Compston relate their analyses to the lives and experiences
of individual patients, placed in social context and identifiable to
any archival scout by their initials and case numbers. McAlpine
and Compston used classical neuroanatomical principles of fibre
organization within the spinothalamic tract and dorsal columns
to explain the march of sensory symptoms as inflammation (and
demyelination) spread laterally through the laminations, and
vertically to involve neighbouring segments. The authors dealt at
length with features of the natural history that had not previously
been described in such detail, pointing out the systematic reduction
in relapse rate with time, the interval between the presenting
and first subsequent attack depending on mode of presentation,
the relationship between age at onset and the progressive course
from onset, and aspects of prognosis – observations that were
summarized in a much reproduced cartoon depiction of the
course of multiple sclerosis (see Figure 1.2). Their differential
diagnoses, organized by syndrome, addressed the complex rela-
tionship between cervical spondylosis and spinal cord demyeli-
nation, the nosological status of Devic’s disease and acute
disseminated encephalomyelitis (each considered distinct from
but easily confused with multiple sclerosis) and emphasized the
need for diagnostic caution in the context of a family history,
especially when this involved a stereotyped phenotype amongst
affected individuals.
In conversation, Nigel Compston was never in doubt that he
carried the main burden of collating this information and writing
the first manuscript version of Multiple Sclerosis. McAlpine was
responsible for subsequent editions, working with Lumsden and
(Sir) Donald Acheson, an epidemiologist later appointed Chief
Medical Officer to the Department of Health in the United
Kingdom. Soon after publication of the second edition (1972)
McAlpine approached one of us (WIMcD) with a view to him
taking over the role of clinic l author. McDonald felt that the
time was not right. After the death of both McAlpine and
Lumsden, the publishers handed over editorship of Multiple
Sclerosis to Bryan Matthews (1920–2001) for the 1985 edition
with Acheson, Richard Batchelor and Roy Weller. Matthews also
s w throug the press a second edition of McAlpine’s Multiple
Sclerosis (1991) with (Dame) Ingrid Allen, Christopher Martyn
and the present editor. He contributed to the third edition 
published in 1998.
Quintessentially whimsical and dry to the point of dehy-
dration, Bry  Matthews brought natural charm and personal
diffidence to his dealings with patient and profession, securing
the admiration and deep affection of both fraternities (Figure
1.1D). Matthews combined rich clinical experience of neuro-
logical disease with original research contributions; these 
cred ntials together with a marvellous literary style mad
famous his writings on neurology. He is most often quoted for
1Naming and classifying the disease: 1868–1983
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Figure 1.2 (A) Relapses with early and increasing disability. 
(B) Many short attacks, tending to increase in duration and
severity. (C) Slow progr s ion fr m onset, superim osed relapse,
and increasing disability. (D) Slow progression from onset without
relapses. (E) Abr pt onset with good remission followed by long
latent phase. (F) Relapses of diminishing freque cy and sev rity;
slight residual disability only. From McAlpine et al (1955) with
permission.
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‘reactive astrocytes’ could be responsible for detrimental effects in the CNS lesions; 
while, ‘activated astrocytes’ might play beneficial roles and promote CNS repair 
(reviewed in Barnett and Linington, 2012).   
1.3 CNS myelinating culture systems 
1.3.1 Organotypic slice cultures 
The first attempt to generate brain slice cultures involved tissue from embryonic chick 
rhomboencephalon and was not very successful as the cultures could not be mainted for 
a long period of time (Levi and Meyer, 1941). Myelin formation was later observed in 
culture of mammalian CNS, where it was visualised by its refractive pattern on light 
microscopy (Hild, 1956). Cerebellar sections from neonatal mice have provided an ex 
vivo system to observe myelination when optic nerve explants were transplanted onto 
them (Stanhope et al., 1986). It has later been shown that these slice cultures also have 
the capacity to support myelination in the absence of any transplantation (Seil and 
Herndon, 1991). They have also provided a model to study effects of a treatment on 
myelination. For example, progesterone stimulated myelination, which was assessed by 
immunofluorescence of MBP (myelin basic protein) in both mouse and rat cerebellar 
slice cultures (Ghoumari et al., 2003). However, MBP expression does not appear to 
reflect solely the amount of axonal ensheathment around axons. To assess the 
myelination more precisely, electron microscopy has been utilised in many other studies 
including those in embryonic spinal cord slice cultures (Bunge and Wood, 1973; Billing-
Gagliardi et al., 1980; Shrager and Novakovic, 1995). An automated way has been used 
recently to quantify myelination levels in mouse cerebellar slice cultures. The images 
obtained via fluorescence microscopy were analysed by a software, which quantified 
the colocalisation of MBP (representing myelin) and NFH (neurofilament, representing 
axons) immunofluorescence (Huang et al., 2011; Zhang et al., 2011). Despite these new 
improvements, slice cultures still remain laborious especially due to the requirement of 
tissue slicing using special equipment like microtome or vibratome.  
1.3.2 Cocultures containing dorsal root ganglion neurons 
Dissociated embryonic rodent spinal cord cells or glial cells, which are isolated from 
spinal cord cell suspensions, are added onto 3-4 weeks old dorsal root ganglion (DRG) 
neuronal cultures to generate cocultures that will present CNS myelination in the 
following 4-6 weeks (Mithen et al., 1983; Wood and Williams, 1984; Wood and Bunge, 
1986). Watkins et al. (2008) have shortened this period by seeding oligodendrocyte 
precursor cells on retinal ganglion cells, where the generation of compact myelin has 
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been observed within six days. Because DRG neurons are primarily considered to be part 
of peripheral nervous system due to their roles in conveying peripheral signals to the 
CNS and regulating vascular and other tissue functions in the area of their peripheral 
terminations (reviewed in Holzer and Maggi, 1998), it cannot be guaranteed that they 
will behave similar to CNS neurons under all circumstances even if they are cultured in 
the presence of CNS spinal cord cells or purified astrocytes (Chan et al., 2004). 
Therefore, other culture types could be more convenient for the purposes of studying 
CNS myelination.     
1.3.3 Dissociated mixed CNS cultures 
Dissociated cells from an embryonic CNS region such as the forebrain, cerebellum, or 
spinal cord can be used to prepare mixed cultures to observe myelination. The number 
of myelinated fibres per unit of surface increased gradually in cerebral hemisphere 
cultures from embryonic day 15 (E15) mice between days 13 and 22 as observed by 
electron microscopy after immunocytochemistry (Lubetzki et al., 1993). Unlike mouse 
cerebral cultures, embryonic rat cerebellar cultures have presented continuous 
myelination at least up to 3 months, where cultures were dense and axonal 
ensheathment was abundant (Svenningsen et al., 2003). On the other hand, Thomson et 
al. (2006) developed embryonic mouse spinal cord myelinating cultures that could be 
maintained in defined media rather than serum, which contains undefined components. 
Additionally, they showed that these cultures provided robust myelination when a 
supportive monolayer of neurosphere-derived mouse astrocytes was used, which could 
also allow the study of the effect of different astrocyte phenotypes on myelination. 
Their protocol was later adapted to rats by Sorensen et al. (2008).    
Embryonic rat spinal cord cultures are prepared from dissociated rat spinal cord cells, 
obtained from embryonic day 15 Sprague Dawley rats. Dissociated spinal cord cells are 
plated onto a confluent monolayer of astrocytes, derived from postnatal day 1 rat 
striatum neurospheres. The cultures develop over 24-28 days. They allow the study of 
neuronal survival and neurite outgrowth in the first 12 days, which are followed by 
oligodendrocyte precursor proliferation and oligodendrocyte process extension to axons 
in the following 6 days. At days 22-28, the formation of myelin internodes and nodes of 
Ranvier can be observed (Sorensen et al., 2008).   
Applying immunocytochemistry to spinal cord myelinating cultures allows the 
observation of morphological properties such as oligodendrocyte development, and axon 
and myelin sheath integrity by using specific antibodies. Neurites are usually visualised 
using an antibody against phosphorylated neurofilament SMI-31 and neurite density is 
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measured using Image J software, where the pixel value of SMI-31 fluorescence 
reactivity is measured as a percentage of the total pixel value in one image, taken using 
a fluorescent microscope. Mature myelin is visualized using the AA3 antibody, which 
labels PLP/DM20 proteins, present both in myelin sheaths and in oligodendrocyte cell 
bodies. Therefore, to calculate the percentage of myelination, the myelinated axons 
have to be manually identified on images using Adobe Photoshop software (Sorensen et 
al., 2008).   
Astrocytes, which are used as a feeder monolayer underneath  embryonic rat spinal cord 
cultures, are plated on poly-L-lysine (PLL)-coated coverslips to obtain a control 
condition. These spinal cord myelinating cultures on PLL-astrocytes (PLL-myelinating 
cultures) are considered to be the control phenotype in vitro, but it cannot be assumed 
that they represent quiescent (inactivated) astrocytes present in the healthy CNS in 
vivo. For instance, primary rat astrocytes grown on a 3D collagen gel system express 
lower levels of reactivity markers like GFAP, vimentin and aquaporin 4 compared to 
those grown in a monolayer (East et al., 2009). Cultural processes such as dissection and 
enzymatic dissociation might induce an activated cell phenotype. Moreover, cultured 
astrocytes are exposed to foetal bovine serum; whereas those in normal human brain 
are not. Therefore, artificial culture conditions might cause astrocyte monolayers to 
have a different state of activation compared to that at their tissue source and thus 
affect activities of spinal cord myelinating cultures. Nevertheless, PLL-myelinating 
cultures can still be used as controls to compare effects of different treatments on cell 
proliferation, differentiation and myelination.  
Alternatively, rat astrocytes can be plated on tenascin C (TnC)-coated coverslips (Nash 
et al., 2011b). TnC is an extracellular matrix (ECM) glycoprotein that has been shown to 
induce a quiescent phenotype in cultured adult human astrocytes (Holley et al., 2005). 
Among other tested ECM molecules, including laminin, collagen IV, fibronectin, 
vitronectin and proteoglycans, TnC reduced the expression of activated/reactive 
astrocyte markers (e.g., nestin, neural cell adhesion molecule, EGF receptor, and basic 
FGF) and slowed down the proliferation of astrocytes the greatest (Holley et al., 2005).  
Thus, plating astrocytes on TnC-coated coverslips is currently considered as a method to 
generate a more quiescent phenotype compared to reactive phenotypes. It could be 
argued that the phenotype of TnC-astrocytes resembles that of astrocytes in the healthy 
CNS because the expression level of astrocyte reactivity markers in TnC-astrocytes were 
comparable to those of astrocytes in normal cerebral white matter in vivo (Holley et 
al., 2005). Therefore, TnC-astrocytes and hence TnC-myelinating cultures could also be 
preferred as the control conditions. However, further studies are required to validate 
this view.  
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1.4 The roles of cytokines and chemokines in the CNS 
Cytokines are a group of small glycoproteins that may function as membrane-bound 
complexes or be secreted into the microenvironment by various cells. Cytokine 
superfamily includes several groups of signaling protein families such as chemokines, 
interferons, interleukins, lymphokines, and tumor necrosis factors. Chemokines are 
divided into four classes based on the positions of key cysteine residues: C, CC, CXC, 
and CX3C (Bajetto et al., 2001). The main function that differentiates chemokines from 
other cytokines is their roles in cell recruitment, which they provide through both 
specific and shared G-protein coupled receptors. Both chemokines and other cytokines 
have been shown to take part in various functions in the CNS as will be explained below. 
1.4.1 The roles of cytokines in the development of the CNS 
Both in vitro and in vivo experiments have suggested important roles for several 
cytokines in the CNS development. Among them, IL-6 family cytokines (IL-6, IL-11, IL-
27, CLC, CNTF, CT-1, LIF, NP, and OSM) appear to regulate 1) the self-renewal of 
radial glial cells (RGCs) that can generate neurons and glia during embryogenesis, 2) the 
shift from neuronogenesis to astrogliosis at early stages of development, 3) 
determination of neuronal identity, and 4) cell survival (reviewed in Deverman and 
Patterson, 2009). Essential components of their signaling pathway such as i) the 
common receptor subunit GP130 that binds all IL-6 family members (Fig 1.6), ii) more 
specific receptor subunits LIFRβ and CNTFRα, and iii) STAT3 that is a transcription 
factor primarily mediating GP130 signaling are all expressed in the early ventricular 
zone, which is populated by RGCs (Yoshimatsu et al., 2006; Alfonsi et al., 2008) and the 
cytokines CT-1, CNTF, NP, LIF are also expressed in the embryonic brain (Derouet et al., 
2004; Barnabe-Heider et al., 2005; Gregg and Weiss, 2005). The stimulation of the 
crosstalk between STAT3 and Notch signaling, which can be activated by CNTF 
(Chojnacki et al., 2003), is suggested to inhibit neuronal differentiation and to promote 
the RGC fate (Kamakura et al., 2004; Yoshimatsu et al., 2006). On the other hand, 
GP130 family cytokines induce GFAP expression at later stages of embryogenesis as can 
be seen in the impaired astrogliogenesis of Gp130 or Lifrβ knockout embryos (Koblar et 
al., 1998; Nakashima et al., 1999). It is suggested that they do not promote a full 
maturation of astrocytes but rather contribute to the generation of GFAP positive 
multipotent astroglial progenitors that will occupy adult subventricular zone. The 
involvement of LIF signaling in control of the neuronal subtype identity; and the 
increased motor neuron loss in knockout animals lacking an IL-6 family cytokine or 
receptor present other examples of present IL-6 family cytokine roles in CNS 
development (reviewed in Deverman et al., 2009). 
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Figure 1. 6 Interleukin-6 (IL-6) family of cytokines and their receptors.  
IL-6 family cytokines bind to their respective α-receptors (IL-6R, IL-11R, CNTF-R) that induce the dimerisation 
of gp130, LIFR, or OSMR to conduct their signaling. IL-6 and IL-11 bind their corresping α-receptors that can 
be either membrane-bound or found in the soluble form, and signal through a gp130 homodimer. LIF and 
OSM do not require an α-receptor and signal through a heterodimer of LIF receptor (LIFR) and OSM receptor 
(OSMR). OSM can also use a heterodimer of OSMR and gp130.  CT-1 also uses a heterodimer of 
LIFR/gp130 but requires an α-receptor, currently not known. CNTF, NP, and CLC all signal through a 
heterodimer of LIFR/gp130 after binding CNTF α-receptor (CNTFR). The image was modified from Kraakman 
et al., 2013. CLC: cardotrophin-like cytokine-like factor; CNTF: ciliary neurotrophic factor; CT-1: cardiotrophin 
1; LIF: leukamia inhibitory factor; NP: neuropoietin; OSM: oncastatin M; R: receptor 
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Other cytokines such as granulocyte colony stimulating factor (G-CSF) and IL-1β are also 
expressed in embryonic CNS tissue and are suggested to promote neurogenesis. 
Moreover, TGFβ, TNFα, and IL-9 cytokines have been associated with functions such as 
neuronal subtype differentiation, regulation of cell survival, and synaptic modulation 
and elimination; while, bone morphogenetic proteins (BMPs), a subgroup of TGFβ 
cytokine family, suppress neurogenesis (reviewed in Deverman et al., 2009). 
1.4.2 The role of cytokines in the adult CNS 
Even though cytokines have been suggested to be secreted by all neuronal and glial 
cells, astrocytes and microglia appear as the major cellular source of cytokines in the 
CNS. Cytokines in the healthy CNS can regulate various functions including synthesis of 
neurotrophic factors, neurogenesis, astrogenesis and astrocytic survival, 
oligodendroglial maturation, neurotransmission, synaptic maturation and plasticity, and 
myelination (reviewed in Camacho-Arroyo et al., 2009; in Schmitz and Chew, 2009). IL-
1β, IL-2, IL-6 cytokines can promote γ-aminobutyric acid (GABA)-mediated inhibitory 
signal transduction; while, IFNγ decreases GABAergic neuron activation and IFNα 
treatment changes the balance between excitatory and inhibitory neurotransmission by 
reducing the former and increasing the latter (Vikman et al., 2001; Brask et al., 2004). 
In addition to its neuroprotective roles and its effects on neurotransmitters, IL-3 can 
also play a role in differentiation and maintenance of cholinergic neurons (Tabira et al., 
1998; Wen et al., 1998).     
CNTF, an IL-6 family cytokine, and CNTF receptor alpha (CNTFRα), which is a specific 
component of its receptor complex, are constitutively expressed in astrocytes of white 
matter and grey matter, respectively, of normal mouse brain  (Stockli et al., 1991; 
Dallner et al., 2002). Microglia also present CNTFRα expression unlike astrocytes in 
mixed glial cultures, which might be due to the brain region dissociated to set up the 
cultures (Krady et al., 2008). Therefore, it is likely that this spatial control of CNTF 
ligand and receptor expression determines which cells will respond to CNTF that will be 
important for final CNTF effects in the brain. CNTF knockout mice present increased 
degeneration in spinal motor neurons with increasing age, which shows the role of CNTF 
in neuroprotection (Masu et al., 1993). CNTF also stimulates oligodendrocyte survival 
and maturation in vitro and in vivo (Stankoff et al., 2002; Cao et al., 2010), enhances 
migration of subventricular zone-derived progenitors (Vernerey et al., 2013), and 
protects oligodendrocytes from apoptosis and decreases myelin destruction in 
demyelinating pathological conditions (Linker et al., 2002).     
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1.4.3 The role of cytokines in CNS pathology 
CNTF has presented up-regulated mRNA levels during remyelination phase of a 
cuprizone-induced demyelinating disease model, which has suggested association 
between this cytokine and re/myelination (Gudi et al., 2011). In parallel with that, 
subcutaneous CNTF injection at the remyelination phase of the same animal model has 
shown increased myelin oligodendrocyte glycoprotein (MOG) expression in cerebral 
cortex (Salehi et al., 2013). Moreover, intraperitoneal injections of CNTF and 
intravenously transplanted mesenchymal stem cells that overexpress CNTF have both 
led to reduced loss of neurons and disease severity, and increased neuronal functional 
recovery in EAE mice, an animal model for multiple sclerosis (Kuhlman et al., 2006; Lu 
et al., 2009).  
Pro-inflammatory cytokines have been seen to play roles in many CNS pathologies 
(reviewed in Schmitz et al., 2009). For instance, IL-1β, IL-6, IL-18, and IFNγ cytokine 
levels are related with the development or presence of white matter disease and 
impaired neurologic development in preterm infants. IL-1β, IL-6, and TNFα take place 
among induced cytokines upon the inflammatory response initiated in cerebral 
ischemia. Additional cytokines such as IL-1β, IL-6, IL-8, TNFα, IL-4, and IL-10 are 
observed in traumatic CNS injury. Positive correlation can be seen for some of these 
pro-inflammatory cytokines with the severity of disease symptoms; e.g., TNFα 
expression in MS lesions is linked to clinical course; and the concentrations of IL-6 in the 
serum and cerebrospinal fluid (CSF) of acute stroke patients are associated with brain 
infarct volume and stroke severity. As discussed by Schmitz et al. (2009), cytokines can 
present both beneficial and detrimental effects in CNS pathophysiology and lead to cell 
damage and death on one hand, and promote tissue repair on the other. 
1.4.4 The chemokines and their roles in the CNS 
Chemokines are usually associated with the immune system due to their ability to 
regulate cell trafficking of immune system cells. However, constitutively expressed 
chemokines have been detected in healthy CNS in addition to inflammatory chemokines 
that can either be secreted by activated glial cells, mainly astrocytes and microglia, or 
by leucocytes that enter the CNS upon a CNS injury. All of these homeostatic and 
inflammatory chemokines belonging to four classes (C, CC, CXC, and CX3C) generate a 
complex signaling network together with their receptors, many of which have been 
shown to be promiscuous and to lead to chemokine redundancy (Fig 1.7).   
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Constitutive CNS expressions have been reported for several chemokines including CCL2, 
CCL3, CCL19, CCL21, CXCL12, and CX3CL1 (reviewed in Jaerve and Muller, 2012). 
Cellular sources for such chemokines appear to be activated/reactive astrocytes and/or 
microglia, endothelial cells, and/or neurons, which also express corresponding 
receptors. Depending on the severity of the injury, expressions of chemokines and 
chemokine receptors can be up-regulated in the CNS within minutes to hours and 
remain for several days after trauma. Many chemokines such as CCL2-5, CCL7-8, CCL12, 
CCL20-21, CXCL1-3, CXCL5, CXCL8, CXCL10, CXCL12, and CX3CL1 have been shown to be 
up-regulated in spinal cord injury, traumatic brain injury and/or stroke (Jaerve and 
Muller, 2012).  
The lymphoid chemokines, CCL19, CCL21, and CXCL13, can also be induced in the CNS 
upon inflammatory processes such as autoimmune demyelinating disease or non-
inflammatory insults in addition to their role in the development and maintenance of 
secondary lymphoid tissues (reviewed in Lalor and Segal, 2010). Increased glutamate 
mediated excitotoxicity in ischemia is suggested to stimulate neuronal production and 
secretion of CCL21, which in turn activates microglia. In addition to their suggested 
protective roles in CNS infections, the lymphoid chemokines have been proposed to take 
part in lymphocyte recruitment, B cell maintenance or expansion, and microglial 
activation/ chemotaxis in MS. Elevated chemokine expressions have been detected in 
EAE spinal cords in parallel with clinical relapses and chronic progression and in both 
active and inactive MS lesions. While CCL19 and CCL21 are constitutively expressed in 
cerebrovascular endothelium and choroid plexus and are responsible for the immune 
surveillance of the subarachnoid and perivascular spaces of healthy CNS; CXCL13 
presence is in the CNS detected upon autoimmune demyelination. Infiltrating myeloid 
dendritic cells are suggested as possible cellular source for this chemokine that presents 
increased expression during EAE relapses and possibly contributes to encephalitogenic T 
cell migration towards dendritic cells in the CNS (McMahon et al., 2005; Bagaeva et al., 
2006). Both CXCL13 deficiency and neutralisation reduce the severity of EAE early 
clinical course. Several other chemokines and their receptors are expressed in EAE 
and/or MS, where they are suggested to mediate trafficking of inflammatory cells in the 
CNS, regulate the migration of regulatory cells, and/or restrict the spreading of the 
inflammation (reviewed in Hamann et al., 2008). Therefore, chemokines appear to be 
beneficial with their homeostatic immune surveillance and clearance of immune 
infections; while, they may show detrimental effects with their ectopic expressions in 
CNS injury or autoimmune demyelination.  
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Figure 1. 7 A list of chemokines and their receptors.                      
Currently known chemokines are listed above with their old acronyms (on the left) and their names based on 
the new nomenclature (in the middle). A chemokine receptor (on the right) can bind more than one chemokine 
and a chemokine can signal through multiple chemokine receptors as shown in the figure. This is associated 
with the redundancy observed in functions of the chemokine system. The image was taken from Borroni et al., 
2006.  
 
1.5 The use of ‘omic’ studies to detect the differential 
mechanisms in distinct astrocyte phenotypes 
‘Omic’ technologies provide detailed information about different molecules that make 
up a cell. They can be categorised as genomics, transcriptomics, proteomics, and 
metabolomics that target the universal detection of genes, mRNA, proteins and 
metabolites, respectively, in a specific biological sample (Horgan and Kenny, 2011). 
They can be integrated to form systems biology, which usually would require 
collaborations between investigators from different research areas or can be followed 
individually to obtain insights about one particular complex system at a time. Two 
examples, transcriptomics and metabolomics, will be explained in more detail below in 
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their relation to distinguishing different astrocyte phenotypes; whereas, genomics and 
proteomics will be skipped as they are beyond the scope of this thesis.   
1.5.1 Transcriptomics 
The transcriptome reflects the genes that are actively expressed at any given moment 
in the cells analysed. Currently, a high-scale analysis is carried out by means of gene 
expression microarrays that allow the observation of changes in expressions of 
thousands of genes in one experimental run. The microarrays consist of basically probes 
that are attached on glass slides, often named chips. The probes could be in the form of 
complementary DNA (cDNA) or an oligonucleotide, both of which allow the binding of 
the sample cDNA to assess the amount of mRNA for each gene in a specific condition 
compared to that in a control condition. Because of the very high numbers of variables 
in microarray experiments, the statistics become more complicated and the possibility 
of false positives increases. Therefore, the microarray gene expression profiling 
analyses are usually followed by other experiments such as real-time PCR in an attempt 
to validate those changes in gene expressions. Some other validating experiments can 
also be preferred depending on the purposes of the investigation, for which the 
examples will be given below.  
Microarrays have been utilised to identify astrocytic markers that present either very 
low or no expression in other cell types such as oligodendrocytes and neurons, isolated 
from mouse forebrain (Cahoy et al., 2008) or olfactory ensheathing cells and Schwann 
cells from rats (Vincent et al., 2005). Astrocytes positive for ALDH1L1 and GLT1, two 
astrocytic markers, have also been compared by means of microarray gene expression 
profiling analysis, which presented highly similar expression profiles for astroglial genes 
but also showed the expression of some neuronal genes in GLT1 positive astrocytes 
(Yang et al., 2011). Differences have also been observed between cultured astrocytes 
that were plated on either poly-l-lysine (PLL)-coated or tenascin C (TnC)-coated glass 
coverslips (Nash et al., 2011b). Because PLL-astrocytes have been shown to be more 
supportive for myelination in embryonic rat spinal cord myelinating cultures compared 
to TnC-astrocytes, the differentially expressed genes between PLL- and TnC-astrocytes 
have been associated with regulation of myelination. After selecting several candidates 
to continue to work with, the expressional change has been validated for Cxcl10 that 
was up-regulated in TnC-astrocytes. The follow-up in vitro studies also presented 
decreased levels of myelination in the presence of CXCL10 treatment and increased 
myelination levels in cultures with TnC-astrocytes that were treated with anti-CXCL10 
neutrilising antibodies, both of which validated the results of the microarray (Nash et 
al., 2011b). 
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Astrocytes with different properties can also be studied using other strategies. 
Cytokine-treated cultured human astrocytes, which were isolated from healthy adult 
donors, have been compared against their controls using a lower-scale cDNA array that 
contained probes for a relevant functional group of 268 genes encoding cytokines, 
chemokines, growth factors and their receptors (Meeuwsen et al., 2003). The genes that 
were induced by pro-inflammatory cytokines (TNFα, IL-1β, or IFN-γ) have been listed in 
a way presenting the fold changes for all three separate treatments to provide basis for 
future studies.  On the other hand, Zamanian et al. (2012) have carried out a more 
extensive study using reactive mouse astrocytes isolated at various time points after the 
onset of ischemic stroke or neuroinflammation induced by middle cerebral artery 
occlusion or intraperitoneal LPS injection, respectively. The heat map, generated by 
hierarchical clustering using the genes that were differentially expressed between the 
astrocytes from the two injury models, suggested that these astrocytes could present 
different expression profiles despite the presence of reactive gliosis in both types of 
CNS damage. They have identified two reactivity markers based on the most highly 
increased expressions in both injury models and have validated the results by 
immunohistrochemistry. The lists of top 50 changes in astrocytes from the two injuries 
compared to their controls and Gene Ontology grouping of these genes have provided 
further insights into understanding the common and differential mechanisms between 
reactive astrocytes from distinct CNS traumas.  
1.5.2 Metabolomics 
The information obtained from transcriptomics can provide the basis for a targeted 
metabolomics study investigating the differences between distinct astrocyte 
subpopulations or between astrocytes and other CNS cell types (Lovatt et al., 2007). A 
microarray gene expression profiling analysis has shown enhanced expression of genes 
encoding glycogenic and glycolytic enzymes in mouse cortical astrocytes, which has lead 
to mass spectrometry analysis to detect the levels of radioactively-labelled glucose-
derived metabolites (Lovatt et al., 2007). The results from microarray and mass 
spectrometry experiments have confirmed each other in that particular study, where 
active oxidative metabolism has been identified and validated in protoplasmic 
astrocytes.  
Another metabolomics approach has been applied on lipid samples isolated from whole-
brain extracts from neonatal and adult mice (Camargo et al., 2012). Transgenic mice 
that lacked the astrocytic expression of SCAP (sterol regulatory element-binding protein 
cleavage-activating protein) have been used to observe the effects of the inhibition of 
astrocytic lipid synthesis. Lipid chromatography tandem mass spectrometry (LC-MS/MS) 
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has played role in the detection of relative levels of different types of lipids and fatty 
acids between wild type and conditional knockout animals. Therefore, this method has 
not only formed a way to validate the suppression of lipid synthesis in vivo but has also 
provided detailed information about astrocyte lipid metabolism.  
It is also possible to follow untargeted analytical methods in metabolomics if different 
conditions are compared without extensive knowledge of which metabolites could be 
expressed in certain cell types and/or under certain conditions (reviewed in Dunn et al., 
2012). The samples collected from the cells and the spent medium of astrocyte cultures 
can be analysed with LC-MS/MS to reveal several hundreds of putative metabolites that 
could highlight the differences between quiescent and reactive astrocytes or between 
astrocytes with other distinctive properties. Such a study has not been published yet to 
my knowledge.  
1.6 Conclusions 
Astrocytes are now accepted to present a continuum of phenotypes ranging from 
quiescent to reactive. Even though reactive astrocytes are mostly associated with 
various CNS pathologies, they have been shown to exhibit beneficial roles in addition to 
their previously established detrimental effects. The mechanisms that lead a specific 
astrocyte reactivity phenotype to exert protective and stimulatory or inhibitory roles 
under particular conditions are not yet fully understood. Cytokines and chemokines 
appear to be important regulators of astrocyte activation, which is usually observed as 
increased GFAP and nestin expression in astrocytes, cell hypertrophy, and increased cell 
proliferation rate. Regardless of the fact that whether these morphological changes 
appear or not, these signaling molecules and other environmental changes such as the 
use of a different cell culture-adhering substrate can still alter the astrocyte properties 
and allow them to be supportive or cause them to be inhibitory depending on 
circumstances (Nash et al., 2011b). Therefore, it would be crucial to find out what 
explicit changes occur in astrocytes in relation to their positive or negative roles. Once 
identified, these mechanisms could later be exploited for therapeutic discoveries to be 
used in neurodegenerative diseases like multiple sclerosis, where there is a dynamic 
regulation of extracellular matrix and cytokine secretion.    
1.7 Aims 
The main aim of this thesis is to address how various astrocyte phenotypes can influence 
myelination and identify their mechanism of action. This will be carried out by 
continuing previous studies on microarray gene profiling (Array 1) of various phenotypes 
 
 
41 
 
of monocultures of astrocytes with the addition of complex neuronal cultures plated on 
top (Array 2). Thus we are now considering how the crosstalk of neural cells can affect 
astrocyte gene expression.    
i) To address if any identified proteins are important in the astrocyte regulation for 
myelination, genes identified in the array will be validated in our embryonic rat spinal 
cord myelinating cultures.  
ii) To identify mechanism of action of CNTF on astrocyte reactivity and myelination, we 
will use a web-based program that will identify putative transcription factors involved 
in the transcriptional regulation of the molecules detected in Array 2.  
iii) To address if CNTF plays a role in astrocyte metabolism, lipid chromatography 
tandem mass spectrometry will be carried out using samples from astrocyte monolayers 
plated on different coating substrates (PLL or TnC).
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Chapter 2  
 
Materials and Methods 
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2.1 Animals and animal care 
All experimental animals were bred at the facility of University of Glasgow Biological 
Services (UGBS). All procedures were carried out in accordance with the guidelines, set 
forth by the Animal Scientific Procedures Act, under a project license (No: 6003895) 
granted by the UK Home Office with the approval of the University of Glasgow Ethical 
Review Process Applications Panel. Sprague Dawley (SD) rats and C57BL/6 mice were 
bred and killed according to UK Home Office standards by the trained staff of UGBS. 
The animals used for the experiments were either time-mated and embryos were 
collected on embryonic day 13.5 (E13.5) or 15.5, the day of plugging being E0.5, or 
were dissected at postnatal day 1 (P1).  
All Sprague Dawley rats used were wild type. C57BL/6 mice consisted of three 
genotypes, one of them being the wild type and the other two both carrying the Gp130 
gene, flanked by two loxP sites that would allow the binding of Cre recombinase to 
these sites and hence the excision and inactivation of the target gene (Lakso et al., 
1992; Betz et al., 1998; Bajenrau et al., 2002; Drogemuller et al., 2008). One strain was 
GFAP-Cre-/-gp130fl/fl, which did not contain the expression of Cre recombinase; 
whereas, GFAP-Cre+/-gp130 fl/fl mice showed constitutive Cre recombinase expression, 
controlled by Gfap promoter, and thus had their astrocytic Gp130 gene inactivated 
(Haroon et al., 2011). GFAP-Cre-/-gp130 fl/fl mice were used as controls compared to 
GFAP-Cre+/-gp130fl/fl mice in the experiments as these animals have been shown to 
resemble the wild type phenotype (Drogemuller et al., 2008; Haroon et al., 2011). 
Gp130fl/fl colonies were maintained by breeding GFAP-Cre-/-gp130fl/fl with GFAP-Cre+/-
gp130fl/fl animals (Fig 2.1). The colony was started using animals, obtained from 
Schluter Lab, Germany (Institut für Medizinische Mikrobiologie, Otto-von-Guericke 
Universität Magdeburg, Leipziger).   
2.2 Cell culture 
All cultures were maintained in a humidified incubator at 37oC of 7% CO2/93% air. All 
media and reagents were filtered through a 0.22 µm filter.  
2.2.1 Neurosphere-derived astrocyte cultures 
Neurospheres were generated using the dissociated striata of Sprague Dawley rats aged 
16-36 hours (Postnatal day 1). The tissue was mechanically dissociated using a glass 
Pasteur pipette in 1-2 ml of L-15 media (Invitrogen, Paisley, UK). The suspension was  
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Figure 2. 1 C57BL/6 gp130fl/fl mouse colony was maintained by crossing GFAP-Cre+/-
gp130fl/fl with GFAP-Cre-/-gp130fl/fl.                                      
Astrocytic gp130 knockout (KO) mice were bred as shown above so that a litter would provide both the Cre 
recombinase (-) controls and the Cre recombinase (+) KO mouse pups. Cre-lox recombination system, used 
to generate astrocytic gp130 KO mice, allows the site-specific nucleotide sequence excision to inactivate a 
target gene. This system was targeted to function in astrocytes under the control of Gfap promoter and the 
Gp130 gene was flanked with two loxP sites. The Cre recombinase enzyme in the astrocytes of GFAP-Cre+/-
gp130fl/fl mice would, thus, inactivate the Gp130 gene; whereas, this inactivation could not take place in 
GFAP-Cre-/-gp130fl/fl control mice due to the lack of Cre expression. GFAP-Cre+/-gp130fl/fl mice and GFAP-
Cre-/-gp130fl/fl mice were crossed to provide new generations, where the possibility of obtaining the animals 
from each genotype was 50% as seen in the diagram. GFAP: glial fibrillary acidic protein. 
 
 
then centrifuged at 800 rpm (136 RCF) for 5 min. The pellet was resuspended in 1-2 ml 
of neurosphere media (NsM) consisting of Dulbecco’s Modified Eagle Medium:Nutrient 
Mixture F-12 supplemented with other reagents seen in Table 2.1. The cell pellet was 
then mechanically dissociated again with a glass Pasteur pipette and placed into a 75 
cm3 tissue culture flask (Greiner, Gloucestershire, UK) containing 20 ml of NsM. The cell 
suspension was supplemented with 20 ng/ml recombinant human epidermal growth 
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factor (EGF, R&D Systems). Every 2 days, 5 ml NsM and 4 µl EGF (20 ng/ml) were added 
into the flask. When 60-70% of spheres were large enough (>200  µm), the spheres were 
differentiated into astrocytes as described by Thomson et al. (2006). Briefly, the 
spheres were plated onto poly-L-lysine-coated-coverslips (13 mm diameter, VWR 
International, Leicestershire, UK) with 10% FBS in DMEM  (Table 2.1) for 5-10 days until 
a confluent monolayer formed. The coverslips were coated either with poly-L-lysine 
(PLL) or tenascin C (TnC). For PLL-coating, the coverslips were kept in PLL solution 
(13.3 µg/ml in distilled water, Sigma) for 1-24 hr at 37oC, washed in distilled water and 
left to air dry in the tissue culture hood before being used. For TnC-coating, each 
coverslip was incubated in 75 µl of TnC solution (5 µg/ml, CC065, Millipore) for 1-2 hr at 
37oC. TnC solution was then removed and the coverslips were left to dry. For 
experiments that would compare PLL and TnC conditions, PLL-coated coverslips were 
also prepared using 75 µl of PLL solution per coverslip but the coverslips were washed 
with PBS unlike TnC-coated coverslips. 
A modified version of the above-mentioned protocol was followed when tissue from 
gp130fl/fl neonatal mice were used because cultures had to be made from single pups 
prior to genotyping. Since the genotype from each pup from a litter of the breeding of 
GFAP-Cre-/-gp130fl/fl with GFAP-Cre+/-gp130fl/fl could not be known until tissue was 
genotyped by PCR, each striatal tissue had to be treated in separate microcentrifuge 
tubes due to the possibility of their genotypes being different from one another. Thus 
mechanical dissociation of the tissue samples was carried out using a 21-gauge (G) 
needle in 1 ml of L15 as this was more practical when dealing with an increased number 
of microcentrifuge tubes. The samples were centrifuged in a microcentrifuge, where 
centrifugation at 1200 rpm for 6 min generated less delicate pellets. The samples were 
then resuspended in 1 ml of L15 media again using a 21G needle. This 1 ml of cell 
suspension and 1 µl of EGF were added into 4 ml of NsM in 25 cm3 tissue culture flask. 
The cultures were fed with 1 ml of fresh NsM and 1 µl of EGF every 2 days until the 
spheres were large enough to be used for the next stage of cell plating (5-9 days). The 
coverslips to be coated with astrocytes were coated with PLL solution, prepared using 
boric acid (0.25% boric acid and 0.38% sodium tetraborate in distilled water, all from 
Sigma) instead of water (13.3 µg/ml PLL, Sigma). This is believed to be more optimal 
for mouse cell attachment. 
The astrocyte cultures were treated with various reagents by removing 250 µl of their 
culture medium and replacing it with 250 µl of fresh medium containing appropriate 
reagent at a concentration, twice the amount intended, to account for dilution once 
added to the total volume each coverslip was maintained in. For example, if cultures  
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Table 2. 1 The list of principal medium types and their ingredients used for cell culture. 
Medium	  	   Ingredients	   Source	  
Neurosphere	  
Medium	  (NsM)	  
Dulbecco’s	   Modified	   Eagle	   Medium:Nutrient	   Mixture	   F-­‐12	  
(DMEM/F12	  containing	  3,151	  mg/L	  glucose,	  #21331)	  
Life	  Tech.	  
0.1%	   NaHCO3,	   2	   mM	   L-­‐glutamine,	   5,000	   IU/ml	   penicillin,	   5	  
µg/ml	   streptomycin,	   5	   mM	   HEPES,	   0.01%	   bovine	   serum	  
albumin	  	  	  
Life	  Tech.	  
0.6%	   glucose	   (#G7021),	   25	   µg/ml	   insulin,	   100	   µg/ml	  
apotransferrin,	   60	   µM	   putrescine	   (P-­‐7505),	   20	   nM	  
progesterone	  (P-­‐6149)	  and	  30	  nM	  sodium	  selenite	  (S-­‐9133)	  
Sigma	  
10%	   FBS	   in	  
DMEM	  	  
low	  glucose	  (1000	  mg/L)	  DMEM	  (#21885-­‐025)	   Life	  Tech.	  
10%	  foetal	  bovine	  serum,	  2	  mM	  L-­‐glutamine	   Sigma	  
Plating	  
Medium	  (PM)	  
50%	   high-­‐glucose	   (4,500	   mg/L)	   DMEM	   (#41966),	   25%	   horse	  
serum	  (#26050-­‐088),	  25%	  Hank’s	  Balanced	  Salt	  Solution	  (HBSS,	  
#14170-­‐088)	  
Life	  Tech.	  
Differentiation	  
Medium	  (DM)	  
high-­‐glucose	  (4,500	  mg/L)	  DMEM	  (#41966)	  	   Life	  Tech.	  
10	  ng/ml	  biotin,	  50	  nM	  hydrocortisone,	  0.5	  mg/ml	  insulin,	  and	  
0.5%	   hormone	   mixture	   (1	   mg/ml	   apotransferrin,	   20	   mM	  
putrescine,	   4	   μM	   progesterone	   and	   6	   μM	   selenium,	  
formulation	  based	  on	  N2	  mix	  of	  Bottenstein	  and	  Sato,	  1979)	  
Sigma	  
The table shows the ingredients of neurosphere medium (NsM), 10% FBS in DMEM, plating medium (PM) 
and differentiation medium (DM). NsM is used to culture striatum-derived neurospheres and 10% FBS in 
DMEM is a medium for the maintenance of neurosphere-derived astrocyte cultures. Embryonic spinal cord 
myelinating cultures are initiated in PM and are maintained in DM from then on. The catalogue numbers and 
the company source are also presented above for the reagents. DMEM: Dulbecco’s Modified Eagle Medium; 
FBS: foetal bovine serum; Life Tech.: Life Technologies. 
 
were going to be treated with 10 ng/ml of a reagent, a solution was prepared at 20 
ng/ml and 250 µl of that was added into each well during the treatment.  
2.2.2 Embryonic spinal cord myelinating cultures 
The method of generating myelinating embryonic mixed spinal cord cultures is based on 
that developed for mice (Thomson et al., 2008) and rat cultures (Sorensen et al., 2008). 
The spinal cords of embryonic day 15.5 (E15.5) SD rats or E13.5 C57BL/6 wild type mice 
were dissociated and the meninges were removed before placing the tissue in a bijou 
containing L-15 on wet ice. The spinal cords (4-5) were dissociated mechanically using 
Pasteur pipettes and then enzymatically using trypsin (100 µl of 2.5%, Invitrogen, 
Paisley, Scotland) and collagenase (100 µl of 1.33%, ICN Pharmaceuticals, UK) for 15 min 
at 37oC. Enzymatic activity was stopped by adding 1 ml of a solution containing 0.52 
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mg/ml soybean trypsin inhibitor (T-9003), 3.0 mg/ml bovine serum albumin (A2153) and 
0.04 mg/ml DNase (D-4263, all from Sigma).  The cells were triturated using a Pasteur 
pipette and centrifuged at 1200 rpm for 5 min. The cell pellet was resuspended in 
plating medium (PM, Table 2.1). The coverslips, covered in a confluent monolayer of 
astrocytes, were placed in a dry 35 mm Petri dish and the mixed spinal cord cell 
suspension was plated on top as a droplet at a density of 150,000 cells per 100 µl. Two 
coverslips were placed in each dish and they were incubated at 37oC for 2 hours to allow 
for stable attachment.  A mixture of 400 µl of PM and 600 µl of differentiation medium 
(DM, Table 2.1) was added into each dish. The insulin was removed from DM after 12 
days in culture to prevent excessive proliferation of non-myelinating oligodendrocytes 
that could obscure the myelin sheaths (Thomson et al., 2006, 2008). Cultures were fed 
every other day by removing 400 µl of media and replacing it with fresh 500 µl DM to 
avoid the possible decrease in volume of medium that could occur over time due to 
evaporation at 37oC. The cultures were maintained for 24-28 days in vitro (DIV). 
This protocol was also modified for generation of myelinating cultures of spinal cord 
tissue from C57BL/6 gp130fl/fl mouse embryos (E13.5) as each embryo obtained from the 
same litter would have to be treated separately since they could not be genotyped until 
the myelinating cultures were set up. Each spinal cord was placed in 500 µl of L15 
media. Mechanical dissociations and titrations were made using 1000 µl and 200 µl 
pipette tips respectively. Enzymatic dissociation was stopped by adding 500 µl of the 
solution containing soybean trypsin inhibitor, bovine serum albumin and DNase solution. 
The samples were centrifuged using a microcentrifuge at 1200 rpm for 6 min. The cell 
suspension, ready to be used in plating medium, was either plated on glass coverslips, 
previously coated with PLL, dissolved in boric acid buffer, or on coverslips, each 
containing a confluent monolayer of GFAP-Cre-/-gp130fl/fl or GFAP-Cre+/-gp130fl/fl  
mouse astrocytes. Immediately after adding a mixture of PM and DM media into the 
Petri dish, the coverslips were pressed down gently at the edges using a 200 µl pipette 
tip to avoid them from floating later on. The process was repeated 2 days later, during 
the second feeding of the cultures. If any coverslips were seen to float from then on, 
they were again pinned down using a pipette tip. 
The embryonic spinal cord myelinating cultures were treated with various reagents 
starting from 12 DIV, by removing 400 µl of the used medium and replacing it with 500 
µl of fresh medium containing such a reagent at the appropriate concentration, 2.4 fold 
of the amount intended, as it would be halved once dissolved in the total volume in the 
dish (1.2 ml).   
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2.2.3 Oligondendrocyte cultures 
Cortical astrocytes were isolated from cerebral cortices of 1 day old SD rats as 
described in Noble and Murray (1984). Briefly, the cortex was dissected from P1 pups 
and enzymatically dissociated. The cells were maintained in 10% FBS in DMEM (Table 
2.1) and grown to confluency in a 75 cm3 flask for 5-8 days. The flasks were shaken at 
37oC for 4-5 hours to remove the more lightly attached oligodendrocyte precursor cells 
(OPCs). The detached cells were removed from the intact astrocyte monolayer and 
placed into a 15 cm Petri dish and incubated at 37oC for 15 min to allow the microglia to 
attach to the dish. The remaining cell suspension was then centrifuged at 1200 rpm for 
3 min. The pellet was resuspended in 2.5 ml of DMEM-BS media (Bottenstein and Sato, 
1979) containing 10 ng/ml of PDGF and 10 ng/ml of FGF2 (both from Peprotech, UK), 
known OPC mitogens (Bogler et al., 1990). The cells were plated onto PLL-coated 
coverslips in a 24-well plate at a volume of 100 µl and incubated at 37oC for 15 min to 
allow the cells to attach. Then an additional 400 µl of DMEM-BS media with PDGF and 
FGF2 was added into each well. The cells were fed every other day. The growth factors 
were removed from the media for some of the cells after 4-5 days so as to treat with 
various reagents. The cells were fed every other day for 8 days by removing 250 µl of 
the original media and replacing it with 250 µl of fresh media. OPC cultures were 
treated with various reagents as described in the treatment of astrocyte cultures 
(Section 2.2.1). 
2.2.4 Reagents used for treatments  
Astrocytes, oligodendrocytes and embryonic spinal cord myelinating cultures were 
treated with various reagents. These are rat recombinant CNTF (#557-NT-010, R&D 
Systems, USA), anti-CNTF neutralising antibody (MAB557, R&D Systems), recombinant 
rat CCL2 (3144-JE-025/CF, R&D Systems), recombinant rat CCL7 (CHM-280, Prospec, 
USA), recombinant human CTGF (#120-19, Peprotech, UK), and recombinant human 
SERPINB2 (ab69515, Abcam, UK).  
2.3 Immunocytochemistry 
Coverslips, on which cells were plated, were taken out of 24-well plates or 35 mm 
dishes using forceps and excess media was blotted against tissue paper and placed on a 
staining tray which lifts the coverslip off the surface and is receptive for a small amount 
of antibody for staining. For cell surface markers, antibodies were diluted in culture 
media; whereas, for intracellular markers antibodies were diluted in blocking buffer 
(BB) consisting of 0.1% Triton-X-100 and 0.2% gelatine in PBS. If only external markers 
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were used, cells were treated first with primary antibodies followed by fluorochrome 
labeled class specific secondary antibodies, each step for 20 min, followed by mounting 
in Vectashield with or without DAPI. If intracellular markers were to be used in 
combination with a cell surface marker, after the treatment with its class specific 
antibody cells were fixed and permeabilised with ice cold methanol at -20oC for 10 min. 
Some primary antibodies required fixation with 4% paraformaldehyde (Para, Table 2.2), 
which was then followed by permeabilisation with 0.5% Triton-X-100 for 15 min. Cells 
were blocked in BB for 15 min. Primary antibodies of internal markers were incubated 
for 40-60 min and secondary fluorochrome class specific antibodies were incubated for 
30-40 min. The coverslips were then mounted in Vectashield. All the reagents and 
antibodies were added as 50 µl onto each coverslip at room temperature (RT) unless 
otherwise stated. Coverslips were washed between each subsequent staining step 2-3 
times in PBS. The primary and secondary antibodies used are listed in Tables 2.2 and 
2.3. 
Table 2. 2 The list of primary antibodies used for immunocytochemistry. 
Antigen	   Raised	  in	   Istotype	   Dilution	   Fixation	  method	  
Internal/	  
cell	  surface	   Source	  
A2B5	   Mouse	   IgM	   1:1	   n/a	   Cell	  surface	   Hybridoma	  
PLP	  (AA3)	   Rat	   IgG	   1:100	  
4%	  Para/	  
ice	  cold	  
methanol	  
Internal	   Hybridoma	  
GFAP	   Rabbit	   IgG	   1:500	  
4%	  Para/	  
ice	  cold	  
methanol	  	  
Internal	   DAKO	  
MOG	   Mouse	   IgG2a	   1:100	   n/a	   Cell	  surface	   Hybridoma	  
MBP	   Mouse	   IgG2a	   1:100	  
Ice	  cold	  
methanol	   Internal	   Hybridoma	  
Nestin	   Mouse	   IgG1	   1:200	  
Ice	  cold	  
methanol	   Internal	   Abcam	  
O4	   Mouse	   IgM	   1:1	   n/a	   Cell	  surface	   Hybridoma	  
SMI-­‐31	   Mouse	   IgG1	   1:1500	  
4%	  Para/	  
ice	  cold	  
methanol	  
Internal	   Covance	  
Table of the primary antibodies used to detect the listed antigens for immunocytochemistry with animal 
species they were raised in, their isotypes, the optimum dilution of use, the fixation method, the type of 
detection they would provide (internal or external) and the company they were purchased from. Some primary 
antibodies could be fixed using 4% Para or ice cold 100% methanol, both of which revealed similar results. 
A2B5: oligodendrocyte progenitor marker; GFAP: glial fibrillary acidic protein; Ig: immunoglobulin; MBP: 
myelin basic protein; MOG: myelin oligodendrocyte glycoprotein; n/a: not applicable; O4: oligodendrocyte 
marker; Para: paraformaldehyde; PLP: myelin proteolipid protein; SMI-31: phosphorylated neurofilament.  
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Table 2. 3 The list of secondary antibodies used for immunocytochemistry. 
Antibody	   Conjugate	   Dilution	   Source	  
Goat	  anti-­‐mouse	  IgG1	   Alexa	  Fluor:555	   1:600	   Molecular	  Probes	  
Goat	  anti-­‐mouse	  IgM	   Alexa	  Fluor:555	   1:600	   Molecular	  Probes	  
Goat	  anti-­‐rat	  IgG	   Alexa	  Fluor:488	   1:600	   Molecular	  Probes	  
Goat	  anti-­‐rat	  IgG	   FITC	   1:100	   Southern	  Biotech	  
Goat	  anti-­‐mouse	  IgM	   TRITC	   1:100	   Southern	  Biotech	  
Goat	  anti-­‐mouse	  IgG2a	   FITC	   1:100	   Southern	  Biotech	  
Goat	  anti-­‐rabbit	  IgG	   FITC	   1:100	   Southern	  Biotech	  
Shown in the table are the secondary antibodies used in immunocytochemistry. They were conjugated to the 
fluorochromes to allow indirect visualisation of the antigens using fluorescent microscopy. Their optimum 
dilution and company source are also listed in the table. FITC: fluorescein isothiocyanate; Ig: immunoglobulin; 
TRITC: tetramethylrhodamine.  
 
2.4 Microarray gene expression profiling 
2.4.1 Sample description 
Embryonic rat spinal cord myelinating cultures (Section 2.2.2) were used for microarray 
gene expression profiling. These cultures were plated on astrocytes, seeded either on 
PLL- or TnC-coated coverslips. At 12 DIV, they were either fed with standard medium 
(control) or treated with recombinant rat CNTF (1ng/ml, R&D systems, 557-NT-010) and 
total RNA was extracted from these cultures 4 hr or 24 hr after the feeding or the 
treatment. Thus, 8 different conditions were generated to test: 1) PLL-control-4 hr, 2) 
PLL-CNTF-4hr, 3) TnC-control-4hr, 4) TnC-CNTF-4hr, 5) PLL-control-24 hr, 6) PLL-CNTF-
24hr, 7) TnC-control-24hr, 8) TnC-CNTF-24hr. The cultures were generated and 
maintained by Dr. Besma Nash in three biological replicates. 
2.4.2 RNA extraction 
Total RNA was extracted from embryonic rat spinal cord myelinating cultures 4 hr and 
24 hr after standard medium feeding or CNTF-treatment using a Qiagen Kit. The samples 
were then frozen at -20oC in RNAse free microcentrifuge tubes. The RNA extraction was 
performed together with Dr. Besma Nash.  
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Figure 2. 2 A microarray gene expression profiling analysis was carried out using 
embryonic rat spinal cord myelinating cultures, at different conditions.                           
The spinal cords of E15.5 Sprague Dawley rat embryos were mechanically and enzymatically dissociated and 
seeded on astrocyte monolayers, plated on coverslips coated with PLL or TnC.  After 12 days in vitro some of 
these cultures were additionally treated with 1 ng/ml of recombinant rat CNTF while sister cultures were fed 
with standard medium. Total RNA was extracted from these cultures 4 hr and 24 hr after the standard medium 
feeding or CNTF treatment. Using the RNA samples, biotinylated cRNA samples were prepared for microarray 
gene expression profiling analysis. The analysis of differentially expressed transcripts between cultures at 
different conditions provided suggestions for potential regulators of myelination. The cultures were prepared in 
three biological replicates. CNTF: ciliary neurotrophic factor; PLL: Poly-L-lysine; TnC: Tenascin C. 
 
2.4.3 Checking the RNA integrity 
The integrity of the total RNA from these samples was assessed using the Agilent 2100 
Bioanalyser before the process of RNA amplification and biotinylation. Agilent 2100 
Bioanalyser uses microfluidics/capillary electrophoresis to analyse nucleic acids. It 
compares the fluorescence of the sample, to which an RNA-specific dye has been added, 
with that of a standard. High quality total RNA is presented with the presence of two 
distinct bands for 28S and 18S subunits, with a ratio of 2:1, respectively, in the 
electropherograms (see Fig 2.3 for example) obtained from Agilent 2100 Bioanalyser 
analyzing software.  In order to provide a more quantitative data for RNA integrity, a 
software algorithm (Expert 2100 software, starting with Rev 02.01) calculates the RNA 
integrity number (RIN). RIN is not influenced by instrument, sample integration and 
concentration variability. Examples for several RINs are presented in Fig 2.3. The RIN 
values and electropherograms of the total RNA samples used for microarray gene 
expression profiling are shown in Appendix I. The RIN values for our samples ranged 
between 8.9-10.  
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2.4.4 RNA amplification and biotinylation 
RNA was amplified to maximise the complementary RNA (cRNA) yield and biotinylated 
using an Illumina Total Prep RNA Amplification Kit (AMIL1791, Ambion, Life 
Technologies, UK) following the manufacturer’s guideline that included the following 
major steps: Total RNA was reverse-transcribed to synthesize first strand cDNA, the 
second strand cDNA was synthesized following that, cDNA was purified, cDNA was 
transcribed in vitro to synthesize cRNA, and cRNA was purified. cRNA was biotinylated 
during the in vitro transcription (IVT) step. 250 ng of total RNA in 11 µl was used to 
start the RNA amplification process. The purity of biotinylated cRNA samples was 
assessed again using the Agilent 2100 Bioanalyser and its software (Appendix II), where 
the ribosomal contamination can be detected as two distinct peaks as shown in the 
example electropherogram in Fig 2.4. Since the concentration of one particular cRNA 
sample (#8, Appendix III) was very low (13.5 ng/µl) compared to others, the 
amplification and biotinylation steps were repeated for that one sample only (new 
concentration 75 ng/µl) to avoid further expenditure of other total RNA. Because the 
concentration of some cRNA were lower than the required 150 ng/µl for the direct 
hybridisation assay, all the samples were centrifuged in a high-speed vacuum centrifuge 
for 40 (2 x 20) min.  The cRNA integrity was assessed again using the Agilent 2100 
Bioanalyser and the concentrations were measured using a Nanodrop 2000 
spectrophotometer. cRNA concentrations are listed in Appendix III. The 
electropherograms, showing the cRNA quality of the samples before the vacuum 
centrifugation, presented some contamination for two samples (Appendix II, samples #2 
and #12), although this was not considered to be high enough to exclude them in the 
microarray gene expression profiling analysis. Electropherograms after the vacuum are 
not presented, as the Agilent 2100 Bioanalyser does not produce any sensible readings 
at highly increased concentrations such as those above 250-300 ng/µl. Only the 
electropherogram for sample #8 is shown both before and after vacuum centrifugation 
due to the above-mentioned reason (Appendix II).   
2.4.5 Direct hybridisation assay 
Two Sentrix Beadchip RatRef-12 v1 arrays (serial numbers: #5842733044, #5842733065, 
Illumina, USA) were used to carry out the direct hybridisation assay. Each of these gene 
expression Beadchip arrays contain over 22,000 oligonucleotide probes targeting all 
known genes and known alternative splice variants. These probe sequences are 
attached to 3-micron beads that are assembled into the microwells of the BeadChip 
substrate. The main purpose of the direct hybridisation assay is thus to hybridise the 
cRNA sequences to the beads.   
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Figure 2. 3 Examples of RNA integrity using the results obtained from the Agilent 2100 
Bioanalyser.                           
A software algorithm (Expert 2100 software, starting with Rev 02.01) is used to calculate the RNA integrity 
number (RIN) for each RNA sample entered into Agilent 2100 Bioanalyser. A higher RIN presents a sample 
with higher quality. Good quality RNA samples are expected to present two distinct bands 18S and 28S 
subunits, with a ratio of 1:2, respectively. A) Samples with higher RINs present two clear bands for those 
subunits; while, those with lower RINs present less clear bands due to increased RNA degradation. B) The 
expected ratio for the subunits is observed clearly for a RIN of 10; whereas, this ratio is disturbed for lower 
RINs such as 5 and 3. (Image taken from Agilent 2100 bioanalyser, application compendium, 
http://www.chem.agilent.com/Library/applications/5989-3542EN.pdf) 
 
 
 
 
 
 
 
Figure 2. 4 Examples of ribosomal RNA (rRNA) contamination detected by the Agilent 2100 
Bioanalyser in mRNA samples.  
Shown in the image is the analysis of mRNA quality of two commercially available RNA samples by Agilent 
2100 Bioanalyser and its software. A) The contamination with two rRNA subunits present themselves as clear 
peaks in the electropherogram; whereas, B) such peaks are less visible or not existent in samples with less or 
no contamination. (Image taken from Agilent 2100 Bioanalyser, application compendium, 
http://www.chem.agilent.com/Library/applications/5989-3542EN.pdf) 
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The hybridisation process was carried out following the manufacturer’s guidelines. 
Briefly, 10 µl of Hybridisation (Hyb) Mix, provided in the kit, was mixed with 5 µl of 
cRNA at 150 ng/µl. The mixture was heated at 65oC for 5 min and then applied on the 
arrays that have previously been placed in a Hyb Chamber Insert. The samples were 
loaded into the BeadChip arrays in the order shown in Table 2.4 (designed by the 
statistician Dr. John Mcclure, Mcbride Lab, Institute of Cardiovascular and Medical 
Sciences, University of Glasgow) to maximise the randomness in the system to provide a 
higher level of significance in the end. The inserts containing the arrays were then 
loaded into a BeadChip Hyb Chamber. The Chamber lid was closed and locked securely 
and the arrays were left in the 58oC Illumina Hybridisation Oven overnight. The 
following day the coverseal of each array slide was removed and the arrays were 
washed in several steps using ethanol and other washing solutions provided by the 
manufacturer. After the washes, the arrays were incubated with streptavidin-Cy3 for 10 
min at RT to develop the signal provided by hybridisation and washed again. They were 
then dried by centrifugation at 275 rcf for 4 min at RT. Once ready, the BeadChip arrays 
were scanned on the Illumina BeadArray Reader on the same day. Ms. Wendy Crawford 
(Mcbride Lab, Institute of Cardiovascular and Medical Sciences, University of Glasgow) 
was of great help on all steps of the direct hybridisation assay and scanning the arrays. 
Please see the manufacturer’s manual for further details (http://support.illumina.com/ 
content/dam/illumina-support/documents/myillumina/3466bf71-78bd-4842-8bfc-
393a45d11874/wggex_direct_hybridization_assay_guide_11322355_a.pdf).   
Table 2. 4 The order of the biotinylated cRNA samples loaded into the BeadChip Arrays. 
 
BeadChip	  #5842733044	  
	  
	  
BeadChip	  	  	  #5842733065	  
	  	  
	  Lane	   Group	  
Time	  
Point	  
Biological	  
repeat	  (n)	   Lane	   Group	  
Time	  
Point	  
Biological	  
repeat	  (n)	  
1	   PLL	  +	  CNTF	  	   4	  hr	   1	   1	   TnC	  +	  CNTF	   24	  hr	   3	  
2	   TnC	  +	  CNTF	   24	  hr	   1	   2	   TnC	  Control	  	   4	  hr	   2	  
3	   TnC	  Control	  	   4	  hr	   1	   3	   PLL	  +	  CNTF	  	   24	  hr	   2	  
4	   PLL	  Control	  	   4	  hr	   3	   4	   TnC	  +	  CNTF	   24	  hr	   2	  
5	   PLL	  +	  CNTF	  	   24	  hr	   3	   5	   PLL	  Control	  	   4	  hr	   2	  
6	   TnC	  +	  CNTF	   4	  hr	   1	   6	   PLL	  Control	  	   24	  hr	   3	  
7	   TnC	  Control	  	   24	  hr	   1	   7	   PLL	  +	  CNTF	  	   4	  hr	   3	  
8	   PLL	  Control	  	   24	  hr	   1	   8	   TnC	  +	  CNTF	   4	  hr	   2	  
9	   TnC	  +	  CNTF	   4	  hr	   3	   9	   PLL	  Control	  	   24	  hr	   2	  
10	   PLL	  +	  CNTF	  	   24	  hr	   1	   10	   TnC	  Control	  	   4	  hr	   3	  
11	   PLL	  Control	  	   4	  hr	   1	   11	   TnC	  Control	  	   24	  hr	   2	  
12	   TnC	  Control	  	   24	  hr	   3	   12	   PLL	  +	  CNTF	  	   4	  hr	   2	  
Total RNA was isolated from embryonic rat spinal cord cultures plated on astrocyte monolayers on PLL or 
TnC, 4 hr or 24 hr after standard medium feeding (control) or recombinant rat CNTF feeding (+CNTF). The 
cultures were maintained in three biological replicates (n). Total RNA was amplified in means of in vitro 
transcription reactions and was biotinylated using the same RNA amplification kit (AMIL1791, Ambion), the 
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processes of which generated hundreds to thousands copies of biotinylated cRNA. These samples were then 
loaded in the order, shown in the table, into two Sentrix BeadChip RatRef-12 v1 arrays (Illumina) for the direct 
hybridisation assay. This order was designed by Dr. John Mcclure (Univeristy of Glasgow). CNTF: ciliary 
neurotrophic factor.    
 
2.4.6 Analysis of BeadChip data 
Data was quantile normalised in BeadStudio (Illumina, San Diego, USA) and Rank 
Products (RP, Breitling et al., 2004) was used to assess the statistical significance of 
pairwise intergroup differences. A false discovery rate (FDR) cut-off value of 5% was 
used to determine significances by means of FDR multiple testing correction method 
(Benjamin and Hochberg, 1995). Venn diagrams were generated to look at the 
differences in gene expressions between embryonic rat spinal cord myelinating cultures 
at different conditions as explained in detail in Chapter 3.  
2.5 Quantitative real time polymerase chain reaction 
(qRT-PCR) 
2.5.1 RNA extraction 
Total RNA was extracted from primary cell cultures using PureLink RNA Mini Kit 
(Ambion, Life Technologies, UK) following the manufacturer’s guideline. Briefly, cells 
were washed with PBS and then lysed with a Lysis Buffer, included in the kit, containing 
2-mercaptoethanol. This was then homogenised by passing through a 21G syringe needle 
5-10 times, treated with 70% ethanol and the microcentrifuge tubes were flicked to 
disperse any remaining precipitates. Samples were centrifuged in spin cartridges for 
RNA to bind to the filters during the following RNA-purifying, washing steps. Finally, 
total RNA was collected in 14 µl of RNA-se free water and stored at -20oC until future 
use. The concentrations of the samples were measured using the RNA setting of the 
NanoDrop 2000.    
2.5.2 cDNA synthesis 
Total RNA, extracted from the cell cultures as described above, was used as a starting 
material for reverse transcription to generate cDNA. The process was carried out using 
TaqMan Reverse Transcription Reagents kit (N808-0234, Applied Biosystems, Life 
Technologies, UK) and following the manufacturer’s guideline. Basically, 7.7 µl or 15.4 
µl of total RNA was added into a mixture of TaqMAN reverse transcription (RT) buffer, 
magnesium chloride, deoxy nucleoside triphosphates (dNTPs), oligodeoxythymidylic acid 
(oligo-dT) primers (or random hexamers), RNase inhibitor and MultiScribe reverse 
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transcriptase, creating a total volume of 20 µl or 40 µl, respectively, for each reaction 
mix. To increase the cDNA yield, the reactions were prepared mostly in 40 µl even if the 
volumes of the total RNA samples were not large enough, in which case RNA-se free 
water was added to make its volume up to 15.4 µl.  An imporatn point was to insure 
that the total RNA used should not be greater than 2 µg, which was never the case in 
our samples as their concentrations never reached to such high levels. Samples were 
incubated at 25oC for 10 min, at 48oC for 30 min, and at 95oC for 5 min using a 
previously set-up program in Veriti 96-well Thermal Cycler (#9902, Applied Biosystems). 
Their concentrations were measured using the ‘single stranded (ss) DNA’ setting of 
NanoDrop 2000 spectrophotometer. The cDNA samples were stored at -20oC until further 
analysis by qRT-PCR.  
2.5.3 Running the qRT-PCR plate 
qRT-PCR reactions were run in 384-well plates (Axygen PCR-384M2-C-BC,Thistle 
Scientific, UK). Each reaction consisted of 2 µl of TaqMan Gene Expression Master Mix 
(#4369016, Applied Biosystems), 0.25 µl of rat Gapdh endogenous control primer (the 
housekeeping gene, # 4352338E, Applied Biosystems), 0.25 µl of the probe (primer set) 
and 2 µl of the cDNA sample (at 50 ng/µl). All the probes were also from Applied 
Biosystems with the following catalogue numbers shown in brackets: Ccl2 
(Rn00580555_m1), Ccl7 (Rn01467286_m1), Ctgf (Rn01537279_g1), Cxcl11 
(Rn00788262_g1), Cxcl13 (Rn01450028_m1), Lcn2 (Rn00590612_m1), Serpinb2 
(Rn00572553_m1), Thbs2 (Rn02111874_s1), and Wif1 (Rn00586968_m1). A master mix 
was prepared for each probe to speed up the process and to minimise the technical 
variations in the system. Each reaction was run in three technical replicates. Control 
reactions were also prepared, where cDNA was not added, to check whether the probes 
were free of contamination. The 384-well plate then was sealed with an optical 
adhesive film (4360954, Applied Biosystems) and centrifuged briefly at 500-600 rpm for 
40-60 sec. Once ready, it was run using the 7900HT Instrument (Applied Biosystems), 
controlled by the SDS 2.4 software, where real time PCR was carried out with VIC-MGB 
and FAM-MGB dyes selected to show the expressions of Gapdh and the probes, 
respectively. During the run, samples were incubated at 50oC for 2 min, at 95oC for 10 
min and 40 cycles of the following program was performed: 15 sec at 95oC and 1 min at 
60oC.  
2.5.4 Analysing the qRT-PCR data 
Once the qRT-PCR run was completed, data was exported from the SDS 2.4 software in 
Microsoft Excel sheets as Ct (cycle threshold) values. Ct is the number of cycles 
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required for the fluorescent signal to cross the threshold, i.e. to exceed the background 
level. ΔCt value was calculated as the subtraction of the VIC (Gapdh) Ct from the FAM 
(probe) Ct. Then the mean ΔCt was calculated by taking the average of three technical 
repeats per sample. The average of the mean ΔCt values of three biological replicates 
formed another mean ΔCt (mean ΔCt 2 in Table 2.5). Mean ΔCt 2 value for PLL-control-4 
hr cultures was substracted from the mean ΔCt 2 values of other samples to obtain ΔΔCt 
values standardised to PLL-control-4 hr samples. Relative quantification was calculated 
by using the formula “POWER(2, -ΔΔCt)” in Microsoft Excel as seen in Table 2.5. 
Standard error of mean for relative quantification values were calculated separately for 
plus and minus error bars as shown in Table 2.5. One way repeated measures ANOVA 
test was used to determine any possible significance between the three mean 
ΔCt values of one culture condition (n=3) and those of another.   
Table 2. 5 The calculation of relative quantification and standard error of mean at the end of 
qRT-PCR analysis 
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10	   	   	   11.9	   0.73	   0.42	   3.80	   0.07	   0.05	   0.096	   0.018	   0.024	  
An example is given in the table above for the calculations carried away to obtain relative quantification (RQ) 
and standard error of mean values at the end of qRT-PCR experiments. The values presented are from the 1st 
qRT-PCR experiment carried away using the probe for Serpinb2 expression. Mean ΔCt values for three 
biological repeats for the culture conditions of PLL-control-4 hr and TnC-control-4hr are used to begin the 
calculations in the example above. The formulas shown in the table were used in Microsoft Excel to calculate 
the relevant values.   
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2.6 Analysing the microarray gene expression profiling 
data using oPPOSUM 
The genes that were found to be differentially expressed in the microarray gene 
expression profiling analysis, where total RNA from embryonic rat spinal cord 
myelinating cultures at different conditions was collected (Array 2), were also used to 
determine any possible transcription factors that could be regulating the expressions of 
these genes. The genes that were differentially regulated at one direction (up or down) 
in a comparison of two culture conditions (e.g. PLL-control-4 hr vs TnC-control-4 hr) 
were entered into oPOSSUM 3.0 (Kwon et al., 2012; 
http://opossum.cisreg.ca/oPOSSUM3), a web-based program that allows single site 
analysis (SSA), which detects over-represented conserved transcription factor binding 
sites in a set of human, mouse, fly, worm or yeast genes. As mouse is the closest 
species to rat, we had to use the mouse SSA in our analysis. The conservation cut off 
value was left as 0.40 and matrix score threshold as 85%. It was selected that all the 
results to be displayed at the end. These results were copied to Microsoft Excel to 
produce scatter (XY) plots, showing Fisher score vs Z-score values of the hits for 
transcription factor binding sites. The values with Z-score≥10 and Fisher score≥7 were 
considered statistically significant as directed by the developers of the program (Kwon 
et al., 2012). The analysis was run for all the possible upstream/ downstream sequence 
lengths (2000/0, 2000/2000, 5000/2000, 5000/5000, 10000/5000, 10000/10000).   
2.7 Metabolomics 
2.7.1 Preparation of cells 
When neurospheres were being isolated from postnatal day 1 rats as described above in 
Section 2.2.1, three brains from one litter (usually of 6-12 pups) were prepared 
separately to culture in one of 3 x 75 cm3 tissue flask of neurospheres, and were 
considered as one ‘n’. When the neurospheres were large enough, which is 
approximately at 7 DIV, each flask of neurospheres was used for preparing two 24-well 
plates of astrocytes, one with PLL-coated coverslips and one with TnC-coated 
coverslips. Half a millilitre of triturated neurosphere suspension was seeded on the 
coverslips at a density of 250,000 cells/ml. Four days later, half of the coverslips in 
each plate were treated with rat recombinant CNTF (ciliary neurotrophic factor) of a 
final concentration of 1 ng/ml and at 7 DIV they were treated again. Six coverslips of 
astrocytes for each condition were used for isolating metabolites at 9 DIV. So the four 
culture conditions for each n were: PLL-Control, PLL+CNTF, TnC-Control, and 
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TnC+CNTF. The extra sister coverslips from each plate were used for 
immunocytochemistry. 
2.7.2 Extracting the metabolites  
The cells were cooled down rapidly to 4oC by being placed on wet ice. From each 
condition 5 µl of spent media was collected and added into 200 µl of ice cold 
chloroform/methanol/water (in 1:3:1 ratio), mixed well, placed on ice for the time 
being and then frozen at -80oC. It was important to mix vigorously during cooling stage 
to avoid freezing and possible cell lysis. The rest of the spent media was removed and 
the cells were washed twice in ice cold PBS. Then 250 µl of ice cold 
chloroform/methanol/water (in 1:3:1 ratio) was added into each well containing a 
coverslip. The 24-well plates were then placed on a shaker at 4oC for 1 hr. The lysate 
was then removed and centrifuged for 3 min at 13000g at 4oC. The supernatant was 
then removed and stored at -80oC. A sample of non-spent media was also prepared as a 
control by adding 5 µl of fresh media into 200 µl of chloroform/methanol/water (in 
1:3:1 ratio) and freezing it at -80oC. The samples were sent on dry ice to the 
Metabolomics Facility of University of Glasgow to be processed in Q-Exactive Hybrid 
Quadrupole-Orbitrap mass spectrometer (Thermo Scientific, USA). A list of data was 
sent to us as an IDEOM file, which is a Microsoft Excel template with a collection of VBA 
(Visual Basic for Applications) macros that enable automated data processing of mass 
spectrometry data (Creek et al., 2012). Each putative metabolite detected was 
presented with mean peak intensity relative to control condition (PLL-control) in this 
IDEOM file. The list also contained Student’s t-test significance values, obtained by 
comparing the data sets of each two culture conditions. 
2.8 Genotyping the gp130 transgenic C57BL/6 mice 
2.8.1 DNA isolation 
Genomic DNA was isolated from E13.5 brains of GFAP-Cre-/-gp130fl/fl and GFAP-Cre+/-
gp130fl/fl C57BL/6 mice using PureLink Genomic DNA Mini Kit (K1820-01, Invitrogen, Life 
Technologies) and following the manufacturer’s guideline. The brains were frozen at -
20oC on the day the embryos were used for setting up spinal cord myelinating cultures 
and were thawed on another day on ice to be used for DNA extraction. The extraction 
was carried out briefly by 1) incubating the samples in Digestion Buffer with Proteinase 
K at 55oC overnight, 2) treating them with RNAse A, Lysis/Binding Buffer, 96-100% 
ethanol, respectively, 3) washing them in Spin Columns with Washing Buffers, and 4) 
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eluting the samples in 100 µl of Elution Buffer, also provided in the kits like the above-
mentioned other buffers and reagents. The purified DNA was stored at -20oC.  
A faster and less expensive technique was used to obtain the genomic DNA from tails 
samples of neonatal animals (P1) and of animals aged 3 weeks or older (teenage/adult). 
Tail clips were performed by the experienced staff of University of Glasgow Biological 
Services. The tail samples were incubated in 250 µl of alkaline lysis buffer (25 mM 
NaOH, 0.2 mM EDTA, pH=12) at 95oC for 1 hr, which was followed by the addition of 250 
µl of neutralising buffer (40 mM Tris, pH=5), after which the samples were ready to be 
used for PCR without the need of further purification steps. This same method was also 
applied on embryonic tissue but it was discontinued because the processes of PCR and 
agarose gel electrophoresis did not reveal consistent, reproducible, and reliable results 
for embryonic samples, which was not the case seen for postnatal/adult tail samples. 
The samples could also be stored at -20oC after the neutralisation step.  
2.8.2 Polymerase chain reaction (PCR) and agarose gel 
electrophoresis 
Genomic DNA, extracted from embryonic or adult mouse tissue, was used for PCR to 
check samples for the presence of GFAP-Cre transgene or of loxP site-flanked exon 16 of 
Gp130 gene (gp130fl). Each PCR reaction consisted of a total volume of 25 µl, which 
included 5 µl of 5X GoTaq DNA polymerase buffer (M3171, Promega, USA), 0.5 µl of 
forward primer (20 µM stock), 0.5 µl of reverse primer (20 µM stock), 0.5 µl of dNTPs (10 
mM stock, N0447S, New England BioLabs, USA), 0.25 µl GoTaq DNA polymerase (5u/µl, 
M3171, Promega, USA), RNAse-free water and genomic DNA, whose volumes were 
calculated according to the stock genomic DNA concentrations available so that the 
initial DNA amount would be 100-200 ng per sample. The samples were run according to 
the following program: 1) 15 sec at 95oC, 2) 38 cycles of 45 sec at 95oC, 45 sec at 65oC, 
30 sec at 72oC, 3) 30 sec at 72oC, and 4) finish at 4oC. The GFAP-Cre transgene was 
detected as a 850 bp band (Fig 2.5) using the primers 5´-GAC ACC AGA CCA ACT GGT 
AAT GGT AGC GAC – 3` and 5´-GCA TCG AGC TGG GTA ATA AGC GTT GGC AAT-3`. 
Gp130fl was detected as a 400 bp band (Fig 2.5) using the primers 5´- GTG AAC AGT 
CAC CAT GTA CAT CTG TAC GC-3` and 5´- TGG CTT GAG CCT CAG CTT GGC TAG-3`. All 
primers were purchased from Sigma-Aldrich. The samples were incubated in Veriti 96-
well Thermal Cycler (#9902, Applied Biosystems) and either were used immediately in 
agarose gel electrophoresis or were stored at 4oC up to 72 hours. The agarose gel was 
prepared using UltraPure Agarose (#16500-500, Life Technologies) as 1.5-2% and run at 
60-80 V for 45-60 min. The samples were run in the gel along with 1 Kb Plus DNA Ladder 
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(#10787-018, Life Technologies) at a concentration of 0.042 µg/µl. The gel was later 
visualised using the instrument and the software Alpha Imager (Alpha Innotech). 
 
 
 
 
 
 
Figure 2. 5 GFAP-Cre-/-gp130fl/fl and GFAP-Cre+/-gp130fl/fl  transgenic mice were genotyped 
using PCR followed by agarose gel electrophoresis.                                               
A) The tail DNA from 4 transgenic mice (2 females and 2 males) obtained from Schluter Lab, Germany 
(Institut fur Medizinische Mikrobiologie, Otto-von-Guericke Universitat Magdeburg, Leipziger) presented a 850 
bp band for GFAP-Cre transgene and a 400 bp band for the loxP site-flanked exon 16 of Gp130 gene 
(gp130fl), which was in accordance with the findings of Schluter et al. B) Presented is an example for the 
genotyping of the litters generated from the crossing of the original breeders in A. Both litters (litter size 11 and 
6) consisted of pups positive for the loxP site-flanked gp130. Some pups were positive for GFAP-Cre while the 
others were not. All the GFAP-Cre animals used in this project carried a flanked Gp130. 
 
2.9 Microscopy and image analysis 
Cells were imaged using an Olympus BX51 fluorescent microscope and Image-Pro 
software. An image of each channel (red, green or blue) was taken individually. They 
were merged to create a composite image. Experiments were performed in triplicate. 
For the quantification of neurite density and myelination, 10-15 images were taken at 
random at 10x magnification from each coverslip. Each condition was performed at 
least in two 35 mm Petri dishes, each containing two coverslips. Therefore, 40-60 
images were analysed on average per condition in one experiment..To quantify the cell 
numbers for OPCs and astrocytes, 15-20 images were taken at random at 20x 
magnification from each coverslip. Each condition was performed at least in duplicate 
and therefore 30-40 images were analysed per condition in one experiment.  
2.9.1 Neurite density and myelin quantification 
Neurite density and myelination level of the myelinating spinal cord cultures plated on 
each glass cover slip were quantified using the “myelin.cp” pipeline of the software Cell 
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Profiler (Carpenter et al., 2006). The pipeline separates the red and green channels 
from the composite image and applies the necessary adjustments as described in 
https://github.com/muecs/cp. The axons are shown in the red channel, detected by 
the SMI-31 antibody, and the myelin is shown in the green channel, stained by the PLP 
antibody. Data is quantified for the percentage of SMI31 positive fibres that are 
ensheathed by myelin. The quantification results are exported to Microsoft Excel sheets 
and represent the number of pixels as the percentage of the total number of pixels.  
2.9.2 Cell number quantification 
The pipeline “dapi.cp” (https://github.com/muecs/cp) of Cell Profiler software was 
used to detect the total number of DAPI positive cells (seen in blue channel) on each 
glass coverslip of astrocytes or OPCs. The positive cells for a particular marker (seen in 
green and/or red channel) were counted using the Cell Counter function of the Image J 
software and they were expressed as percentage of the total number of cells. This 
percentage per coverslip was calculated by the division of the total number of specific-
marker-positive cells in 10-15 images by the total number of cells in all those images. 
Then the overall percentage was calculated by taking the average of percentages found 
for all coverslips with the same condition.  
2.9.3 Quantification of GFAP and nestin immunofluorescence 
intensity  
Image J was used to measure mean brightness of the fluorescence detected in green 
(GFAP) and red (nestin) channels per image for each coverslip of astrocyte cultures 
used. The mean brightness of fluorescence value was multiplied by the whole image 
area to calculate the total intensity of GFAP or nestin fluorescence per field of view. 
Total intensity of fluorescence was divided by the DAPI positive cell number per field of 
view to obtain the average GFAP and nestin intensity per cell per field of view.  
2.10 Statistical analysis 
Graphpad Prism software was used to analyse data when multiple conditions were 
compared. One-way repeated measures ANOVA test was applied to data followed by 
either Bonferroni correction or Dunnett’s test in an attempt to detect any significance. 
Paired Student’s t-test was used when only two conditions were compared to each 
other.  All values were expressed as means ±the standard error of the mean (SEM). 
Values were designated as significant if p≤0.05, which was presented using asterisks.
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Chapter 3  
 
Identification of secreted factors that may 
play a role in myelination 
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3.1 Introduction 
A common pathological feature of CNS injury and disease is reactive astrocytes 
(Sofroniew and Vinters, 2010). Astrocytes have been shown to exist in different 
reactivity states both in vivo and in vitro. Astrocyte phenotypes are now believed to 
exist as a continuum of reactivity status rather than a specific defined phase, namely 
quiescent, activated and reactive. As explained in Section 1.2.2, such different states 
have been shown to exist in vitro, and Nash et al. (2011b) have exploited this 
phenomenon using embryonic rat myelinating spinal cord cultures to demonstrate that 
different astrocyte phenotypes can have distinct effects on axonal ensheathment, the 
final stage of myelination. The definitions of the cultures they used are shown in Table 
3.1. They demonstrated that myelinating cultures plated on TnC-astrocytes (TnC-As) 
resulted in less myelination than those plated on PLL-astrocytes (PLL-As). On the other 
hand, CNTF (ciliary neurotrophic factor), a method to activate astrocytes  (Winter et 
al., 1995; Levison et al., 1996; Hudgins and Levison, 1998; Levison et al., 1998; 
reviewed in Liberto et al. 2004), increased the percentage of axons myelinated both in 
cultures plated on PLL- and on TnC.  
The above-mentioned observations are in accordance with the previously reported CNTF 
functions, i.e., 1) to enhance the survival of neurons (Barbin et al., 1984; Hagg and 
Varon, 1993; Naumann et al., 2003; Krady et al, 2008), 2) to promote the 
differentiation of glial progenitors into astrocytes, and 3) to stimulate the maturation 
and survival of oligodendrocytes (Barres et al., 1996; Marmur et al., 1998; Sleeman et 
al., 2000; Stankoff et al., 2002; Albrecht et al., 2007; Cao et al., 2010) and 4) to 
decrease the severity of disease course, to increase the neuronal functional recovery, 
and to be up-regulated during the remyelination phases of  neurodegenerative disease 
models (Butzkueven et al., 2002; Linker et al., 2002; Albrecht et al., 2003; Kuhlmann et 
al., 2006; Lu et al, 2009; Gudi et al., 2011). 
Previously in the lab, Nash et al. (2011b) compared  differentially regulated genes using 
an Illumina array for the astrocyte treatments and thus phenotypes, shown in Table 3.2, 
to reveal several astrocytic factors that could affect axonal ensheathment (Array 1). 
The validation of the expressional changes of these factors narrowed down the list to 
Cxcl10 chemokine only. Since Cxcl10 expression was down-regulated in PLL-astrocytes 
when comparison was made to the less myelination-supportive TnC-astrocytes, this has 
suggested CXCL10 as a negative regulator of myelination.  Embryonic rat spinal cord 
myelinating cultures plated on PLL-astrocytes and treated with this factor myelinated 
less when compared to untreated controls (Nash et al., 2011b). Thus, the authors have 
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produced a validated method from gene profiling of monolayers of different astrocyte 
phenotypes to identify potential astrocytic factors that could play a role in myelination. 
Table 3. 1 Definitions of cultures that were used in this project. 
Culture	  Name	   Definition	  
PLL-­‐astrocytes	  (PLL-­‐As)	   Neurosphere-­‐derived	   astrocytes	   are	   plated	   on	   cover	   slips,	  
coated	  with	  PLL.	  
TnC-­‐astrocytes	  (TnC-­‐As)	   Neurosphere-­‐derived	   astrocytes	   are	   plated	   on	   cover	   slips,	  
coated	  with	  TnC.	  	  
PLL-­‐myelinating	  cultures	   Embryonic	  mixed	  spinal	  cord	  cells	  are	  plated	  on	  PLL-­‐As.	  
TnC-­‐myelinating	  cultures	   Embryonic	  mixed	  spinal	  cord	  cells	  are	  plated	  on	  TnC-­‐As.	  
PLL: poly-l-lysine; TnC: tenascin C. 
Table 3. 2 The conditions of the astrocyte cultures used for the microarray gene expression 
profiling analysis 1 (Array 1, Nash et al., 2011b). 
	  	   Array	  1	   	  	  
Astrocyte	  cultures	   Treatment	   Time	  Point	  (hr)	  
PLL-­‐As	   control	   4	  
PLL-­‐As	   control	   24	  
PLL-­‐As	   CNTF	   4	  
PLL-­‐As	   CNTF	   24	  
TnC-­‐As	   control	   4	  
Rat neurospheres obtained from postnatal day 1 striata were plated on glass coverslips, previously coated 
with PLL (poly-L-lysine) or TnC (tenascin C) to generate astrocyte cultures as monolayers. PLL-astrocytes and 
TnC-astrocytes were either untreated or treated with rat CNTF (ciliary neurotrophic factor) to generate 
astrocytes with different reactivity phenotypes. Total RNA lysates were collected from these cultures 4 or 24 hr 
after standard medium feeding or CNTF treatment to be used for Array 1. RNA samples were obtained from 
three biological replicates.  
 
Despite the fact that Nash et al. (2011b) identified a negative regulator of myelination, 
they could not find a factor that increased myelination (positive for myelination). The 
promyelinating condition was CNTF treatment of astrocytes and under these conditions 
very few genes were differentially regulated upon CNTF treatment compared to 
controls. The fact that few possible candidates to promote myelination were identified 
in the comparisons of CNTF treatment of astrocytes to the conditions that led to lower 
myelination levels in culture (no treatment) led to the hypothesis that crosstalk 
between the astrocytes and the other cell types in the spinal cord mixed cultures will 
be required to activate astrocytes to influence myelination. Thus, another microarray 
gene expression profiling analysis was set up using embryonic mixed spinal cord 
myelinating cultures plated on astrocyte monolayers on different substrates and treated 
or not treated with CNTF to identify potential positive regulators of myelination. This 
second microarray (Array 2) and its analysis is the basis of this chapter.   
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For our microarray gene expression profiling analysis (Array 2), RNA samples were 
harvested from embryonic rat mixed spinal cord cultures plated on the various astrocyte 
monolayers at 12 days in vitro (DIV), 4 hr or 24 hr after the CNTF treatment or standard 
medium feeding. The eight culture conditions used were as shown in Table 3.3.  For the 
purpose of this chapter, I will refer to these embryonic rat spinal cord cultures as 
“myelinating cultures”. Even though it is possible to observe different stages of 
myelination in these cultures (Sherman and Brophy, 2005; Nash et al., 2010), I will 
suggest the effects of different candidates on the regulation of axonal ensheathment, 
which is the initial stage of myelination and can be observed at 22-28 DIV.  
Table 3. 3 The conditions of the embryonic mixed spinal cord myelinating cultures used for 
the microarray gene expression profiling analysis 2 (Array 2). 
Array	  2	   	  	   	  	   	  	  
Myelinating	  spinal	  cord	  cultures	   Treatment	   Myelination	   Time	  
plated	  on	  the	  following	  astrocytes	  (As)	   	  	   Degree	   Point	  (hr)	  
PLL-­‐As	   control	   ++	   4	  
PLL-­‐As	   control	   ++	   24	  
PLL-­‐As	   CNTF	   +++	   4	  
PLL-­‐As	   CNTF	   +++	   24	  
TnC-­‐As	   control	   +	   4	  
TnC-­‐As	   control	   +	   24	  
TnC-­‐As	   CNTF	   +++	   4	  
TnC-­‐As	   CNTF	   +++	   24	  
Dissociated and enzyme-treated embryonic rat spinal cords were plated on neurosphere-derived rat astrocyte 
monolayers, previously plated on PLL- or TnC-coated glass coverslips to generate embryonic rat mixed spinal 
cord myelinating cultures. These myelinating cultures were either untreated or treated with rat CNTF (ciliary 
neurotrophic factor) to generate cultures with different levels of axonal ensheathment. Total RNA was 
collected from these cultures 4 or 24 hr after standard medium feeding or CNTF treatment to be used for Array 
2. RNA samples were obtained from three biological replicates. The myelination levels these myelinating 
cultures present are shown relative to each other based on the study of Nash et al. (2011b). + is the lowest 
level and +++ shows the highest level of myelination.  
 
3.2 Aims 
The overall aim of this chapter is to identify secreted astrocytic factors that modulate 
myelination. This was carried out as follows: 
• A microarray gene expression profiling analysis was performed using dissociated 
spinal cord cells (Array 2) plated on a range of astrocytes to determine whether 
the crosstalk between astrocytes and these neural cells affects the expression 
profiles of astrocytes and the secretion of myelination-regulating factors. 
• Comparison was made between the transcriptional profiles of astrocyte 
monolayers (Array 1) and myelinating spinal cord cultures plated on astrocytes 
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(Array 2) under different conditions in an attempt to validate the previous 
findings of Array 1 (Nash et al., 2011b) and thus the current findings of Array 2. 
This comparison was also necessary for identification of potential myelination-
regulating transcripts, stimulated by the above-mentioned crosstalk and not 
detected in the astrocyte monolayers alone. 
• Array 2 was analysed by identifying the expressional changes between the 
myelinating cultures at different conditions that were grouped mainly as 
coating-substance (PLL or TnC), treatment (CNTF or none), and time point (4 or 
24 hr). To simplify the analysis, expressional changes were analysed in binary 
comparisons to identify the effects of CNTF in PLL-myelinating cultures and in 
TnC-myelinating cultures and to determine the effect of the coating-substance 
on the untreated myelinating cultures. Such analysis was required for 
establishing the expression profiles of the myelinating cultures with varying 
degrees of myelination as seen in Table 3.3.  
3.3 Results  
3.3.1 Comparison of the expression profiles of astrocyte 
monolayers (Array 1) with those of the myelinating spinal 
cord cultures (Array 2)  
The microarray gene expression profiling analysis using myelinating cultures plated on 
neurosphere-derived astrocyte monolayers (Array 2) revealed a higher number of genes 
that were differentially expressed between different conditions compared to those 
detected in Array 1. As seen in Fig 3.1 A, there were 32 genes differentially regulated 
between PLL- and TnC- untreated (control) astrocytes (Array 1); as opposed to the 131 
genes in the myelinating cultures (Array 2).  
There were 7 genes shared between the comparisons of PLL- and TnC- conditions of 
astrocyte monolayers and myelinating cultures (Fig 3.1 A). These genes were Aldh1a1, 
Cxcl10, Fn1, Igfbp2, Krt19, Tagln, and an unidentified gene locus. Six of them showed 
the same direction of regulation. Aldh1a1 was up-regulated in cultures on PLL compared 
to those on TnC, but Cxcl10, Fn1, Krt19, Tagln genes and the gene locus Loc497841 
were all down-regulated on PLL in both arrays. Igfbp2 was up-regulated in PLL-
astrocytes but was down-regulated in PLL-myelinating cultures compared to TnC 
conditions.  
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Figure 3. 1 A higher number of differentially regulated transcripts was detected in 
embryonic rat spinal cord myelinating cultures (Array 2) compared to in astrocyte 
monolayers (Array 1, Nash et al., 2011b).                                             
Venn diagrams present the number of differentially regulated transcripts in cultures at different conditions in 
Array 1 and Array 2. Microarray gene expression profiling analysis was carried out using samples from 
astrocyte monolayers (Array 1, Nash et al., 2011b) and myelinating cultures, plated on astrocyte monolayers 
(Array 2). Both arrays were prepared using astrocytes, which were seeded on glass coverslips coated with 
poly-L-lysine (PLL) or tenascin C (TnC). Both culture types used for these arrays were either untreated 
(control) or treated with ciliary neurotrophic factor (CNTF) and total RNA was collected from the cultures 4 hr 
or 24 hr after standard medium feeding or CNTF treatment. Three biological replicates were prepared for each 
array and each biological replicate was run in three technical replicates in both arrays. False discovery rate 
was designated as 5%. A) There were 32 differentially regulated transcripts between PLL-control and TnC-
control astrocyte monolayers (Array 1) and 131 transcripts detected between PLL-control and TnC-control 
myelinating cultures. There were 7 common genes detected in both of these comparisons. B) There were 2 
transcripts differentially regulated upon CNTF treatment in PLL-astrocyte monolayers and they were detected 
at 24 hr (Array 1); whereas, 13 transcripts were differentially regulated in total upon CNTF treatment in PLL-
myelinating cultures (Array 2), with 3 of them detected at 4 hr and 10 of them detected at 24 hr.  
 
Identifying common factors that were differentially regulated in the same direction in 
both simple and complex culture systems not only validates the results of the previous 
microarray analysis (Array 1) but also confirms the Array 2 results. Nash et al. (2011b) 
identified CXCL10 as a potential negative regulator of myelination since its expression 
was down-regulated in PLL-control astrocyte monolayers compared to TnC-control 
astrocytes, which the authors have shown to be less supportive for myelination. 
Thereafter, CXCL10 treatment of myelinating spinal cord cultures on PLL-astrocytes 
lowered the myelination levels when compared to non treated controls. The down-
regulation of Cxcl10 mRNA in myelinating cultures on PLL-astrocytes (Array 2) also 
correlates with previous findings of Nash et al. (2011b).  
Previously in Array 1, it was expected to identify a candidate molecule, which would 
potentially stimulate myelination, by comparing the differentially regulated genes 
between the PLL-control astrocytes and the PLL+CNTF astrocytes that show higher 
levels of myelination. However, only two genes were differentially regulated upon CNTF 
treatment on PLL-astrocytes (Fig 3.1 B). As these genes, Gdf15 and Cd93, from the 
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literature did not appear to be candidates that could have specifically a direct role in 
myelination; they were not considered as potential myelination regulators. On the other 
hand, three genes were differentially regulated upon CNTF treatment in PLL-
myelinating cultures at 4 hr and 10 genes at 24 hr in Array 2 (Fig 3.1 B). It is possible 
that these new 13 genes were predominantly expressed by the other cell types and not 
astrocytes in the myelinating cultures. However, it is also possible that the crosstalk 
between the astrocyte monolayers and the spinal cord cells induced their expression in 
astrocytes. 
The differentially regulated genes between the PLL- and TnC-control conditions in 
astrocyte monolayers (Array 1) and in the myelinating spinal cord cultures (Array 2) 
were also used in PANTHER Classification System (http://www.pantherdb. org), which 
can generate pie charts based on Gene Ontology categorisation, i.e. by molecular 
function, biological process, cellular component, protein class and pathway. The 
number of genes that were found to be associated with pathways and/or biological 
processes is shown in Table 3.4. The percentages of genes assigned to each category of 
pathway or biological process are presented in Fig 3.2. There appears to be a higher 
variety of pathways detected for the myelinating spinal cord cultures (Array 2) 
compared to astrocyte monolayers (Array 1). Immune system pathways constitute 32-
33% of the pathways detected in both culture types, suggesting the importance of the 
immune system elements in these cultures. In addition, several different immune 
system pathway subcategories were detected in myelinating cultures (Array 2) in 
agreement with their higher complexity compared to astrocyte monolayers (Array 1). 
The substrate difference (PLL vs TnC) appears to affect apoptotic and localisation 
processes in both culture types in similar ratios (Fig 3.2). On the other hand, a higher 
percentage of genes appears to be associated with biological regulation and metabolic, 
immune system, response to stimulus and multicellular organismal processes in 
myelinating cultures as opposed to a lower percentage of genes associated with 
developmental, biological adhesion and cellular processes, which could also be due to 
their complexity.       
 
 
 
70 
 
 
Figure 3. 2 Gene Ontology categorizations of the differentially regulated transcripts detected 
in Array 1 and Array 2.                             
Microarray gene expression profiling analysis was carried out using samples from astrocyte monolayers (Array 
1, Nash et al., 2011b) and embryonic rat spinal cord myelinating cultures, plated on astrocyte monolayers 
(Array 2). Both arrays were prepared using astrocytes, which were seeded on glass coverslips coated with 
poly-L-lysine (PLL) or tenascin C (TnC). Total RNA was collected from the cultures 4 hr after standard medium 
feeding. Three biological replicates were prepared for each array and each biological replicate was run in 
three technical replicates in both arrays. False discovery rate was designated as 5%. The lists of transcripts 
differentially regulated between the cultures on PLL and TnC were entered into PANTHER Classification 
System (http://www.pantherdb.org) to generate pie charts, showing the percentages of transcripts associated 
with the presented pathways and biological processes in A) Array 1, and B) Array 2.  
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Table 3. 4 PANTHER Classification analysis of the differentially regulated genes between 
PLL and TnC control conditions in Array 1 (astrocytes) and 2 (myelinating cultures). 
	   #	  of	  differentially	  
regulated	  genes	  
#	  of	  genes	  included	  
in	  PANTHER	  analysis	  
Total	  #	  of	  
pathway	  hits	  	  
Total	  #	  of	  biological	  
process	  hits	  
Array	  1	   32	   28	   6	   56	  
Array	  2	   131	   105	   57	   258	  
Genes identified in the expressional comparisons of PLL and TnC control (untreated) conditions in Array 1 and 
2 were entered into PANTHER online analysis program, which revealed the genes associated with various 
cellular processes and pathways and calculated the percentages for each subcategory. The numbers of 
transcripts originally detected in the microarray gene expression profiling between the PLL and TnC control 
conditions are shown in the 1st column and the number of genes, for which PANTHER could detect any 
associations are presented in the 2nd column. There were 6 and 57 genes associated with pathways shown in 
Fig 3.2 in Array 1 and Array 2, respectively. The total numbers of genes associated with the biological 
processes shown in Fig 3.2 are 56 and 258 for Array 1 and 2, respectively. Different pathways and biological 
processes detected in the analysis shared some of the genes, which increased the total number of biological 
process hits above the initial numbers of genes entered into the PANTHER program.  
 
3.3.2 CNTF appears to show its pro-myelinating effect on PLL and 
on TnC via different mechanisms (Array 2) 
CNTF has been shown to promote myelination in myelinating cultures plated on PLL-
astrocytes and on TnC-astrocytes (Nash et al., 2011b). Since it had a supportive effect 
on myelination in both cultures, the anticipation was that CNTF would trigger similar 
expressional changes on both substrates. Surprisingly, some unexpected differences 
were observed upon CNTF treatment in PLL- and TnC-myelinating cultures (Array 2), 
which led to the suggestion that CNTF might be stimulating myelination in PLL- and 
TnC-cultures via different mechanisms. Supporting evidences are explained below. 
3.3.2.1 The transcriptional changes in PLL- and TnC-myelinating cultures 
upon CNTF treatment at 4 hr and 24 hr  
One piece of evidence suggesting the differential effect of CNTF in PLL- and TnC-
myelinating cultures is the difference in the percentage of the differentially regulated 
genes at early and late time points (Fig 3.3). The majority of the expressional changes 
appeared to occur at the later time point in PLL-cultures in contrast to that seen for 
TnC-cultures (Fig 3.3). Nevertheless, the possibility that CNTF triggers the same changes 
at different rates on the two substrates cannot be excluded. 
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Figure 3. 3 Majority of the transcriptional changes upon CNTF treatment appears to occur at 
24 hr in PLL-myelinating cultures but at 4 hr in TnC-myelinating cultures.          
Microarray gene expression profiling analysis (Array 2) was carried out using samples from embryonic rat 
spinal cord myelinating cultures, plated on astrocyte monolayers on glass coverslips, coated with poly-L-lysine 
(PLL) or tenascin C (TnC). The cultures were either untreated (control) or treated with ciliary neurotrophic 
factor (CNTF) and total RNA was collected from the cultures 4 hr or 24 hr after standard medium feeding or 
CNTF treatment. Three biological replicates were prepared for the array and each biological replicate was run 
in three technical replicates. False discovery rate was designated as 5%. Shown in the figure are the Venn 
diagrams, presenting the number of differentially regulated transcripts upon CNTF treatment in PLL- and TnC-
myelinating cultures. A) Majority of the transcriptional changes upon CNTF treatment appears to occur at 24 
hr in PLL-myelinating cultures (77%); whereas, B) CNTF treatment appears to trigger majority of such 
changes at 4 hr in TnC-myelinating cultures (79%). There were not any common transcripts that were 
differentially regulated upon CNTF treatment between the two time points (4 hr and 24 hr) in either of the 
cultures.   
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Interestingly, there were two common genes that were differentially regulated in the 
same direction upon CNTF treatment on both substrates; however, those on TnC were 
detected at the earlier time point while those on PLL were detected at the later time 
point (Fig 3.4 D). Fmod was down-regulated and Crem was up-regulated on both 
substrates upon CNTF treatment. Thus these two candidates, FMOD and CREM, could be 
playing essential roles in the promotion of myelination by CNTF. Ingenuity Pathway 
Analysis (IPA) showed that these two candidates interact with different proteins in PLL- 
and TnC-myelinating cultures (Figs 3.5, 3.6). For example, FMOD appeared to intearact 
with collagens on TnC, which was not observed on PLL (Figs 3.5, 3.6).  This also suggests 
a differential CNTF-initiated mechanism in these two cultures. Please see discussion 
(Section 3.4) for further explanation.    
Apart from Fmod and Crem, there was one other common gene locus, Loc499554, 
differentially expressed at the later time point in both PLL- and TnC- cultures (Fig 3-4, 
B). If the changes occurring after 24 hr reflect the changes that would affect the 
biological processes in the cells more closely compared to those after 4 hr, the above-
mentioned comparison and hence the common gene revealed from this comparison will 
be more relevant as a candidate to regulate myelination. However, it is also possible 
that  metabolic changes, initiated by the expressional changes at the earlier time point, 
will have a long-lasting effect on the cell functions and since these will be metabolic 
changes, they will not be detected by microarray gene expression profiling. Whatever 
the case is, Loc499554 might be an interesting locus to study in the future. As this is not 
an established gene yet, it is difficult to speculate whether this transcript could have an 
effect on myelination or not. However, it was down-regulated in both PLL- and TnC- 
cultures 24 hr after the CNTF treatment (Fig 3.4 B), which Nash et al. (2011b) have 
shown to be more supportive for axonal ensheathment. Its down-regulation in more 
supportive conditions suggests a possible negative role on axonal ensheathment. Once 
the gene function is characterised, a role in myelination could also be considered in the 
future.    
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Figure 3. 4 Exogenous CNTF appears to trigger the differential expression of Crem, Fmod 
and Loc499544 in both PLL- and TnC-myelinating cultures.      
Microarray gene expression profiling analysis (Array 2) was carried out using samples from embryonic rat 
spinal cord myelinating cultures, plated on astrocyte monolayers, on glass coverslips, coated with poly-L-
lysine (PLL) or tenascin C (TnC). The cultures were either untreated (control) or treated with ciliary 
neurotrophic factor (CNTF) and total RNA was collected from the cultures 4 hr or 24 hr after standard medium 
feeding or CNTF treatment. Three biological replicates were prepared for the array and each biological 
replicate was run in three technical replicates. False discovery rate was designated as 5%. In an attempt to 
determine the early and late effect of CNTF in both PLL- and TnC-myelinating cultures, the transcripts 
differentially regulated upon CNTF treatment on one substrate at one time point were compared with those on 
the other substrate at the same or different time point. A) Early effects of CNTF in PLL- and TnC-myelinating 
cultures did not cause a common change between the cultures. B) The CNTF treatment after 24 hr decreased 
the expression of Loc499554 in both PLL- and TnC-myelinating cultures, revealing a gene locus that could be 
important for myelination, triggered by CNTF treatment. C) In the comparison of the early CNTF effect in PLL-
myelinating cultures and the late CNTF effect in TnC-myelinating cultures, there was not a common transcript 
revealed. D) In the comparison of the late CNTF effect in PLL-myelinating cultures and the early CNTF effect 
in TnC-myelinating cultures, Fmod was found to be down-regulated and Crem was seen to be up-regulated in 
both cultures. Thus, Crem, Fmod and Loc499554 appear to be among the common transcripts affected by 
exogenous CNTF treatment in myelinating cultures on PLL or TnC. 
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Figure 3. 5 Ingenuity Pathway Analysis (IPA) diagram showing the interactions of the 
molecules in PLL-myelinating cultures upon CNTF treatment (PLL+CNTF vs PLL-control) at 
24 hr.                         
Microarray gene expression profiling analysis (Array 2) was carried out using samples from embryonic rat 
spinal cord myelinating cultures, plated on astrocyte monolayers on glass coverslips, coated with poly-L-lysine 
(PLL). The cultures were either untreated (control) or treated with ciliary neurotrophic factor (CNTF) and total 
RNA was collected from the cultures 24 hr after standard medium feeding or CNTF treatment. Three 
biological replicates were prepared for the array and each biological replicate was run in three technical 
replicates. False discovery rate was designated as 5%. There were 10 transcripts differentially regulated upon 
CNTF treatment in PLL-myelinating cultures at 24 hr. The diagram shows the pathway network consisting of 
the highest number (6) of molecules. Red and green represent up- and down-regulated transcripts, 
respectively, upon CNTF treatment. Crem, Lcn2, and Serpinb2 were up-regulated but Col16a1, Fmod and 
Postn were down-regulated upon CNTF treatment in PLL-myelinating cultures at 24 hr, affecting the possible 
interactions shown in the diagram. Col16a1: collagen type XVI, alpha 1; Crem: cAMP responsive element 
modulator; Fmod: fibromodulin; Lcn2: lipocalin 2, neutrophil gelatinase-associated lipocalin; Postn: periostin; 
Serpinb2: serpin peptidase inhibitor. 
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Figure 3. 6 Ingenuity Pathway Analysis (IPA) diagram showing the interactions of the 
molecules in TnC-myelinating cultures upon CNTF treatment (TnC+CNTF vs TnC-control) at 
4 hr.                                         
Microarray gene expression profiling analysis (Array 2) was carried out using samples from embryonic rat 
spinal cord myelinating cultures, plated on astrocyte monolayers on glass coverslips, coated with tenascin C 
(TnC). The cultures were either untreated (control) or treated with ciliary neurotrophic factor (CNTF) and total 
RNA was collected from the cultures 4 hr after standard medium feeding or CNTF treatment. Three biological 
replicates were prepared for the array and each biological replicate was run in three technical replicates. 
False discovery rate was designated as 5%. There were 37 transcripts differentially regulated upon CNTF 
treatment in TnC-myelinating cultures at 4 hr. The diagram shows the pathway network consisting of the 
highest number (19) of molecules. Red and green represent up- and down-regulated transcripts, respectively, 
upon CNTF treatment. Arc, Crem and Penk were up-regulated but Cckar, Col18a1, Col3a1, Col5a1, Cyp1b1, 
Emp1, Fmod, Fstl1, Igf2, Igfbp2, Lox, Loxl1, Nfatc4, Ngfr, Reg3g, and Thbs2 were down-regulated upon 
CNTF treatment in TnC-myelinating cultures at 4 hr, affecting the possible interactions shown in the diagram.  
Arc: activity-regulated cytoskeleton-associated protein; Cckar: cholecystokinin A; Col18a1: collagen type XVIII 
alpha 1; Col3a1: collagen type III alpha 1; Col5a1: collagen type VI alpha I; Crem: cAMP responsive element 
modulator; Cyp1b1: cytochrome P450 family 1 subfamily B; Emp: epithelial membrane protein 1; Fmod: 
fibromodulin; Fstl: follistatin; Igf2: insulin-like growth factor 2; Igfbp2: insulin-like growth factor-binding protein 
2; Lox: lysyl oxidase; Lox1: lipoxygenase 1; Nfatc4: nuclear factor of activated T cells; Ngfr: nerve growth 
factor receptor; Penk: preproenkephalin; Reg3g: regenerating islet-derived 3 gamma; Thbs2: thrombospondin 
2.      
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3.3.2.2 CNTF treatment in PLL- and TnC-myelinating cultures over time 
The data of expressional changes over time hint as well that CNTF might be acting in 
PLL- and TnC-myelinating cultures via different mechanisms. It is possible to exclude 
the expressional changes over time in control conditions from the ones in CNTF-treated 
conditions on both substrates separately (Fig 3.7, grey areas). The common genes 
between the 39 and 14 genes differentially regulated specifically upon CNTF treatment 
over time on PLL and TnC, respectively, would have the potential of having essential 
roles in the CNTF effect on both substrates. Interestingly, there were no such common 
genes, suggesting again a difference in the CNTF mechanism in PLL- and TnC-
myelinating cultures. The differentially regulated genes specifically upon CNTF 
treatment over time in PLL- and TnC-myelinating cultures are presented in Table 3.5.  
Even though similar types of gene categories are seen in both culture conditions (Table 
3.5), the members of these groups are quite different. For example, the 
metalloprotease (MMP), Mmp12 was down-regulated over time in PLL+CNTF myelinating 
cultures. CNTF appears to trigger the up-regulation of Mmp12 in PLL-myelinating 
cultures temporarily at 4 hr, an effect that is lost at 24 hr (Table 3.8). No expressional 
changes of Mmp12 were seen in TnC-myelinating cultures at all.  
On the other hand, another metalloprotease, Mmp3, was up-regulated over time both in 
PLL-control and PLL+CNTF myelinating cultures (Table 3.6). Its levels remained constant 
over time in TnC-control myelinating cultures but increased in TnC+CNTF cultures 
(Table 3.7). These changes suggest that the up-regulation of Mmp3 in TnC-myelinating 
cultures is triggered by CNTF; whereas, apparently, this up-regulation occurs in PLL-
cultures without exogenous induction over time. Similarly, the members of the 
cytokines and chemokines listed under the secreted factors and the directions of their 
regulation were different in PLL- (Ccl6, Ccl12, Cxcl1, Cxcl9) and TnC-cultures (Cxcl13, 
Table 3.5). 
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Figure 3. 7 Exogenous CNTF appears to trigger distinct mechanisms over time in PLL- and 
TnC-myelinating cultures.                                   
Microarray gene expression profiling analysis (Array 2) was carried out using samples from embryonic rat 
spinal cord myelinating cultures, plated on astrocyte monolayers on glass coverslips, coated with poly-L-lysine 
(PLL) or tenascin C (TnC). The cultures were either untreated (control) or treated with ciliary neurotrophic 
factor (CNTF) and total RNA was collected from the cultures 4 hr or 24 hr after standard medium feeding or 
CNTF treatment. Three biological replicates were prepared for the array and each biological replicate was run 
in three technical replicates. False discovery rate was designated as 5%. The grey areas represent the 
differentially regulated transcritps over time (24 hr vs 4 hr) in A) PLL-control myelinating cultures and in B) 
TnC-control myelinating cultures. Those transcripts were excluded from the list of transcripts, differentially 
expressed over time in A) PLL+CNTF and in B) TnC+CNTF myelinating cultures to obtain the transcripts, 
whose expression was significantly changed over time only in the presence of exogenous CNTF. The 
numbers of such transcripts were 39 and 14 in PLL- and TnC-myelinating cultures, respectively. There were 
not any common transcripts between the lists of those 39 and 14 transcripts, which suggested a distinct 
mechanism for the exogenous CNTF effect in PLL- and TnC-myelinating cultures. 
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Table 3. 5 Categorisation of differentially regulated genes upon CNTF treatment over time in 
PLL- and TnC-myelinating cultures (Array 2), excluding the genes differentially expressed 
over time also in control conditions. 
	  
PLL	   TnC	  
Categories	   Differentially	  regulated	  genes	   Diff.	  reg.	  genes	  
Chemokines	   Ccl6,	  Ccl12,	  Cxcl1,	  Cxcl9	   Cxcl13	  
Coenzyme	   -­‐	   Coq10b,	  Slamf9	  
Enzymes	   Acot1,	  Cyp1b1,	  Mat2a,	  Mmp12,	  Adcy8,	  Agpat7,	  
Cbs,	  Nqo1,	  Pkm2,	  Plcd4,	  Ppp1r1b,	  Ptprn	  
Hmox1,	  Mmp3,	  
Oas1a	  
Growth	  factor	   -­‐	   Bdnf	  
Hormones	   Adcyap1,	  Crh	   -­‐	  
Lipid-­‐binding	  protein	   Fabp4	   -­‐	  
Membrane	  proteins	   Emp1,	  Rilp,	  Slco1c1	   -­‐	  
Neuropeptides	   Hcrt,	  Penk1	   -­‐	  
Other	  nuclear	  proteins	   Rbm3,	  Rilp	   Zbp1	  
Receptor	   Cckar	   Slamf9	  
Secreted	  factors	   	  Ccl6,	  Ccl12,	  Cxcl1,	  Cxcl9,	  Igfbp2,	  Mmp12,	  
Adcyap1,	  Crh,	  Penk1	  
Bdnf,	  Cxcl13,	  
Mmp3	  
Signaling	  protein	   Arhgef19	   Mx1	  
Solute	  carrier	   Slco1c1	   -­‐	  
Transcription	  factors	   Msx1,	  Npas4,	  Plagl1,	  Scg2	   Crem,	  	  Fos,	  Irf7	  
Microarray gene expression profiling analysis was carried out using embryonic myelinating spinal cord 
cultures (Array 2). Illustrated in the table are the differentially expressed transcripts over time in PLL+CNTF 
and TnC+CNTF myelinating cultures. The transcripts differentially regulated over time in PLL- and TnC- 
control (untreated) myelinating cultures were excluded from this list. The transcripts up-regulated over time are 
shown in red and those down-regulated over time are shown in green. The transcripts were categorised based 
on the classification in UniProt (http://www.uniprot.org/).  
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Table 3. 6 Differentially regulated genes over time in PLL-control and PLL+CNTF-
myelinating cultures (Array 2). 
PLL-­‐control-­‐myelinating	  cultures	  
	  
	  	   	  	   24	  hr	  vs	  4	  hr	   	  	  
PROBE_ID	   ILMN_GENE	   False	  Discovery	  
Rate	  
Fold	  Change	  
ILMN_1349555	   COQ10B	   0.000	   -­‐4.64	  
ILMN_1375922	   NR4A3	   0.000	   -­‐4.61	  
ILMN_1376694	   CREM	   0.002	   -­‐3.93	  
ILMN_1375583	   CREM	   0.002	   -­‐3.62	  
ILMN_1375833	   CREM	   0.002	   -­‐3.27	  
ILMN_2039673	   ARC	   0.004	   -­‐2.84	  
ILMN_1365302	   SNF1LK	   0.003	   -­‐2.69	  
ILMN_1355906	   NR4A2	   0.003	   -­‐2.57	  
ILMN_1371574	   GEM_PREDICTED	   0.004	   -­‐2.47	  
ILMN_1367486	   DUSP1	   0.010	   -­‐2.47	  
ILMN_1650285	   HMOX1	   0.004	   -­‐2.36	  
ILMN_1369914	   RASD1	   0.004	   -­‐2.34	  
ILMN_1357229	   CCL2	   0.004	   -­‐2.29	  
ILMN_1368356	   FOS	   0.004	   -­‐2.27	  
ILMN_1356140	   LOC501170	   0.015	   -­‐2.21	  
ILMN_1360447	   BDNF	   0.009	   -­‐2.06	  
ILMN_1361968	   RGD1560523_PREDICTED	   0.029	   -­‐1.95	  
ILMN_1360615	   LOC503409	   0.010	   -­‐1.94	  
ILMN_1351429	   SERPINB2	   0.010	   -­‐1.91	  
ILMN_1358226	   USP2	   0.010	   -­‐1.91	  
ILMN_1375203	   PTP4A1	   0.015	   -­‐1.86	  
ILMN_1369005	   EGR1	   0.042	   -­‐1.86	  
ILMN_1367740	   MT1A	   0.015	   -­‐1.85	  
ILMN_1364929	   BAMBI	   0.038	   -­‐1.80	  
ILMN_1374218	   RIBC2	   0.030	   -­‐1.77	  
ILMN_1363606	   LCN2	   0.031	   -­‐1.76	  
ILMN_1354131	   PORF1	   0.034	   -­‐1.75	  
ILMN_1357783	   HBEGF	   0.021	   -­‐1.73	  
ILMN_1349422	   PTGS2	   0.042	   -­‐1.71	  
ILMN_1364972	   AGTR1A	   0.034	   -­‐1.71	  
ILMN_1353835	   RGD1310149_PREDICTED	   0.039	   -­‐1.71	  
ILMN_1356628	   NFKBIA	   0.038	   -­‐1.63	  
ILMN_1371918	   AFF4_PREDICTED	   0.004	   -­‐1.62	  
ILMN_1363228	   ELL2	   0.011	   -­‐1.62	  
ILMN_1350498	   FGF2	   0.046	   -­‐1.52	  
ILMN_1354272	   LOC310926	   0.046	   -­‐1.51	  
ILMN_1376421	   MRPS10	   0.048	   -­‐1.50	  
ILMN_1360188	   NFIL3	   0.030	   -­‐1.44	  
ILMN_1367288	   PQLC1	   0.039	   -­‐1.41	  
ILMN_1366196	   NEGR1	   0.015	   -­‐1.40	  
ILMN_1372032	   RGD1307986_PREDICTED	   0.013	   -­‐1.33	  
ILMN_1357093	   TPM4	   0.038	   -­‐1.31	  
ILMN_2040245	   MAP1B	   0.029	   -­‐1.24	  
ILMN_1349593	   SRRM2_PREDICTED	   0.010	   1.34	  
ILMN_1350091	   G0S2	   0.022	   1.35	  
ILMN_1356608	   LOC499201	   0.034	   1.40	  
ILMN_1367525	   RGD1308141_PREDICTED	   0.024	   1.46	  
ILMN_1364931	   ADORA2A	   0.010	   1.48	  
ILMN_1366294	   GSTP2	   0.013	   1.51	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ILMN_1371684	   LOC499103	   0.003	   1.51	  
ILMN_1375744	   KCNC2	   0.029	   1.55	  
ILMN_1376443	   ASCL1	   0.034	   1.62	  
ILMN_1353353	   ALK	   0.006	   1.68	  
ILMN_1361666	   MMP3	   0.000	   1.80	  
	  	   	  	   	  	   	  	  
PLL+CNTF-­‐	  myelinating	  cultures	  
	  
	  	   	  	  	   24	  hr	  vs	  4	  hr	   	  	  
PROBE_ID	   ILMN_GENE	  
False	  Discovery	  
Rate	  
Fold	  
Change	  
ILMN_1375922	   NR4A3	   0.000	   -­‐5.38	  
ILMN_1349555	   COQ10B	   0.001	   -­‐3.01	  
ILMN_1357890	   MMP12	   0.001	   -­‐2.96	  
ILMN_1350836	   CCKAR	   0.001	   -­‐2.45	  
ILMN_1368356	   FOS	   0.002	   -­‐2.45	  
ILMN_1365302	   SNF1LK	   0.002	   -­‐2.18	  
ILMN_1355906	   NR4A2	   0.001	   -­‐2.17	  
ILMN_1349422	   PTGS2	   0.009	   -­‐2.07	  
ILMN_1361968	   RGD1560523_PREDICTED	   0.010	   -­‐2.00	  
ILMN_1361869	   LOC690943	   0.034	   -­‐1.90	  
ILMN_1353833	   ACOT1	   0.038	   -­‐1.90	  
ILMN_1363228	   ELL2	   0.013	   -­‐1.84	  
ILMN_1376635	   CYP1B1	   0.022	   -­‐1.81	  
ILMN_1350180	   EMP1	   0.011	   -­‐1.80	  
ILMN_1359095	   MAT2A	   0.031	   -­‐1.75	  
ILMN_1372537	   MSX1	   0.038	   -­‐1.73	  
ILMN_1530238	   LOC684681	   0.021	   -­‐1.71	  
ILMN_1368224	   CCL12_PREDICTED	   0.039	   -­‐1.71	  
ILMN_1353835	   RGD1310149_PREDICTED	   0.017	   -­‐1.68	  
ILMN_2039673	   ARC	   0.006	   -­‐1.68	  
ILMN_1363453	   NPAS4	   0.026	   -­‐1.67	  
ILMN_1364222	   PLAGL1	   0.038	   -­‐1.66	  
ILMN_1355237	   CXCL1	   0.044	   -­‐1.64	  
ILMN_1353336	   RBM3	   0.020	   -­‐1.60	  
ILMN_1369914	   RASD1	   0.032	   -­‐1.57	  
ILMN_1369168	   CCL6	   0.038	   -­‐1.52	  
ILMN_1363606	   LCN2	   0.011	   -­‐1.49	  
ILMN_1367600	   RGD1565540_PREDICTED	   0.033	   -­‐1.30	  
ILMN_1376344	   FABP4	   0.043	   -­‐1.14	  
ILMN_1360048	   IGFBP2	   0.009	   -­‐1.06	  
ILMN_1361632	   CXCL9	   0.010	   -­‐1.05	  
ILMN_1373954	   RGD1560030_PREDICTED	   0.047	   -­‐1.04	  
ILMN_1355694	   LOC363492	   0.041	   1.01	  
ILMN_1362918	   LOC361912	   0.031	   1.16	  
ILMN_1370261	   RGD1566401_PREDICTED	   0.017	   1.20	  
ILMN_1366004	   PLCD4	   0.044	   1.34	  
ILMN_1353874	   CBS	   0.014	   1.39	  
ILMN_1366452	   PKM2	   0.010	   1.40	  
ILMN_1351683	   RILP_PREDICTED	   0.028	   1.49	  
ILMN_1372370	   AGPAT7_PREDICTED	   0.049	   1.50	  
ILMN_1355146	   HCRT	   0.043	   1.52	  
ILMN_1350196	   ADCY8	   0.031	   1.56	  
ILMN_1376782	   ADCYAP1	   0.020	   1.58	  
ILMN_1352810	   ARHGEF19_PREDICTED	   0.016	   1.60	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ILMN_1360716	   SCG2	   0.011	   1.64	  
ILMN_2039396	   NQO1	   0.011	   1.69	  
ILMN_2040370	   PPP1R1B	   0.002	   1.70	  
ILMN_1352410	   PENK1	   0.006	   1.74	  
ILMN_1353353	   ALK	   0.004	   1.88	  
ILMN_1351429	   SERPINB2	   0.004	   1.89	  
ILMN_1358429	   CRH	   0.002	   2.04	  
ILMN_1363020	   PTPRN	   0.010	   2.22	  
ILMN_1357978	   SLCO1C1	   0.001	   2.42	  
ILMN_1361666	   MMP3	   0.001	   7.16	  
An Illumina array was carried out on myelinating spinal cord cultures of different phenotypes (Array 2). The 
genes differentially expressed over time (24 hr vs 4 hr) in PLL-control and PLL+CNTF myelinating cultures are 
listed in the table. RNA samples were collected from myelinating cultures, at 12 DIV, 4 hr and 24 hr after 
standard medium feeding. Three biological replicates were used for the experiment. Gene fold changes are 
shown in the table. Negative and positive values represent the down-regulations and up-regulations, 
respectively. False discovery rate was designated as 5%. The genes highlighted in grey are common between 
PLL-control and PLL+CNTF cultures. 
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Table 3. 7 Differentially regulated genes over time in TnC-control and TnC+CNTF 
myelinating cultures (Array 2). 
TnC-­‐control-­‐myelinating	  cultures	  
	  	  
	  	   	  	   24	  hr	  vs	  4	  hr	   	  	  
PROBE_ID	   ILMN_GENE	   False	  Discovery	  
Rate	  
Fold	  Change	  
ILMN_1375909	   SLC14A2	   0.002	   -­‐3.40	  
ILMN_1372537	   MSX1	   0.002	   -­‐2.63	  
ILMN_1350576	   LOC290704	   0.012	   -­‐2.55	  
ILMN_1372919	   CYR61	   0.021	   -­‐2.50	  
ILMN_1360048	   IGFBP2	   0.024	   -­‐2.47	  
ILMN_1350836	   CCKAR	   0.021	   -­‐2.05	  
ILMN_1371407	   FMOD	   0.021	   -­‐2.04	  
ILMN_1354884	   FSTL1	   0.024	   -­‐1.99	  
ILMN_1360481	   PLEC1	   0.040	   -­‐1.87	  
ILMN_1650537	   GPC4	   0.040	   -­‐1.87	  
ILMN_1351900	   FCNB	   0.012	   -­‐1.82	  
ILMN_1350180	   EMP1	   0.023	   -­‐1.70	  
ILMN_1375922	   NR4A3	   0.021	   -­‐1.69	  
ILMN_1357452	   GDA	   0.023	   -­‐1.65	  
ILMN_1367695	   TMEM37	   0.026	   -­‐1.64	  
ILMN_1356721	   CCR1	   0.026	   -­‐1.64	  
ILMN_1366649	   LOC501087	   0.040	   1.55	  
ILMN_1354725	   LOC500490	   0.032	   1.57	  
ILMN_1350958	   LOC498644	   0.039	   1.61	  
ILMN_1371124	   LOC500960	   0.021	   1.63	  
ILMN_1348840	   SNAP25	   0.021	   1.66	  
ILMN_1371063	   LOC498048	   0.013	   1.74	  
ILMN_1352230	   LOC362543	   0.012	   1.80	  
ILMN_1373694	   LOC362315	   0.012	   1.80	  
ILMN_1361190	   RGD1559917_PREDICTED	   0.040	   1.81	  
ILMN_1369444	   LOC361942	   0.013	   1.88	  
ILMN_1355694	   LOC363492	   0.021	   1.92	  
ILMN_1650120	   CLDN11	   0.004	   1.92	  
ILMN_1363606	   LCN2	   0.040	   2.01	  
ILMN_1375194	   LOC500867	   0.004	   2.08	  
	  	   	  	   	  	   	  	  
TnC+CNTF-­‐myelinating	  cultures	  
	  	  
	  	   	  	   24	  hr	  vs	  4	  hr	   	  	  
PROBE_ID	   ILMN_GENE	   False	  Discovery	  Rate	   Fold	  
Change	  
ILMN_1375833	   CREM	   0.017	   -­‐2.08	  
ILMN_1650285	   HMOX1	   0.002	   -­‐2.01	  
ILMN_1376694	   CREM	   0.016	   -­‐2.01	  
ILMN_1360447	   BDNF	   0.029	   -­‐1.94	  
ILMN_1368356	   FOS	   0.016	   -­‐1.80	  
ILMN_1349555	   COQ10B	   0.012	   -­‐1.77	  
ILMN_1369833	   LOC501538	   0.043	   -­‐1.53	  
ILMN_1356758	   CXCL13	   0.016	   1.27	  
ILMN_1368490	   LOC24906	   0.022	   1.31	  
ILMN_1358414	   ZBP1	   0.016	   1.49	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ILMN_1373648	   MX1	   0.016	   1.63	  
ILMN_1367846	   SLAMF9_PREDICTED	   0.022	   1.66	  
ILMN_1362908	   OAS1A	   0.018	   1.81	  
ILMN_1352469	   IRF7	   0.016	   1.93	  
ILMN_1361666	   MMP3	   0.016	   3.13	  
An Illumina array was carried out on myelinating spinal cord cultures of different phenotypes (Array 2). The 
genes differentially expressed over time (24 hr vs 4 hr) in TnC-control and TnC+CNTF myelinating cultures 
are listed in the table. RNA samples were collected from myelinating cultures, at 12 DIV, 4 hr and 24 hr after 
standard medium feeding or CNTF treatment. Three biological replicates were used for the experiment. Gene 
fold changes are shown in the table. Negative and positive values represent the down-regulations and up-
regulations, respectively. False discovery rate was designated as 5%. The genes highlighted in grey are 
common between TnC -control and TnC+CNTF cultures. 
 
3.3.3 Binary comparisons reveal potential candidates that could 
regulate axonal ensheathment (Array 2) 
CNTF is likely to show its effect in PLL- and TnC-myelinating cultures via different 
mechanisms, as explained above. Therefore, the expressional changes occurring upon 
CNTF treatment in PLL- and TnC- myelinating cultures were analysed separately as the 
next step of the Array 2 analysis. Another binary comparison was necessary to analyse 
the expressional changes between PLL-control and TnC-control myelinating cultures as 
they also were demonstrated to exhibit different levels of myelination (Nash et al., 
2011b). 
3.3.3.1 PLL+CNTF vs PLL-control myelinating cultures 
There were only three genes differentially regulated upon CNTF treatment in PLL-
myelinating cultures at 4 hr, and 10 genes/gene loci at 24 hr with no genes overlapping 
between the two time points (Table 3.8). At 4 hr, the metalloproteinase Mmp12 and 
the chemokine ligand Cxcl13 were up-regulated and Ribc2 was down-regulated upon 
CNTF treatment in PLL-myelinating cultures (Table 3.8). The expression of Mmp12 was 
down-regulated over time in PLL-CNTF cultures (Table 3.6) back to control levels. Its 
temporary up-regulation might be triggering signalling pathways that would eventually 
have a positive effect on myelination as explained in Section 3.4. As for Cxcl13, such a 
down-regulation over time in PLL+CNTF myelinating cultures or up-regulation over time 
in PLL-control myelinating cultures was not seen, making it more difficult to explain the 
lack of its differential expression between PLL-control and PLL+CNTF cultures at 24 hr 
(Table 3.8). It is possible that Cxcl13 expression naturally increases on PLL slowly over a 
long period of time without any exogenous treatment and at 24 hr reaches the same 
levels as those in CNTF-treated cultures. This could be interpreted as CNTF facilitates 
the up-regulation of Cxcl13 in PLL-myelinating cultures. This increase at a specific early 
time point could influence the cell biology in the myelinating cultures in a way that 
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would positively affect myelination since PLL+CNTF myelinating cultures exhibit higher 
myelination levels compared to untreated PLL-cultures (Nash et al., 2011b).  
Table 3. 8 Differentially regulated genes detected 4 hr and 24 hr after CNTF treatment in 
PLL-myelinating cultures (Array 2). 
at	  4	  hr	   	  	   	  	   	  	  
	  	   	  	   PLL	  CNTF	  vs	  PLL	  control	  
PROBE_ID	   ILMN_GENE	   False	  Discovery	  
Rate	  
Fold	  Change	  
ILMN_1374218	   RIBC2	   0.006	   -­‐2.10	  
ILMN_1357890	   MMP12	   0.009	   1.59	  
ILMN_1356758	   CXCL13 	   0.035	   1.69	  
	  	   	  	   	  	   	  	  
at	  24	  hr	   	  	   	  	   	  	  
	  	   	  	   PLL	  CNTF	  vs	  PLL	  control	  
PROBE_ID	   ILMN_GENE	   False	  Discovery	  
Rate	  
Fold	  Change	  
ILMN_1371407	   FMOD	   0.003	   -­‐2.02	  
ILMN_1360313	   POSTN_PREDICTED	   0.010	   -­‐1.83	  
ILMN_1364416	   COL16A1	   0.025	   -­‐1.11	  
ILMN_1363227	   LOC499554	   0.013	   -­‐1.08	  
ILMN_1375194	   LOC500867	   0.045	   1.01	  
ILMN_1362918	   LOC361912	   0.018	   1.02	  
ILMN_1355694	   LOC363492	   0.018	   1.12	  
ILMN_1363606	   LCN2 	   0.002	   1.56	  
ILMN_1376694	   CREM	   0.037	   1.69	  
ILMN_1375833	   CREM	   0.025	   1.74	  
ILMN_1351429	   SERPINB2 	   0.013	   1.98	  
An Illumina array was carried out on myelinating spinal cord cultures of different phenotypes (Array 2). The 
genes differentially expressed upon CNTF (cilliary neurotrophic factor) treatment in PLL-myelinating cultures 
are listed in the table. RNA samples were collected from myelinating cultures, at 12 DIV, 4 hr and 24 hr after 
standard medium feeding or treatment. The transcripts highlighted in a black box were selected as potential 
regulators of myelination. Three biological replicates were used for the experiment. Gene fold changes are 
shown in the table. Negative and positive values represent the down-regulations and up-regulations, 
respectively. False discovery rate was designated as 5%. 
 
Unlike Mmp12 and Cxcl13, Ribc2 was down-regulated upon CNTF treatment in PLL-
myelinating cultures at 4 hr. Its expression was also down-regulated over time in PLL-
control cultures (Table 3.6) explaining the lack of its differential expression at 24 hr 
(Table 3.8). It is difficult to speculate whether the faster drop in its expression upon 
CNTF treatment will have an effect on myelination as there is very little known about 
this gene in the literature. Ribc2 stands for RIB43A domain with coiled-coils 2 and seems 
to be an uncharacterised microtubule ribbon protein, which might be important for the 
proper segregation of chromosomes during cell proliferation (Arango et al., 2004). Other 
than that, not much is known about this protein in mammals. It might help process 
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extension in oligodendrocytes as a cytoskeleton protein but it is difficult to reach a 
definite conclusion at this stage. 
Down-regulation of the extracellular matrix (ECM) organisation proteins 24 hr after the 
CNTF treatment in PLL-myelinating cultures (Table 3.9) could provide a more suitable 
environment for axonal ensheathment by providing ample space for oligodendrocyte 
processes to extend and wrap around axons. Fibromodulin (Fmod) was down-regulated 
upon CNTF treatment also in TnC-myelinating cultures. Since CNTF has been suggested 
to increase axonal ensheathment also on TnC (Nash et al., 2011b), down-regulation of 
Fmod expression upon CNTF would present FMOD as a negative regulator of axonal 
ensheathment as explained in Section 3.4.  
On the other hand,  up-regulation of Lcn2 (lipocalin 2, neutrophil gelatinase-associated 
lipocalin), Serpinb2 (serpin peptidase inhibitor) and Crem (cAMP responsive element 
modulator) upon CNTF treatment in PLL-myelinating cultures (Table 3.8) would suggest 
them as positive regulators of axonal ensheathment. Serpinb2 continued to present 
itself as a possible stimulator of myelination when its differential expressions in other 
comparisons were observed. It was also up-regulated in PLL-control myelinating cultures 
compared to TnC-control cultures at 4 hr (Table 3.14). Its expression was down-
regulated over time in PLL-control cultures but this was reversed upon CNTF treatment 
(Table 3.6). Thus, CNTF treatment maintained the 4 hr Serpinb2 levels until at least 24 
hr after the onset of the treatment and also elevated them by a fold change of 1.89.  
Table 3. 9 Categorisation of differentially regulated genes 4 hr and 24 hr after CNTF 
treatment in PLL-myelinating cultures (Array 2). 
	  
4	  hr	   24	  hr	  
Categories	   Differentially	  regulated	  genes	   Diff.	  reg.	  genes	  
Chemokine	   Cxcl13	   -­‐	  
Enzymes	   Mmp12	   Serpinb2	  
Extracellular	  matrix	  
proteins	  
Mmp12	   Fmod,	  Col16a1,	  
Postn	  
Others	   Ribc2	   -­‐	  
Secreted	  factors	   Cxcl13,	  Mmp12	   Fmod,	  Col16a1,	  
Postn,	  Lcn2,	  
Serpinb2	  
Transcription	  factor	   -­‐	   Crem	  
Microarray gene expression profiling analysis was carried out using embryonic myelinating spinal cord 
cultures (Array 2). Illustrated in the table are the differentially expressed transcripts 4 hr and 24 hr after CNTF 
(cilliary neurotrophic factor) treatment in PLL-myelinating cultures. The transcripts up-regulated upon CNTF 
treatment are shown in red and the ones down-regulated are shown in green. The transcripts were 
categorised based on the classification in UniProt (http://www.uniprot.org/). Diff: differentially; reg: regulated.  
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SERPINB2, also named PAI-2, is a member of the serine protease inhibitor superfamily. 
It can play a role in cell survival and differentiation, innate immune response, and 
neuroprotection (Masos and Miskin, 1997; Sharon et al., 2002; Fan et al., 2004; 
reviewed in Medcalf, 2011). PAI-2 promoter contains a CRE-site, which could be 
controlled by the transcriptional factor CREM (Zhang et al., 2009). The up-regulation of 
Crem upon CNTF treatment in PLL-cultures at 24 hr, and in PLL-control cultures 
compared to TnC-cultures at 4 hr is in parallel with the change seen for PAI-2. Thus, 
CREM could be playing a role in the up-regulation of Serpinb2 in these conditions. 
Interestingly, no change is detected for Serpinb2 upon CNTF treatment in TnC-cultures 
despite the up-regulation of Crem at 4 hr, which suggests that CREM is not enough on its 
own to affect the expression of Serpinb2 upon CNTF treatment. FOS has also been 
suggested to affect Serpinb2 expression via AP-1 site binding (Stringer et al., 2012). The 
up-regulation of Fos in PLL-cultures compared to TnC-cultures at 4 hr is again in 
accordance with that finding.  
Even though Lcn2 (Lipocalin-2) was suggested to have a positive effect on myelination 
due to its up-regulation upon CNTF treatment in PLL-cultures at 24 hr (Table 3.8), its 
down-regulation in PLL-control cultures when compared to TnC-cultures (3.14) poses a 
contradiction since PLL-control cultures have been shown to have higher levels of 
myelination (Nash et al., 2011b). Unlike the case seen for Serpinb2, CNTF treatment did 
not sustain or increase the Lcn2 levels in PLL-cultures over time (Table 3.6). On the 
other hand, Lcn2 expression was elevated in TnC-control cultures over time, the 
opposite of what was seen for PLL-control cultures. The association of LCN2 with 
disease onset and/or progression in spinal cord injury, EAE, MS and neuromyelitis optica 
(NMO) (Rathore et al., 2011; Berard et al., 2012; Marques et al., 2012; Howe et al., 
2014) and of LCN2 deficiency with myelin sparing at the spinal cord epicentre (Rathore 
et al., 2011) appear to contradict the suggestion that LCN2 could have a positive role in 
myelination. However, its role in promotion of neuronal processes and neuron migration 
(Bi et al., 2013) and the removal of the damaged or unhealthy cells in nervous system 
(Lee et al., 2012a) might be important in our relatively young myelinating cultures (12 
DIV) for a healthy development. These contradictory observations make it difficult to 
propose a steady, solid effect of LCN2 on myelination; however, they do not exclude 
the possibility of LCN2 playing a role in myelination, either.  
After this detailed analysis of transcriptional changes in PLL+CNTF vs PLL-control 
myelinating cultures, CXCL13, LCN2 and SERPINB2 were chosen to study further as 
potential positive regulators of axonal ensheathment in biological validation assays 
(Table 3.10). The fact that they are secreted proteins was important, as they would 
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need to be exogenously added to the embryonic rat spinal cord myelinating cultures 
plated on PLL-astrocytes to prove they had any effects on axonal ensheathment (Nash 
et al., 2011b). ECM proteins (FMOD, COL16A1), CREM and MMP12 were not selected 
despite being secreted factors since studying them in the myelinating cultures would be 
more difficult than studying the other selected candidates. The ECM proteins may be 
negative regulators of myelination due to their down-regulation upon CNTF treatment 
on PLL. Thus, their removal from the cultures would possibly be necessary to observe 
increased myelination levels rather than adding exogenous ECM proteins to the cultures 
where they may not be able to reduce myelination further. Working with CREM, a 
transcription factor, and MMP12 that might require zymographic assays would also be 
more complicated. Additionally, to keep the list of genes of interest short, priority was 
given to CXCL13, LCN2, SERPINB2. 
Table 3. 10 Candidates selected from the comparison of PLL+CNTF vs PLL-control 
myelinating cultures to study further. 
Cand.	   Suggested	  
Effect	  on	  
Myelination	  
Supporting/Contradicting	  Evidence	   References	  
Cxcl13	   supportive	   o Elevated	  levels	  detected	  in	  the	  spinal	  cords	  of	  
mice	  with	  EAE	  and	  the	  CNS	  of	  MS	  patients.	  
o Rituximab,	  a	  drug	  that	  is	  used	  in	  MS	  
treatment,	  has	  been	  shown	  to	  reduce	  CXCL13	  
levels	  in	  the	  CSF	  and	  serum	  of	  MS	  patients	  
o Promoted	  CNS	  myelination	  in	  cerebellar	  slice	  
cultures.	  
Magliozzi	  et	  
al.,	  2004;	  
Bagaeva	  et	  al.,	  
2006;	  
Krumbholz	  et	  
al.,	  2006;	  
Piccio	  et	  al.,	  
2010;	  Yuen	  et	  
al.,	  2013	  
Lcn2	   supportive	   o Induced	  cortical	  neuron	  death	  in	  a	  time-­‐	  and	  
dose-­‐dependent	  manner	  in	  primary	  cultures	  
but	  was	  not	  toxic	  to	  glia	  in	  vitro.	  
o Increased	  the	  number	  of	  neuronal	  processes	  
and	  promoted	  neuron	  migration	  in	  primary	  
mouse	  neuronal	  cultures.	  	  
Lee	  et	  al.,	  
2012a;	  	  
Bi	  et	  al.,	  2013	  
SB2	   supportive	   o Its	  expression	  increased	  in	  mouse	  neurons	  
where	  neuronal	  survival	  was	  promoted.	  	  
o It	  was	  shown	  to	  inhibit/regulate	  the	  levels	  of	  
uPA,	  whose	  degrading	  activity	  against	  MBP	  
has	  been	  detected	  in	  conditioned	  media	  from	  
primary	  rat	  microglia.	  	  
Kawano	  et	  al.,	  
1970;	  
Nakajima	  et	  
al.,	  1992;	  	  
Zhang	  et	  al.,	  
2009	  	  
Microaray gene expression profiling analysis was carried out using embryonic rat spinal cord cultures plated 
on astrocyte monolayers on coverslips, coated with PLL (PLL-myelinating cultures). Illustrated in the table are 
the candidates selected as potential regulators of myelination based on their differential expression between 
the untreated and CNTF-treated PLL-myelinating cultures. Basic facts, which are/could be related to 
myelination-regulating roles, are also presented for these candidates with their references. Cand.: candidates; 
CNS: central nervous system; CNTF: cilliary neurotrophic factor; Cxcl13: chemokine 13; Lcn2: lipocalin2; PLL: 
poly-L-lysine; SB2: serpinb2; uPA: urokinase-type plasminogen activator. 
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3.3.3.2 TnC+CNTF vs TnC-control myelinating cultures 
Similar to the case seen in PLL-myelinating cultures, there were no common genes that 
were differentially regulated upon CNTF treatment in TnC-myelinating cultures at both 
time points (Table 3.11). Thus, the effects of CNTF treatment on gene expression in 
TnC-myelinating cultures appear to be different at the early and later time points.   
There were 34 genes that were differentially regulated at 4 hr after CNTF treatment in 
TnC-myelinating cultures as opposed to 9 differentially regulated genes at 24 hr (Table 
3.11). Some of the genes that were down-regulated upon CNTF treatment at 4 hr were 
also down-regulated over time in TnC-control cultures. These genes were Msx1 (Msh 
homeobox 1), Cckar (cholecystokinin A receptor), Igfbp2 (insulin-like growth factor 
binding protein 2), Fstl1 (follistatin-like 1), Slc14a2 (urea transporter member 2), Fmod 
(fibromodulin) and Emp1 (epithelial membrane protein 1, Table 3.7). Even though their 
down-regulation upon CNTF treatment at 4 hr may suggest that they are inhibitory to 
axonal ensheathment, the facts that they were not down-regulated at 24 hr and that 
they were also down-regulated over time in control cultures without any CNTF 
treatment show that they may not be highly related to CNTF functions in these cultures. 
If we exclude such genes from the down-regulated genes upon CNTF treatment at 4 hr 
(Table 3.11), the secreted myelination-inhibiting candidates (Table 3.12) will be the 
collagens Col18a1, Col3a1 and Col5a1, Fbn2 (fibrillin 2), Igf2 (insulin-like growth 
factor 2), lysyl oxidase-like proteins Loxl1 and Loxl2, Megf6 (multiple EGF-like-domains 
6), Reg3b (regenerating islet-derived 3 beta), Thbs2 (thrombospondin 2), and Wif1 
(WNT inhibitory factor 1). After excluding the ECM proteins from this list due the above-
mentioned reasons, we selected Thbs2 and Wif1 to study further (Table 3.13). The 
matricellular protein THBS2 especially was interesting as THBS4 was also suggested as a 
negative myelination-regulator at the end of the microarray analysis carried away using 
astrocyte monolayers alone (Array1, Nash et al., 2011b). The down-regulation of Thbs2 
and Wif1 upon CNTF treatment in TnC-cultures suggested that these could be negative 
regulators of myelination. 
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Table 3. 11 Differentially regulated genes detected 4 hr and 24 hr after CNTF treatment in 
TnC-myelinating cultures (Array 2). 
at	  4	  hr	   	  	   	  	   	  	  
	  	   	  	   TnC	  CNTF	  vs	  TnC	  control	  
PROBE_ID	   ILMN_GENE	   False	  Discovery	  
Rate	  
Fold	  Change	  
ILMN_1372537	   MSX1	   0.004	   -­‐2.38	  
ILMN_1350836	   CCKAR	   0.004	   -­‐2.34	  
ILMN_1360048	   IGFBP2	   0.007	   -­‐2.15	  
ILMN_1351352	   LOXL2_PREDICTED	   0.014	   -­‐1.91	  
ILMN_1354884	   FSTL1	   0.010	   -­‐1.90	  
ILMN_1375909	   SLC14A2	   0.010	   -­‐1.89	  
ILMN_1364899	   COL18A1	   0.010	   -­‐1.88	  
ILMN_1365512	   NGFR	   0.014	   -­‐1.84	  
ILMN_1354941	   COL3A1	   0.017	   -­‐1.75	  
ILMN_1357508	   REG3B	   0.022	   -­‐1.73	  
ILMN_1376260	   MEGF6	   0.022	   -­‐1.71	  
ILMN_1650153	   THBS2 	   0.026	   -­‐1.67	  
ILMN_1376846	   LOXL1	   0.026	   -­‐1.67	  
ILMN_1364986	   WIF1 	   0.036	   -­‐1.64	  
ILMN_1371407	   FMOD	   0.038	   -­‐1.64	  
ILMN_1366296	   PRPH1	   0.038	   -­‐1.64	  
ILMN_1351076	   FBN2	   0.026	   -­‐1.63	  
ILMN_1370683	   NFATC4	   0.042	   -­‐1.59	  
ILMN_1376635	   CYP1B1	   0.042	   -­‐1.59	  
ILMN_1359301	   IGF2	   0.042	   -­‐1.58	  
ILMN_1359457	   COLEC12	   0.042	   -­‐1.58	  
ILMN_1350180	   EMP1	   0.049	   -­‐1.58	  
ILMN_1360227	   BOC_PREDICTED	   0.049	   -­‐1.56	  
ILMN_1353887	   COL5A1	   0.038	   -­‐1.54	  
ILMN_1530405	   LOXL1	   0.042	   -­‐1.53	  
ILMN_1369190	   PDLIM7	   0.042	   -­‐1.52	  
ILMN_1371773	   CD248_PREDICTED	   0.049	   -­‐1.50	  
ILMN_1376823	   LOX	   0.049	   -­‐1.50	  
ILMN_1362820	   SSG1	   0.049	   -­‐1.49	  
ILMN_1651027	   RGD1566042_PREDICTED	   0.017	   1.52	  
ILMN_2039673	   ARC	   0.049	   1.54	  
ILMN_1349555	   COQ10B	   0.049	   1.62	  
ILMN_1361431	   RPE65	   0.026	   1.74	  
ILMN_1375833	   CREM	   0.026	   1.76	  
ILMN_1352410	   PENK1	   0.017	   1.83	  
ILMN_1375583	   CREM	   0.017	   1.88	  
ILMN_1376694	   CREM	   0.007	   2.23	  
	  	   	  	   	  	   	  	  
at	  24	  hr	   	  	   	  	   	  	  
	  	   	  	   TnC	  CNTF	  vs	  TnC	  control	  
PROBE_ID	   ILMN_GENE	   False	  Discovery	  
Rate	  
Fold	  Change	  
ILMN_1650120	   CLDN11	   0.011	   -­‐1.80	  
ILMN_1350345	   LOC499638	   0.048	   -­‐1.23	  
ILMN_1361494	   LOC498901	   0.041	   -­‐1.20	  
ILMN_1363227	   LOC499554	   0.040	   -­‐1.08	  
ILMN_1356110	   KLF4	   0.011	   1.25	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ILMN_1364113	   CTGF 	   0.016	   1.37	  
ILMN_1367546	   TBX15_PREDICTED	   0.044	   1.97	  
ILMN_1372919	   CYR61	   0.016	   2.74	  
ILMN_1361666	   MMP3	   0.011	   3.31	  
An Illumina array was carried out on myelinating spinal cord cultures of different phenotypes (Array 2). The 
genes differentially expressed upon CNTF (cilliary neurotrophic factor) treatment in TnC-myelinating cultures 
are listed in the table. RNA samples were collected from myelinating cultures, at 12 DIV, 4 hr and 24 hr after 
standard medium feeding or treatment. The transcripts highlighted in a black box were selected as potential 
regulators of myelination. Three biological replicates were used for the experiment. Gene fold changes are 
shown in the table. Negative and positive values represent the down-regulations and up-regulations, 
respectively. False discovery rate was designated as 5%. TnC: tenascin C.  
 
Thbs2 encodes for thrombospondin-2 (TSP2), a matricellular protein that is involved in 
a variety of cellular processes in the extracellular matrix rather than contributing to the 
physical properties of structural elements in tissues (Sage and Bornstein, 1991). 
Elevated levels of TSP2 in CNS pathology (Lin et al., 2003; Liauw et al., 2008, Huang et 
al., 2013) could be attributed to an inhibitory function of TSP2 in the CNS; however, 
TSP2 has also been shown to contribute to synaptic recovery, axonal sprouting and 
behavioural recovery after stroke (Liauw et al., 2008). On the other hand, TSP2 was also 
postulated as a clearance factor for MMP2 that is associated with the regulation of PNS 
myelination (Lehmann et al., 2009). As MMP2 is also present in the CNS (Cuzner et al., 
1996; Heo et al., 1999), it could be important for CNS myelination despite its 
proteolytic activity against MBP in vitro (Latronico et al., 2013). In spite of some 
positive roles of TSP2, our results showed that its transcript is down-regulated in 
cultures that has been shown to be more supportive of myelination, i.e. TnC-CNTF-
cultures (Table 3.11) and was thus suggested as a negative regulator of myelination.  
Wif1 was also down-regulated in PLL-control myelinating cultures compared to TnC-
contol myelinating cultures, suggesting once more a negative role for WIF1 in 
myelination. Wnt inhibitor factor (WIF1) is an extracellular antagonist of Wnt secreted 
proteins. Therefore, Wnt signalling would be expected to have a positive role on axonal 
ensheathment once it is not inhibited by WIF1. Despite the supporting evidence in Table 
3.13, there are also some contradictory results presented. As Tawk et al. (2011) remind 
the readers, Wnt signalling components so far examined in oligodendrocyte 
development are all shared between the canonical Wnt and other major signalling 
pathways, such as PI3/AKT pathway. In addition, Wnt signalling could have a distinct 
effect on oligoglial cell differentiation based on their differentiation stage, e.g., 
stimulating PLP expression in oligodendrocyte-enriched cultures but not in primary OPC 
cultures (Shimizu et al., 2005; Feigenson et al., 2009; Li and Richardson, 2009; Ye et 
al., 2009; Fancy et al., 2011; Tawk et al., 2011; Zhong et al., 2011). The interception of 
Wnt signalling components with other signalling pathways (Tawk et al., 2011) and their 
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possible distinct actions at different developmental stages (Xie et al., 2013) create a 
very complex system. Nevertheless, there is clear evidence suggesting involvement of 
Wnt signalling in oligodendrocyte maturation and myelination (Fancy et al., 2009; Tawk 
et al., 2011). 
Table 3. 12 Categorisation of differentially regulated genes 4 hr and 24 hr after CNTF 
treatment in TnC-myelinating cultures (Array 2). 
	  
4	  hr	   24	  hr	  
Categories	   Differentially	  regulated	  genes	   Diff.	  reg.	  genes	  
Cell	  junction	  protein	   -­‐	   Cldn11	  
Coenzyme	   Coq10b	   -­‐	  
Developmental	  
proteins	  
Pdlim7,	  Arc	   -­‐	  
Enzymes	   Boc,	  Cyp1b1,	  Fbn2,	  Loxl2,	  Rpe65	   Mmp3	  
Extracellular	  matrix	  
proteins	  
Col18a1,	  Col3a1,	  Col5a1,	  Fbn2,	  
Fmod,	  Loxl1,	  Ssg1,	  Thbs2	  
-­‐	  
Growth	  factor	   Igf2	   Ctgf	  
Membrane	  proteins	   Cd248,	  Colec12,	  Emp1,	  Lox	   -­‐	  
Neuropeptide	   Penk1	   -­‐	  
Others	   Igfbp2	   Cyr61	  
Receptors	   Cckar,	  Ngfr	   -­‐	  
Secreted	  factors	   Col18a1,	  Col3a1,	  Col5a1,	  Fbn2,	  
Fmod,	  Fstl1,	  Igf2,	  Igfbp2,	  Lox,	  
Loxl1,	  Loxl2,	  Megf6,	  Penk1,	  
Reg3b,	  Ssg1,	  Thbs2,	  Wif1	  
Ctgf,	  Cyr61,	  
Mmp3	  
Signaling	  protein	   Wif1	   -­‐	  
Solute	  carrier	   Slc14a2	   -­‐	  
Structural	  protein	   Prph1	   -­‐	  
Transcription	  factors	   Msx1,	  Nfatc4,	  Crem	   Klf4,	  Tbx15	  
Microarray gene expression profiling analysis was carried out using embryonic myelinating spinal cord 
cultures (Array 2). Illustrated in the table are the differentially expressed transcripts 4 hr and 24 hr after CNTF 
(cilliary neurotrophic factor) treatment in TnC-myelinating cultures. The transcripts up-regulated upon CNTF 
treatment are shown in red and the ones down-regulate are shown in green. The transcripts were categorised 
based on the classification in UniProt (http://www.uniprot.org/). Diff: differentially; reg: regulated.  
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Table 3. 13 Candidates selected from the comparison of TnC+CNTF vs TnC-control 
myelinating cultures to study further. 
Cand.	   Suggested	  
Effect	  on	  
Myelination	  
Supporting/Contradicting	  Evidence	   References	  
Thbs2	   inhibitory	   o Its	   expression	   increased	   in	  neurons,	  
microglia	  and	  As	  in	  CNS	  pathology.	  	  
o It	   promoted	   neurite	   growth	   and	  
synaptic	   formation	   in	   vitro	   and	   in	  
vivo.	  	  
o It	   was	   shown	   to	   regulate	   the	   levels	  
of	  MMP2	  whose	   inhibition	   leads	   to	  
incomplete	  myelin	  formation.	  	  
Bornstein,	  2001;	  Yang	  et	  
al.,	   2001;	   Lin	   et	   al.,	  
2003;	  Christopherson	  et	  
al.,	   2005;	   Liauw	   et	   al.,	  
2008;	   Eroglu	   et	   al.,	  
2009;	   Lehmann	   et	   al.,	  
2009;	   Huang	   et	   al.,	  
2013;	  	  
Wif1	   inhibitory	   o Inhibits	  Wnt	  signalling,	  known	  to	  act	  
in	  axon	  regeneration	  after	  SCI,	  
neurogenesis,	  axon	  and	  dendrite	  
development,	  differentiation	  of	  
neural	  progenitors,	  axon	  
synaptogenesis	  during	  
development,	  support	  of	  the	  
viability	  of	  neurons	  in	  adult	  brain.	  	  
o Wnt	  could	  promote	  olig	  maturation	  
and	  myelination	  in	  zebrafish.	  	  
o Dominant	  active	  Wnt	  signalling	  led	  
to	  hypomyelination	  in	  P15	  mouse	  
CNS.	  
Lee	  et	  al.,	  2004;	  	  
Li	  et	  al.,	  2005;	  	  
Gao	  et	  al.,	  2007,	  	  
Liu	  et	  al.,	  2008b;	  	  
Salinas	  and	  Zou,	  2008,	  
Toledo	  et	  al.,	  2008,	  
Fancy	  et	  al.,	  2009;	  	  
Yang	  et	  al.,	  2010;	  	  
Zhang	  and	  Ma,	  2010;	  
Hanafy	  and	  Sloane,	  
2011;	  Tawk	  et	  al.,	  2011;	  	  
Wu	  et	  al.,	  2012,	  	  
Chen	  et	  al.,	  2013	  
Ctgf	  
	  
	  
supportive	   o Ctgf/CTGF	   levels	   were	   increased	   in	  
different	   types	   of	   rat,	   mouse	   and	  
human	  CNS	  pathology.	  
o Suggested	   to	   play	   a	   role	   in	  
differentiation	   of	   As	   and	   oligs	   in	  
vitro.	  	  
o Inhibited	  olig	  maturation	  in	  vitro	  and	  
in	  vivo.	  	  
o CTGF	  treatment	  decreased	  the	   level	  
of	   myelination	   in	   embryonic	   rat	  
myelinating	  cultures.	  
Hertel	   et	   al.,	   2000;	  
Schwab	   et	   al.,	   2001;	  
Meeuwsen	   et	   al.,	   2003;	  
Spliet	   et	   al.,	   2003;	  
Ueberham	   et	   al.,	   2003;	  
Conrad	   et	   al.,	   2005;	  
Zhao	   et	   al.,	   2005b;	  
McClain	   et	   al.,	   2009;	  
Obayashi	   et	   al.,	   2009;	  
Stritt	   et	   al.,	   2009;	   Lu	  
and	   Ramanan,	   2012;	  
Zamanian	   et	   al.,	   2012;	  	  
Lamond	  et	  al.,	  2013	  
Microaray gene expression profiling analysis was carried out using embryonic rat spinal cord cultures plated 
on astrocyte monolayers on coverslips, coated with TnC (TnC-myelinating cultures). Illustrated in the table are 
the candidates selected as potential regulators of myelination based on their differential expression between 
the untreated and CNTF-treated TnC-myelinating cultures. Basic facts, which are/could be related to 
myelination-regulating roles, are also presented for these candidates with their references. As: astrocytes; 
Cand.: candidates; CNS: central nervous system; CTGF: connective tissue growth factor; Olig: 
oligodendrocyte; Thbs2:	  Thrombospondin	  2;	  TnC:	  tenascin	  C;	  Wif1:	  WNT	  inhibitory	  factor	  1.	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Among the transcripts differentially regulated upon CNTF treatment in TnC-cultures at 
24 hr were the transcripts of the secreted proteins Ctgf, Cyr61 and Mmp3 (Table 3.12), 
which were all up-regulated in the presence of CNTF and thus could be suggested as 
positive regulators of myelination. MMP3 was not selected as a myelination-regulating 
candidate to work with due to the above-mentioned reasons (Section 3.3.3.1). Ctgf and 
Cyr61, both members of the matricellular protein family CCN (CYR61/CTGF/NOV, Jones 
and Bouvier, 2014), are expressed in the human CNS (Schwab et al., 2001; Goodwin et 
al., 2010). Cyr61 has been studied mainly in terms of its effects in cancer (Sin et al., 
2008; Young et al., 2009; Goodwin et al., 2010; Haseley et al., 2012); whereas, CTGF 
(connective tissue growth factor) has been implicated to play a role in oligodendrocyte 
development and hence in myelination even though its effect appeared to be a negative 
one rather than a positive one (Table 3.13). Nash et al. (2011b) have also suggested 
CTGF as a negative regulator of myelination at the end of their microarray gene 
expression analysis (Array 1). They used neither exogenous THBS4 nor CTGF, though, to 
prove their possible negative effects on axonal ensheathment in myelinating cultures 
since the differential expression of the endogenous transcripts were not found to be 
significant by means of qRT-PCR. My results were based on myelinating cultures on 
astrocytes (Array 2), though, a more complex system compared to astrocyte monolayers 
alone (Array 1), where different results could thus be seen. The study showing the 
inhibitory effect of CTGF in axonal ensheathment (Lamond et al., 2013) had not been 
published yet at the time I chose the candidates to work with. Lamond et al (2013) have 
recently published that CTGF is secreted by Schwann cells at high levels, which inhibits 
myelination. However, it is possible that unlike the high levels of CTGF in Schwann 
cells, embryonic rat spinal cord myelinating cultures present lower levels of CTGF and 
that exogenous CTGF treatment of these cultures at different concentrations will show 
different results as protein levels may affect function. Thus, CTGF stood out as a strong 
candidate to show some effect on myelination, which required further investigation.  
Consequently, after detailed analysis of the comparison of TnC+CNTF vs TnC-control 
myelinating cultures, the following candidates were selected as possible myelination 
regulators to work with: CTGF, THBS2, and WIF1 (Table 3.13).  
3.3.3.3 PLL-control vs TnC-control myelinating cultures 
The comparisons that revealed the highest numbers of differentially regulated hits were 
PLL-control vs TnC-control myelinating cultures at both time points. At the early time 
point (4 hr) 131 genes and at the late time point (24 hr) 59 genes were differentially 
regulated (Table 3.14). There were 24 hits common between the two time points. Thus, 
approximately 64.5% of the changes took place only at 4 hr, leaving 21% to happen at 24 
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hr alone and 14.5% at both time points. Similar to the case seen for CNTF treatment in 
TnC-myelinating cultures, most of the expressional changes occurred at the early time 
point between PLL- and TnC-control cultures.  
Interestingly, Wif1 was among the down-regulated genes in PLL-control myelinating 
cultures compared to TnC-control ones at 4 hr, which would suggest that it is a negative 
regulator of myelination; whereas, Serpinb2 was up-regulated on PLL compared to on 
TnC, which proposed the likelihood of Serpinb2 being a positive myelination regulator. 
These observations are in accordance with the conclusions drawn after the above-
mentioned comparisons of PLL-control vs PLL+CNTF and TnC-control vs TnC+CNTF 
myelinating cultures. This provided stronger evidence for the possibility of these genes 
being associated with a negative effect on myelination.  
Penk1 (proenkephalin), Crh (corticotropin releasing hormone) and Vgf (neurosecretory 
protein VGF) were the up-regulated secreted factors in PLL-control cultures with the 
highest fold changes at 24 hr (3.39, 2.93, 2.62 respectively) and with less but still 
moderately high levels at 4 hr (3.34, 2.53, 1.90, respectively, Tables 3.14, 3.16). The 
differential regulation of Vgf was not seen at the end of any other comparisons. Crh was 
seen to be up-regulated over time in PLL+CNTF myelinating cultures (Table 3.6) but this 
expressional change did not appear to be directly related to CNTF treatment due to lack 
of significant expressional change of Crh upon CNTF treatment at either time points or 
over time in PLL-control myelinating cultures. Penk1, however, was significantly up-
regulated upon CNTF treatment in TnC-myelinating cultures at 4 hr (Table 3.11) with 
the second highest fold change among the up-regulated genes on that list. 
Consequently, PENK1 appears to be an essential candidate for a positive regulator of 
myelination. In contrast, there does not seem to be any proof in the literature to back 
up this theory, as it is a part of the opioid system, involved mainly in pain perception, 
cognitive functions, affective behaviours and locomotion (Diaz and Asai, 1990; Konig et 
al., 1996; Roques et al., 2000).  
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Table 3. 14 Differentially regulated genes detected at 4 hr and 24 hr between PLL- and TnC-
control myelinating cultures. 
at	  4	  hr	   	  	   	  	   	  	  
	  	   	  	   PLL	  control	  vs	  TnC	  control	  
PROBE_ID	   ILMN_GENE	   False	  Discovery	  
Rate	  
Fold	  
Change	  
ILMN_1373199	   KRT19	   0.006	   -­‐3.53	  
ILMN_1363606	   LCN2 	   0.006	   -­‐2.96	  
ILMN_1357368	   LOC497841	   0.005	   -­‐2.36	  
ILMN_1368490	   LOC24906	   0.004	   -­‐2.28	  
ILMN_1351900	   FCNB	   0.005	   -­‐1.99	  
ILMN_1364008	   KCNN4	   0.006	   -­‐1.93	  
ILMN_1359301	   IGF2	   0.006	   -­‐1.90	  
ILMN_1360484	   TBC1D17_PREDICTED	   0.011	   -­‐1.86	  
ILMN_1352911	   PLEK	   0.010	   -­‐1.84	  
ILMN_1349895	   RGD1565140_PREDICTED	   0.010	   -­‐1.83	  
ILMN_1348956	   FN1	   0.018	   -­‐1.82	  
ILMN_1360038	   CD37	   0.020	   -­‐1.82	  
ILMN_1348883	   TREM2_PREDICTED	   0.026	   -­‐1.79	  
ILMN_1354712	   COL1A2	   0.011	   -­‐1.77	  
ILMN_1364986	   WIF1 	   0.020	   -­‐1.76	  
ILMN_1374014	   SLC2A5	   0.012	   -­‐1.75	  
ILMN_1353896	   TLR2	   0.019	   -­‐1.74	  
ILMN_1376550	   H19	   0.011	   -­‐1.71	  
ILMN_1376842	   TAGLN	   0.017	   -­‐1.70	  
ILMN_1376635	   CYP1B1	   0.017	   -­‐1.69	  
ILMN_1371535	   CXCL11 	   0.018	   -­‐1.69	  
ILMN_1358836	   SLCO2B1	   0.042	   -­‐1.67	  
ILMN_1367546	   TBX15_PREDICTED	   0.005	   -­‐1.65	  
ILMN_1356721	   CCR1	   0.023	   -­‐1.62	  
ILMN_1374661	   LIPA	   0.026	   -­‐1.58	  
ILMN_1371160	   TRAF4AF1	   0.022	   -­‐1.58	  
ILMN_1368619	   ANXA3	   0.026	   -­‐1.56	  
ILMN_1376740	   GLIPR1	   0.023	   -­‐1.55	  
ILMN_1363050	   BUB1_PREDICTED	   0.035	   -­‐1.55	  
ILMN_1355463	   TLR3	   0.045	   -­‐1.55	  
ILMN_1350851	   P2RY14	   0.035	   -­‐1.54	  
ILMN_1367421	   CH25H	   0.011	   -­‐1.54	  
ILMN_1357053	   LPL	   0.038	   -­‐1.53	  
ILMN_1355260	   MSR2_PREDICTED	   0.036	   -­‐1.52	  
ILMN_1361476	   KIF11	   0.021	   -­‐1.52	  
ILMN_1366430	   LOC498363	   0.042	   -­‐1.51	  
ILMN_1374846	   MRC1_PREDICTED	   0.043	   -­‐1.50	  
ILMN_1364335	   CXCL10	   0.033	   -­‐1.50	  
ILMN_1365800	   RAC2	   0.046	   -­‐1.50	  
ILMN_1376765	   LCP1	   0.028	   -­‐1.49	  
ILMN_1372349	   ARHGDIB	   0.047	   -­‐1.49	  
ILMN_1352748	   SOSTDC1	   0.030	   -­‐1.48	  
ILMN_1359219	   AIF1	   0.034	   -­‐1.46	  
ILMN_1357030	   LAPTM5	   0.040	   -­‐1.46	  
ILMN_1353170	   RGD1309107	   0.028	   -­‐1.44	  
ILMN_1371182	   TLR7_PREDICTED	   0.034	   -­‐1.43	  
ILMN_1359930	   PAX3	   0.035	   -­‐1.43	  
ILMN_1359086	   FCGR3A	   0.014	   -­‐1.43	  
ILMN_1650502	   LOC362792	   0.034	   -­‐1.37	  
ILMN_1365447	   CRYAB	   0.014	   -­‐1.36	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ILMN_1366566	   CD68	   0.044	   -­‐1.30	  
ILMN_1354506	   ICAM1	   0.046	   -­‐1.29	  
ILMN_1357508	   REG3B	   0.029	   -­‐1.29	  
ILMN_1360048	   IGFBP2	   0.014	   -­‐1.07	  
ILMN_1372919	   CYR61	   0.016	   -­‐1.06	  
ILMN_1350836	   CCKAR	   0.003	   1.05	  
ILMN_1371407	   FMOD	   0.003	   1.16	  
ILMN_1371285	   MAFF_PREDICTED	   0.034	   1.18	  
ILMN_1366540	   LOC500721	   0.020	   1.24	  
ILMN_1353486	   SLC38A1	   0.035	   1.29	  
ILMN_1365894	   SERPINF1	   0.020	   1.31	  
ILMN_1371252	   RGD1563002_PREDICTED	   0.046	   1.37	  
ILMN_1354748	   OSGIN1	   0.036	   1.40	  
ILMN_1369005	   EGR1	   0.020	   1.44	  
ILMN_1370682	   ACSBG1	   0.049	   1.45	  
ILMN_1352960	   SPAG4	   0.048	   1.45	  
ILMN_1352810	   ARHGEF19_PREDICTED	   0.044	   1.46	  
ILMN_1360188	   NFIL3	   0.020	   1.47	  
ILMN_1357605	   RGD1564664_PREDICTED	   0.043	   1.48	  
ILMN_1354070	   ISG12(B)	   0.035	   1.51	  
ILMN_1350597	   DLX2	   0.034	   1.52	  
ILMN_1368902	   YPEL4	   0.034	   1.52	  
ILMN_1650120	   CLDN11	   0.028	   1.54	  
ILMN_1366187	   BAALC	   0.026	   1.54	  
ILMN_1370171	   NMBR	   0.046	   1.55	  
ILMN_1360404	   STC1	   0.027	   1.56	  
ILMN_1356628	   NFKBIA	   0.026	   1.57	  
ILMN_1368246	   NPTX2_PREDICTED	   0.024	   1.58	  
ILMN_1373804	   GPR103	   0.023	   1.59	  
ILMN_1375203	   PTP4A1	   0.023	   1.60	  
ILMN_1370828	   CTH	   0.022	   1.61	  
ILMN_1349422	   PTGS2	   0.022	   1.63	  
ILMN_1363228	   ELL2	   0.035	   1.63	  
ILMN_1363020	   PTPRN	   0.021	   1.63	  
ILMN_1373113	   RAB27B	   0.020	   1.65	  
ILMN_1355386	   LOC246266	   0.020	   1.65	  
ILMN_1353839	   PER1	   0.020	   1.65	  
ILMN_1354991	   LOC499837	   0.022	   1.66	  
ILMN_1370796	   RGD1565064_PREDICTED	   0.019	   1.67	  
ILMN_1362093	   EMD	   0.018	   1.68	  
ILMN_1650285	   HMOX1	   0.011	   1.70	  
ILMN_1373449	   TNNC2	   0.009	   1.72	  
ILMN_1365302	   SNF1LK	   0.009	   1.72	  
ILMN_1359665	   CHGB	   0.040	   1.74	  
ILMN_1360716	   SCG2	   0.014	   1.75	  
ILMN_1367103	   ADAMTS1	   0.024	   1.76	  
ILMN_1372537	   MSX1	   0.019	   1.82	  
ILMN_1370567	   LOC363410	   0.012	   1.83	  
ILMN_1363468	   OXNAD1_PREDICTED	   0.017	   1.83	  
ILMN_1356902	   CARTPT	   0.026	   1.84	  
ILMN_1364821	   LOC500720	   0.009	   1.86	  
ILMN_1357783	   HBEGF	   0.011	   1.87	  
ILMN_1364414	   VGF	   0.011	   1.90	  
ILMN_1368356	   FOS	   0.011	   1.92	  
ILMN_1356140	   LOC501170	   0.029	   1.93	  
ILMN_1367475	   ALDH1A1	   0.005	   2.02	  
ILMN_1376258	   DDIT4L	   0.009	   2.02	  
ILMN_1369914	   RASD1	   0.008	   2.04	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ILMN_1351517	   VIP	   0.007	   2.07	  
ILMN_1354131	   PORF1	   0.006	   2.09	  
ILMN_1358226	   USP2	   0.008	   2.11	  
ILMN_1366467	   DLX1	   0.011	   2.11	  
ILMN_1367180	   RGD1562092_PREDICTED	   0.006	   2.15	  
ILMN_1364960	   LOC497675	   0.005	   2.17	  
ILMN_2039673	   ARC	   0.005	   2.27	  
ILMN_1367486	   DUSP1	   0.005	   2.30	  
ILMN_1357890	   MMP12	   0.004	   2.34	  
ILMN_1355906	   NR4A2	   0.005	   2.36	  
ILMN_1376782	   ADCYAP1	   0.005	   2.39	  
ILMN_1351429	   SERPINB2 	   0.004	   2.42	  
ILMN_1358429	   CRH	   0.005	   2.53	  
ILMN_1360447	   BDNF	   0.004	   2.57	  
ILMN_1357978	   SLCO1C1	   0.005	   2.74	  
ILMN_1357229	   CCL2 	   0.004	   2.78	  
ILMN_1366023	   CCL7 	   0.004	   2.88	  
ILMN_1374218	   RIBC2	   0.004	   2.90	  
ILMN_1375922	   NR4A3	   0.005	   3.20	  
ILMN_1371574	   GEM_PREDICTED	   0.003	   3.24	  
ILMN_1352410	   PENK1	   0.004	   3.34	  
ILMN_1375833	   CREM	   0.003	   3.78	  
ILMN_1375583	   CREM	   0.003	   3.94	  
ILMN_1376694	   CREM	   0.002	   4.41	  
ILMN_1349555	   COQ10B	   0.003	   4.74	  
	  	   	  	   	  	   	  	  
at	  24	  hr	   	  	   	  	   	  	  
	  	   	  	   PLL	  control	  vs	  TnC	  control	  
PROBE_ID	   ILMN_GENE	   False	  Discovery	  
Rate	  
Fold	  
Change	  
ILMN_1376740	   GLIPR1	   0.018	   -­‐2.42	  
ILMN_1349895	   RGD1565140_PREDICTED	   0.029	   -­‐2.39	  
ILMN_1364744	   LOC294942	   0.007	   -­‐2.32	  
ILMN_1376635	   CYP1B1	   0.009	   -­‐2.25	  
ILMN_1376550	   H19	   0.011	   -­‐2.21	  
ILMN_1368490	   LOC24906	   0.011	   -­‐2.13	  
ILMN_1373199	   KRT19	   0.034	   -­‐1.99	  
ILMN_1361248	   LOC500428	   0.015	   -­‐1.97	  
ILMN_1374789	   LOC497804	   0.032	   -­‐1.92	  
ILMN_1364008	   KCNN4	   0.018	   -­‐1.91	  
ILMN_1372861	   ZDHHC20	   0.034	   -­‐1.91	  
ILMN_1360484	   TBC1D17_PREDICTED	   0.029	   -­‐1.87	  
ILMN_1367877	   FCGR3	   0.029	   -­‐1.86	  
ILMN_1348883	   TREM2_PREDICTED	   0.029	   -­‐1.86	  
ILMN_1361190	   RGD1559917_PREDICTED	   0.030	   -­‐1.84	  
ILMN_1370152	   RGD1565785_PREDICTED	   0.047	   -­‐1.83	  
ILMN_1357973	   LOC500829	   0.032	   -­‐1.82	  
ILMN_1354725	   LOC500490	   0.032	   -­‐1.82	  
ILMN_1370302	   LOC500755	   0.038	   -­‐1.78	  
ILMN_1649797	   LOC499560	   0.040	   -­‐1.76	  
ILMN_1369211	   LOC500949	   0.041	   -­‐1.74	  
ILMN_1649767	   LOC498896	   0.042	   -­‐1.74	  
ILMN_1361017	   LOC500398	   0.042	   -­‐1.73	  
ILMN_1353994	   P2RY12	   0.044	   -­‐1.72	  
ILMN_1359301	   IGF2	   0.047	   -­‐1.70	  
ILMN_1368071	   UBE1C	   0.047	   -­‐1.70	  
ILMN_1362483	   AXL	   0.047	   -­‐1.70	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ILMN_1367541	   S100A13_PREDICTED	   0.047	   1.59	  
ILMN_1363716	   SORL1_PREDICTED	   0.042	   1.61	  
ILMN_1359665	   CHGB	   0.041	   1.63	  
ILMN_1358491	   GSTM7	   0.034	   1.68	  
ILMN_1365716	   GSTM1	   0.039	   1.68	  
ILMN_1353193	   GLDC_PREDICTED	   0.034	   1.68	  
ILMN_1355484	   ROM1	   0.040	   1.68	  
ILMN_1366467	   DLX1	   0.032	   1.70	  
ILMN_1361016	   AGT	   0.042	   1.70	  
ILMN_1360716	   SCG2	   0.032	   1.71	  
ILMN_1376782	   ADCYAP1	   0.032	   1.72	  
ILMN_1371684	   LOC499103	   0.039	   1.73	  
ILMN_1367453	   GADD45G	   0.030	   1.73	  
ILMN_1367475	   ALDH1A1	   0.028	   1.76	  
ILMN_1364960	   LOC497675	   0.041	   1.76	  
ILMN_1376443	   ASCL1	   0.032	   1.77	  
ILMN_1365068	   S100A3	   0.029	   1.80	  
ILMN_1368575	   LGI4	   0.018	   1.82	  
ILMN_1364821	   LOC500720	   0.017	   1.87	  
ILMN_1353696	   HBB	   0.014	   1.87	  
ILMN_1351517	   VIP	   0.011	   1.95	  
ILMN_1359976	   GPR37L1	   0.032	   1.96	  
ILMN_1368643	   THRSP	   0.011	   2.00	  
ILMN_1353353	   ALK	   0.014	   2.17	  
ILMN_1363020	   PTPRN	   0.011	   2.33	  
ILMN_1357978	   SLCO1C1	   0.004	   2.47	  
ILMN_1364414	   VGF	   0.011	   2.62	  
ILMN_1358429	   CRH	   0.011	   2.93	  
ILMN_1372537	   MSX1	   0.018	   3.02	  
ILMN_2040370	   PPP1R1B	   0.004	   3.12	  
ILMN_1352410	   PENK1	   0.003	   3.39	  
ILMN_1361666	   MMP3	   0.000	   5.38	  
An Illumina array was carried out on myelinating spinal cord cultures of different phenotypes (Array 2). The 
genes differentially expressed between PLL- and TnC-control (untreated) myelinating cultures are listed in the 
table. RNA samples were collected from myelinating cultures, at 12 DIV, 4 hr and 24 hr after standard medium 
feeding. The transcripts highlighted in a black box were selected as potential regulators of myelination. Three 
biological replicates were used for the experiment. Gene fold changes are shown in the table. Negative and 
positive values represent the down-regulations and up-regulations, respectively. False discovery rate was 
designated as 5%. The genes highlighted in grey were differentially regulated at both time points. 
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Some of the secreted factors, differentially expressed at 4 hr between PLL-control and 
TnC-control myelinating cultures (Table 3.14), appeared to be temporarily up- or down-
regulated on specific substrates. Among the transcripts that were up-regulated only at 
4hr on PLL compared to those on TnC some were down-regulated over time in PLL- 
cultures but not differentially expressed over time in TnC- cultures (Table 3.15 A). 
Thus, these transcripts appeared to be related more with the changes occurring in PLL-
cultures rather than those in TnC-cultures as they clearly occurred on PLL alone when 
no treatments were present. These genes (Table 3.15 A1) formed a potential list of 
candidates that could be responsible for higher levels of axonal ensheathment on PLL 
cultures compared to TnC ones. On the other hand, the transcripts down-regulated only 
at 4 hr in PLL-control cultures compared to TnC-control cultures and down-regulated 
over time in TnC- cultures (Table 3.15 B2) represented the ones associated with the 
TnC-cultures and hence with the lower myelination levels seen in them compared to 
PLL-cultures in the absence of any treatments. We concentrated on the transcripts that 
could be associated with positive regulation of myelination (Table 3.15 A1). 
BDNF has been excluded from the list of genes of interest as it has previously been 
studied extensively. Its positive effects on myelin formation have been proposed in 
many studies before (Mitew et al., 2013; Song et al., 2013; From et al., 2014). PORF1 
and USP2 do not appear to be closely related to myelination functions as according to 
UniProt Database, PORF1 is a precursor for a gonadotropin regulatory hormone, a 
primary regulator in the neuroendocrine control of reproduction, (Krsmanovic et al., 
2003) and USP2 is listed to function in muscle organ and skeletal muscle tissue 
development, protein deubiquitination and stabilisation, myogenesis and transcription. 
The functions of HBEGF have been suggested as enhancement of the invasion of cancer 
cells (Bos et al., 2009), heart and embryonic development (Hope et al., 2004; Kimber et 
al., 2008), gonadotropin-related activation (Shah et al., 2004) and promoting astrocyte 
survival in serum-free culture (Foo et al., 2011). Finally, Serpinb2 and Ccl2 have been 
chosen to continue to work with from the list in Table 3.15 A1 based on the evidence 
suggesting that they may be playing a role in myelination (Table 3.16). 
CCL2 is a chemokine associated with the migration of macrophages and leukocytes into 
the CNS during pathology. CCL2 expression has been shown to be raised in a cuprizone-
induced demyelination model, where putative second inflammatory response generated 
both pro- and anti-inflammatory cytokines and increased the expression of CCR2, the 
CCL2 receptor, within a short time window (Biancotti et al., 2008). The authors 
suggested that this might present a microenvironment conductive for recruitment of 
astrocytes, neural progenitors and OPCs for the process of further injury or repair 
(Biancotti et al., 2008). The balance between further injury and repair could be one of 
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Table 3. 15 Temporary expressional changes detected between PLL-control and TnC-control 
myelinating cultures. 
	   Explanation	   	   Explanation	  
A)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
éPLL	  	  	  	  	  
	  	  	  	  	  vs	  
	  	  	  	  TnC	  
	  at	  4	  hr	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
64	  transcripts	  	  were	  up-­‐regulated	  
in	   PLL-­‐control	   cultures	   compared	  
to	   TnC-­‐control	   cultures	   at	   4	   hr	   ,	  
not	  at	  24	  hr.	  
B)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
êPLL	  	  	  	  	  
	  	  	  	  	  vs	  
	  	  	  	  TnC	  
	  at	  4	  hr	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   
45	  transcripts	   	  were	  down-­‐
regulated	   in	   PLL-­‐control	  
cultures	   compared	   to	   TnC-­‐
control	   cultures	   at	   4	   hr	   ,	  
not	  	  at	  24	  hr.	  
1)	  PLL	  ê 	   
	  or	  	  
2)	  TnCé	  	  	  	  	  
over	  time	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
In	   order	   for	   these	   64	   transcripts	  
to	   reach	   similar	   levels	   of	  
expression	   between	   PLL-­‐	   and	  
TnC-­‐cultures	   at	   24	   hr,	   they	  must	  
be	  either	  1)	  down-­‐regulated	  over	  
time	   on	   PLL	   or	   2)	   up-­‐regulated	  
over	  time	  on	  TnC.	  
1)	  PLL	  é 	   
	  or	  	  
2)	  TnCê	  	  	  	  	  
over	  time	  
In	   order	   for	   these	   42	  
transcripts	   to	   reach	   similar	  
levels	   of	   expression	  
between	   PLL-­‐	   and	   TnC-­‐
cultures	  at	  24	  hr,	  they	  must	  
be	   either	   1)	   up-­‐regulated	  
over	   time	   on	   PLL	   or	   2)	  
down-­‐regulated	   over	   time	  
on	  TnC.	  
Transcripts	   Transcripts	  
A1)	   Bdnf	   (brain-­‐derived	   neurotrophic	   factor	   ),	  
Ccl2	   (chemokine	   ligand	   2)	   ,	   Hbegf	   (heparin-­‐
binding	  EGF-­‐like	  growth	  factor),	  Porf1	  (preoptic	  
regulatory	  factor	  1	  ),	  Serpinb2	  (serpin	  peptidase	  
inhibitor),	  Usp2	  (ubiquitin	  specific	  peptidase	  2)	  
B1)	  none	  
A2)	  none	   B2)	   Cyr61	   (cysteine-­‐rich,	   angiogenic	  
inducer,	   61),	   Fcnb	   (ficolin	   B),	   Igfbp2	  
(insulin-­‐like	  growth	  factor	  binding	  protein	  
2)	  
Microarray gene expression profiling analysis was carried out using embryonic myelinating spinal cord 
cultures (Array 2). RNA samples were collected 4 hr and 24 hr after standard medium feeding from PLL- and 
TnC- control (untreated) myelinating cultures. The transcripts that were differentially regulated between PLL- 
and TnC-control myelinating cultures at both time points (4 hr, 24 hr) were excluded from those at 4 hr. Their 
differential expression at 4 hr but not at 24 hr meant that they were up/down-regulated at the early time point 
temporarily. In order for these transcripts to reach similar expressional levels at 24 hr between PLL- and TnC- 
cultures, the changes explained above should have taken place. The transcripts that were up-regulated at 4 hr 
in PLL-cultures compared to TnC-cultures but were down-regulated over time in PLL-cultures are shown in 
A1. Those that were down-regulated at 4 hr on PLL compared to that on TnC and were down-regulated over 
time on TnC are presented in B2. There were no transcripts up-regulated over time to overcome the initial 
differential expression between PLL- and TnC-cultures (A2 and B1).  
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the reasons for contradicting results for the effect of CCL2 in CNS pathologies (Table 
3.17), e.g., exacerbating the disease in EAE mice (Glabinski et al., 2003) but helping the 
EAE mice to recover faster when overexpressed (Elhofy et al., 2005). In addition, the 
deteriorating effect of CCL2 in EAE onset and development could be that it provides 
adherence of leukocytes to the pia mater vasculature and thus increases the BBB 
permeability rather than recruiting the phagocytic immune cells from the periphery or 
than having a direct effect on axonal ensheathment or repair (Huang et al., 2005; Dos 
Santos et al., 2005; Yao and Tsirka, 2011). In addition, another chemokine CXCL13 has 
been shown to enhance myelination despite its elevated levels in EAE spinal cords and 
CNS of MS patients (Yuan et al., 2013). The contradicting results suggest how 
complicated the role of CCL2 could be in EAE. It might be crucial for the right 
concentrations of CCL2 to be obtained in the microenvironment to prevent and/or 
recover from pathology. 
Ccl7 was another chemokine up-regulated in PLL-control cultures at 4 hr (Table 3.14), 
suggesting a possible positive role in myelination. CCL7 expression might be affected by 
Th1 (activated helper T cell) response since the pro-inflammatory cytokines IL-1β and 
TNF-α have been shown to increase the levels of both Ccl2 and Ccl7 in primary rat and 
macaque astrocyte cultures (Thompson and Eldik, 2009; Renner et al., 2011). It is likely 
that CCL7 plays a role in chemotaxis of peripheral mononuclear cells into the CNS in 
pathology (Okada et al., 2009; Renner et al., 2011). In accordance with that suggestion, 
the expression of Ccr1, a CCL7 receptor, was detected in the infiltrating macrophages 
but not in astrocytes, microglia or T-cells in EAE mice (Sunnemark et al., 2003). Ccr1 
expression correlated with the clinical symptom severity probably related to the higher 
numbers of infiltrating cells due to higher CCR1 levels (Sunnemark et al., 2003). CCL7 
has also been suggested as a factor that influences neuronal differentiation and 
neuritogenesis (Edman et al., 2008). Despite its predominant immune system-related 
functions in the CNS, CCL7 is still likely to affect axonal ensheathment directly or 
indirectly as seen in the case of CXCL10 (Nash et al., 2011b). 
Among the differentially regulated secreted factors between PLL- and TnC-cultures, the 
other two interesting candidates were the chemokines Cxcl10 and Cxcl11. Cxcl10 has 
been shown before to be inhibitory to myelination in embryonic rat spinal cord cultures 
(Nash et al., 2011b). Cxcl11, however, has not been studied in such circumstances 
before. Its down-regulation in PLL-myelinating cultures compared to TnC-cultures 
suggests an inhibitory role for CXCL11 in myelination. The potential role of CXCL11 in  
MS pathogenesis has been suggested to be related to its capability to recruite the 
activated CXCR3+ Th1 cells to the sites of inflammation (Szczucinski et al., 2007), a  
 
 
103 
 
Table 3. 16 Categorisation of the differentially regulated genes at 4 hr and 24 hr between 
PLL- and TnC-control myelinating cultures. 
	  
4	  hr	   24	  hr	  
Categories	   Differentially	  regulated	  genes	   Diff.	  reg.	  genes	  
Cell	  junction	  
protein	  
Cldn11	   -­‐	  
Coenzyme	   Coq10b	   -­‐	  
Developmental	  
proteins	  
Arc,	  Dlx1	   Ascl1,	  Dlx1,	  
Gadd45g	  
Enzymes	   Bub1,	  Ch25h,	  Cyp1b,	  Kif11,	  Lipa,	  Lpl,	  Rac2,	  
Tbc1d17,	  Acsbg1,	  Adamts1,	  Aldh1a1,	  Cth,	  
Dusp1,	  Emd,	  Hmox1,	  Mmp12,	  Oxnad1,	  Per1,	  
Ptgs2,	  Ptp4a1,	  Ptprn,	  Serpinb2,	  Serpinf1,	  
Snf1lk,	  Usp2	  
Axl,	  Cyp1b,	  
Tbc1d17,	  Ube1c,	  
Agt,	  Aldh1a1,	  Alk,	  
Gldc,	  Gstm1,	  
Gstm7,	  Mmp3,	  
Ppp1r1b,	  Ptprn	  	  
Extracellular	  matrix	  
proteins	  
Col1a2,	  Fcnb,	  Fn1,	  Fmod	   Mmp3	  
Growth	  factor	   Igf2,	  Hbegf,	  Vgf	   Igf2,	  Vgf	  
Hormones	  and	  
neuropeptides	  
	  Adcyap1,	  Bdnf,	  Cartptp,	  Chgb,	  	  Crh,	  Porf1,	  
Penk1,	  Stc1,	  Vip	  	  
Adcyap1,	  Chgb,	  
Crh,	  Vip,	  Penk1	  
Immune	  system	  
proteins	  
Ccr1,	  Cd37,	  Cxcl10,	  Cxcl11,	  Fcgr3a,	  Lcn2,	  
Reg3b,	  Tlr2,	  Tlr3,	  Tlr7,	  Ccl2,	  Ccl7,	  Kcnn4	  
Fcgr3,	  Kcnn4	  
Membrane	  
proteins	  
Cd68,	  Glipr1,	  Laptm5,	  Isg12(b),	  Spag4	   Glipr1,	  Rom1	  
Others	   Anxa3,	  H19,	  Icam1,	  Kcnn4,	  Plek,	  Traf4af1,	  
Baalc,	  Dlx2,	  Ddit4l,	  Nptx2,	  Osgin1,	  Ribc2,	  
Ypel4	  
H19,	  Zdhhc20,	  Hbb,	  
Lgi4,	  S100a13,	  
S100a3,	  Thrsp	  
Receptors	   Ccr1,	  Fcgr3a,	  Mrc1,	  Msr2,	  P2ry14,	  Tlr2,	  Tlr3,	  
Tlr7,	  Trem2,	  Cckar,	  Gpr103,	  Nmbr	  
P2ry12,	  Trem2	  
Gpr37l1,	  Sorl1	  	  
Secreted	  factors	   Col1a2,	  Cxcl10,	  Cxcl11,	  Cyr61,	  Fcnb,	  Fn1,	  
Igf2,	  Igfbp2,	  Lcn2,	  Reg3b,	  Wif1,	  Adamts1,	  
Adcyap1,	  Bdnf,	  Cartpt,	  Ccl2,	  Ccl7,	  Chgb,	  Crh,	  
Fmod,	  Hbegf,	  Mmp12,	  Nptx2,	  Penk1,	  Porf1,	  
Serpinb2,	  Serpinf1,	  Stc1,	  Usp2,	  Vgf,	  Vip	  
Igf2,	  Adcyap1,	  
Chgb,	  Crh,	  Gldc,	  
Gstm1,	  Lgi4,	  
Mmp3,	  Penk1,	  
S100a13,	  Vgf,	  Vip	  	  
Signaling	  protein	   Arhgdib,	  Sostdc1,	  Wif1,	  Arhgef19,	  Gem,	  
Nfkbia,	  Rab27b,	  Rasd1	  
-­‐	  
Solute	  carrier	   Slc2a5,	  Slco2b1,	  Slc38a1,	  Slco1c1	   Slco1c1	  
Structural	  protein	   Aif1,	  Cryab,	  Krt19,	  Lcp1,	  Tagln,	  Tnnc2	   Krt19	  
Transcription	  
factors	  
Pax3,	  Tbx15,	  Crem,	  Ell2,	  Egr1,	  Fos,	  Maff,	  
Msx1,	  Nfil3,	  Nr4a2,	  Nr4a3,	  Scg2	  	  
Ascl1,	  Msx1,	  Scg2	  	  
Microarray gene expression profiling analysis was carried out using embryonic myelinating spinal cord 
cultures (Array 2). Illustrated in the table are the differentially expressed transcripts 4 hr and 24 hr after 
standard medium feeding between PLL- and TnC- control (untreated) myelinating cultures. The transcripts up-
regulated on PLL are shown in red and the ones down-regulated are shown in green. The transcripts were 
categorised based on the classification in UniProt (http://www.uniprot.org/). Diff: differentially; reg: regulated.  
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Table 3. 17 Candidates selected from the PLL-control vs TnC-control myelinating cultures 
comparison to study further. 
Cand.	   Suggested	  
Effect	  on	  
Myelination	  
Supporting/Contradicting	  
Evidence	  
References	  
Ccl2	   supportive	   o Elevated	   levels	   in	   the	   CNS	   of	  
EAE	  mice	  and	  in	  MS	  lesions.	  	  
o Inhibition	   of	   its	   expression	   in	  
mouse	   As	   reduced	   EAE	  
severity.	  
o Treatment	  of	  the	  animals	  with	  
a	  malfunctioning	  CCL2	  protein	  
delayed	   the	   onset	   of	   EAE	   and	  
decreased	   demyelination	   and	  
axonal	  loss.	  
o Th1	   response	   compromised	   in	  
mice	   constitutively	   expressing	  
CCL2	   in	   their	   As.	   These	   mice	  
exhibited	   less	   severe	   EAE	  
despite	   the	   presence	   of	  
enhanced	   numbers	   of	  
mononuclear	   cells	   infiltrates	  
into	  the	  CNS	  compared	  to	  wild	  
types.	  
McManus	   et	   al.,	   1998;	  
Vorn	   et	   al.,	   1999;	  
Glabinski	  et	  al.,	  2003;	  	  
Elhofy	  et	  al.,	   2005;	  Dos	  
santos	   et	   al.,	   2005;	  
Tanuma	   et	   al.,	   2006;	  	  
Biancotti	   et	   al.,	   2008;	  
Dogan	   et	   al.,	   2008;	  	  	  	  
Brini	  et	  al.,	  2009	  	  	  	  
Zaheer	   et	   al.,	   2012;	  
Hidaka	  et	  al.,	  2014	  	  
Paul	  et	  al.,	  2014	  	  
Ccl7	   supportive	   o Elevated	  in	  MS	  lesions	  and	  in	  
some	  EAE	  rat	  models.	  
o Inlfuences	  neuronal	  
differentiation	  and	  
neuritogenesis.	  
McManus	  et	  al.,	  1998;	  
Edman	  et	  al.,	  2008;	  
Zheng	  and	  Zhang,	  2014	  
Cxcl11	   inhibitory	   o Elevated	  levels	  present	  in	  the	  
CSF	  and	  sera	  of	  MS	  patients.	  
o Its	  expression	  was	  increased	  in	  
the	  CNS	  of	  EAE	  mice.	  
Hamilton	   et	   al.,	   2002;	  
McColl	   et	   al.,	   2004;	  
Szczucinski	  et	  al.,	  2007;	  
Jernas	  et	  al.,	  2012;	  	  
	  
Lcn2	   inhibitory	   o See	  Table	  3-­‐11.	   See	  Table	  3-­‐11.	  
Serpinb2	   supportive	   o See	  Table	  3-­‐11.	   See	  Table	  3-­‐11.	  
Wif1	   inhibitory	   o See	  Table	  3-­‐14.	   See	  Table	  3-­‐14.	  
Microaray gene expression profiling analysis was carried out using embryonic rat spinal cord cultures plated 
on astrocyte monolayers on coverslips, coated with PLL or TnC (PLL-myelinating cultures, TnC-myelinating 
cultures). Illustrated in the table are the candidates selected as potential regulators of myelination based on 
their differential expression between the untreated PLL- and TnC-myelinating cultures. Basic facts, which 
are/could be related to myelination-regulating roles for these candidates are also presented in the table with 
their references. As: astrocytes; Cand.: candidates; CCL2: chemokine (C-C motif) ligand 2; CCL7: chemokine 
(C-C motif) ligand 7; CNS: central nervous system; factor 1; CSF: cerebrospinal fluid; CXCL11: chemokine (C-
X-C motif) ligand 11; EAE: Experimental autoimmune encephalomyelitis; Lcn2: lipocalin 2; MS: multiple 
sclerosis; Serpinb2: serpin peptidase inhibitor clade B member 2; Wif1: Wnt inhibitory factor 1. 
 
 
 
 
105 
 
hypothesis that was contradicted by another study (Liu et al., 2006). The increased 
expression of this chemokine in EAE and MS lesions could suggest a negative role for it in 
terms of myelination. This suggestion is in agreement with its proposed effect on 
myelination revealed by Array 2 analysis. 
Based on the comparison of differentially regulated genes between PLL- and TnC-
untreated myelinating cultures, Ccl2, Ccl7 and Serpinb2 were selected as potential 
positive regulators and Cxcl11, Lcn2 and Wif1 were selected as potential negative 
regulators of myelination (Table 3.17).   
3.4 Conclusions and discussion 
3.4.1 Astrocyte monolayers (Array 1) vs embryonic spinal cord 
myelinating cultures (Array 2) 
The only common analysis between the microarray gene expression profiling of 
astrocyte monolayers (Array 1, Nash et al., 2011b) and the myelinating cultures (Array 
2) is the comparison of PLL-control vs TnC-control conditions at 4 hr (Tables 3.2 and 
3.3). Only 22% (7 genes/gene loci) of the differentially regulated astrocytic transcripts 
found in Array 1 were also differentially expressed in myelinating cultures (Array 2, 
Table 3.18). Failure to detect the differential expression of the rest of the transcripts 
could be due to the crosstalk between the astrocytes and the other CNS cell types, 
namely astrocytes, oligodendrocytes or their precursors, microglia, and neurons from 
the spinal cords. 
One example for such a crosstalk is the tripartite synapses, where astrocyte processes 
can interact with both presynaptic and postsynaptic elements of the synapse and hence 
with the neurons (Araque et al., 1999). The neurotransmitters in the synaptic cleft can 
trigger astrocytic signalling pathways that would result in the secretion of 
gliotransmitters, which can activate the receptors at the pre- and post-synaptic neuron 
(Reviewed in Haydon et al., 2007 and in Orellana and Stehberg, 2014). The solute 
carrier (SLC) transport proteins at the membranes of both astrocytes and neurons are 
indispensable for such a complex functioning. Interestingly, the SLCs up-regulated in 
PLL-control astrocytes (Array 1) are Slc22a3 and Slc4a4, which were not differentially 
regulated between PLL- and TnC-control myelinating cultures (Array 2). Slc4a4 could 
contribute to acid/base homeostasis and glycolysis regulation in astrocyte monolayers 
(Array 1, Ruminot, 2011; Theparambil et al., 2014), which could be a possible intrinsic 
attempt of the astrocytes to prepare a homeostatic environment for themselves, 
neurons and other CNS cells. Slc22a3, as well, could contribute to such a homeostasis by 
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regulating the concentrations of all four amines (Vialou et al., 2008). The loss of their 
differential regulation in Array 2 could be because the older astrocytes (12 DIV as 
opposed to 7-8 DIV cells in Array 1) in myelinating cultures adapt different functions or 
because the crosstalk between astrocytes and neurons leads the astrocytes to new 
functions, leaving the ones involved in the maintenance of homeostasis at minimal 
levels. In addition, new SLCs were found to be differentially regulated in myelinating 
cultures (Array 2), where it is likely that CNS cell types other than astrocytes express 
them. However, for example Slco1c1 has been shown to be expressed predominantly in 
astrocytes in the brain and to be responsible for the transport of thyroxin and 
prostaglandins across the BBB (Baklaushev, 2013), a complex function, for which the 
astrocytes in the myelinating cultures could be becoming ready despite the lack of any 
vasculature in these cultures.  
Astrocytes could also have crosstalk with microglia or oligodendrocytes in myelinating 
cultures (Array 2). Astrocytes express a variety of pattern recognition receptors (PRRs) 
that include Toll-like receptors (TLRs), mannose receptors, scavenger receptors and 
complement receptors (Farina et al., 2007). Following the activation of such receptors, 
astrocytes secrete cytokines, chemokines and neurotrophins that target other CNS cells 
(Farina et al., 2007; Tian et al., 2012). Those other cells can re-activate or inhibit the 
astrocytic receptors in return, which would affect the secretion profile of astrocytes. 
The initial activation of the receptors could also be influenced by the factors expressed 
by the CNS cells other than astrocytes. In astrocyte monolayers (Array 1), only Cxcl10 
was seen to be differentially regulated between PLL- and TnC-control conditions; 
however, in myelinating cultures (Array 2), Ccl2, Ccl7 and Cxcl11 were also 
differentially expressed in addition to Cxcl10. The differential expression of these three 
chemokines in Array 2 could be due to the astrocyte-CNS cells’ crosstalk mentioned 
above.  
There were seven transcripts that were differentially regulated between PLL- and TnC- 
conditions in both astrocyte monolayers (Array 1) and in myelinating cultures (Array 2, 
Table 3.18). Igfbp2 was the only transcript that showed a different direction of change 
in each array, i.e. up-regulated in astrocyte monolayers and down-regulated in 
myelinating cultures. This suggests that either the mixed spinal cord cells in the 
myelinating cultures are expressing Igfbp2 in an opposite dominant way to that 
expressed by astrocytes in the supporting astrocyte monolayer underneath or that the 
presence of these cells has an effect on the astrocyte monolayer resulting in a down-
regulation of Igfbp2 instead of up-regulating it on PLL. One explanation for this 
difference could be the change of medium in which the cultures are maintained. The 
astrocyte monolayers are maintained in a medium with 10% serum; while, the medium  
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Table 3. 18 The common transcripts that were differentially regulated in the comparison of 
PLL-cultures vs TnC-cultures at 4 hr in astrocyte monolayers (Array 1) and in myelinating 
cultures (Array 2). 
Transcripts	   Change	   Key	  features	   References	  
Aldh1a1	  	  
(Aldehyde	  
dehydrogena
se	  1	  family,	  
member	  A1)	  
	  
Up	   o Catalyses	  the	  conversion	  of	  aldehydes	  
to	  the	  corresponding	  acids.	  Can	  
produce	  9-­‐cis-­‐retinoic	  acid,	  shown	  to	  be	  
stimulatory	  for	  myelination.	  
o More	  highly	  expressed	  in	  As	  from	  P17-­‐
30	  mice	  compared	  to	  in	  neurons,	  OPCs	  
and	  oligs.	  
o Its	  expression	  increases	  during	  the	  
development	  of	  the	  human	  CNS.	  
o Highly	  expressed	  in	  mature	  human	  As	  
but	  not	  in	  neurons	  or	  oligs.	  
Niederreither	  et	  al.,	  
2002;	  	  	  	  	  	  	  	  
Cahoy	  et	  al.,	  2008;	  
Huang	  et	  al.,	  2011	  
Adam	  et	  al.,	  2012	  	  
Paterson	  et	  al.,	  2013	  
Igfbp2	  	  
(Insulin-­‐like	  
growth	  
factor	  
binding	  
protein	  2)	  
As:	  	  	  	  	  
Up	  
MC:	  
Down	  
o The	  predominant	  insulin-­‐like	  growth	  
factor	  binding	  protein	  in	  the	  CNS	  and	  
CSF.	  	  
o Expressed	  in	  some	  neurons,	  microglia,	  
oligs	  and	  As.	  
o Can	  bind	  to	  the	  growth	  factors	  IGF1	  and	  
IGF2,	  present	  in	  the	  CNS.	  
o Prevents	  IGF2	  signaling	  by	  inhibiting	  the	  
interaction	  of	  IGF2	  with	  its	  receptor.	  
o IGF1/2-­‐IGFBP2	  binding	  will	  prolong	  the	  
half-­‐life	  of	  IGFs	  and	  will	  help	  them	  to	  be	  
carried	  and	  released	  in	  the	  vicinity	  of	  
the	  target	  cells.	  
Baxter	  and	  Martin,	  
1989;	  Ocrant	  et	  al.,	  
1990;	  Roghani	  et	  al.,	  
1991;	  Jones	  and	  
Clemmons,	  1995;	  	  	  	  	  	  	  	  	  	  	  	  	  
Collett-­‐Solberg	  and	  
Cohen,	  1996;	  Baxter,	  
2000;	  O’donnell	  et	  
al.,	  2002;	  Chesik	  et	  
al.,	  2004;	  Chesik	  et	  
al.,	  2007;	  	  Sim	  et	  al,	  
2009;	  Fletcher	  et	  al.,	  
2013	  	  
Cxcl10	  	  
(Chemokine	  
ligand	  10)	  
Down	   o Is	  a	  microglia/macrophage	  attractant.	  	  
o Highly	  expressed	  at	  the	  rim	  of	  
demyelinating	  MS	  plaques.	  
o As	  were	  suggested	  as	  the	  major	  source	  
of	  Cxcl10	  mRNA	  expression	  in	  
cuprizone-­‐induced	  demyelination.	  
o Is	  also	  expressed	  by	  microglia	  upon	  
INFγ	  treatment.	  
o Inhibited	  myelination	  levels	  in	  
embryonic	  rat	  spinal	  cord	  MC.	  
Tanuma	  et	  al.,	  2006;	  
Carter	  et	  al.,	  2007;	  	  
Van	  zwam	  et	  al.,	  
2010;	  Nash	  et	  al.,	  
2011;	  Skripuletz	  et	  
al.,	  2013	  
Fn1	  	  
(Fibronectin	  
1)	  
Down	   o Extracellular	  matrix	  glycoprotein.	  
o Specifically	  localises	  in	  areas	  of	  
demyelination	  in	  MS	  and	  EAE.	  Injection	  
of	  FN1	  aggregates	  into	  lesions	  and	  
inhibits	  olig	  differentiation	  and	  
remyelination.	  
o Expression	  is	  increased	  in	  
microglia/macrophages	  and	  reactive	  As	  
in	  the	  rat	  brain	  upon	  cryoinjury.	  	  
o FN1	  expressed	  in	  As	  of	  injured	  CNS	  may	  
play	  a	  role	  in	  the	  formation	  of	  the	  glial	  
scar.	  
Camand	  et	  al.,	  2004;	  
Stenzel	  et	  al.,	  2011;	  
Kim	  et	  al.,	  2013;	  
Stoffels	  et	  al.,	  2013	  
Krt19	  	   Down	   o Intermediate	  filament	  protein,	  
expressed	  in	  epithelia,	  such	  as	  the	  small	  
	  Omary	  et	  al.,	  2009	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(Keratin	  19)	   intestine,	  colon,	  exocrine	  pancreas,	  
bladder,	  gallbladder,	  and	  ductal	  cells	  of	  
liver.	  
Loc497841	   Down	   o Unidentified,	  hypothetical	  gene	  	   NCBI/Gene	  
Tagln	  	  
(Transgelin)	  
Down	   o Suggested	  to	  play	  a	  role	  in	  
neuroprotection	  of	  ischemic	  rat	  cortical	  
neurons.	  
o Increased	  expression	  in	  rat	  spinal	  cord	  
after	  SCI	  was	  interpreted	  as	  a	  possible	  
role	  in	  the	  response	  to	  tissue	  damage	  
or	  the	  repair	  following	  SCI.	  
Lin	  et	  al.,	  2005;	  
Prasad	  et	  al.,	  2012;	  
Microarray gene expression profiling analysis was carried out using astrocyte monolayers (Array 1, Nash et 
al., 2011b) and embryonic myelinating spinal cord cultures (Array 2). RNA was collected 4 hr after standard 
medium feeding from 7-8 DIV old astrocyte monolayers (Array 1) or 12 DIV old embryonic spinal cord 
myelinating cultures (Array 2). The differentially regulated transcripts between PLL- and TnC-astrocyte 
monolayers were compared with those between PLL- and TnC-myelinating cultures. Illustrated in the table are 
the 7 common transcripts detected in that comparison. As: astrocytes; Change: Direction of differential 
regulation; MC=myelinating cultures; olig: oligodendrocyte; SCI: spinal cord injury. 
 
for myelinating cultures have defined hormones in the absence of serum (Table 2.1). 
Chesik et. al.(2004) have demonstrated that 10% serum could enhance IGFBP2 
expression in astrocytes as opposed to those maintained in chemically defined, insulin- 
and serum-free medium. Thus, it is possible that the factors in the media affect the 
astrocyte reactivity and in addition alter their gene expressions on different substrates 
in a different way. Interestingly, Igfbp2 expression is induced upon CNS injury in 
reactive astrocytes and reactive microglia (Chesik et al., 2004; O’donnell et al., 2002; 
Fletcher et al., 2013). Since PLL-astrocytes have been indicated to be more reactive 
than TnC-astrocytes due to their increased GFAP expression (Nash et al., 2011b), the 
up-regulation of Igfbp2 in PLL-astrocyte monolayers is in accordance with the previous 
studies. Therefore, the down-regulation of Igfbp2 in PLL-myelinating cultures compared 
to TnC-myelinating cultures (Array 2) could also suggest that these two culture types 
are reversed in terms of astrocyte reactivity compared to astrocyte monolayers alone 
(Array 1).  
In young astrocyte cultures (as in Array 1), the primary role of IGFBP2 could be 
preventing IGF1, the major insulin growth factor in fetal tissues (Bondy et al., 1992), 
from degradation and thereby preparing a more suitable environment for healthy 
cultures that will support myelination in the future since IGF1 has been shown to 
stimulate migration and differentiation of oligodendrocyte precursor cells and promote 
remyelination (Kuhl et al, 2002; Yao et al., 1996; Li et al., 1998). In this case, the 
increased IGFBP2 levels in PLL-astrocytes will contribute towards a more myelination-
supportive phenotype compared to TnC-astrocytes.  
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Both IGFBP2 and IGF2 have been detected in the myelin sheaths of individual 
myelinated fibers of all of the major nerve tracts in adult rats (Logan et al., 1994).  
Conversely, in the later stages of the cultures (as in Array 2), the predominant function 
of IGFBP2 could be blocking the IGF1/2 signalling maybe to prevent myelination or 
further maturation of oligodendrocytes at a time when the axons or other components 
in the environment are not yet ready for myelination. It is possible that in the 
myelinating spinal cord cultures, IGFBP2 binding to IGFs prevents their positive effects 
on myelination. So it could be considered that the suppression of IGFBP2 will allow a 
supportive phenotype in PLL-myelinating cultures (Array 2). The lowered Igfbp2 levels in 
PLL-myelinating cultures could also be to accompany depressed Igf2 levels (Table 3.14). 
In either case, despite its proven roles on myelination, the controversial roles of IGFBP2 
make it a difficult candidate to use in the myelinating cultures. 
Detection of the differentially regulated astrocytic factors between PLL- and TnC- 
myelinating cultures (Table 3.18) confirmed the previous study that was done using 
astrocyte monolayers alone (Array 1, Nash et al., 2011b). The up-regulation of Aldh1a1 
in PLL-cultures compared to TnC-cultures would suggest that it has a stimulatory effect 
on myelination based on the previous findings showing higher levels of myelination in 
PLL-cultures (Nash et al., 2011b). On the other hand, down-regulation of Cxcl10, Fn1, 
Krt19 and Tagln in PLL-cultures would suggest a negative role for these molecules on 
myelination. Indeed, the supporting evidences are in agreement with most of these 
findings (Table 3.18). Krt19 has not been reported to be expressed in the CNS to our 
knowledge. Thus, its detection in the astrocyte monolayers in Array 1 (Nash et al., 
2011b) and in the myelinating cultures in Array 2 is very interesting. Because astrocytes 
on PLL and TnC can present different morphologies, the differential regulation of this 
intermediate filament protein could be one of the factors playing a role in this 
difference (Holley et al., 2005). Therefore, out of these seven common transcripts 
(Table 3.18), differentially regulated in astrocyte monolayers and in myelinating 
cultures on different substrates, Aldha1a1, Fn1 and Tagln stand out as potential 
candidates to play a role in myelination and require further investigation.    
3.4.2 Candidates that appear to be important for myelination in 
both PLL- and TnC-myelinating cultures 
The analysis of the expressional changes in PLL- and TnC-myelinating cultures upon 
CNTF treatment revealed FMOD and CREM as common possible myelination-regulators 
stimulated by the CNTF effect (Section 3.3.2.1). IPA diagrams presented interactions of 
Fmod and Crem with different types of molecules in these cultures (Fig 3.5, 3.6), 
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suggesting distinct CNTF-initiated mechanisms between myelinating cultures on PLL and 
TnC.  
Fibromodulin (FMOD) is a proteoglycan that plays a role in organising the structure of 
type I and II collagen fibrils in extracellular matrix (Vogel, K.G. et al., 1984; Olberg, A. 
et al., 1989; Svensson, L. et al., 2000). If FMOD contributes towards a more inhibitory 
environment for axonal ensheathment as suggested by its down-regulation upon CNTF 
treatment on both PLL and TnC substrates (Tables 3.8, 3.11), it is contradictory to see 
its up-regulation in PLL-myelinating cultures compared to TnC-myelinating cultures 
(Table 3.14), where the amount of myelination has been shown to be lower (Nash et al., 
2011b). Different pathways could be related with FMOD function on these two 
substrates. Looking at the PLL-control vs TnC-control comparison, there seems to be an 
association between NFκBIα (also up-regulated on PLL) and Fmod, which might include 
the involvement of JNK signalling (Lee et al., 2011) that does not appear to be affected 
by CNTF treatment as NFκBIα was differentially regulated neither on PLL nor on TnC 
upon CNTF treatment.  
Considering the roles of FMOD reported in other studies, it is possible that FMOD is 
active in cell survival/apoptosis, antigen presentation, cell fate determination, cell 
attachment and cytoskeletal reorganisation in the myelinating cultures (Mayr et al., 
2004; Bi et al., 2007; Zheng et al., 2008; Choudhury et al., 2010; Lee et al., 2011; 
Zheng et al., 2011; Zheng et al., 2012; Jian et al., 2013). Its role in PLL-myelinating 
cultures might be one that promotes axonal ensheathment maybe by stimulating cell 
survival and differentiation in relatively young cultures (12 DIV). Perhaps FMOD 
functions start to focus on ECM organisation once the cultures are more mature creating 
a less permissive environment for axonal ensheathment. CNTF signalling might be 
targeting this presumably myelination-inhibitory function of FMOD, an action perhaps 
programmed to occur at later stages of the cultures upon possible increased endogenous 
CNTF levels (Stockli et al., 1991; Kirsch et al., 1997; Eddie et al., 2012). In addition, the 
IPA analysis suggests that different pathways that include FMOD are present in PLL- and 
TnC-myelinating cultures. On TnC, FMOD appears to be related mostly to collagens and 
lysysl oxidases (LOXes), indicating clearly a role in ECM organisation (Fig 3.6). On the 
other hand, FMOD is linked to complement factor H (CFH), colony stimulating factor 
(CSF) and tumor necrosis factor (TNF) in PLL-cultures upon CNTF treatment, suggesting 
a role in immunity more than in ECM organisation (Fig 3.5).  
In parallel with the suggestion of Lee et al. (2011) that there could be a functional link 
between FMOD and LOX, Fmod and Lox were both down-regulated upon CNTF 
treatment in TnC-myelinating cultures (Table 3.11). Moreover, several collagens 
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(Col18a1, Col3a1, Col5a1) and Fbn2 (fibrillin-2) were also down-regulated upon CNTF 
treatment in TnC-myelinating cultures. Because  microfibrils are made up of fibrillins 
and because microfibril-associated glycoproteins serve as scaffolds for extracellular 
matrix protein monomers to be polymerised by LOX or a LOXL (Kielty et al., 2002), 
decreased quantities of such scaffolds would eventually lead to a less stable, less dense 
extracellular matrix. Thus, it appears that the myelination-stimulatory role of CNTF 
treatment in TnC-cultures might be due to the fact that CNTF creates a less densely-
packed extracellular environment that presumably provides a more suitable setting for 
oligodendrocytes to extend their processes that would myelinate the axons nearby. In 
parallel with that, other members of the LOX family, Loxl1 that plays a role in elastin 
polymerisation and Loxl2 were also down-regulated upon CNTF treatment in TnC-
myelinating cultures (Table 3.11). LOXL1 has been shown to be expressed in the adult 
mouse brain, in the neural tube of fetal mice, and to surround the axon fibers (Hayashi 
et al., 2004). A lower expression of LOXL1, thus, could provide a less compact 
extracellular matrix around axon fibers, which might promote axon-oligodendrocyte 
process interaction. In conclusion, I think it would be worthwhile considering LOX family 
members as potential regulators of myelination in future studies even though they may 
not be astrocytic factors as suggested by Gilad et al. (2001).    
In contrast to Fmod, Crem was up-regulated on both substrates upon CNTF treatment 
(Tables 3.8, 3.11), suggesting a positive role in myelination. CREM is a member of the 
transcription regulating family CREB/CREM/ATF that bind to cAMP-response elements 
(CREs) in the promoters of cAMP-regulated genes (reviewed in De Cesare and Sassone-
Corsi, 2000). The Crem gene encodes for several transcripts due to initiation of  
translation from different internal promoters and due to alternative splicing 
(Mioduszewska et al., 2003). Some of these proteins are translation activators; whereas, 
the others, mostly ICER proteins, are associated with translation inhibition. In Array 2, 
the probe used for Crem (ILMN_1376694) can detect the eight validated Crem 
transcripts (Crem 2-9), listed in NCBI Gene Database. It is, therefore, very difficult to 
comment on the possible functions of CREM in the myelinating cultures since we cannot 
be sure which Crem isoforms were up-regulated. There are some indicators as to what 
type of CREM proteins these could be, however. For example, it is known that ICER 
expression peaks around 2-6 hr after stimulation, depending on types of stimulation and 
cell types (Luckman and Cox, 1995; Maronde et al., 1999; Pfeffer et al., 1999; Storvik et 
al., 2000; Liu et al, 2006b; Hu et al., 2008). As Crem up-regulation in TnC-myelinating 
cultures was observed at 4 hr upon CNTF treatment, this transcript might be an ICER. 
On the other hand, the expressional change of Crem in PLL-myelinating cultures was 
detected at 24 hr, suggesting this may not be an ICER. In addition, ICER has been shown 
to repress c-FOS (Monaco and Sassone-Corsi, 1997; Misund et al., 2007; Kojima et al., 
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2008); however, both Crem and Fos were up-regulated in PLL-cultures compared to 
TnC-cultures at 4 hr. Therefore, it is possible that CNTF enhances the expression of a 
translation-activating Crem isoform in PLL-myelinating cultures as opposed to a 
translation-inhibiting Crem in TnC-myelinating cultures. 
Crem expression was down-regulated over time in untreated PLL-cultures (Table 3.6), 
suggesting that CNTF maintains the on-going Crem expression in PLL-cultures rather 
than initiating it from the start. This could be obtained, for example, if CREM provides a 
negative feedback by acting as a transcriptional repressor of its own gene when it 
eventually reaches  a certain expression level. CNTF could be triggering a potent 
transcriptional activator that would compete with the CREM protein for the promoter or 
enhancer region of the Crem gene. In contrast, Crem expression in untreated TnC-
myelinating cultures appeared to be stable over time (Table 3.7). It was up-regulated 
upon CNTF treatment at 4hr and decreased at 24 hr back to the level seen at 4 hr 
(Table 3.11). So, in this case CNTF must be triggering mechanisms that would enhance  
Crem expression possibly via transcriptional activators in TnC-cultures. These 
transcriptional activators may not be dominant enough in competing for the Crem 
promoter or their half-life might not be long enough to support Crem expression further 
as the increased expression is down-regulated over time.  
Interestingly, another difference between the PLL- and TnC-myelinating cultures seems 
to be the apparent association of CREM with CREB-NFkB complex upon CNTF treatment 
on PLL but not on TnC, as seen in the IPA analysis (Fig 3.5, 3.6). It is possible for CREB 
phosphorylation (activation) to be associated with myelin formation and 
oligodendrocyte maturation (Sato-Bigbee and DeVries, 1996). CREB has been shown 1) 
to take part in the stimulation of MBP expression by cAMP in primary rat 
oligodendrocyte cultures (Afshari et al., 2001), 2) to be immunolabeled in a way to be 
continuous with oligodendrocyte processes in chicken cerebella, where overlapping p-
CREB and MBP staining was also observed (Kim et al., 2005), 3) to be present in its 
phosphorylated (active) state at higher levels in the rat spinal cord at the peak stage of 
EAE (Kim et al., 2007), where it could be contributing towards remyelination apart from 
leading to the occurrence of reactive astrogliosis (Kim et al., 2007). In that sense, it is 
interesting that CREB appears as a potential factor among the network of molecules, 
playing a role in the CNTF effect in PLL-myelinating cultures, which does not appear to 
be the case in TnC-myelinating cultures.  
It is also interesting that Snf1lk, a kinase responsible for negative regulation of CREB 
activity, was up-regulated in untreated PLL-myelinating cultures compared to TnC-
cultures at 4 hr (Table 3.14). Snf1lk was down-regulated over time both in untreated 
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and treated PLL-cultures, suggesting that the decreased levels of this p-CREB inhibitor 
at the late time point allowed the p-CREB activity in PLL-cultures. This change at 24 hr 
in PLL-cultures could be one of the reasons why there were more genes differentially 
regulated in PLL+CNTF myelinating cultures at 24 hr as opposed to at 4hr (Fig 3.3) since 
CREB would then be able to regulate the expressions of genes including CREs in their 
promotors.  
3.4.3 The CNTF effect in PLL- and TnC-myelinating cultures over 
time 
Genes differentially regulated over time in PLL+CNTF and TnC+CNTF myelinating 
cultures were compared after the expressional changes that occurred in the untreated 
conditions were excluded from the lists (Fig 3.7, areas shown in blue boxes). This 
analysis showed that there were different members of chemokines/cytokines, enzymes, 
and transcription factors differentially regulated in PLL- and TnC-myelinating cultures 
(Tables 3.6, 3.7). 
The chemokines/cytokines identified in PLL-myelinating cultures (Ccl6, Ccl12, Cxcl1 and 
Cxcl9) were all down-regulated over time upon CNTF treatment (Table 3.6), which 
could suggest a negative effect on myelination. However, the absence of any significant 
expressional change for these transcripts between control and CNTF-treated cultures at 
any time point weakens this suggestion. On the other hand, Cxcl13 was up-regulated 
over time in TnC+CNTF myelinating cultures, a fact that could be interpreted as a 
possible positive effect on myelination according to the previous findings (Nash et al., 
2011b). Additionally, Cxcl13 was up-regulated upon CNTF treatment in PLL-cultures at 4 
hr. So its differential expression does not seem to be specific to TnC-cultures. 
Therefore, CXCL13 appears to have the potential to play a positive role in myelination 
in both cultures. The fact that CXCL13 can promote CNS myelination in cerebellar slice 
cultures from newborn mice (Yuen et al., 2013) also supports the suggestion for a 
positive CXCL13 effect in myelination. However, CXCL13 has also been proposed to show 
a negative effect in neurodegenerative diseases such as MS by maintaining pathogenic T 
cell responses (Bagaeva et al., 2006; Rainey-Barger et al., 2011). Since the myelinating 
cultures do not contain any B- or T-cells, CXCL13 could be expressed by microglia or 
astrocytes as they are known to secrete  chemokines. CNTF might be initiating an 
immune-like response in PLL-cultures and leading to secretion of CXCL13, which in turn 
could activate other signalling pathways. Because both microglia and astrocytes express 
the CXCL13 receptor, CXCR5, it is possible that the secreted CXCL13 in turn affects 
microglia and/or astrocytes (Flynn et al., 2003). 
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There was a higher number of enzyme transcripts differentially regulated over time in 
PLL+CNTF myelinating cultures compared to in TnC+CNTF cultures (Table 3.5). Out of 12 
enzyme transcripts differentially regulated in PLL+CNTF cultures, three transcripts 
showed changes in other comparisons, as well. Ppp1r1b and Ptprn were not only up-
regulated over time in CNTF-treated PLL-cultures, but they were also up-regulated in 
PLL-control cultures compared to TnC-control cultures, which suggested that they could 
be potential enhancers of myelination. PPP1R1B could possibly enhance myelination by 
inactivating protein phosphatase PP1 that has been shown to contribute to 
oligodendrocyte loss and hypomyelination in mice expressing INF- γ in their CNS and in 
cultured rat hippocampal slices upon INF-γ treatment (Lin et al., 2008). Similarly, the 
protein tyrosine phosphatase PTPRN could be playing a role in cellular processes such as 
growth and differentiation in such a way that would stimulate myelination. However 
currently less is known about this transmembrane receptor enzyme that is highly 
expressed in rat primary hippocampal neurons (Chiang and Flanagan, 1996; Jiang et al., 
1998; Jiang et al., 2006). On the other hand, the results indicated Cyp1b1 as a negative 
regulator of myelination since it was down regulated 1) over time in PLL+CNTF cultures, 
2) upon CNTF treatment in TnC-cultures at 4 hr, 3) in PLL-control cultures compared to 
TnC-cultures both at 4 and 24 hr. CYP1B1 is one of the cytochrome P450 
monooxygenases, expressed in the human CNS (Rieder et al., 1998). Even though 
cerebral P450 enzymes can detoxify foreign toxic compounds and are thus important for 
cell homeostasis, they can also metabolise endogenous compounds such as steroids and 
eicosanoids and generate reactive oxygen radicals and lipid peroxides that could cause 
cellular damage or cell death (Mesnil et al., 1984; Guengerich et al., 1985; 
Anandatheerthavarada et al., 1990; Mills et al., 1995; Montoliu et al., 1995; Rieder et 
al., 1998). Interestingly, CYP1B1 has been found to be highly associated with BDNF and 
MBP (Luo et al., 2013). Higher reactive oxygen species generation by this enzyme may 
cause apoptotic changes that lead to glaucoma development (Luo et al., 20013) and 
maybe to reduction in myelination levels. 
A subgroup of enzymes, namely matrix metalloproteinases (MMPs), was also identified 
in the analysis. Mmp-3 was not only up-regulated over time in TnC+CNTF myelinating 
cultures (Table 3.5), but also in PLL-control and in PLL+CNTF cultures (Table 3.6). Its 
expression level at 24 hr was the lowest in TnC-control cultures, higher in PLL-control 
cultures, and the highest in TnC+CNTF cultures. As Nash et al. (2011b) have observed 
increased levels of myelination in this same order, our data suggest a positive 
correlation between MMP-3 and myelination. Similarly, the expression level of Mmp-12 
at 4 hr was the lowest in TnC-control cultures, higher in PLL-control cultures, and the 
highest in PLL+CNTF cultures. Based on these expressional changes, MMP-3 and MMP-12 
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appear to be playing positive roles in myelination. Even though MMP-12 protein and 
Mmp-3 mRNA expressions have been shown to be elevated in MS lesions (Lindberg et al., 
2001; Vos et al., 2003); MMP-12 has also been associated with myelination in mouse CNS 
(Laersen et al., 2006) and a positive role has been suggested for MMP-3 in remyelination 
due to its proteolytic activity required for releasing growth factors like IGF-1, heparin 
binding EGF-like factor (HBEGF) and transforming growth factor-β (Dubois-Dalcq and 
Murray, 2001; McCawley and Matrisian, 2001; Fowlkes et al.,2004) and due to its 
expressional association with remyelination in a cuprizone-induced demyelination model 
(Skuljec et al., 2011). The expression of Mmp-3 increased over time in PLL-cultures both 
before and after the CNTF treatment; however, it was up-regulated in TnC-cultures only 
upon CNTF treatment at 24 hr. The enhancement of different MMP transcripts upon 
CNTF treatment on different substrates could account for distinct mechanisms CNTF 
triggers on these substrates. 
As for the transcriptional factor transcripts detected in the analysis, Msx1, Npas4, 
Plagl1, Scg2 were differentially regulated over time in PLL+CNTF cultures and Crem, 
Fos, Irf7 were differentially expressed over time in TnC+CNTF cultures (Table 3.5). 
Msx1 (msh homeobox 1) and Scg2 (secretogranin II) were both up-regulated in PLL-
control cultures compared to TnC-control cultures at both time points, suggesting a 
positive role for these transcription factors in myelination. As SCG-2 has been shown to 
play a role in neuronal protection and differentiation and inflammatory responses, it is 
possible for this neuropeptide precursor to be involved in increase of myelination 
(Wiedermann, 2000; Taupenot et al., 2003; Hung and Porter, 2008; Shyu et al., 2008). 
Its involvement in Stat3 signalling also correlates with its up-regulation over time in the 
presence of CNTF, which has also been shown to signal via Stat3 (Shyu et al., 2008). On 
the other hand, the down-regulation of Msx1 in PLL-CNTF cultures over time and in TnC-
cultures upon CNTF treatment contradicts the above-mentioned suggestion for a 
positive role of MSX1 in myelination. On the other hand, Irf7 was up-regulated but Crem 
and Fos were down-regulated over time in TnC+CNTF cultures (Table 3.5). CREM has 
been discussed above extensively in Section 3.4.2. Even though the up-regulation of Irf7 
could be interpreted as a possible positive effect on myelination especially when its 
putative roles on myelin stability and remyelination are considered (Salem et al., 2011), 
the absence of any significant expressional changes for Irf7 in other comparisons in 
Array 2 makes it difficult to draw such a conclusion.  
Fos, on the other hand, did not appear to be a TnC-specific transcript like Irf7. It was 
down-regulated over time in PLL-control cultures, in PLL+CNTF cultures, and in 
TnC+CNTF cultures. Its change in TnC-cultures appears to be CNTF-dependent and this 
might be explained with the dominant enhancing effect of CNTF on oligodendrocyte 
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differentiation (Tanaka et al., 2013). Since FOS levels are lowered in later stages of 
differentiating oligodendrocyte cultures with the levels decreased to almost 50% at 24 
hr (Bichenkov and Ellingson, 2009), CNTF could stimulate oligodendrocyte maturation 
that would lead to Fos down-regulation over time, which could then allow MBP 
transcription since the repression of FOS on MBP promoter would be lifted (Miskimins 
and Miskimins, 2001). Apparently this occurs in PLL-cultures naturally over time; 
whereas, a stimulating-agent like CNTF is needed in TnC-cultures to induce the Fos 
reduction. If down-regulation of Fos by CNTF allows increased myelination levels, what 
would be the explanation for higher Fos expression in PLL-cultures compared to TnC-
cultures at 4hr? Even though Fos was down-regulated over time in PLL-cultures and 
reached similar levels of expression with TnC-cultures at 24 hr, the initial high levels of 
Fos in PLL-cultures could be one of the factors that leads to the stimulation or inhibition 
of different transcripts upon CNTF treatment on the two substrates.  
3.4.4 General Conclusions and Summary 
The microarray gene expression profiling analysis was carried out using samples from 
embryonic rat spinal cord myelinating cultures, plated on PLL- or TnC-astrocyte 
monolayers. Detection of differentially expressed common astrocytic factors in 
myelinating cultures, plated on various astrocyte phenotypes (Array 2) and in astrocyte 
monolayers (Array 1, Nash et al., 2011b) confirmed candidates identified in the original 
study and therefore the second array. The differentially regulated genes associated with 
CNTF treatment and with different substrates used were mainly chemokines and other 
immune system proteins, ECM proteins and ECM-modifying proteins, enzymes, growth 
factors/hormones, membrane proteins, neuropeptides, receptors, signalling proteins, 
solute carriers, structural proteins, and transcription factors. Thus, it appears that 
exogenous recombinant CNTF or changing the coverslip-coating agent from PLL to TnC, 
or vice versa, are enough to initiate or repress the expression of a wide range of genes 
that could very well be part of different pathways that would eventually lead to the 
difference in myelination levels observed in these cultures (Nash et al., 2011b).  
It is interesting to observe many differentially regulated chemokines in these CNS 
cultures despite the lack of any lymphoid cells such as lymphocytes, macrophages, B- 
and T-cells. It is likely that these chemokines were expressed by microglia and/or 
astrocytes as shown previously (reviewed in Williams et al., 2014). For example, 
astrocytes and microglia can be activated by LCN2 (lipocalin-2) in an autocrine manner, 
which leads to the secretion of pro-inflammatory cytokines and makes the astrocytes 
and microglia secrete higher levels of LCN2, creating a loop of positive feedback (Jang 
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et al., 2013a; Jang et al., 2013b). Thus, LCN2 could be one of the factors that 
contribute to an inflammatory response in the myelinating cultures. 
There were mainly four pieces of evidence, suggesting that CNTF could initiate different 
mechanisms in PLL- and TnC-myelinating cultures despite its common positive effect on 
myelination in these cultures; 1) Detection of the majority of the differentially 
regulated transcripts upon CNTF treatment at different time points (Fig 3.3), 2) IPA 
diagrams, showing the interaction of common transcripts with different molecules in 
distinct pathways in CNTF-treated cultures on different substrates (Figs 3.5 and 3.6), 3) 
lack of any common genes differentially regulated over time in CNTF+cultures on PLL 
and TnC (Fig 3.7), and 4) differential expression of distinct members of gene function 
categories upon CNTF treatment in PLL- and TnC-cultures. The effect of CNTF in TnC-
cultures could be specifically to create a more permissive extracellular environment for 
oligodendrocyte process extension and axonal ensheathment as interpreted from its 
effects on the expressions of ECM and ECM-modifying proteins. Its positive effect in PLL-
cultures does not appear to be as clear. 
Following the conclusion that CNTF could be exerting its myelination-promoting effect 
in PLL- and TnC-myelinating cultures (Array 2) via different mechanisms, the 
differentially expressed transcripts were analysed in the following binary comparisons: 
1) PLL-control vs PLL+CNTF, 2) TnC-control vs TnC+CNTF, 3) PLL-control vs TnC-control. 
The candidates selected from these comparisons as potential regulators that might play 
a role in myelination are shown in Fig 3.8. The selection was made based on the 
previous observation that the myelination level is the lowest in TnC-myelinating 
cultures, followed by PLL-myelinating cultures and the highest in both PLL+CNTF and 
TnC+CNTF myelinating cultures (Nash et al., 2011b). Thus, the transcripts up-regulated 
in 1) CNTF-treated conditions compared to untreated (control) cultures and in 2) PLL-
control cultures compared to in TnC-control cultures could be candidates that play 
positive roles in myelination; whereas, those down-regulated could be the ones that 
play negative roles. The selection of the potential regulators of myelination was based 
on the facts that the candidates 1) would be small secreted molecules, whose effects on 
myelination could be observed by treating the cultures for a specific period of time and 
2) could be associated with myelination based on their reported roles in the literature 
such as neuronal survival, neurite extension, oligodendrocyte proliferation and/or 
maturation, elevated/lowered expressions in demyelinated lesions in CNS diseases like 
multiple sclerosis. The next step would be to validate the expressional changes for the 
selected candidates by means of qRT-PCR and continue with tissue culture experiments 
to observe their possible effects on myelination levels in embryonic rat spinal cord 
myelinating cultures (Chapter 4).  
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Figure 3. 8 The potential myelination-regulating candidates selected for further analysis 
following the binary comparisons of lists of differentially regulated genes in myelinating 
cultures at different conditions.                    
Microarray gene expression profiling analysis (Array 2) was carried out using samples from embryonic rat 
spinal cord myelinating cultures, plated on astrocyte monolayers on glass coverslips, coated with poly-L-lysine 
(PLL) or tenascin C (TnC). The cultures were either untreated (control) or treated with ciliary neurotrophic 
factor (CNTF) and total RNA was collected from the cultures 4 hr or 24 hr after standard medium feeding or 
CNTF treatment. Three biological replicates were prepared for the array and each biological replicate was run 
in three technical replicates. False discovery rate was designated as 5%. The differentially regulated 
transcripts between the conditions shown in the diagram were compared in an attempt to identify potential 
regulators of myelination based on the previous finding that myelination level is the lowest in TnC-control 
myelinating cultures, higher in PLL-control myelinating cultures, and the highest in PLL+CNTF and in 
TnC+CNTF myelinating cultures (Nash et al., 2011) A) Serpinb2, Lcn2, Cxcl13 were selected as potential 
positive regulators of myelination due to their up-regulation upon CNTF treatment in PLL-cultures. B) Wif1 and 
Thbs2 were selected as potential negative regulators of myelination and Ctgf was selected as a potential 
positive regulator of myelination due to their up-regulations in the conditions shown in the diagram. C) The 
analysis of the differentially regulated genes between PLL- and TnC-control cultures revealed Ccl2, Ccl7, and 
Serpinb2 as potential positive regulators of myelination and Cxcl11, Lcn2, Wif1 as potential negative 
regulators. D) The table presents a summary of the selected candidates from the binary comparisons shown 
in A, B, and C. Ccl2: chemokine (C-C) ligand 2; Ccl7: chemokine (C-C) ligand 7; Ctgf: connective tissue 
growth factor; Cxcl11: chemokine (C-X-C) ligand 11; Cxcl13: chemokine (C-X-C) ligand 13; Lcn2: lipocalin-2; 
Serpinb2: serpin peptidase inhibitor; Thbs2: thrombospondin 2; Wif1: WNT inhibitory factor 1. 
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Chapter 4  
 
Validation of the putative protein candidates 
that modulate myelination 
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4.1 Introduction 
Our microarray gene expression profiling analysis (Array 2) was carried out using 
embryonic rat spinal cord mixed cultures, which were referred to as “myelinating 
cultures”, to identify factors that could play a role in axonal ensheathment that is 
observed at later stages (24-30 DIV) of these cultures. The microarray analysis identified 
CCL2, CCL7, CTGF, CXCL11, CXCL13, LCN2, SERPINB2, THBS2, and WIF1 as possible 
regulators of myelination (Chapter 3). Because the possibility of false positives is 
increased in transcriptomics due to high numbers of variables analysed, the up/down-
regulations of the expression of the selected candidates at different conditions were 
required to be validated by quantitative real-time polymerase chain reaction (qRT-PCR). 
The following validation step would be to treat the myelinating cultures with the 
selected candidates to observe their possible effects on myelination. Neurite density 
and myelination level of the myelinating cultures were quantified using the “myelin.cp” 
pipeline of the software Cell Profiler (Carpenter et al., 2006). This method of 
quantification has recently been validated to be sensitive enough to detect changes in 
myelination percentages (Lindner et al., 2015).  
4.2 Aims 
The overall aim of this chapter was to validate candidates obtained from the microarray 
as modulators of myelination. This will be carried out as follows: 
• Performing qRT-PCR using RNA samples i) from the stock solutions that were 
used for Array 2 and ii) that were isolated from another set of three biological 
replicates of embryonic rat spinal cord myelinating cultures at different 
conditions (PLL-control, PLL+CNTF, TnC-control, TnC+CNTF). Selecting the 
candidates, which present significant expressional changes that validate the 
results of Array 2, to treat the myelinating cultures with. 
• Assessing effects of candidates on myelination by treating the embryonic rat 
spinal cord myelinating cultures from an early time point (10 or 12 DIV onwards) 
with recombinant proteins at various concentrations. Assessing their effects on 
myelination in myelinating cultures set up on various astrocyte phenotypes 
plated on PLL (PLL-As) or on TnC (TnC-As) substrates since these astrocyte 
monolayers have distinct capacities to support myelination and since this 
difference could affect the way and/or the magnitude of the effects of the 
exogenous proteins on myelination.  
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4.3 Results 
4.3.1 Validation of the expressional changes detected in Array 2 
by means of qRT-PCR 
Nine potential myelination-regulating candidates were chosen after the three main 
comparisons were made, i.e. PLL+CNTF vs PLL-control, TnC+CNTF vs TnC-control and 
PLL-control vs TnC-control myelinating cultures, whose results were also related with 
changes that occurred over time. The candidates that were suggested as potential 
positive regulators were CCL2, CCL7, CTGF, CXCL13, and SERPINB2; whereas, CXCL11, 
THBS2, and WIF1 were suggested as negative regulators. LCN2 was associated both with 
more and less supportive myelination phenotypes due to its increased expression upon 
CNTF treatment in PLL-myelinating cultures and reduced expression in PLL-myelinating 
cultures compared to TnC-myelinating cultures, respectively.  
4.3.1.1 qRT-PCR using cDNA samples from Array 2 (1st qRT-PCR) 
In order to validate the expressional changes detected by microarray analysis, cDNA 
prepared from the same RNA samples used for Array 2 was used to perform a second set 
of qRT-PCR experiments. Gapdh was used as the experimental housekeeping control 
gene. In addition, measuring the expression of the gene of interest and the expression 
of Gapdh in the same reaction well by means of TaqMan assay provided more accuracy 
for these experiments.  
Significances were calculated by the application of repeated-measures one-way ANOVA 
test. The Bonferroni correction of a multiple comparison was applied later to detect any 
significant comparisons. It was important to exclude the comparisons that were not 
biologically relevant from the analysis because the higher the number of comparisons 
are the more difficult it is to obtain significance with Bonferroni test. Due to the 
presence of three variables in the cultural conditions, i.e. substrate, treatment and 
time point, there were 8 (23) different conditions, which would form 28 possible binary 
comparisons (8C2 = the number of ways 8 items can be combined, taking 2 at a time). 
For the ANOVA analysis with Bonferroni’s correction 16 comparisons (Table 4.1) that 
were considered to be biologically relevant were included. One variable was compared 
for most of the comparisons, i.e. the substrate (PLL or TnC, #1, 5, 11, 14), the 
treatment (control or CNTF, #2, 8, 12, 16) or the time point (4 hr or 24 hr, #3, 6, 9, 10), 
to be able to identify the effect of each factor on the expression of the gene of 
interest. There were four comparisons where both substrates and treatments were 
different (#4, 7, 13 and 15 in Table 4.1) but these were biologically relevant as 
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myelination phenotypes were compared at the same time point. As mentioned earlier, 
PLL+CNTF and TnC+CNTF myelinating cultures have shown similar levels of axonal 
ensheathment which was higher than that in PLL-control cultures and than in TnC-
control cultures, with the lowest level (Nash et al., 2011b). For example, the transcripts 
up-regulated in TnC-CNTF cultures compared to PLL-control cultures (#4 and 13 in Table 
4.1) at early and late time points would be associated with increased myelination 
levels. On the other hand, comparisons of different conditions over time (e.g., PLL-con-
4 hr vs TnC-con-24 hr, TnC-con-4 vs PLL-CNTF-24) were not considered biologically 
relevant because the transcriptional changes detected in those comparisons would be 
associated with both the myelination phenotype and the change over time preventing to 
conclude what those transcriptional changes reflected.  
Table 4. 1 The comparisons included in repeated measures one-way ANOVA test with 
Bonferroni correction to analyse the significance of transcriptional changes detected by 
qRT-PCR. 
	  	  
Substrate	   Treatment	   Time	  
Point	  (hr)	  
	   Substrate	   Treatment	   Time	  
Point	  (hr)	  
1	   PLL	   control	   4	   vs	   TnC	   control	   4	  
2	   PLL	   control	   4	   vs	   PLL	   CNTF	   4	  
3	   PLL	   control	   4	   vs	   PLL	   control	   24	  
4	   PLL	   control	   4	   vs	   TnC	   CNTF	   4	  
	  	  
	   	   	  
	  	  
	   	   	  5	   PLL	   CNTF	   4	   vs	   TnC	   CNTF	   4	  
6	   PLL	   CNTF	   4	   vs	   PLL	   CNTF	   24	  
7	   PLL	   CNTF	   4	   vs	   TnC	   control	   4	  
	  	  
	   	   	  
	  	  
	   	   	  8	   TnC	   control	   4	   vs	   TnC	   CNTF	   4	  
9	   TnC	   control	   4	   vs	   TnC	   control	   24	  
	  	  
	   	   	  
	  	  
	   	   	  10	   TnC	   CNTF	   4	   vs	   TnC	   CNTF	   24	  
	  	  
	   	   	  
	  	  
	   	   	  11	   PLL	   control	   24	   vs	   TnC	   control	   24	  
12	   PLL	   control	   24	   vs	   PLL	   CNTF	   24	  
13	   PLL	   control	   24	   vs	   TnC	   CNTF	   24	  
	  	  
	   	   	  
	  	  
	   	   	  14	   PLL	   CNTF	   24	   vs	   TnC	   CNTF	   24	  
15	   PLL	   CNTF	   24	   vs	   TnC	   control	   24	  
	  	  
	   	   	  
	  	  
	   	   	  16	   TnC	   control	   24	   vs	   TnC	   CNTF	   24	  
Microarray gene expression profiling analysis was carried out using embryonic myelinating spinal cord 
cultures (Array 2). Illustrated in the table is a list of comparisons of the myelinating cultures at different 
conditions. Out of the 28 possible comparisons, 16 comparisons were used in the Bonferroni’s method of one-
way ANOVA analysis since these comparisons were considered to be biologically relevant. 
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After Bonferroni’s test, Dunnett’s post-hoc test was run by including all conditional 
datasets for each gene of interest by designating one of four possible control conditions: 
1) PLL-control 4 hr, 2) PLL-control 24 hr, 3) TnC-control 4 hr, 4) TnC-control 24 hr. 
Although untreated PLL-astrocytes condition was previously used as a control in a 
similar study (Nash et al., 2011b), it is also possible to assign TnC-control condition as a 
reference for comparison because the lowest myelination level is seen on TnC-control 
myelinating cultures. It has also been suggested that PLL-cultures could be more 
representative of activated astrocytes and hence more distant to what in vivo CNS 
environment would be like (Holley et al., 2005; Nash et al., 2011b). In parallel with 
that, SERPINB2 protein, which has been detected in the astrocytes of injured brains but 
not in those of healthy control brains (Dietzmann et al., 2000), was up-regulated in PLL-
control myelinating cultures compared to TnC-control myelinating cultures. Therefore, 
TnC-myelinating cultures could be more representative of the healthy CNS in vivo in 
some aspects compared to PLL-myelinating cultures.  
As seen in Figures 4.1 and 4.2, the only candidates that showed significant expressional 
changes were Serpinb2, Ccl2 and Ccl7. Surprisingly, the up-regulation of Serpinb2 in 
PLL-control cultures compared to TnC-control cultures was significant only for the 24 hr 
time point; whereas this up-regulation was detected significant at 4 hr in the 
microarray analysis. However, the mean value of TnC-control 4 hr condition was indeed 
much lower than the mean value of PLL-control 4 hr as seen in Fig 4.1 C. The 
significance appeared to be lost due to the biological variance between the three 
biological repeats of PLL-control 4 hr condition since the Ct values for Gapdh and 
Serpinb2 expressions were within one cycle between the technical replicates. The mean 
ΔCt values between the technical replicates were also within one cycle. Thus, it 
appeared that Serpinb2 expression in PLL- control myelinating cultures prepared from 
different animals could be quite variable 4 hr after feeding with fresh media. Such 
variation was lost at 24 hr.  Treating with CNTF appeared to cause less variation 
between different biological replicates of PLL cultures at 4 hr but this variation rose at 
24 hr (Fig 4.1 C). In TnC conditions, however, the variations were much lower due to 
the fact that Serpinb2 expression was also very low (below 0.1 fold) here. Due to the 
above-mentioned variations, the Bonferroni test including the 16 comparisons in Table 
4.1 revealed no significant changes.  
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Figure 4. 1 The 1st qRT-PCR results for the possible myelination-regulating candidates 
selected at the end of Array 2.          
Microarray gene expression profiling analysis was carried out using samples from embryonic rat spinal cord 
myelinating cultures, plated on astrocyte monolayers on glass coverslips, coated with poly-L-lysine (PLL) or 
tenascin C (TnC). The cultures were either untreated (control) or treated with ciliary neurotrophic factor 
(CNTF) and total RNA was collected from the cultures 4 hr or 24 hr after standard medium feeding or CNTF 
treatment. Three biological replicates were prepared for the array and each biological replicate was run in 
three technical replicates. False discovery rate was designated as 5%. The RNA samples used were from the 
same batches used for Array 2. Relative expressions were normalised to PLL-control-4hr levels for each 
transcript. The significance seen for differential Serpinb2 expression (p<0.05) in the graph was detected using 
repeated measures of one-way ANOVA test. The error bars represent ± standard error of the mean relative to 
the housekeeping gene Gapdh. Darker and lighter bars represent the 4 hr and 24 hr samples, respectively. 
Ctgf: connective tissue growth factor; Lcn2: lipocalin-2; Serpinb2: serpin peptidase inhibitor; Thbs2: 
thrombospondin 2; Wif1: WNT inhibitory factor 1. 
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Figure 4. 2 The 1st qRT-PCR results for the possible myelination-regulating chemokines 
selected at the end Array 2.                   
Array 2 was carried out using samples from embryonic rat spinal cord myelinating cultures, plated on astrocyte 
monolayers on glass coverslips, coated with poly-L-lysine (PLL) or tenascin C (TnC). The cultures were either 
untreated (control) or treated with ciliary neurotrophic factor (CNTF) and total RNA was collected from the 
cultures 4 hr or 24 hr after standard medium feeding or CNTF treatment. Three biological replicates were 
prepared for the array and each biological replicate was run in three technical replicates. False discovery rate 
was designated as 5%. The RNA samples used for the 1st qRT-PCR were from the same batches used for 
Array 2. Relative expressions were normalised to PLL-control-4hr levels for each transcript. The significance 
seen for differential Ccl2 and Ccl7 expression (*, p≤0.05) in the graph was detected using repeated measures 
of one-way ANOVA test. The error bars represent ± standard error of the mean relative to the housekeeping 
gene Gapdh. Darker and lighter bars represent the 4 hr and 24 hr samples, respectively. Ccl2: chemokine (C-
C) ligand 2; Ccl7: chemokine (C-C) ligand 7; Cxcl11: chemokine (C-X-C) ligand 11; Cxcl13: chemokine (C-X-
C) ligand 13. 
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Nevertheless, Dunnett’s test presented the expressional change between PLL-control 24 
hr vs TnC-control- 24 hr as significant when the control condition was designated as PLL-
control-24 hr or TnC-control-24 hr. This result was still in accordance with the 
microarray assay results. Carrying out qRT-PCR validated the increase of Serpinb2 
expression in cultures, with a higher level of axonal ensheathment. Thus, there was 
further proof to support the suggestion of SERPINB2 as a positive regulator of 
myelination.  
As for the chemokines checked, Ccl2 and Cc7 were the only ones that showed significant 
expressional changes in qRT-PCR results (Fig 4.2). The Bonferroni test demonstrated the 
increased Ccl2 expression to be significant in PLL-control cultures compared to TnC-
control cultures at 4 hr (Fig 4.2 A). This significance was confirmed by the Dunnett’s 
test, as well, where PLL-control-4 hr or TnC-control-4 hr values were designated as the 
control. This significance of raised Ccl2 expression in PLL-control cultures compared to 
TnC-control cultures at 4 hr was in accordance with the microarray assay results. 
Similarly, this expressional change supported the suggestion of CCL2 as a positive 
regulator of axonal ensheathment.  
The Bonferroni test for Ccl7, however, revealed the expressional change in a different 
binary comparison as significant. Unexpectedly, Ccl7 was up-regulated in PLL+CNTF 
cultures compared to TnC+CNTF cultures at 24 hr (Fig 4.2 B). This significance was not 
detected in the microarray assay and was difficult to interpret in terms of the effect of 
CCL7 on myelination as both PLL+CNTF and TnC+CNTF cultures have been shown to have 
similar levels of myelination (Nash et al., 2011b). The Dunnett’s test, on the other 
hand, validated the up-regulation in PLL-control cultures compared to TnC-control 
cultures at 4 hr when the control was designated as PLL-control 4 hr or TnC-control 4 hr 
values. Therefore, Ccl7 was also validated as a candidate for positive regulation of 
axonal ensheathment.  
The expressional changes for the other candidates were not found to be significant with 
one-way ANOVA. However, the relative quantification graphs showed some differential 
expression tendencies in accordance with the ones found in the microarray analysis. For 
example, Thbs2 expression was down-regulated in TnC+CNTF cultures compared to TnC-
control cultures at 4 hr (Fig 4.1 D). Cxcl11 expression was down-regulated in PLL-control 
samples compared to TnC-control ones at 4 hr (Fig 4.2 C). Cxcl13 expression was up-
regulated over time in TnC-CNTF samples (Fig 4.12 D). Wif1 was up-regulated on TnC 
compared to on PLL at 24 hr without treatment (Fig 4.1 E). None of these changes were 
found to be significant. 
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Ctgf was suggested as a potential positive regulator of axonal ensheathment as it was 
up-regulated upon CNTF treatment in TnC cultures at 24 hr in Array2. This expressional 
change was not significant in qRT-PCR analysis (Fig 4.1 A). There was an expressional 
change that was found to be significant for Ctgf with unpaired Student’s T-test, a test 
that is used only to compare two conditions and that has less power in an experiment 
with multiple conditions. Ctgf was down-regulated upon CNTF treatment on PLL at 24 
hr, which would indicate it as a negative regulator of axonal ensheathment. Nash et al. 
(2011b) have indeed suggested it is a negative regulator since their microarray analysis 
have indicated Ctgf to be up-regulated in TnC-control cultures compared to both PLL-
control cultures and the PLL+CNTF cultures at 4 hr (Array 1). Their qRT-PCR results for 
Ctgf were also not significant but there was a tendency for down-regulation in 
PLL+CNTF-24 hr compared to TnC-control-4 hr, which again could be interpreted as a 
possible negative effect on axonal ensheathment. These controversial facts about CTGF 
either could be artefacts of a variable culture system or of possible technical errors or 
they could imply a highly complex mechanism for CTGF in these cultures. Therefore, it 
would be interesting to further investigate the role of CTGF in these myelinating 
cultures especially at different concentrations. 
In conclusion, there were significant changes detected in the expression of Ccl2, Ccl7 
and Serpinb2 by means of qRT-PCR using the cDNA samples synthesised from the original 
RNA samples that were extracted from the myelinating cultures used for Array 2 
analysis. Even though, there was not any significance detected for Ctgf, it was also 
selected for further study as explained above. 
 
4.3.1.2 qRT-PCR using new cDNA samples, not used in Array 2 (2nd qRT-
PCR) 
Total RNA was also collected from three different biological replicates of the embryonic 
rat spinal cord myelinating cultures 4 hr after standard medium feeding or treatment, 
forming the following four conditions: PLL-control, TnC-control, PLL+CNTF, and 
TnC+CNTF. The cDNA obtained from these RNA samples were used for another qRT-PCR 
analysis also in attempt to validate the transcriptional changes observed in Array 2. The 
significances were calculated by repeated measures one-way ANOVA statistical analysis, 
followed by Bonferroni’s multiple comparison and/or Dunnett’s tests. 
As seen in Fig 4.3 and 4.4, significant transcriptional changes were observed for Ccl2, 
Ccl7, and Cxcl11. The significance detected for increased Serpinb2 expression in PLL-  
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Figure 4. 3 The 2nd qRT-PCR results for the possible myelination-regulating candidates 
selected at the end Array 2.                       
The RNA samples used for the 2nd qRT-PCR were not from the same batches used for Array 2. Three 
biological replicates of embryonic rat spinal cord myelinating cultures, plated on astrocyte monolayers on 
glass coverslips, coated with poly-L-lysine (PLL) or tenascin C (TnC) were cultured until 12 days in vitro. The 
cultures were then either treated with ciliary neurotrophic factor (CNTF) or fed with standard medium. Total 
RNA was harvested from the cultures 4 hr after standard medium feeding or CNTF feeding. Relative 
expressions were normalised to PLL-control levels for each transcript. The error bars represent ± standard 
error of the mean relative to the housekeeping gene Gapdh. Repeated measures of one-way ANOVA test was 
applied to the results to detect any possible significances. There were not any significances observed for the 
candidates shown in the graphs above. Ctgf: connective tissue growth factor; Lcn2: lipocalin-2; Serpinb2: 
serpin peptidase inhibitor; Thbs2: thrombospondin 2; Wif1: WNT inhibitory factor 1. 
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myelinating cultures compared to that in TnC-myelinating cultures at 24 hr in the 
previous qRT-PCR (Fig 4.1) was not seen in the one where new cDNA samples were used 
(Fig 4.3). This could be because only 4 hr samples were used this time and that the 
standard error was also very high for PLL-control-4 hr myelinating cultures in the second 
qRT-PCR (Fig 4.3) similar to the case seen previously (Fig 4.1). On the other hand, there 
were significant expressional changes observed for Cxcl11 (Fig 4.4) unlike the first qRT-
PCR (Fig 4.2). Dunnett’s test revealed that Cxcl11 was up-regulated upon CNTF 
treatment in PLL-myelinating cultures and it was also up-regulated in PLL+CNTF 
myelinating cultures compared to TnC-control cultures (Fig 4.4). In addition, the 
Bonferroni’s multiple comparison test presented that Cxcl11 was up-regulated in 
TnC+CNTF cultures compared to in PLL-control cultures (Fig 4.4). All of these significant 
changes suggested that CXCL11 might be a positive regulator of myelination due to its 
increased expression in myelinating cultures with a higher capacity of myelination. 
However, CXCL11 was proposed as a possible negative regulator of myelination after 
Array 2 due to its down-regulation in PLL-control myelinating cultures compared to TnC-
control cultures. Such a down-regulation was also detected in the second qRT-PCR (Fig 
4.4) but was not found to be significant. The lack of any significant differential 
expression of Cxcl11 in the first qRT-PCR (Fig 4.2) and the above-mentioned 
controversial results of the second qRT-PCR weakened the argument that CXCL11 could 
be a strong candidate that could be effective in myelination.  
Similar to the results of the first qRT-PCR (Fig 4.2), significant up-regulations were seen 
for Ccl2 and Ccl7 in myelinating cultures that have been shown to present higher levels 
of myelination (Fig 4.4). Ccl2 was up-regulated both in PLL+CNTF and TnC+CNTF 
myelinating cultures compared to TnC-control cultures, where significances were 
detected both by Bonferroni’s multiple comparison and Dunnett’s tests (Fig 4.4). Ccl7 
was up-regulated in TnC+CNTF cultures compared to PLL-control cultures; and also in 
PLL+CNTF cultures compared to TnC-control myelinating cultures (Fig 4.4), which were 
detected by Dunnett’s test only. Even though these specific differential expressions for 
Ccl2 and Ccl7 were not detected in Array 2, they were still in agreement with the 
suggestion that these factors could have a positive role in myelination as indicated by 
the up-regulation of Ccl2 and Ccl7 in PLL-control cultures compared to TnC-control 
cultures in Array 2.  
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Figure 4. 4 The 2nd qRT-PCR results for the possible myelination-regulating chemokines 
selected at the end of microarray gene expression profiling analysis (Array 2).            
The RNA samples used for the 2nd qRT-PCR were not from the same batches used for Array 2. Three 
biological replicates of embryonic rat spinal cord myelinating cultures, plated on astrocyte monolayers on 
glass coverslips, coated with poly-L-lysine (PLL) or tenascin C (TnC) were cultured until 12 days in vitro. The 
cultures were then either treated with ciliary neurotrophic factor (CNTF) or fed with standard medium. Total 
RNA was harvested from the cultures 4 hr after standard medium feeding or CNTF feeding. Relative 
expressions were normalised to PLL-control levels for each transcript. The error bars represent ± standard 
error of the mean relative to the housekeeping gene Gapdh. Repeated measures of one-way ANOVA test was 
applied to the results to detect any possible significances. Significances were observed for Ccl2, Ccl7 and 
Cxcl11 (*, p≤0.05; **, p≤0.01). Ccl2: chemokine (C-C) ligand 2; Ccl7: chemokine (C-C) ligand 7; Cxcl11: 
chemokine (C-X-C) ligand 11; Cxcl13: chemokine (C-X-C) ligand 13. 
 
 
 
 
 
 
 
131 
 
In conclusion of both qRT-PCRs, the chemokines CCL2 and CCL7, and SERPINB2 were 
selected as the potential candidates that could play a positive role in myelination in 
embryonic rat spinal cord myelinating cultures. The next step would be to test their 
exogenous effects on axonal ensheathment in these cultures.  
4.3.2 Treatment of myelinating cultures with myelination-
regulating candidates identified in Array 2 
The expressional changes detected in Array 2 were validated for Ccl2, Ccl7, and 
Serpinb2 out of the nine candidates that were suggested to regulate myelination after  
the microarray analysis. Even though the up- and down- regulations of Ctgf seen in 
Array 2 could not be validated by qRT-PCR, CTGF was also included in the list of 
candidates to be tested in myelinating cultures since it was also previously suggested to 
play a role in myelination due to its increased expression in astrocyte monolayers that 
have been shown to be less supportive for myelination (Nash et al., 2011b). Therefore, 
embryonic rat myelinating cultures were treated separately with recombinant CCL2, 
CCL7, CTGF and SERPINB2 proteins and the myelination levels under different conditions 
were later visualised and calculated.  
4.3.2.1  CTGF did not lead to any significant changes in myelination levels  
The myelinating cultures were treated with recombinant human CTGF (#120-19, 
Peprotech, UK) starting from 12 DIV onwards once every other day until they were used 
for immunocytochemistry on day 24-28 in vitro. In the first set of experiments (1st 
titration), the myelinating cultures were treated with CTGF at concentrations ranging 
between 0.05-50 ng/ml (Fig 4.5 A&B). Even though one-way repeated measures ANOVA 
statistical test did not reveal any significance for the changes in myelination level in the 
cultures treated with different concentrations of CTGF, the decrease at 12.5 ng/ml was 
investigated further. The 2nd titration consisted of five concentrations between 4 and 20 
ng/ml, which did not lead to any significant changes in the level of myelination or 
neurite density in myelinating cultures, either (Fig 4.5 C&D).  
The myelination percentages were standardised to the control (no treatment) within 
each biological repeat to avoid high variations when the average raw myelination values 
were taken. A specific range of myelination percentages has not been identified yet to 
reflect clearly the health of these myelinating cultures; however, as the myelination 
percentage drops below 1-2%, the neurite density tends to decrease leading to a sparse 
culture, and the myelin stained with the antibody against PLP tends to appear less 
organised in neat long tubular sheaths, which are normally the shapes detected and  
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Figure 4. 5 CTGF does not have a significant effect on myelination levels in rat myelinating 
cultures.                  
Embryonic rat spinal cord myelinating cultures, set up using PLL-astrocytes, were treated with recombinant rat 
CTGF from 12 DIV onwards every other day at the concentrations shown in the graphs above. The cultures 
were immunostained at 24-28 DIV using AA3 antibody to detect PLP green and hence myelin and using SMI-
31 to detect neurites. Myelination percentage is shown as standardised to control (no treatment) condition. 
CTGF was applied to the cultures in two titrations as seen above (A&B, C&D). Neither of them showed any 
significance for myelination percentage or neurite density. Representative images from the control and CTGF-
treated cultures are presented in E and F, respectively, where PLP is shown in green and neurites in red. The 
staining for PLP (green) and the paranodal protein Caspr (red) suggested the profile of healthy axonal 
ensheathment (G&H). Each titration was carried out in three experimental repeats. One-way repeated 
measures ANOVA test was used to detect any possible significance. The error bars represent ± standard error 
of the mean. All scale bars represent 25 µm. PLL: poly-L-lysine; PLP: proteolipid protein. 
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quantified by the Cell Profiler. The raw myelination level values varied between 2.8-
7.8% for CTGF treatments. The representative images also presented healthy-looking 
myelinating cultures (Fig 4.5 E&F), which was also supported by the presence of Caspr, 
a paranodal protein, in the cultures (Fig 4.5 G&H). Therefore, the failure to show an 
expected positive effect on myelination using recombinant CTGF seemed not to be 
related at least to the health of the cultures used. 
4.3.2.2 SERPINB2 did not affect myelination in rat embryonic spinal cord 
myelinating cultures  
Full-length human SERPINB2 protein (ab69515, Abcam, UK) was added into the medium 
of the rat myelinating cultures in two sets of titration. In the first one, the cultures 
were treated with 1, 10 and 100 ng/ml of SERPINB2, which did not appear to affect the 
myelination levels as no significant changes were detected for the concentrations used 
(Fig 4.6 A&B). Therefore, a second titration was carried out using the concentrations 
equal to and below 1 ng/ml (Fig 4.6 C&D) in case SERPINB2 could show an effect 
specifically at lower concentrations rather than at higher concentrations like 10 and 100 
ng/ml. Similarly, there were no significant changes observed using one-way repeated 
measures ANOVA test. As Serpinb2 expression was detected to be higher in PLL-
myelinating cultures compared to in TnC-myelinating cultures (Array 2, Chapter 3), it 
was possible that the exogenously added SERPINB2 did not affect myelination any 
further due to the comparatively higher levels of endogenous SERPINB2 in PLL-
myelinating cultures. Therefore, TnC-myelinating cultures that were set up using 
astrocytes plated on TnC-coated coverslips (TnC-As) were also treated with SERPINB2 
starting from 12 DIV onwards at a concentration range of 0.01-10 ng/ml (Fig 4.6 E&F), 
which did not reveal a significant effect of SERPINB2 on axonal ensheathment. No 
significant difference was detected in the myelination level or the neurite density of 
the untreated PLL- and TnC-cultures (Fig 4.6 E&F). 
Despite a lower neurite density observed in the myelinating cultures used for SERPINB2 
treatments compared to that seen in cultures used for CTGF treatments above, the 
representative images showed the presence of long and solid myelin sheaths (Fig 4.6 
G&H) as expected from healthy cultures. The raw values for myelination levels were 
also all above 3% in these cultures. Consequently, the lack of any apparent effect of 
SERPINB2 on axonal ensheathment in these myelinating cultures did not appear to be 
related to the quality of the cultures.  
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Figure 4. 6 SERPINB2 does not affect myelination levels in rat myelinating cultures  
Embryonic rat spinal cord myelinating cultures were treated with recombinant human SERPINB2 from 12 DIV 
onwards every other day at the concentrations shown in the graphs above. The cultures were set up using 
astrocytes, plated on either PLL or TnC. The cultures were immunostained at 24-35 DIV using AA3 (PLP) 
antibody to detect myelin and using SMI-31 to detect neurites. Myelination percentage is shown as 
standardised to control (no treatment) condition. SERPINB2 was applied to the cultures in two titrations as 
seen above (A&B, C&D). Neither of them showed any significance for myelination percentage or neurite 
density. The 2nd titration of concentrations was also applied to TnC-myelinating cultures, where SERPINB2 did 
not show any significant effect (E&F). Representative images show PLP in green and SMI-31 in red (G&H). 
Each titration was carried out in three experimental repeats. One-way repeated measures ANOVA test was 
used to detect any possible significance. The error bars represent ± standard error of the mean. DIV: days in 
vitro; PLL: poly-L-lysine; PLP: proteolipid protein; TnC: tenascin C. 
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4.3.2.3 CCL2 did not affect myelination 
Recombinant rat CCL2 (3144-JE-025/CF, R&D Systems, USA) was used for treatments at 
five different concentrations ranging between 0.1-100 ng/ml (Fig 4.7). There were not 
any significant changes in percentage of myelinated fibres or neurite densities detected 
upon CCL2 treatment in PLL-myelinating cultures (Fig 4.7 A&B) or in TnC-myelinating 
cultures (Fig 4.7 C&D).  
The average raw values for myelin sheath percentages detected in control conditions 
were all above 2.5%. As mentioned above for the other candidates, which were selected 
as possible regulators of myelination, exogenous CCL2 appeared to be tested on 
healthy-looking myelinating cultures, where no change in myelination levels could be 
detected.  
4.3.2.4 CCL7 did not affect myelination  
Recombinant rat CCL7 (CHM-280, Prospec, USA) was also used at a concentration range 
of 0.1-100 ng/ml (Fig 4.8). Failing to detect any significant changes in myelination 
levels upon CCL7 treatment in myelinating cultures on PLL-As (Fig 4.8 A&B) the same 
concentration range was also applied to the cultures set up on TnC-As (Fig 4.8 C&D). 
Despite the trend towards decrease in myelination levels upon CCL7 treatment, those 
changes were not found to be significant using one-way repeated measures ANOVA 
analysis. Similar to the other cultures mentioned above, the average unstandardised 
myelination levels for PLL-myelinating cultures were above 2% and those in TnC-
myelinating cultures ranged between 5.9-7.3%. The representative images of the 
cultures (Fig 4.8 E-H) also suggested healthy axonal ensheathment, which did not 
present increased or decreased levels upon CCL7 treatments. 
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Figure 4. 7 CCL2 does not affect the myelination levels in rat myelinating cultures        
Embryonic rat spinal cord myelinating cultures, set up using PLL- or TnC-astrocytes, were treated with 
recombinant rat CCL2 from 12 DIV onwards. The cultures were immunostained at 24-30 DIV using AA3 (PLP, 
green) and SMI-31 (red) antibody to detect myelin sheaths and neurites, respectively. Myelination percentage 
is shown as standardised to untreated condition. CCL2 treatment did not lead to any significant change in 
myelination or neurite percentages in PLL- (A&B) or in TnC-myelinating cultures (C&D). Representative 
images for PLL- (E&F) and TnC-myelinating cultures (G&H) are also presented. PLL- and TnC-experiments 
were repeated six and three times, respectively. One-way repeated measures ANOVA test was used to detect 
significance. The error bars represent ± standard error of the mean. DIV: days in vitro; PLP: proteolipid 
protein. 
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Figure 4. 8 CCL7 does not affect the myelination levels in rat myelinating cultures        
Embryonic rat spinal cord myelinating cultures, set up using PLL- or TnC-astrocytes, were treated with 
recombinant rat CCL7 from 12 DIV onwards. The cultures were immunostained at 24 DIV using AA3 (PLP, 
green) and SMI-31 (red) antibody to detect myelin sheaths and neurites, respectively. Myelination percentage 
is shown as standardised to untreated condition. CCL7 treatment did not lead to any significant change in 
myelination or neurite percentages in PLL- (A&B) or in TnC-myelinating cultures (C&D). Representative 
images for PLL- (E&F) and TnC-myelinating cultures (G&H) are also presented. The experiments were 
repeated three times. One-way repeated measures ANOVA test was used to detect significance. The error 
bars represent ± standard error of the mean. DIV: days in vitro; PLP: proteolipid protein. 
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4.3.2.5 Treatment of myelinating cultures with SERPINB2, CCL2 and CCL7 
starting from different time points 
Myelinating cultures were treated starting from an earlier time point, 10 DIV, in case 
the selected candidates affected the axonal ensheathment only when applied to 
cultures at a specific early time frame. The myelinating cultures that were treated from 
10 DIV and 12 DIV onwards with 10 ng/ml of CCL2, CCL7 or SB2 showed average 
myelination percentages of 7.6-9.2 and 5.8-11.1, respectively, for the control (no 
treatment) conditions. The average myelination percentages were all standardised to 
the control values of 10 DIV condition within each experimental repeat. The statistical 
analysis showed that there were not any significant changes upon the above-mentioned 
treatments at 10 DIV or 12 DIV within each time point or between the two time points 
(Fig 4.9). Therefore, it could be concluded that CCL2, CCL7 and SB2 did not affect 
myelination levels when treated from 10 DIV or 12 DIV onwards.  
 
Figure 4. 9 Treatments from 10 DIV onwards did not affect myelination levels              
Embryonic rat spinal cord myelinating cultures were treated with 10 ng/ml of SERPINB2, CCL2 or CCL7 
starting from 10 DIV or 12 DIV onwards. The cultures were set up using PLL-astrocytes. The cultures were 
immunostained at 24 DIV using AA3 (PLP) and SMI-31 antibody to detect myelin sheaths and neurites, 
respectively.Statistical analysis did not show any significant changes in myelination (A) or neurite (B) 
percentages between the different conditions of the same time point or between the different time points for 
the same condition. The experiments were carried out in three replicates. One-way repeated measures 
ANOVA test was applied to the results to detect significance. The error bars represent ± standard error of the 
mean.  DIV: days in vitro; PLP: proteolipid protein. 
 
4.4 General conclusions and discussion 
The microarray gene expression profiling analysis carried out using samples from 
untreated and CNTF-treated rat embryonic spinal cord myelinating cultures that were 
set up using astrocytes plated on PLL or TnC (Array 2, Chapter 3) revealed several 
candidates that could play a role in myelination. The expressional changes detected in 
Array 2 for these candidates were validated for Ccl2, Ccl7, and Serpinb2 when qRT-PCR 
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was conducted. Even though such a validation could not be observed for Ctgf, it was 
also included in the list of candidates to apply to the cultures exogenously to observe 
their effects on myelination since it has been suggested previously to regulate 
myelination (Nash et al., 2011b). The data demonstrated that these candidates had no 
effect using neural co-cultures to examine levels of myelination. 
Connective tissue growth factor (CTGF) takes part in functions such as angiogenesis, 
fibrotic and glial scarring, and extracellular matrix remodelling in the central nervous 
system (Hertel et al., 2000; Schwab et al., 2001). Immunohistochemical studies have 
presented CTGF protein expression in a subset of neurons in neonatal mouse brains 
(Hoerder-Suabedissen and Molnar, 2013), in a subpopulation of pyramidal neurons in 
adult rat cortex, where majority of CTGF immunoreactivity was detected in astrocytes; 
while, spinal cords showed the immunoreactivity mainly in ependymal cells, tanycytes 
and gray matter (Kondo et al., 1999). While its expression has been mainly detected in 
neurons of the human post-mortem brain tissue using immunohistochemistry (Ueberham 
et al., 2003), another study detected CTGF protein expression mainly in astrocytes of 
the human post-mortem spinal cords (Spliet et al., 2003). Thus, it is possible that the 
Ctgf expression detected in our rat spinal cord myelinating cultures is provided mainly 
by the astrocytes. As opposed to the control post-mortem brain tissue, samples from the 
patients with Alzheimer’s Disease presented increased CTGF labelling in both neurons 
and astrocytes, associated with plaques (Ueberham et al., 2003). Similarly, cryosections 
from spinal cords of ALS (amyotrophic lateral sclerosis) patients showed elevated CTGF 
immunereactivity in astrocytes (Spliet et al., 2003). Kainic acid-induced injury in mouse 
hippocampus and spinal cord injury in rats have also led to increased CTGF protein 
levels in GFAP positive astrocytes (Hertel et al., 2000; Conrad et al., 2005). Such 
evidences showing increased levels of CTGF in various types of CNS pathology oppose 
the suggestion that CTGF could have a supportive role in myelination as concluded at 
the end of the analysis of Array 2. However, another protein, CXCL13 that has also 
presented increased levels in CNS pathologies such as EAE and MS has been shown to 
enhance myelination in cerebellar slice cultures from newborn mice (Yuen et al., 2013). 
Therefore, CTGF could also demonstrate such a positive effect in vitro.  
Interestingly, Lamond et al. (2013) reported more than two fold decrease in myelination 
levels in rat embryonic spinal cord cultures treated with 10 ng/ml of the same source of 
recombinant CTGF that was used in our experiments. The main difference between 
their report and my experiments appears to be the quantification of myelination and 
neurite density. They have more control on the analysis by manually drawing over 
myelin sheaths in Adobe Photoshop (PS) to allow a specifically designed custom-made 
macro to quantify these drawn-over pixels. The pipeline I used in the analysis of my 
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experiments was tailored to quantify overlapping neurite and myelin sheath pixels in 
the program named Cell Profiler that did not require such manual adjustments and thus 
facilitated and expedited the analysis. Each method of quantification has its own 
advantages and therefore one could be preferred over the other based on the personal 
choice of the investigator. In theory, both methods should provide similar results but as 
it can be seen in Table 4.2, some differences are observed between the results of the 
two methods. In those particular experiments analysed in Table 4.2, the Cell Profiler 
method generally revealed higher standardised myelination levels that were closer to 
control levels, which would decrease the likelihood of obtaining significance for the 
treatments analysed. Considering the highest difference of 0.39 seen in that table (for 
16 ng/m), it is possible that the Cell Profiler method will reveal the 0.3 value, detected 
by Lamond et al., as 0.7 for the standardised myelination level, which then might not 
be significantly different from the control levels. 
Lamond et al. have used paired Student’s t-test to detect the significant decrease upon 
CTGF treatment since their experiment consisted of only the control (no treatment) and  
Table 4. 2 The comparison of the standardised myelination percentage values detected 
using methods involving Adobe Photoshop or Cell Profiler upon CTGF treatments 
	  1st	  titration	  of	  CTGF	  treatments	  
	  Treatment	   Control	   0.05	  
ng/ml	  
0.5	  
ng/ml	  	  
2.5	  
ng/ml	  
5.0	  
ng/ml	  
12.5	  
ng/ml	  
25	  
ng/ml	  
50	  
ng/ml	  
Adobe	  PS	   1	   1.10	   1.00	   1.06	   0.99	   0.59	   0.91	   0.91	  
Cell	  Profiler	   1	   0.96	   0.92	   1.08	   0.95	   0.78	   1.11	   1.04	  
	   	   	   	   	   	   	   	   	  
Difference	   0.00	   -­‐0.14	   -­‐0.08	   0.03	   -­‐0.04	   0.19	   0.19	   0.13	  
2nd	  titration	  of	  CTGF	  treatments	  
Treatment	   Control	   4	  	  
ng/ml
ml	  
8	  	  
ng/ml	  
12	  
ng/ml	  
16	  
ng/ml	  
20	  
ng/ml	  
	   	  
Adobe	  PS	   1	   0.86	   0.74	   1.00	   0.57	   0.65	   	   	  
Cell	  Profiler	   1	   0.97	   0.99	   1.19	   0.96	   0.99	   	   	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	   	  
Difference	   0.00	   0.10	   0.25	   0.19	   0.39	   0.33	   	   	  
Embryonic rat spinal cord myelinating cultures were treated with recombinant human CTGF from 12 DIV 
onwards. In the 1st titration of treatments, concentrations ranged between 0.05-50 ng/ml; whereas, those in 
the 2nd titration were between 4-20 ng/ml as seen in the table. The cultures were used for 
immunocytochemistry at 24-28 DIV. Images taken using fluorescence microscopy presented SMI-31 positive 
neurites in red and PLP positive myelin and oligodendrocytes in green. Myelination levels were quantified in 
two separate ways from there on. 1) Myelin sheaths were drawn over using a blue brush stroke in Adobe 
Photoshop (PS) and a custom-made micro was then run on the modified images to detect the pixel value of 
where blue (myelin sheath) and red overlap with each other. The pixel value from this analysis was used to 
calculate the myelination percentages together with the values obtained for neurite densities after doing 
manual adjustments in Image J. 2) A custom-made pipeline in Cell Profiler was run on the unmodified images 
to detect the pixel values that represent the neurites and the myelin sheaths. These values were then used to 
calculate the neurite and myelination percentages since the total number of pixels always remained the same. 
Average myelination levels were standardised to control (no treatment) levels within each experimental repeat 
of each CTGF titration. Presented in the table are the overall averages of standardised myelination levels 
obtained from three experimental repeats for each titration. The differences between the values obtained from 
the method using Cell Profiler and the method using Adobe PS are also presented in the table. CTGF: 
connective tissue growth factor; DIV: days in vitro; PLP: proteolipid protein. 
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10 ng/ml of CTGF conditions; whereas, I used repeated measures one–way ANOVA test 
because there were more than two conditions for each titration. When t-test is applied 
on my CTGF data obtained using manual drawing in PS, significant decrease is seen in 
myelination levels upon treatments with 12.5 ng/ml CTGF and 16 ng/ml CTGF in the 1st 
and 2nd titration, respectively (Table 4-2), which is in accordance with the finding of 
Lamond et al. Nevertheless, the lack of a significant change for 12 ng/ml of CTGF in the 
2nd titration despite the presence of one for 12.5 ng/ml CTGF in the 1st titration could 
suggest a high biological variation among the cultures and thus could require a higher 
number of experimental repeats to observe a clear effect of the treatment. Such a 
biological variation could necessitate the use of a stricter statistical test like ANOVA; 
however, because this test requires the analysis of more than two conditions, it would 
always be necessary to treat the cultures with a reagent at different concentrations or 
with different reagents to observe a highly reliable significant effect. Because this is 
practically difficult, the experiments consisting of myelinating cultures at two 
conditions (untreated and treated) seem inevitable, in which case t-test will be the 
major role-player. Therefore, it is very hard to decide which results are more reliable 
since both types of analysis follow strategies suitable for the design of the experiments. 
Their finding of CTGF having a negative role in myelination is also supported by the 
other experiments of Lamond et al. (2013) and another study that has suggested CTGF 
as an inhibitor of oligodendrocyte precursor cell (OPC) differentiation (Stritt et al. 
2009). Because my results are in accordance with these reports when their myelin 
sheath quantification method and statistical test are used, it can be concluded that 
CTGF has a negative effect on myelination at specific concentrations and this effect is 
observed more clearly when the PS method is utilised followed by the Student’s t-test. 
Stritt et al. (2009) have shown that injection of CTGF into neonatal mouse brain can 
reduce the number of MBP (myelin basic protein)-positive cells by the time the mice are 
6 days old and that CTGF reduces the number of mature oligodendrocytes both in 
oligodendrocyte-enriched cultures and in mixed neuron/glial cell culture, with a dose-
dependent effect in the latter. They also proposed that CTGF could contribute to such 
inhibition using its insulin growth factor binding protein (IGFBP) domain since pre-
incubation of insulin growth factor 1(IGF1) with CTGF antagonised IGF1-stimulated 
oligodendrocyte maturation by reducing the number of mature oligodendrocytes. 
However, Lamond et al. (2013) have shown that CTGF can reduce the percentage of 
mature oligodendrocytes in purified oligodendrocyte cultures even though their CTGF 
contained only the C-terminus cysteine knot domain, excluding the other three 
domains; namely, IGFBP domain, Von Willebrand Factor-Type C Repeat, and 
Thrombospond Type-1 Repeat (UniProt database). Even though the C-terminus domain 
could be enough to provide signals that will suppress the OPC differentiation and hence 
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the myelination, the effects of its IGFBP domain could be much stronger, providing 
clearer results in myelination experiments. It would be interesting to see how a full-
length CTGF affects the myelination levels in rat embryonic spinal cord cultures 
compared to its shorter version containing only the cysteine knot domain.  
CTGF could also be applied to myelinating cultures at higher concentrations like 2 
µg/ml as Stritt et al. (2009) have tried. Our experiments were carried with treatments 
at nanogram level to avoid possible cell toxicity (Nash et al., 2011b). However, 
microgram levels might be more suitable in this particular case. In addition, the rat 
myelinating cultures could be treated with CTGF starting from earlier time points. 
Highly branched oligodendrocytes, stained with the O4 antibody, appear to have already 
been formed by 8 DIV in rat myelinating cultures (Sorensen et al., 2008). Therefore, it 
could be that the treatment from 12 DIV onwards is less effective in terms of reducing 
the percentage of mature oligodendrocytes and hence the myelination in the 
myelinating cultures. Treatments starting before 8 DIV could be more effective.  
The myelinating cultures were also treated with CCL2, CCL7, and SERPINB2 to observe 
their effects on myelination but none of them led to any significant changes in 
myelination levels. CCL2 is a chemokine that has been shown to play a role in the 
disease onset of EAE in mice mainly by playing a role in T cell activation (Izikson et al., 
2000; Huang et al., 2001; Elhofy et al., 2005). Increased CCL2 expression has been 
detected in the astrocytes of EAE mice (Glabinski et al., 2003; Santos et al., 2005) and 
of MS patients around the lesions (Voorn et al., 1999; Tanuma et al., 2006). Even though 
CCL2 was suggested as a potential positive regulator of myelination due to its up-
regulation in PLL-myelinating cultures compared to its expression in TnC-myelinating 
cultures (Array 2, Chapter 3), above-mentioned observations appear to contradict that. 
However, it could be that CCL2 has other roles that have not been discovered yet in the 
CNS. CCL2 was not detected in the healthy human brain or in the normal appearing 
white matter of MS patients by immunohistochemistry (Voorn et al., 1999, Tanuma et 
al., 2006), but its presence has been shown in the healthy mouse brain using ELISA 
(Santos et al., 2005; Gruol et al., 2014), suggesting physiological roles for CCL2 in the 
normal CNS. Therefore, embryonic rat spinal cord myelinating cultures were treated 
with CCL2 to examine its effect on myelination level.  
CCL7 is another chemokine that has been found to be secreted by astrocytes in vitro 
and in vivo (McManus et al., 1998; Thompson et al., 2009, Renner et al., 2011). CCL7 
protein is also detected at increased levels in hypertrophic astrocytes in MS lesions 
(McManus et al., 1998). CCL7 has also been suggested to play a role in chemotaxis of 
peripheral mononuclear cells into the CNS in pathology (Okada et al., 2009; Renner et 
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al., 2011). In addition to its immune system-related roles, the presence of CCL7 and its 
receptor, CCR1, in the midbrain of healthy embryonic and neonatal mice and the fact 
that it could promote neuronal differentiation and neuriteogenesis in primary cultures 
(Edman et al., 2008) suggests that CCL7 could have other distinct roles in the CNS in 
health and pathology. Therefore, rat embryonic spinal cord myelinating cultures were 
treated with CCL7 in an attempt to observe its stimulatory effects on myelination as we 
suggested at the end of the microarray gene expression profiling analysis (Array 2, 
Chapter 3). 
The other candidate that was tested in myelinating cultures was SERPINB2, which is a 
serine protease inhibitor that could inhibit both types of plasminogen activators (PAs), 
namely tPA and uPA, with a much greater efficiency of inhibition of the latter (Kruithof 
et al., 1995). Even though PAs could promote neruite extension in the nervous system, 
it would be important to keep the uPA levels under tight control as the degrading 
activity of uPA against myelin basic protein has been detected in conditioned media 
from primary rat microglia cultures, where tPA was also detected but to a smaller 
extent (Nakajima et al., 1992). In that sense, inhibiting uPA could prevent myelin 
degradation, in which case the inhibitor of uPA, SERPINB2, could be considered as a 
potential positive regulator of myelination as also suggested by our microarray gene 
expression profiling analysis (Array 2). Therefore, embryonic rat spinal cord myelinating 
cultures were treated with recombinant SERPINB2 to study the effect of this protein on 
myelination level.  
None of the above-mentioned candidates, CCL2, CCL7, or SERPINB2, showed positive or 
negative effects on myelination levels in the rat embryonic spinal cord myelinating 
cultures. To investigate their possible roles in myelination further, their effects were 
observed in purified rat OPC cultures since they have not been tested previously in 
terms of their effects on OPC differentiation. OPC cultures were treated with 1 ng/ml 
and 10 ng/ml of CCL2, CCL7 and SERPINB2 and they were immunolabeled with the O4 
antibody and anti-PLP at 8-10 DIV to detect the mature oligodendrocytes (Appendix IV) 
but due to time constraints, only two successful experimental repeats could be carried 
out. Even though the results present a very high level of variation and are inconclusive, 
they show a tendency towards inhibition of OPC differentiation with 10 ng/ml of CCL2 
and with 1 ng/ml of SERPINB2 (Appendix IV, Figure IV.I, Table IV-I). The representative 
images also appear to support these tendencies (Appendix IV, Fig IV.II&III). However, 
even if further experiments prove that these candidates do indeed inhibit OPC 
maturation, that result would propose a negative role for them in the regulation of 
myelination, which is the opposite of what was suggested at the end of our microarray 
gene expression profiling analysis (Array 2, Chapter 3). Therefore, another possibility 
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emerges for the interpretation of their differential regulation at different conditions in 
Array 2 such as linking those changes with the astrocyte reactivity. 
Ccl2, Ccl7, and Serpinb2 were identified as potential positive regulators of myelination 
due to their increased expression in PLL-myelinating cultures compared to that in TnC-
myelinating cultures. However, those two cultures not only differ in terms of 
myelination levels (Nash et al., 2011b) but possibly also in terms of astrocyte reactivity 
since differences between the astrocyte monolayers plated on PLL and those on TnC 
have been observed previously (Holley et al., 2005; Nash et al., 2011b). PLL-astrocytes 
are larger and express increased nestin levels compared to TnC-astrocytes (Nash et al., 
2011b), which resemble a quiescent phenotype, described previously by Holley et al. 
(2005). If we assume that the astrocyte monolayers will continue to present these 
differences when used as feeders for spinal cord myelinating cultures, it can be 
concluded that PLL-myelinating cultures contain activated astrocytes, while TnC-
myelinating cultures contain quiescent astrocytes. Therefore, the above-mentioned 
candidates, CCL2, CCL7 and SERPINB2, could be responsible for increased astrocyte 
reactivity in these cultures. 
Similarly, CTGF might also be playing a role in astrocyte reactivity as it was up-
regulated in TnC-myelinating cultures upon CNTF treatment (Array 2), which has also 
been demonstrated to increase astrocyte reactivity (Levison et al., 1996; Ye et al., 
2004; Bechstein et al., 2012;). The fact that the levels of CCL2, CCL7, CTGF and 
SERPINB2 have all been found to be elevated in various CNS pathologies, where 
astrocytes were defined as reactive based on their increased GFAP expression and 
hypertrophy, is in accordance with the suggestion that these proteins could be involved 
in the regulation of astrocyte reactivity (McManus et al., 1998; Dietzmann et al., 2000; 
Hertel et al., 2000; Schwab et al., 2001; Spliet et al., 2003; Ueberham et al., 2003; 
Conrad et al., 2005; Dos santos et al., 2005; Tanuma et al., 2006; Biancotti et al., 2008; 
McClain et al., 2009; Hidaka et al., 2014; Zheng and Zhang, 2014). These candidates 
could also be playing a role in the overall reactivity of spinal cord myelinating cultures, 
i.e., their capacity for how fast and efficiently they can recover from pathological 
conditions in general or more specifically how well they can show remyelination in 
demyelinating conditions. CNTF, which has presented elevated mRNA levels during the 
remyelination phase in mice with cuprizone-induced demyelination (Gudi et al., 2011), 
increased the levels of expression of the chemokines Ccl2, Ccl7, and Cxcl11 in both PLL- 
and TnC-myelinating cultures, which was detected by qRT-PCR (Fig 4.4). These 
chemokines could be associated with such a protective CNTF signaling pathway in these 
myelinating cultures.   
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Considering their likely association with astrocyte reactivity and/or the reactivity in 
myelinating cultures in general, it would be interesting to see the roles of these 
candidates on myelination in a scenario of CNS injury. Boomkamp et al. (2012) have 
developed such a culture system that allows the observation of the effects of different 
treatments on myelination in an in vitro model that mimics spinal cord injury (SCI). A 
single cut is made across the embryonic rat spinal cord myelinating cultures on day 22-
24 using a razor blade manually. Initially a cell-free area devoid of neurites appears at 
the site of the cut and it is followed over time with demyelination and reduced neurite 
density adjacent to the lesion, and infiltration of microglia and reactive astrocytes into 
the lesion, features that are similar to SCI in vivo. The lesion remains devoid of neurites 
unless treated with known drugs that promote CNS repair in vivo (Boomkamp et al., 
2012, 2014). 
I tried to exploit this system to observe the effects of SERPINB2, CCL2 and CCL7 on 
myelination during pathology but my inexperience in this model and time constraints 
did not reveal reliable results (Appendix V). The myelinating cultures were set up using 
astrocyte monolayers on PLL and were cut at 23 DIV, treated at 24, 26, and 28 DIV, used 
for immunocytochemistry at 29 DIV. The areas adjacent to cut lesions were used for the 
quantification of myelination level as described by Boomkamp et al. (2012). For each 
condition examined on the cut cultures, uncut cultures were also prepared from the 
same batch of cells to act as controls. The candidates decreased the neurite density in 
cut cultures compared to both cut and uncut control (untreated) cultures (Fig V.I B), 
which would suggest neurotoxic effects for them. However, a similar decrease was also 
seen in uncut cultures (Fig V.I D) that contradicted the previous findings, which were 
carried out in a higher number of experimental repeats (Fig 4.6-4.9).  SERPINB2 
increased the level of myelination in both uncut and cut cultures (Fig V.I A&C) but this 
was likely due to decreased neurite density that would increase the myelination 
percentage since its calculation is based on the ratio of myelin sheath pixels to that of 
the neurite pixels. The lack of the decreased myelination level in untreated cultures 
upon the cut injury, which is one of the main features of this in vitro CNS injury model 
(Boomkamp et al., 2012, 2014), also reduced the reliability of these results. Future 
experiments by other investigators might provide further insight into the roles of these 
candidates in CNS pathology.  
One other point to consider in terms of why the candidates we selected did not affect 
myelination in the rat embryonic spinal cord myelinating cultures is the failure to 
replicate the previous findings of lower myelination levels for mixed neural cells plated 
on astrocytes on TnC compared to those on PLL-astrocytes (Fig 4.6E). The hypothesis 
that those candidates would stimulate myelination was based on the fact that they were 
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up-regulated in PLL-myelination cultures, which present higher myelination levels 
according to Nash et al. (2011b). The basic difference between my experiments and 
those of Nash et al. appears to be the way of quantification of myelination as described 
above. Nevertheless, their representative images present lower levels of myelination in 
TnC-myelinating cultures very clearly (Nash et al., 2011b). So the difference must be 
something concerning the way I have carried out the experiments rather than the 
method of quantification. One clear distinction is that Nash et al. have plated 1 x T75 
flask of striatum-derived neurospheres into 1 x 24-well plate to differentiate into 
astrocytes; whereas, I counted the neurospheres and plated them always at 250,000 
cells/ml in each well to start the astrocyte cultures. The concentration of astrocytes 
could be affecting their capacity to react to different treatments or substrates and thus 
could be accountable for the above-mentioned opposing results, which will be 
investigated in the following chapter.      
In conclusion, some candidates were validated by qRT-PCR experiments to be potential 
regulators of myelination as suggested by Array 2 (Table 4.3). These selected candidates 
did not affect myelination level or neurite density in embryonic rat spinal cord 
myelinating cultures apart from CTGF that reduced the myelination level when the 
Adobe PS quantification method and Student’s t-test were used for the analysis. CCL2, 
CCL7, CTGF, and SERPINB2 could be playing more effective roles in astrocyte reactivity 
or the capacity of myelinating cultures to recover from pathologies rather than in 
myelination. 
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Table 4. 3 The candidates selected as potential regulators of myelination after the binary 
comparisons of Array 2 data and the results of their validations by qRT-PCR and cell 
culturing 
Binary	  
comparison	  
Candidates	  
selected	  as	  
possible	  (+)	  
regulators	  
Candidates	  
selected	  as	  
possible	  (-­‐)	  
regulators	  
Validated	  by	  
the	  1st	  qRT-­‐
PCR	  
Validated	  
by	  the	  2nd	  
qRT-­‐PCR	  
Validated	  
by	  cell	  
culturing	  
PLL-­‐control	   vs	  
PLL+CNTF	  
CXCL13,	  
LCN2,	  
SERPINB2	  
-­‐	   Serpinb2	   none	   none	  
 
TnC-­‐control	   vs	  
TnC+CNTF	  
CTGF	   THBS2,	  
WIF1	  
none	   none	   -­‐	  
PLL-­‐control	   vs	  
TnC-­‐control	  
CCL2,	   CCL7,	  
SERPINB2	  
CXCL11,	  
LCN2,	  WIF1	  
Ccl2,	   Ccl7,	  
Serpinb2	  
Ccl2,	  Ccl7	   none	  
Microarray gene expression profiling analysis was carried out using RNA samples from embryonic rat spinal 
cord mixed cultures (myelinating cultures) at four different conditions: 1) plated on astrocyte monolayers on 
PLL-coated coverslips (PLL-control), 2) plated on PLL-astrocytes and treated with CNTF (PLL+CNTF), 3) 
plated on TnC-astrocytes (TnC-control), 4) plated on TnC-astrocytes and treated with CNTF (TnC+CNTF). 
Differentially expressed transcripts between the cultures shown as binary comparisons in the table were 
analysed and the candidates presented were selected as possible positive or negative regulators of 
myelination. The relative expressions of these transcripts between the shown cultural conditions were 
measured by means of qRT-PCR, where firstly, the original RNA samples from Array 2 were used and 
secondly, new RNA samples extracted from three biological replicates of new myelinating cultures at the same 
four conditions were used. The transcripts, for which the expressional regulations were validated by qRT-PCR, 
are presented in the table. These validated candidates were applied to myelinating cultures as recombinant 
proteins from 12 DIV onwards. The cultures were stained at 24-28 DIV using the antibodies against SMI-31 
and PLP to detect neurites and myelin, respectively. Cell Profiler, followed by microscopy, measured the 
myelination level and neurite density, which were not affected by any of the candidates examined. CCL2: 
chemokine (C-C motif) ligand 2; CCL7: chemokine (C-C motif) ligand 7; CXCL11: chemokine (C-X-C motif) 
ligand 11; CXCL13: chemokine (C-X-C motif) ligand 13; CNTF: ciliary neurotrophic factor; DIV: days in vitro; 
LCN2: lipocalin2; PLL: poly-L-lysine; PLP: proteolipid protein; TnC: tenascin C; THBS2: thrombospondin 2; 
WIF1: WNT inhibitory factor 1.   
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Chapter 5 
 
Fine-tuning embryonic rat spinal cord 
myelinating cultures 
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5.1 Introduction 
The protocol for setting up and maintaining embryonic rat spinal cord myelinating 
cultures (Sorensen et al., 2008) was developed and modified from a method that was 
originally used for mouse spinal cord cultures (Thomson et al. 2006; Thomson et al., 
2008). Briefly, dissociated spinal cords from Sprague Dawley rat embryos were plated on 
top of confluent rat astrocyte monolayers, which were differentiated from striatum-
derived neurospheres directly on the glass coverslips, coated with PLL or TnC. The 
astrocytes on PLL- or TnC-coated coverslips will be called as PLL-astrocytes and TnC-
astrocytes, respectively, in this chapter. In addition, the spinal cord myelinating 
cultures that are prepared using PLL- or TnC-astrocytes will be called PLL-myelinating 
cultures and TnC- myelinating cultures, respectively.  
This established protocol (Sorensen et al., 2008) in my opinion could be further 
modified to be completely optimised as an assay, which can be important to understand 
how the variability can occur in myelinating cultures and to obtain consistent results 
when comparing the effects of a treatment on myelination. One such treatment can be 
provided by CNTF (ciliary neurotrophic factor), which has previously been identified as a 
pro-myelinating factor in these myelinating cultures (Nash et al., 2011b) and which has 
been used to generate the samples analysed in our microarray analysis (Array 2, Chapter 
3). In the first instance I examined one of the main steps that could produce variations 
in myelination and which could be optimised further. This step is the plating numbers of 
the striatum-derived neurospheres on PLL- or TnC-coverslips to generate astrocyte 
monolayers. Each 75 cm2 tissue culture flask of neurospheres are prepared from 3-4 rat 
striata and the entire flask content of cells are plated onto glass coverslips contained in 
1-4 x 24-well plates, according to how dense they appear in the flask under the light 
microscopy. The size and the number of neurosphere clusters may vary depending on 
the tissue volume of striata used, which would be very difficult to control if required. 
Therefore, it would be easier to determine an optimal cell number which will generate 
a constant cell density, at which the neurospheres can be plated down to generate 
astrocytes at an optimised confluency when they are to be used as monolayers for 
myelinating cultures, which is usually around 6-9 DIV (Fig 5.1). Such cell density will be 
referred as “seeding density” in the rest of this chapter. Based on the common dilutions 
used in our lab (e.g. 1 flask of neurospheres plated into 1-4 x 24-well plates), the 
following four seeding densities were chosen to work with: 125, 250, 375, and 500 x 103 
cells/ml. 
The original published protocol for the myelinating cultures suggests using astrocyte 
monolayers at 7-10 DIV prior to the addition of the dissociated spinal cord cells because 
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this is usually the time point when they form a confluent monolayer (Sorensen et al., 
2008). However, personal observations have shown that astrocyte cultures could reach 
confluency and therefore stop/slow down their proliferation rate sooner than this. 
Therefore, it is likely that confluent and healthy-looking astrocytes will be used for 
setting up myelinating cultures by some researchers at earlier time points than 7-10 
DIV. The effects of using younger astrocytes on final myelination levels and neurite 
density will also be examined and data will be presented in this chapter.    
 
Figure 5. 1 Examples of neurosphere-derived rat astrocyte cultures under phase-contrast 
microscopy.                      
Dissociated striata that were isolated from 24-36 hr old Sprague Dawley rats were used to set up neurosphere 
cell suspensions. These neurospheres were plated down on PLL-coated glass coverslips after 6-9 DIV with 
different seeding density and allowed to differentiate into astrocytes. The astrocyte cultures were observed 
under phase-contrast microscopy after 6 DIV. A) The cultures do not appear to be confluent. There are 
several areas devoid of any cells. The cells present different morphology at different locations of the field of 
view possibly due to the lower cell concentration. The cultures that look like this at 6 DIV generally do not 
become confluent in the following few three-four days. B) The image shows a confluent astrocyte culture, 
where all of the field of view is covered with a monolayer of cells. The cells appear to be of uniform shape.  
 
5.2 Aims  
The overall aim of this chapter is to optimise the protocol for setting up rat spinal cord 
myelinating cultures further by 1) finding the optimum seeding density of the striatum-
derived neurospheres that would generate astrocytes at an optimised confluency and 
hence less variable spinal cord myelinating cultures and 2) detecting the effect of the 
astrocyte age on myelination.  
These will be carried out specifically as follows: 
• To analyse the effects of the seeding density of the striatum-derived 
neurospheres on the myelinating cultures the following will be assessed:  
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o the expression of glial fibrillary acidic protein (GFAP) and nestin 
immunoreactivity of the PLL- and TnC-astrocytes.  
o the number/percentage of type-2 astrocytes present in the PLL- and TnC- 
astrocyte cultures by means of immunocytochemistry using O4 and anti-
GFAP antibodies. 
o the number/percentage of PLP positive (PLP+) oligodendrocytes present 
in the PLL- and TnC- astrocyte cultures. 
o myelination and neurite density of the neural cells in PLL- and TnC- 
myelinating cultures.  
o myelination and neurite density in CNTF (ciliary neurotrophic factor; a 
previous identified pro-myelinating factor)-treated PLL-myelinating 
cultures. 
• To examine the effect of PLL-astrocytes at an early time in culture on 
myelination and neurite density in PLL-myelinating cultures that will be 
untreated or treated with CNTF starting from different time points onwards.  
5.3 Results  
The astrocyte cultures were initiated by plating down striatum-derived neurospheres at 
certain seeding density on PLL- or TnC-coated glass coverslips and the cultures were 
maintained to confluency for 3-11 DIV. The cultures were observed under phase-
contrast microscopy to ensure that the coverslips that appeared to contain cultures at 
similar densities for each seeding density were used. The astrocyte cultures that were 
set up using higher and lower concentrations of neurospheres will be called “denser 
astrocyte cultures” and “less dense astrocyte cultures”, respectively, throughout this 
chapter. The astrocyte cultures were then either immunostained and analysed 
separately or were used as a supporting monolayer for spinal cord myelinating cultures. 
Firstly, the effects of the seeding density of the striatum-derived neurospheres on the 
morphology of the PLL- and TnC-astrocytes will be examined. Later, the results will be 
presented for the myelination levels of the untreated and CNTF-treated spinal cord 
myelinating cultures that were set up using striatum-derived neurospheres at various 
seeding densities. Finally, the effects of the age of the astrocytes on myelination will be 
demonstrated in spinal cord myelinating cultures, which were either untreated or 
treated with CNTF starting from different time points.  
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The effects of the seeding density of the striatum-derived neurospheres on the 
morphology of PLL- and TnC-astrocytes will be shown in terms of their GFAP and nestin 
expressions, detected by fluorescence microscopy. GFAP and nestin are not only 
intermediate filament proteins that are found in the astrocytes, but they are also used 
as markers of astrocyte reactivity (Eng et al, 1970; Frisen et al., 1995; Brook et al., 
1999; Clarke et al., 1999; Eng et al., 2000; Pekny et al., 2004; Sofroniew et al., 2010; 
Xue et al, 2011). Monoclonal antibodies will also be used to detect the possible 
oligodendrocytes and type-2 astrocytes present in the astrocytes cultures. Astrocytes in 
cultures of developing rat brain have been divided previously into two types (type-1 and 
2) based on their morphology and their abilities to bind tetanus toxin and the 
monoclonal antibody A2B5 (Raff et al., 1983). The stellate type-2 astrocytes have later 
been shown also to express the sulphatide detected by O4 antibody unlike the 
epithelioid type-1 astrocytes (Aloisi et al., 1988). Therefore, immunocytochemistry will 
also be carried out to detect both GFAP and O4 positive cells, which would represent 
the type-2 astrocytes. O4 antibody can also be used to visualise oligodendrocytes at 
specific differentiation stages and proteolipid protein (PLP), for which the antibody AA3  
(Yamamura et al., 1991) is used, is expressed in more mature stages (Fig 1.1, reviewed 
in Barateiro and Fernandes, 2014). Thus, O4 and PLP positive cells would represent the 
mature oligodendrocytes in the astrocyte cultures. 
5.3.1 The effects of the seeding density of the striatum-derived 
neurospheres on the morphology of PLL-astrocytes 
Increased GFAP expression is a classical hallmark of pathology (reviewed in Mucke et 
al., 1993). Its expression previously has been used as an indicator to distinguish 
astrocyte phenotypes in a way, where low GFAP expression has been associated with 
quiescent or less active astrocytes and high GFAP expression with reactive astrocytes 
(reviewed in Sofroniew and Vinters, 2010). Nestin expression has been used for the 
same purpose but to a lesser extent (Holly et al., 2005). Thus, both GFAP and nestin 
immunoreactivity were analysed in neurosphere-derived rat astrocytes that were 
initiated by plating down 500 µl of striatum-derived neurospheres on PLL-coated 
coverslips at varying densities. The densities were chosen to be 125, 250, and 375 x 103 
cells/ml. They were immunostained to detect GFAP and nestin expressions at 7-9 DIV 
when all cultures were observed to be confluent. 
 
Average DAPI positive (DAPI+) cell density differed significantly between the astrocyte 
cultures that were set up using neurospheres at different seeding density (Fig 5.2 A). 
The denser cultures presented higher numbers of cells at the end of their culture 
period, which shows that they did not reach the contact-dependent inhibition earlier  
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Figure 5. 2 Seeding density of the striatum-derived rat neurospheres appears to induce 
morphological changes in astrocytes on PLL.          
Striatum-derived Sprague Dawley rat neurospheres were plated down (500 µl of cell suspension) on PLL-
coated glass coverslips at 5-8 DIV at different seeding density as shown in the graphs above. They were left 
to differentiate into astrocytes in medium containing 10% FBS and immunocytochemistry was carried out after 
7-9 DIV using the primary antibodies to detect GFAP and nestin positive cells. Images were captured using 
Olympus BX51 fluorescent microscope and Image-Pro imaging software. A) Total DAPI positive cell (in blue) 
number per image was quantified using Cell Profiler and was presented as average DAPI+ cell number, which 
differed significantly between cultures plated at different seeding density (** P<0.01, *** P<0.001). The 
cultures that were initiated with higher seeding density also contained increased cell numbers compared to 
those initiated with lower seeding density. B) Image J was used to quantify the mean intensity of the 
fluorescence per image detected in green and red channels. This value was multiplied by the whole area of 
the image to calculate the total intensity of GFAP or nestin fluorescence. The average of all the images 
captured per condition formed the average intensity values, which were standardised to the values detected in 
the cultures with the lowest seeding density (125 x 103 cells/ml) for both GFAP and nestin separately. Average 
GFAP or nestin intensity did not show significant changes in cultures with different seeding density. C) 
Average GFAP and nestin intensity per cell was calculated for each image as a ratio of the total intensity to 
the total cell number of the image. The averages were standardised to the values for the cultures with the 
lowest seeding density for GFAP and nestin separately. Average intensity per cell decreased significantly for 
both GFAP and nestin as the seeding density increased (* P<0.05, *** P<0.001). D&E) Representative images 
of astrocyte cultures are presented for GFAP (green) and nestin (red) immunostainings. Both denser and less 
dense cultures appear confluent but they present different cell morphology. The cells in the less dense 
cultures appear larger than those in the denser cultures. Experiments were repeated five times. The error bars 
represent ± standard error of the mean. One-way repeated measures ANOVA test was applied to the results 
to detect any possible significance. Scale bar represents 50 µm for all images. Avg: average; DIV: days in 
vitro; FBS: foetal bovine serum; GFAP: glial fibrillary acidic protein; PLL: poly-L-lysine; s.d; seeding density.  
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despite their increased concentration to begin with. The denser cultures would have to 
consist of smaller cells to be able to cover the same area (13 mm coverslips) as it can 
be seen in the representative images, where less dense cultures appeared to consist of 
cells with larger cell areas (Fig 5.2 D) compared to those found in the denser cultures 
(Fig 5.2 E).  
 
The GFAP and nestin fluorescence intensities were measured in Image J using the 
images captured by the fluorescent microscopy. There was no significant difference 
seen for these intensities between the cultures at different densities  (Fig 5.2 B). 
However, the average intensities per cell were decreased for both GFAP and nestin in 
denser astrocyte cultures (Fig 5.2 C), which could also be seen in the representative 
images (Fig 5.2 D & E).  
The astrocyte cultures were also immunostained to detect the nature of the spherical, 
smaller and brighter cells that were seen on top of the astrocytes even after they have 
generated confluent monolayers after 6 DIV (Fig 5.3). The number of such cells 
appeared to be increased in denser astrocyte cultures. One possibility was that these 
were oligodendrocytes or oligodendrocyte progenitor cells (OPCs) since it has been 
previously observed that some of the progenitor cells, which are present in the 
neurosphere-derived astrocyte cultures at the initial stages, could differentiate into 
oligodendrocytes in the same medium, where the majority of the progenitors 
differentiate into astrocytes (Sorensen et al., 2008). Therefore, the astrocyte cultures 
were immunostained using the classic oligodendrocyte marker O4 (Sommer and 
Schachner, 1981) that detects several surface antigens including sulphatide that is 
expressed at various stages of differentiating oligodendrocytes, starting from OPCs. The 
cells double-stained for O4 and PLP (Yamamura et al., 1991) would represent the more 
mature oligodendrocytes compared to those stained with O4 alone (Fig 1.1). On the 
other hand, O4 can also detect OPCs that could generate oligodendrocytes or type-2 
astrocytes depending on the differentiation culture conditions (Raff et al., 1983; Aloisi 
et al., 1988; Trotter and Schachner, 1989). Because serum-containing medium has been 
shown to provide a more suitable environment for OPCs to differentiate into type-2 
astrocytes in vitro rather than into oligodendrocytes (Aloisi et al., 1988; Trotter and 
Schachner, 1989), the astrocyte cultures were also double stained using the O4 antibody 
and GFAP antibodies to distinguish the oligodendrocytes from type-2 astrocytes.   
The results presented significantly higher numbers and percentages of cells that were 
labelled with the O4 antibody (O4+) and that were positive both for GFAP and O4 
(GFAP&O4+) in denser astrocyte cultures (Fig 5.4). The majority of the O4+ cells were 
also stained for GFAP, suggesting that these were type-2 astrocytes rather than  
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Figure 5. 3 Phase-contrast microscopic image of neurosphere-derived rat astrocyte cultures 
that were seeded at different concentrations.                  
Dissociated striata that were isolated from postnatal day 1 Sprague Dawley rats were used to set up 
neurosphere cell suspensions. These neurospheres were plated down on PLL-coated glass coverslips after 6-
9 DIV with a seeding density of A) 125 x 103 cells/ml, B) 250 x 103 cells/ml, C) 375 x103 cells/ml, D) 500 x103 
cells/ml and allowed to differentiate into astrocytes. The astrocyte cultures were observed under phase-
contrast microscopy after 6 DIV. There are several blank areas devoid of any cells in the cultures with the 
lowest seeding density (A). This is not observed in the other cultures (B-D). The sphere-shaped cells that are 
smaller and brighter compared to the astrocytes underneath are likely to be OPC progenitor cells, 
oligodendrocytes, and/or type-2 astrocytes as explained in the text. Some of these cells are shown with white 
arrows. Their number appears to increase as the seeding density of the astrocyte cultures increases. DIV: 
days in vitro; PLL: poly-L-lysine. 
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Figure 5. 4 Seeding density of the striatum-derived rat neurospheres leads to a significant 
increase in the number of type-2 astrocytes in astrocyte cultures on PLL.      
Striatum-derived Sprague Dawley rat neurospheres were plated down after 5-8 DIV as 500 µl of cell 
suspension on PLL-coated glass coverslips at different seeding density as noted above. They were left to 
differentiate into astrocytes in medium containing 10% FBS. The confluent astrocyte cultures after 7-9 DIV 
were immunolabelled for O4 antibody and GFAP to detect the type-2 astrocytes. Images were captured using 
Olympus BX51 fluorescent microscope and Image-Pro imaging software. A) Total DAPI positive cell (in blue) 
number per image was quantified using Cell Profiler and was presented as average DAPI+ cell number per 
field of view, which differed significantly between cultures plated at seeding density of 125 and 375 x 103 
cells/ml (* P<0.05). The cultures that were initiated with higher seeding density also possessed increased cell 
numbers when they reached confluency. B) The cells, which were positive for O4 and for both O4 and GFAP 
(GFAP&O4) were counted manually using Image J and were presented as average cell number per seeding 
density. This was standardised to the O4+ values of the highest seeding density within each experiment. Both 
O4+ and GFAP&O4+ cell numbers were significantly higher in the astrocyte cultures with the sd. of 375 x 103 
cells/ml (*** P<0.001). C) They were also presented as percentages of the total number of cells per image. D) 
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The percentages were standardised to the O4+ values of the highest seeding density within each experiment. 
E-H) Representative images of the astrocyte cultures with different seeding density reflect the changes 
observed in the graphs. Immunoreactivity of GFAP and the O4 antibody are shown in green and red, 
respectively. Experiments were repeated three times. The error bars represent ± standard error of the mean. 
One-way repeated measures ANOVA test was applied to the results to detect any possible significance. Scale 
bar represents 50 µm in E-G and 25 µm in H. Avg: average; DIV: days in vitro; FBS: foetal bovine serum; 
GFAP: glial fibrillary acidic protein; PLL: poly-L-lysine; s.d; seeding density. 
oligodendrocytes. The average percentages of type-2 astrocytes in PLL-astrocytes were 
0.8%, 2.8%, and 7.0% in astrocyte cultures with the seeding density of 125, 250, and 375 
x 103 cells/ml, respectively, with a significance observed between the least dense and 
densest cultures (Fig 5.4 C).  Interestingly, O4+ cells that were found in less dense 
astrocyte cultures (Fig 5.4 E), did not appear to posses multiple or long cell processes 
like the ones observed in denser cultures (Fig 5.4 F-G). Therefore, it is possible that 
these  O4+ cells in less dense cultures are at earlier stages of maturation compared to 
those that reach later stages in denser cultures. Because there was not any significance 
detected for the difference between the numbers of O4+ cells and GFAP&O4+ cells (Fig 
5.4 B), it is likely that the majority of those O4+ cells in Figs 5.4 E-G are type-2 
astrocytes and are less mature in less dense PLL-astrocyte cultures.       
All the cells that showed PLP expression were also positive for O4 staining (O4&PLP+) in 
PLL-astrocyte, for which an example is shown in Fig 5.5 H. The percentages of these 
O4&PLP+ cells were much lower compared to those of type-2 astrocytes, mentioned 
above. These PLP+ oligodendrocytes presented densities of approximately 0.06%, 0.13%, 
and 0.22% in astrocyte cultures with the seeding density of 125, 250, and 375 x 103 
cells/ml, respectively (Fig 5.5 C). Even though there is a trend of increase in the 
numbers and percentages of PLP+ cells in denser astrocyte cultures, those changes were 
not found to be significant (Fig 5.5 B&C). Therefore, the number or the percentage of 
mature oligodendrocytes was not affected by the seeding density of the astrocyte 
cultures on PLL. The representative images presented PLP+ oligodendrocytes at similar 
morphologies in astrocyte cultures with different seeding density (Fig 5.5 E-G). The rest 
of the O4+ cells that were negative for PLP expression (Fig 5.5 H) could be GFAP+ type-2 
astrocytes as observed in Fig 5.4 F. Similarly, DAPI+ cell numbers were higher in denser 
astrocyte cultures (Fig 5.5 A) as seen above (Fig 5.2 A, 5.4A).    
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Figure 5. 5 Seeding density of the striatum-derived rat neurospheres does not affect the 
number of mature oligodendrocytes in astrocyte cultures on PLL.                     
Striatum-derived Sprague Dawley rat neurospheres were plated down after 5-8 DIV as 500 µl of cell 
suspension on PLL-coated glass coverslips at different seeding density as stated above. They were left to 
differentiate into astrocytes in medium containing 10% FBS. The confluent astrocyte cultures after 7-9 DIV 
were used for immunocytochemistry with antibodies to visualise PLP positive mature oligodendrocytes. 
Images were captured using Olympus BX51fluorescent microscope and Image-Pro imaging software. A) Total 
DAPI positive cell number per image was quantified using Cell Profiler and was presented as average DAPI+ 
cell number per field of view, which differed significantly between cultures plated at seeding density of 125 and 
375 x 103 cells/ml (* P<0.05). The cultures that were initiated with higher seeding density showed also 
increased cell numbers when they reached confluency. B) PLP+ cells were counted manually using Image J 
and were presented as average cell number per seeding density. The results were standardised to the highest 
seeding density. C) PLP+ cells were also presented as percentages of the total number of cells per image. D) 
The percentages were standardised to the highest seeding density. No significant changes were detected in 
the results presented in B, C and D.  E-G) Representative images of the astrocyte cultures with different 
seeding density show DAPI+ cells in blue and PLP+ oligodendrocytes in green. H) All PLP positive cells 
(green) also labelled with the O4 antibody (red). Experiments were repeated three times. The error bars 
represent ± standard error of the mean. One-way repeated measures ANOVA test was applied to the results 
to detect any possible significance. Scale bar represents 50 µm in all images. Avg: average; DIV: days in vitro; 
FBS: foetal bovine serum; PLL: poly-L-lysine; PLP: proteolipid protein. 
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5.3.2 The effects of the seeding density of the striatum-derived 
neurospheres on the morphology of TnC-astrocytes 
Neurosphere-derived rat astrocytes, initiated by plating down striatum-derived 
neurospheres on TnC-coated coverslips at varying densities, were also analysed in terms 
of their GFAP and nestin expressions and the percentage of cells that expressed both 
the O4 antibody and GFAP (GFAP&O4+) known as type-2 astrocytes. The results were 
not completely similar to those detected in PLL-astrocytes. 
A number of coverslips of TnC-astrocytes were immunostained for GFAP and the O4 
antibody after 10 DIV; while, the remaining coverslips from the same batch of TnC-
astrocytes were used for the double staining of GFAP and nestin after 11 DIV. Both 
experiments comprised of neurosphere cell suspensions plated down at the 
concentrations of 125, 250, 375 and 500 x 103 cells/ml. Average DAPI+ cell numbers 
counted at the end of the experiment (10 and 11 DIV) were significantly lower in the 
less dense cultures, (125 x 103 cells/ml), compared to DAPI+ cell numbers in the denser 
cultures (Fig 5.6 A and 5.7 A). However, the differences between the cultures with the 
seeding density of 250, 375, and 500 x 103 cells/ml were not found to be significant (Fig 
5.6 A and 5.7 A). In parallel with that, the representative images presented fewer and 
larger astrocytes in the cultures initiated with the seeding density of 125 x 103 cells/ml 
(Fig 5.6 D) compared to those in denser cultures (250-500 x 103 cells/ml) that appeared 
to consist of similar number of cells (Fig 5.6 E-G). 
Average GFAP fluorescence intensity was not significantly different between the 
astrocyte cultures with different seeding density but nestin fluorescence intensity was 
increased in the two highest seeding concentrations compared to the lowest one (Fig 
5.6 B). Despite the increase in nestin intensity, the average nestin intensity per cell was 
still significantly lower in denser cultures (Fig 5.6 C). Consequently, the least dense 
cultures consisted of astrocytes that appeared to be bigger in cell size (Fig 5.6 D) and 
that showed higher GFAP and nestin intensities per cell compared to those in denser 
astrocyte cultures (Fig 5.6 E-G). Because the increased GFAP and nestin expression per 
cell could be interpreted as increased astrocyte reactivity, it is possible that the 
astrocytes in the cultures with a seeding density of 125 x 103 cells/ml are more reactive 
compared to those in the cultures with higher seeding density. 
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Figure 5. 6 Seeding density of the striatum-derived rat neurospheres appears to stimulate 
morphological changes in astrocyte cultures on TnC.                       
Striatum-derived rat neurospheres were plated down in 500 µl on TnC-coated glass coverslips after 11 DIV at 
different seeding density as stated above. They differentiated into astrocytes in medium containing 10% FBS. 
The confluent astrocytes were immunolabelled after 11 DIV using antibodies to detect GFAP (green) and 
nestin (red). A) Total DAPI positive cell number per image was quantified using Cell Profiler and was 
presented as average DAPI+ cell number, which differed significantly between cultures plated at different s.d. 
(***P<0.001). B) Image J was used to quantify the mean intensity of the fluorescence per image for green and 
red channels, which was multiplied by the whole image area to calculate the total intensity of GFAP or nestin 
fluorescence per image. The average of all the images captured per condition formed the avg intensity values, 
which were standardised to the least dense cultures for both GFAP and nestin separately. Avg GFAP intensity 
did not differ significantly in cultures with different s.d. Avg nestin intensity increased significantly at the s.d. of 
375 and 500 x 103 cells/ml compared to that of 125 x 103 cells/ml (# P<0.05). C) Avg GFAP and nestin 
intensity per cell was calculated for each image as a ratio of the total intensity to the total cell number per 
image. The averages were standardised to least dense cultures for GFAP and nestin separately. Avg intensity 
per cell decreased significantly for both GFAP and nestin at higher s.d. compared to the lowest s.d. 
(***P<0.001). D-G) Representative images of astrocyte cultures are presented. Experiments were repeated 
three times. The error bars represent ± standard error of the mean. One-way repeated measures ANOVA test 
was used to detect significance. Scale bar represents 50 µm for all images. Avg: average; DIV: days in vitro; 
FBS: foetal bovine serum; GFAP: glial fibrillary acidic protein; s.d; seeding density; TnC: tenascin C. 
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The average O4+ or GFAP&O4+ cell numbers or percentages did not show any significant 
changes between the TnC-astrocyte cultures with different seeding density (Fig 5.7) 
unlike the situation observed for PLL-astrocytes. Therefore, it could be concluded that 
the number or percentage of type-2 astrocytes is not affected by the seeding density of 
the TnC-astrocyte cultures. Similar to the observations in PLL-astrocytes, the number of 
cells that stained with the antibody to O4, which recognises sulphatide, in less dense 
astrocyte cultures (Fig 5.7 E) did not appear to posses multiple or long cell processes 
like the ones observed in denser cultures (Fig 5.7 F-H). It is likely that the majority of 
these O4+ cells in Figs 5.7 E-H are type-2 astrocytes due to the similar levels of cell 
number and percentage detected for O4+ and GFAP&O4+ cells, and that they are less 
mature in less dense TnC-astrocyte cultures. DAPI+ cell numbers were also higher in 
denser astrocyte cultures (Fig 5.7 A) as seen above (Fig 5.6 A). 
In conclusion, the seeding density of the striatum-derived neurospheres appears to have 
an effect on the average DAPI+ cell density, cell size, average GFAP and nestin 
fluorescence intensity per cell, and morphology of cells (possibly type-2 astrocytes) that 
stained with the antibody to O4 in rat astrocyte cultures, plated on TnC-coated 
coverslips. The differences are observed specifically between the cultures, set up at the 
seeding density of 125 x 103 cells/ml, and the denser cultures, as explained above. 
5.3.3 The effects of the seeding density of the striatum-derived 
neurospheres on myelination  
After analysing the possible effects of the seeding density of the striatum-derived rat 
neurospheres on the morphological features of the astrocyte cultures, this effect was 
also examined on myelination in rat embryonic spinal cord cultures, which were 
prepared using PLL- or TnC-astrocytes at different densities.  
Despite the morphological changes seen above in astrocyte cultures with different 
seeding density, the myelination levels or the neurite density of the spinal cord 
myelinating cultures did not appear to be affected by the use of the astrocyte cultures 
at different densities (Fig 5.8). Both the PLL-myelinating cultures (Fig 5.8 A & B) and 
TnC-myelinating cultures (Fig 5.8 C & D) contained myelination percentages and neurite 
density that were at similar levels at all the seeding densities examined. Representative 
images are also presented for the spinal cord myelinating cultures, prepared with the 
least and the most dense astrocyte cultures on PLL (Fig 5.8 E & F) and on TnC (Fig 5.8 G 
& H).  
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Figure 5. 7 Seeding density of the striatum-derived rat neurospheres does not affect the 
number of type-2 astrocytes significantly in astrocyte cultures on TnC.               
Striatum-derived rat neurospheres were plated down after 11 DIV as 500 µl of cell suspension on TnC-coated 
glass coverslips at different seeding density as seen above. They differentiated into astrocytes in medium 
containing 10% FBS. The confluent astrocytes were immunolabelled after 10 DIV to visualise GFAP positive 
cells (green) and cells the label with the O4 antibody (red) that reflect the type-2 astrocytes. A) Average 
DAPI+ cell number is the total DAPI+ cell number per image that was quantified using Cell Profiler. It was 
significantly lower in cultures plated at the s.d. of 125 x 103 cells/ml compared to that in the cultures with 
higher s.d. (* P<0.05,** P<0.01). B) The cells positive for O4 (O4+) and for both GFAP and O4 (GFAP&O4) 
were counted manually using Image J and were presented as avg cell number per s.d. C) They were also 
presented as percentages of the total number of cells per image. D) The percentages were standardised to 
the O4+ values of the highest s.d. within each experiment. No significant changes were detected in any of the 
comparisons. E-H) Representative images of astrocyte cultures are presented. Experiments were repeated 
three times. The error bars represent ± standard error of the mean. One-way repeated measures ANOVA test 
was used to detect significance. Scale bar represents 50 µm in all the images. Avg: average; DIV: days in 
vitro; FBS: foetal bovine serum; GFAP: glial fibrillary acidic protein; PLL: poly-L-lysine; s.d; seeding density; 
TnC: tenascin C. 
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Figure 5. 8 Seeding density of the striatum-derived neurospheres does not affect the 
myelination levels in rat myelinating cultures on PLL- or TnC-astrocytes.      
Embryonic rat spinal cord myelinating cultures were set up on top of neurosphere-derived rat astrocytes, 
plated on PLL- or TnC-coated glass coverslips. Spinal cord cultures were prepared using astrocytes cultures 
that were started with neurosphere cell suspensions at different seeding density as shown above in the 
graphs. The spinal cord cultures were immunostained after 24 DIV using the AA3 antibody to detect PLP 
(green) and hence mature myelin and using SMI-31 (red) to detect neurites. Myelination percentages and 
neurite density were quantified using “myelin.cp” pipeline in Cell Profiler using images from fluorescent 
microscopy. Myelination percentage is standardised to the value in the least dense cultures (125 x 103 
cells/ml). The initial s.d. of astrocyte cultures did not affect myelination level (A&C) or neurite density (B&D) 
significantly. Representative images illustrate cultures on PLL- (E&F) or TnC- astrocytes (G-H). The 
experiments were repeated three times. One-way repeated measures ANOVA test was applied to the results. 
The error bars represent ± standard error of the mean. Scale bar represents 100 µm for all images. DIV: days 
in vitro; PLL: poly-L-lysine; PLP: proteolipid protein; s.d.: seeding density; TnC: tenascin C. 
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The PLL-myelinating cultures, which were set up using astrocytes with different 
densities, were also used to examine the effect of rat recombinant CNTF on 
myelination. Despite a slight increase in myelination percentages upon CNTF treatment 
for all the astrocyte densities used, none of them was shown to be significant (Fig 5.9 
A).  Similarly, CNTF treatment did not lead to any significant changes on neurite density 
in any of the astrocyte densities used (Fig 5.9 B). Representative images are also given 
to visualise the untreated (control) and CNTF-treated myelinating cultures (Fig 5.9 C-F). 
In short, the seeding density of the striatum-derived neurospheres did not affect the 
myelination levels in untreated or CNTF-treated PLL-myelinating cultures when cell 
densities between 125-500 x 103 cells/ml were used. The CNTF treatment (1ng/ml) did 
not change the myelination levels in any of the cells densities that were examined.  
5.3.4 The effects of the age of the astrocytes on myelination   
Because the previously shown stimulatory effect of CNTF on myelination (Nash et al., 
2011b) could not be validated in any of the myelinating cultures with varying astrocyte 
densities (Fig 5.8 & 5.9), the effect of the astrocyte age on myelination was also 
examined. Since the above-mentioned experiments already presented results from the 
spinal cord myelinating cultures, where 6-9 DIV old astrocyte cultures were used (Fig 
5.8 and 5.9), experiments were carried out this time using astrocytes that had been 
either 3 DIV or 10 DIV. Astrocyte monolayers are used as support monolayers for spinal 
cord myelinating cultures after 7-10 DIV as stated in the original study which described 
these cultures (Sorensen et al., 2008). Therefore, 3 DIV old astrocytes would represent 
young cultures and 10 DIV old astrocytes would represent older cultures. 
PLL-astrocyte cultures were prepared from the striatum-derived neurospheres at the 
seeding density of 250 x 103 cells/ml because the above-mentioned experiments showed 
that less dense astrocyte cultures consisted of fewer number of cells that were larger, 
expressed higher GFAP and nestin fluorescence intensities compared to those in denser 
astrocytes. On the other hand, seeding density between 250-500 x 103 cells/ml 
generated astrocyte cultures with similar morphological properties akin to those 
astrocytes prepared by plating down 1 x T75 (75 cm2) tissue culture flask of 
neurospheres into 1-2 x 24-well plates; the ratio most commonly used in our lab. These 
myelinating cultures were then treated with CNTF starting from 7, 10, or 12 DIV 
onwards. Treatments of the spinal cord myelinating cultures are usually initiated after 
12 DIV to observe any effects on myelination since 15-18 DIV has been determined to be 
the time point around which  myelin sheath formation begins (Thomson et al., 2008; 
Nash B., 2010). However, it is also possible that treatments, starting at earlier days, 
would have an effect on myelination levels at final stages of the cultures.  Addition of  
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Figure 5. 9 Seeding density of the striatum-derived neurospheres does not affect the 
myelination levels significantly in CNTF-treated rat myelinating cultures.              
Embryonic rat (Sprague Dawley) spinal cord myelinating cultures were plated on neurosphere-derived rat 
astrocytes, plated on PLL-coated glass coverslips with a range of different seeding density as stated above in 
the graphs. The spinal cord cultures were treated with 1 ng/ml of recombinant rat CNTF starting from 12 DIV 
onwards and were immunostained at 24 DIV using AA3 antibody to detect PLP (green) and hence mature 
myelin and using SMI-31 (red) to detect neurites. Images were captured using Olympus BX51fluorescent 
microscope and Image-Pro imaging software. Myelination percentages and neurite density were quantified 
using “myelin.cp” pipeline in Cell Profiler. A) Myelination percentage is shown as standardised to the untreated 
(control) cultures with the highest s.d. of 500 x 103 cells/ml. A&B) CNTF treatment did not appear to induce a 
significant effect on myelination levels or on neurite density at any seeding density of astrocytes, which were 
used to support the spinal cord myelinating cultures. Representative images show the control (C&E) and 
CNTF-treated spinal cord myelinating cultures (D&F), prepared with astrocytes at two different seeding 
densities. The experiments were repeated three times. One-way repeated measures ANOVA test was applied 
to the results. The error bars represent mean ± standard deviation for the control cultures with the seeding 
density of 125 x 103 cells/ml (due to the presence of two experimental repeats) and ± standard error of the 
mean for the other values. Scale bar represents 100 µm for all images. CNTF: ciliary neurotrophic factor; DIV: 
days in vitro; PLL: poly-L-lysine; PLP: proteolipid protein; s.d.: seeding density. 
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the treatments at 12 DIV are carried out subsequently in a medium, which does not 
include the insulin hormone. This is to prevent the generation of excessive numbers of 
oligodendroglia that tend to obscure myelin sheaths and to promote differentiation 
(Thomson et al., 2006; Thomson et al., 2008). Therefore, treatments starting at earlier 
time points also had their own control (untreated) cultures, which were fed with 
medium that did not contain insulin.  
 
Figure 5. 10 The age of the astrocytes used for rat myelinating cultures affects the neurite 
density significantly but has no effect on myelination levels.                  
Embryonic rat (Sprague Dawley) spinal cord myelinating cultures were set up on top of neurosphere-derived 
rat astrocytes plated on PLL-coated glass coverslips. Spinal cord cultures were prepared using astrocytes that 
had been either 3 DIV or 10 DIV that were initiated with neurosphere cell suspensions at the seeding density 
of 250 x 103 cells/ml. The spinal cord cultures were treated with 1 ng/ml of recombinant rat CNTF starting from 
7 DIV, 10 DIV or 12 DIV onwards and were immunostained at 26 DIV using the AA3 antibody to detect PLP 
and hence mature myelin and using SMI-31 to detect neurites. Images were captured using Olympus 
BX51fluorescent microscope and Image-Pro imaging software. Myelination percentages and neurite density 
were quantified using “myelin.cp” pipeline in Cell Profiler. A-C) Myelination percentages were standardised to 
the values of the untreated (control) spinal cord myelinating cultures, where the supporting astrocyte 
monolayer had been 3 DIV (young). The myelination level was not affected significantly by the age of 
astrocytes that were used to set up the spinal cord myelinating cultures. Moreover, CNTF treatment did not 
show a significant change on myelination levels at any astrocyte age. D-F) Neurite density increased 
significantly in the spinal cord myelinating cultures that were set up using older astrocytes (* P<0.05, ** 
P<0.01). CNTF-treated myelinating cultures, prepared with older astrocytes also showed significantly 
increased neurite density compared to those prepared with younger astrocytes. The experiments were 
repeated three times. One-way repeated measures ANOVA test was applied to the results to detect any 
possible significance. The error bars represent ± standard error of the mean. CNTF: ciliary neurotrophic factor; 
DIV: days in vitro; PLL: poly-L-lysine; PLP: proteolipid protein. 
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The age of the astrocytes did not affect the myelination levels in untreated or CNTF-
treated embryonic spinal cord myelinating cultures (Fig 5.10 A-C). CNTF did not change 
the myelination levels in cultures, set up using young or older astrocytes at the 
beginning of the experiments. On the other hand, the myelinating cultures that were 
set up using astrocytes that had been 10 DIV contained significantly higher levels of 
neurite density compared to those set up using astrocytes that had been 3 DIV  (Fig 5.10 
D-F). CNTF treatment alone did not affect the neurite density but the CNTF-treated 
myelinating cultures plated on older astrocytes showed also higher neurite density 
compared to CNTF-treated cultures plated on younger astrocytes.  
5.4 General conclusions and discussion 
The protocol for setting up embryonic rat spinal cord myelinating cultures (Sorensen et 
al., 2008) was optimised further mainly by analysing the effects of the seeding density 
of the striatum-derived neurospheres on the morphology of PLL- and TnC-astrocytes (Fig 
5.2-5.7) and on the myelination of PLL- and TnC-myelinating cultures (Fig 5.8-5.9). The 
seeding density of 250 x 103 cells/ml appeared to be the optimum among the other 
seeding densities, namely, 125, 375, and 500 x 103 cells/ml. 
The major differences appeared to be significant between the astrocyte cultures with 
the seeding density of 125 x 103 cells/ml and to those with the seeding density of 250 x 
103 cells/ml. This difference suggests that starting concentrations of the astrocyte 
cultures will have an effect on how dense these cultures become once they are ready to 
be used as supporting monolayers for spinal cord myelinating cultures (6-9 DIV). On the 
other hand, the differences between the astrocytes with the seeding density of 250, 
375, and 500 x 103 cells/ml were less obvious. An example is the average density of 
DAPI+ cells per field of view in astrocytes cultured for 7-11 DIV. Despite the significant 
increase also in astrocytes with the seeding density of 375 x 103 cells/ml compared to 
those with 250 x 103 cells/ml in PLL-astrocytes (Fig 5.2 A), such significance was not 
detected in the other experiments (Fig 5.4-5.7 A). This suggests that the increase in the 
average number of DAPI+ cells per field of view is not directly proportional to the 
seeding density of the striatum-derived neurospheres. The increase appears to reach a 
plateau at the seeding density of 250 x 103 cells/ml in TnC-astrocytes (Fig 5.6 A, 5.7 A). 
Similar results are seen, but are not observed so clearly in PLL-astrocytes (Fig 5.2 A, 5.4 
A, 5.5 A) possibly due to examining three seeding densities (125, 250, 375 x 103 
cells/ml) there rather than four (125, 250, 375, 500 x 103 cells/ml), which can provide a 
clearer profile for the change in terminal DAPI+ cell numbers per field of view as the 
initial seeding density of astrocytes increases.  
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One other example illustrating differences in cell density is seen for the decrease of the 
average GFAP and nestin intensities per cell in the denser astrocyte cultures compared 
to that seen for astrocytes seeded at a density of 125 x 103 cells/ml (Fig 5.2 C, 5.6 C). 
Similarly, these intensity per cell values did not differ between the astrocyte cultures 
with the seeding density of 250, 375, and 500 x 103 cells/ml. Because both GFAP and 
nestin are cytoskeletal proteins, it could be hypothesised that larger astrocytes that 
attempt to cover a larger area of the glass coverslips despite the lower concentrations 
they were seeded at would express higher average GFAP and nestin intensities per cell 
as a consequence of increasing their cell size. Our results agree with this hypothesis in 
that less dense astrocyte cultures present higher GFAP and nestin intensities per cell. 
However, these intermediate filament proteins are also associated with astrocyte 
reactivity. Their increased expressions in individual astrocytes have been detected in 
vivo in rat CNS subjected to tissue insults of different types and in vitro in primary 
astrocytes at the site of mechanical injury (Clarke et al., 1994; Frisen et al., 1995; 
Levison et al., 1996; Wilhelmsson et al., 2006; Sofroniew et al., 2009; Xue et al., 2011). 
Therefore, it is possible to consider that astrocytes with the seeding density of 125 x 103 
cells/ml are more reactive in a sense compared to the denser astrocyte cultures. This 
may be due to the fact that astrocytes are more stressed in a lower density culture than 
comparable cultures with more astrocytes and due to presumably an increased 
autocrine secreted protein environment. Such differences could also lead to the 
stimulation/inhibition of distinct intracellular pathways and hence change the effects of 
a treatment in these cultures or in spinal cord myelinating cultures that are generated 
using these astrocytes.  
Phase contrast microscopy illustrates clear differences between the seeding density of 
cultures at 125 x 103 cells/ml to those densities of the other cultures (Fig 5.3). The least 
dense cultures do not always form confluent monolayers at the same time as the other 
cultures do. In addition, the number of the smaller and brighter spherical cells observed 
on top of the PLL-astrocyte monolayers appears to increase as the seeding density 
increases (Fig 5.3). It is likely that a small percentage of these cells are mature 
oligodendrocytes (Fig 5.5) and that another small percentage of cells consists of NG2 
progenitor cells as detected previously in neurosphere-derived rat astrocyte cultures 
(Sorensen et al., 2008). OPCs are also likely to constitute part of these cells as 
previously demonstrated in a study, where immunocytochemistry and electron 
microscopy have been utilised to show the presence of “small, glossy, and motile” 
“O2A” progenitors on the astrocyte feeder layers (Asou et al., 1995). The majority of 
these cells, however, could be type-2 astrocytes as suggested by the GFAP&O4 
immunoreactivity (Fig 5.4, 5.7). Type-1 and type-2 astrocytes in vitro have been 
associated in general with the protoplasmic and fibrous astrocytes, respectively, in vivo  
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(Raff et al., 1983; Williams et al., 1985). Both in vitro and in vivo astrocyte types have 
presented differences in terms of astrocyte reactivity or sensitivity to injury (Raff et 
al., 1983; Shannon et al., 2007). Such differences in the type of astrocytes between the 
astrocyte cultures generated with different seeding densities could also eventually 
affect the differentiation properties of the spinal cord myelinating cultures plated on 
top.  
Myelination was analysed in PLL- and TnC-myelinating cultures that were set up using 
the astrocytes with different seeding densities to observe whether the above-mentioned 
differences between astrocyte cultures could also affect the myelination levels in spinal 
cord myelinating cultures. No change in myelination levels was observed in PLL- or TnC-
myelinating cultures (Fig 5.8). Similarly, the treatment of the myelinating cultures with 
recombinant CNTF did not affect the myelination levels or neurite density in any of the 
seeding density experiments (Fig 5.9). CNTF treatments, which were initiated at earlier 
time points  (7 DIV and 10 DIV), did not alter the myelination levels or neurite density, 
either (Fig 5.10). Conversely, the astrocyte age appeared to have an effect on neurite 
density of the PLL-myelinating cultures. Myelinating cultures that were set up using 
astrocytes that were 3 DIV had significantly lower neurite density compared to those 
cultures prepared using astrocytes that had been 10 DIV (Fig 5.10). Therefore, it 
appears that even though astrocytes that had been 3 DIV and 10 DIV had originated from 
the same batch of striatum-derived rat neurospheres and even though they can look like 
healthy cultures under phase-contrast microscopy and appear as confluent astrocyte 
monolayers, older astrocytes seem to generate healthier myelinating cultures. Even if 
the significant decrease in neurite density does not appear to affect the myelination 
levels (Fig 5.10), higher neurite density is seen as a sign of healthy cultures and hence is 
preferred. Therefore, these findings are in accordance with the previous suggestions of 
using astrocytes that had been 7-10 DIV to set up spinal cord myelinating cultures 
(Sorensen et al., 2008).  
In conclusion, the seeding density of the neurosphere-derived astrocytes does not 
appear to affect myelination or neurite density in PLL- or TnC-myelinating cultures that 
are prepared using the astrocyte cultures with the seeding density of 125, 250, 375 and 
500 x 103 cells/ml. Similarly, myelination levels are not changed by the CNTF treatment 
despite the use of astrocyte monolayers with different seeding densities. The use of 
astrocytes at different ages or starting the treatments at earlier time points do not 
provide the right conditions to observe an effect of CNTF on myelination, either. 
Therefore, it appears unlikely that the reason why elevated myelination levels were not 
seen in PLL-myelinating cultures compared to TnC-myelinating cultures, or in CNTF-
treated cultures compared to untreated ones as published previously (Nash et al., 
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2011b) is because of plating down the striatum-derived neurospheres at different 
densities or using astrocyte cultures at different ages to set up the myelinating cultures. 
It is more likely that the difference lies within the method used to quantify the 
myelination levels and neurite density or within the variability of the cultures generated 
by the two investigators involved.  
These further optimisation attempts to fine-tune the rat spinal cord myelinating 
cultures suggest 250 x 103 cells/ml as the optimum seeding density to plate down the 
striatum-derived neurospheres to differentiate into PLL- or TnC-astrocyte cultures. 
Astrocytes with this seeding density 1) appear healthy and confluent under phase-
microscopy, 2) generate average DAPI+ cells at densities that are not significantly 
different than those of denser astrocyte cultures, 3) have similar levels of average GFAP 
and nestin intensities per cell and hence possibly similar levels of astrocyte reactivity 
when compared to denser astrocyte cultures, 4) present lower numbers and 
percentages of type-2 astrocytes and thus show reduced astrocyte heterogeneity 
compared to denser cultures.  
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Chapter 6  
 
Further analysis of the role of exogenous 
CNTF in primary astrocytes and spinal cord 
myelinating cultures 
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6.1 Introduction 
Ciliary neurotrophic factor (CNTF), an IL-6 family cytokine, has been shown to promote 
myelination in both PLL- and TnC-myelinating cultures (Nash et al., 2011b) that are the 
embryonic rat spinal cord myelinating cultures that were set up using rat astrocytes on 
PLL (PLL-astrocytes) or TnC (TnC-astrocytes) as feeder monolayers. A microarray gene 
expression profiling analysis was carried out (Array 2, Chapter 3) to identify any 
potential regulators of myelination based on the observation that myelination levels are 
reduced in untreated TnC-myelinating cultures compared to PLL-myelinating cultures, 
and are increased upon CNTF treatment in both PLL- and TnC-myelinating cultures 
(Nash et al., 2011b). The stimulatory effect of 1 ng/ml of rat recombinant CNTF on 
myelination could not be validated in the experiments outlined in this thesis, which 
suggested that this failure was not related to the age of the astrocyte monolayers used 
or to the seeding density of the striatum-derived rat neurospheres that would 
differentiate into astrocytes (Chapter 5). Further experiments and analyses were 
performed to investigate the role of CNTF in neurosphere-derived astrocyte monolayers 
and on myelination in rat and mouse spinal cord myelinating cultures as will be 
explained in this chapter.  
The positive effects of CNTF on myelination levels have been suggested by a number of 
studies, where usually this stimulation was attributed to the CNTF properties of being 
neuroprotective (Barbin et al., 1984; Hagg and Varon, 1993; Naumann et al., 2003; 
Krady et al, 2008), promoting the survival of oligodendrocyte precursor cells (OPCs) and 
oligodendrocytes (Barres et al., 1993; Louis et al., 1993), and stimulating the 
proliferation and maturation of OPCs (Barres et al., 1996; Marmur et al., 1998; Stankoff 
et al., 2002; Albrecht et al., 2007; Cao et al., 2010). CNTF has also been shown to 
decrease the severity of disease course and increase the neuronal functional recovery in 
mice with experimental autoimmune encephalomyelitis (EAE, Butzkueven et al., 2002; 
Linker et al., 2002; Kuhlmann et al., 2006; Lu et al, 2009). Interestingly, the levels of 
Cntf mRNA have been found to be elevated during the remyelination phase in mice with 
cuprizone-induced demyelination (Gudi et al., 2011) and the intracranial injections of 
CNTF have led to increased amounts of MOG (myelin oligodendrocytes glycoprotein) in 
these animals (Salehi et al., 2013). Moreover, CNTF treatment has also been shown to 
be related to the increased expression of myelin proteins in mouse oligodendrocytes 
cultures (Modi et al., 2013).     
In addition to the above-mentioned association of CNTF with myelination, other IL-6 
family cytokines have also been related to increased myelination levels in myelinating 
co-cultures (Stankoff et al., 2002), maintenance of neural stem cells in vivo (Shimazaki 
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et al., 2001), immunoregulation and neuroprotection in EAE (Fitzgerald et al., 2007; 
Gurfein et al., 2009; Yang et al., 2012a; Jafarzadeh et al., 2014), and modulation of the 
expression of genes involved in the remyelination process in demyelinated sites of 
ethidium bromide-induced acute demyelination in mice (Glezer et al., 2010). Despite 
the above-mentioned important roles of these cytokines, mice deficient in one of the 
members of the IL-6 family have milder phenotypes than expected (reviewed in 
Fasnacht et al., 2008) such as mild motor neuron degeneration in CNTF-deficient mice 
(Masu et al., 1993). This has been attributed to the redundancy of IL-6 family cytokines, 
which bind specific α-receptors that induces the homo- or heterodimerisation of the 
transmembrane protein, GP130, to complete the IL-6 family cytokine signaling (Fig 1.6, 
Heinrich et al., 1995; reviewed in Kraakman et al., 2013). Because GP130-deficient 
mice die in early embryonic stages (Yoshida et al., 1996), conditional transgenic mice 
were also generated to observe the effects of GP130-dependent signaling. One example 
is the GFAP-Cre+/-gp130fl/fl mouse line (Drogemuller et al., 2008). 
Primary cultures from GFAP-Cre+/-gp130fl/fl mice were exploited to observe myelination 
in the absence of the expression of Gp130 specifically in the supporting astrocyte 
monolayer. These mice were termed ‘Cre positive (Cre+)’ in short since these mice 
harboured the gene for Cre recombinase with  expression under the control of the GFAP 
promoter. Cre recombinase inactivates the target gene, Gp130 in this case, by removing 
the ‘floxed’ (fl) DNA sequence flanked by two loxP sites (Lakso et al., 1992; Pichel et 
al., 1993). On the other hand, the mice, which carried the floxed gene but not the gene 
for Cre recombinase, were not different to the wild type mice and were termed GFAP-
Cre-/-gp130fl/fl or ‘Cre negative (Cre-)’ in short. Embryos from both genotypes were also 
used to set up spinal cord myelinating cultures, where myelination levels were 
compared, as described in this chapter.  
In addition to the microarray gene expression profiling analysis that revealed potential 
transcripts to be associated with CNTF signaling in embryonic rat spinal cord 
myelinating cultures as explained in Chapter 3, those data sets were also used in a web-
based program, called oPOSSUM 3.0, in attempt to identify prospective transcription 
factors associated with CNTF mechanisms in these cultures. Moreover, to gain a deeper 
insight into the CNTF functions, the metabolites produced in and secreted by astrocyte 
monolayers were also compared using mass spectrometry-based metabolomics. Thus, 
the effect of CNTF in neurosphere-derived astrocytes and embryonic rat spinal cord 
myelinating cultures were analysed from different aspects, some of which were 
presented in Chapter 3 and the rest of which will be presented in this chapter.      
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6.2 Aims 
The overall aim of this chapter was to determine the mechanism of our previous results 
of CNTF promoting myelination in vitro. Specifically we hypothesised that: 
• The seeding density of neurosphere-derived astrocytes would have an effect on 
the way different concentrations of CNTF treatment affect myelination and 
neurite density of rat embryonic spinal cord PLL-myelinating cultures. 
• The timing of CNTF treatment would affect myelination and neurite density of 
rat embryonic spinal cord PLL- and TnC-myelinating cultures. 
• CNTF treatment would affect astrocyte reactivity as assessed by protein 
expression of GFAP and nestin and detected by immunocytochemistry in 
neurosphere-derived rat PLL- and TnC-astrocytes. 
• Neurosphere-derived astrocytes obtained from mice lacking Gp130 expression in 
astrocytes would present different levels of astrocyte reactivity assessed by 
GFAP immunoreactivity compared to cultures from wild type mice.  
• Embryonic spinal cord myelinating cultures prepared using tissue from mice 
lacking Gp130 expression in astrocytes would present a lower level of 
myelination compared to cultures from wild type mice. CNTF treatment would 
increase while treatment with neutralising antibody against CNTF would lower 
the myelination level in wild type cultures; whereas, these treatments would 
have no effect on myelination in transgenic cultures due to the absence of 
Gp130 expression.   
• The changes CNTF treatment triggers on gene expression in rat myelinating 
cultures (Array 2) require signaling provided by transcription factors. Thus, a 
web-based program that detects over-representative conserved transcription 
factor binding sites was used to detect possible transcription factors involved in 
CNTF signaling in rat myelinating cultures.     
• CNTF treatment would stimulate the neurosphere-derived rat astrocytes to 
produce and/or secrete metabolites that could play a role in myelination. The 
metabolites detected by mass spectrometry would be different in PLL-
astrocytes and TnC-astrocytes.  
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6.3 Results 
6.3.1 The effects of CNTF on myelination in embryonic rat spinal 
cord myelinating cultures 
Previously our lab had shown that CNTF added to embryonic rat spinal cord myelinating 
cultures promoted myelination (Nash et al., 2011b). Failing to confirm this observation 
in my experiments, I hypothesised that one of the factors leading to different results 
could be the difference in density of the astrocyte monolayers, used as supporting 
monolayers for the myelinating cultures. However, myelinating cultures treated with 1 
ng/ml of rat recombinant CNTF did not have any change in myelination despite using 
neurosphere-derived astrocytes with different seeding densities (Chapter 5, Fig 5.9). In 
this chapter, the PLL-myelinating cultures were treated with CNTF at different 
concentrations to provide a more detailed analysis for the CNTF effect on myelination 
(Fig 6.1). Even though the astrocyte seeding density of 250 x 103 cells/ml was selected 
to be the optimum cell density to use to prepare astrocyte monolayers to be used for 
spinal cord myelinating cultures (Chapter 5), astrocytes with different seeding densities 
were also used in this experiment to clarify whether the concentration of the exogenous 
CNTF influences the myelination levels differently in cultures with different densities.  
As seen in Fig 6.1, CNTF treatment at the concentrations of 0.5, 1, 1.5, and 2 ng/ml did 
not induce any significant change in myelination levels or neurite density of the spinal 
cord myelinating cultures, plated on astrocyte monolayers with the seeding density of 
125, 250, 375, and 500 x 103 cells/ml. Maintaining the myelinating cultures on astrocyte 
monolayers with different densities did not have an effect on the myelination levels in 
the presence of exogenous CNTF at any concentrations examined. On the other hand, 
analysing the myelinating cultures on astrocytes with the seeding density of 250 x 103 
cells/ml separately showed a significant reduction in myelination levels with 2 ng/ml of 
CNTF treatment (Fig 6.1 C). Therefore, it is likely that CNTF becomes inhibitory for 
myelination at higher concentrations without affecting the neurite density. The 
expected increase in myelination levels was not detected for 0.5, 1, or 1.5 ng/ml of 
CNTF treatment.  
CNTF treatments at 1 ng/ml were also used to condition astrocyte monolayers before 
spinal cord myelinating cultures were plated on top of them. These cultures were 
termed ‘pre-treated’ myelinating cultures and they were not treated with CNTF after 
the dissociated spinal cord cells were plated on top of the conditioned astrocyte 
monolayers. These pre-treatments appeared to affect myelination levels (Fig 6.2). The 
pre-treated PLL-myelinating cultures presented significantly higher myelination levels  
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Figure 6. 1 The effects of CNTF on myelination levels in rat spinal cord myelinating cultures 
appear not to be related to the seeding density of astrocytes.             
Embryonic rat spinal cord myelinating cultures were set up using neurosphere-derived rat astrocytes that were 
plated on PLL-coated glass coverslips and at seeding density of 125, 250, 375 or 500 x 103 cells/ml. The 
spinal cord myelinating cultures were treated with 0.5, 1, 1.5 or 2 ng/ml of recombinant rat CNTF starting from 
12 DIV onwards and they were immunostained at 24 DIV using the AA3 antibody to detect PLP and hence 
mature myelin and SMI-31 to detect neurites. Images were captured using Olympus BX51fluorescent 
microscope and Image-Pro imaging software. Myelination percentages and neurite density were quantified 
using “myelin.cp” pipeline in Cell Profiler. A) Myelination percentage is shown as standardised to the untreated 
cultures with the highest seeding density of 500 x 103 cells/ml. CNTF does not lead to any significant change 
on myelination levels (A) or neurite density (B) in any of the myelinating cultures examined. The seeding 
density of astrocyte cultures does not have a significant effect on myelination level (A) or neurite density (B) in 
untreated or in CNTF-treated myelinating cultures. Experiments in A&B were repeated three times. C&D) 
Spinal cord myelinating cultures that were plated on astrocytes, from neurosphere concentration of 250 x 103 
cells/ml, were treated with CNTF at different concentrations. These experiments were repeated four times. 
Myelination percentage decreases significantly upon CNTF treatment at 2 ng/ml (*P≤0.05); while, no 
significant change is observed in neurite density. One-way repeated measures ANOVA test was applied to the 
results to detect any possible significance. The error bars represent ± standard error of the mean. CNTF: 
ciliary neurotrophic factor; DIV: days in vitro; PLL: poly-L-lysine; PLP: proteolipid protein. 
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compared to 1) untreated PLL-myelinating cultures, 2) untreated TnC-myelinating 
cultures, 3) pre-treated TnC-myelinating cultures, 4) CNTF-treated TnC-myelinating 
cultures. Neurite density did not show any significant change between these conditions 
(Fig 6.2 B). There was a tendency of an increase in myelination levels in CNTF-treated 
PLL-myelinating cultures compared to untreated PLL-myelinating cultures but it appears 
that CNTF has a more potent stimulatory effect on myelination when applied to the 
young, confluent feeder astrocyte monolayers also suggested by Nash et al. (2011b). On 
the other hand, this effect was not observed in TnC-myelinating cultures. The TnC-
myelinating cultures at all three conditions (untreated, pre-treated, CNTF-treated) 
appeared to show similar myelin levels, which were also not significantly different to 
those in untreated PLL-myelinating cultures.   
In conclusion, embryonic rat spinal cord myelinating cultures did not present 
significantly different myelination levels when treated with 0.5, 1, and 1.5 ng/ml of 
CNTF. The seeding density of the astrocyte monolayers that were used for these 
myelinating cultures did not alter this lack of effect of CNTF, either. A further analysis 
of the cultures that were set up with astrocyte monolayers with the seeding density of 
250 x 103 cells/ml showed reduced myelination levels with 2 ng/ml of CNTF treatment. 
CNTF treatment stimulated the myelination in PLL-myelinating cultures but not in TnC-
myelinating cultures only when the astrocyte monolayers were initially pre-treated with 
1 ng/ml of CNTF.   
6.3.2 The effects of CNTF in neurosphere-derived rat astrocyte 
cultures 
CNTF has previously been reported to activate astrocytes both in vitro and in vivo, a 
phenomenon that has been observed mainly based on the increase of GFAP expression 
and cell hypertrophy (Levison et al., 1996; White and Jakeman, 2008). Therefore, the 
untreated and CNTF-treated PLL- and TnC-astrocytes were immunostained for GFAP and 
nestin expressions in an attempt to observe possible differences in astrocyte phenotypes 
under these conditions. Nestin has also been used as a marker for astrocyte reactivity as 
explained previously in Chapter 5. 
The striatum-derived rat neurospheres were plated down on PLL- or TnC-coated glass 
coverslips at a seeding density of 250 x 103 cells/ml, maintained for 9 DIV and then used 
for immunocytochemistry. The average DAPI positive (DAPI+) cell numbers did not differ 
between different conditions at the end of the cultural period (Fig 6.3 A). Because the 
initial seeding density was the same for all the cultures, it can be concluded that 1 
ng/ml of exogenous CNTF did not change the total number of cells detected in astrocyte  
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Figure 6. 2 The effects of CNTF treatments on myelination levels in embryonic rat spinal 
cord myelinating cultures.         
Embryonic rat spinal cord myelinating cultures were plated on neurosphere-derived astrocytes that were 
seeded on PLL- or TnC-coated glass coverslips. Some of astrocytes were previously treated with 1 ng/ml of 
recombinant rat CNTF before they were used to set up the spinal cord myelinating cultures. Those myelinating 
cultures were termed “pre-treated” and were not treated later with CNTF. The spinal cord myelinating cultures 
that were set up using untreated astrocytes were treated with 1 ng/ml of CNTF from 12 DIV onwards. The 
cultures were immunostained at 24 DIV using the AA3 antibody to detect PLP and hence mature myelin and 
SMI-31 to detect neurites. Images were captured using Olympus BX51fluorescent microscope and Image-Pro 
imaging software. Myelination percentages and neurite density were quantified using “myelin.cp” pipeline in 
Cell Profiler. A) Myelination percentage is shown as standardised to the untreated cultures on PLL-astrocytes 
(PLL-control). CNTF treatment increases the myelination level in PLL-myelinating cultures only when pre-
treated astrocytes are used (* P≤0.05). Pre-treated PLL-myelinating cultures also present a significantly higher 
myelination level compared to untreated, CNTF pre-treated, and CNTF-treated TnC-myelinating cultures (* 
P≤0.05, ** P≤ 0.01). B) CNTF pre-treatments or treatments do not affect the neurite density significantly. The 
experiments were repeated five times. One-way repeated measures ANOVA test was applied to the results to 
detect any possible significance. The error bars represent ± standard error of the mean. CNTF: ciliary 
neurotrophic factor; DIV: days in vitro; PLL: poly-L-lysine; PLP: proteolipid protein; TnC: tenascin C.   
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monolayers hence the rate of proliferation. CNTF did not appear to affect the average 
GFAP and nestin intensities detected per image, either, which were measured in Image 
J using the images captured by the fluorescent microscopy (Fig 6.3 B). Similarly, all the 
cultures showed comparable levels for the average GFAP and nestin intensities per cell 
(Fig 6.3 C), which could also be observed in the representative images (Fig 6.3 D-G). In 
conclusion, CNTF did not appear to activate astrocytes based on their GFAP and nestin 
expressions detected by immunocytochemistry. 
6.3.3 The effects of CNTF in astrocytic-Gp130 knockout mouse 
astrocytes and spinal cord myelinating cultures 
The effects of exogenous CNTF on myelination were also investigated in embryonic 
mouse spinal cord myelinating cultures. Transgenic C57BL/6 mice that lacked the 
astrocytic expression of Gp130, a component of the CNTF receptor complex, have been 
previously shown to present reduced numbers of GFAP positive astrocytes and an 
aggravated disease course when infected with Toxoplasma gondii or when immunised 
with MOG35-55 to generate encephalitis or EAE, respectively (Drogemuller et al., 2008; 
Haroon et al., 2011). Especially due to severe demyelination observed in these animals, 
CNTF signaling in astrocytes has been suggested to have positive effects on myelination 
(Haroon et al., 2011). In addition, CNTF-treated astrocytes were shown to increase the 
myelination levels in rat spinal cord myelinating cultures as explained above (Fig 6.2). 
Therefore, both neurosphere-derived astrocyte cultures and spinal cord myelinating 
cultures, generated from the CNS of these transgenic mice, were analysed to observe 
the effects of the absence of the astrocytic CNTF signaling. 
The heterozygous mice that carried the allele for the Cre recombinase (GFAP-Cre+/-
gp130fl/fl, Cre positive) and the homozygous mice that lacked this gene (GFAP-Cre-/-
gp130fl/fl, Cre negative) were crossed to obtain a litter that would consist of Cre 
negative (Cre-) and Cre positive (Cre+, knockout) pups with a 50% possibility of 
occurrence for each genotype (Fig 2.1). The striatum tissue obtained from each pup was 
treated and cultured separately. The striatum-derived neurospheres that were 
generated from the pups with the same Cre genotype were pulled down together to 
generate astrocyte monolayers. These astrocytes were immunostained for GFAP and 
with the O4 antibody to observe morphological differences between the Cre- and Cre+ 
mouse astrocyte cultures (Fig 6.4). 
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Figure 6. 3 CNTF treatment does not affect GFAP and nestin intensities detected in the 
neurosphere-derived rat astrocyte cultures.                           
Striatum-derived rat neurospheres were plated down on PLL- or TnC-coated glass coverslips at 5 DIV at a 
concentration of 250 x 103 cells/ml and were left to differentiate into astrocytes in medium containing 10% 
FBS. Astrocytes were treated with 1 ng/ml of recombinant rat CNTF after 5 and 7 DIV. The confluent astrocyte 
cultures were used for immunocytochemistry at 9 DIV to detect GFAP and nestin expressions. A) The number 
of total DAPI positive cells was quantified using Cell Profiler and was presented as average (avg) cell number 
per filed of view, which did not differ significantly between astrocytes at different conditions. B) Image J was 
used to quantify the mean brightness of the fluorescence detected in green (GFAP) and red (nestin) channels 
per image. This value was multiplied by the whole image area to calculate the total intensity of GFAP or nestin 
fluorescence. Avg intensity per image values were standardised to the untreated PLL-astrocytes for GFAP 
and nestin separately. CNTF treatment or the use of different glass-coating substrates did not affect avg 
GFAP or nestin intensity per image significantly. C) Avg GFAP and nestin intensity per cell was calculated for 
each image as a ratio of the total intensity to the total cell number of the image. The averages were 
standardised to the values of the untreated PLL-astrocytes for GFAP and nestin separately and were not 
affected significantly by the CNTF treatment or the use of different substrates. Representative images present 
untreated and CNTF-treated astrocytes on PLL- (D, E) or TnC-coated coverslips (F, G). Experiments were 
repeated three times. The error bars represent ± standard error of the mean. One-way repeated measures 
ANOVA test was used to detect any possible significance. Scale bar represents 50 µm for all images. Avg: 
average; CNTF: ciliary neurotrophic factor; DIV: days in vitro; FBS: foetal bovine serum; GFAP: glial fibrillary 
acidic protein; TnC: tenascin C.  
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Both Cre- and Cre+ astrocytes were generated by plating down neurospheres at a 
seeding density of 250 x 103 cells/ml. Therefore, both astrocyte cultures were expected 
to present similar average DAPI+ cell numbers at the end of their cultural period unless 
the distinct genotypes affected the cell numbers. As expected, there was no significant 
difference between the average DAPI+ cell numbers of the astrocyte cultures (Fig 6.4 
A). Similarly, the average GFAP intensity per image or per cell did not differ between 
the Cre- and Cre+ astrocytes, either (Fig 6.4 B), suggesting that inhibition of GP130 
signaling in mouse astrocytes may not affect the astrocyte reactivity based on their 
GFAP expressions detected by immunocytochemistry. 
The number of cells labelled with the O4 antibody termed O4 positive (O4+) cells were 
also detected using immunocytochemistry. The majority of these cells appeared to be 
also positive for GFAP staining (Fig 6.4 C-E), which suggested that they were type-2 
astrocytes rather than oligodendrocytes (Raff et al, 1983; Aloisi et al., 1988). Even 
though the number and the standardised percentage of these GFAP and O4+ 
(GFAP&O4+) cells presented a trend towards an increase in Cre+ astrocytes, the change 
was not found to be significant (Fig 6.4 C&E). The representative images of the 
immunostained cultures correlate with the above-mentioned findings and also show that 
O4 negative and O4 positive astrocytes between the Cre- and Cre+ astrocyte cultures do 
not appear to be different in terms of cell size or the number/length of the cell 
processes (Fig 6.4 F-I).  
Cre- and Cre+ astrocytes were also used as feeder monolayers for dissociated spinal 
cords that were obtained from wild type C57BL/6 mouse embryos. These spinal cord 
myelinating cultures were treated with CNTF to observe the effect of exogenous CNTF 
on myelination. As seen in Fig 6.5, CNTF did not alter the myelination levels 
significantly in Cre- or Cre+ mouse myelinating cultures. Therefore, the presence or the 
absence of the expression of the astrocytic Gp130 does not appear to affect myelination 
in these mouse myelinating cultures. In addition, the myelinating cultures were also 
treated with a neutralising antibody against endogenous CNTF starting from 12 DIV 
onwards (Fig 6.5 C&D). This treatment did not affect the myelination levels or the 
neurite density, either.  
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Figure 6. 4 Astrocytes from wild type and astrocytic-gp130 knockout mice do not differ in 
terms of GFAP intensity.           
Striatum-derived mouse neurospheres, obtained from GFAP-Cre-/-gp130fl/fl   (Cre negative, wild type) and 
from GFAP-Cre+/-gp130fl/fl  (Cre positive, knockout) transgenic mice on a C57BL/6 background, were plated 
down on PLL-coated glass coverslips at 5 DIV at a concentration of 250 x 103 cells/ml. They were left to 
differentiate into astrocytes in medium containing 10% FBS. The confluent astrocyte cultures were 
immunolabelled for O4 antibody (red) and GFAP (green). A) The number of total DAPI positive cells was 
quantified using Cell Profiler and was presented as average cell number per field of view, which did not differ 
significantly between astrocytes from mice of the two genotypes. B) Image J was used to quantify the mean 
brightness of the fluorescence detected in green channel, representing GFAP expression. This value was 
multiplied by the whole image area to calculate the total intensity of GFAP per image. Average GFAP intensity 
per cell was calculated for each image as a ratio of the total intensity to the total cell number of the image. 
Both averages were standardised to the values detected in the Cre negative mice. A significant change was 
not observed in average GFAP intensity per cell or in average GFAP intensity per image between the mouse 
astrocytes of two genotypes. C) The cells, which were positive for O4 and for both O4 and GFAP (GFAP&O4) 
were counted manually using Image J and were presented as average cell number. This was standardised to 
the O4+ values of Cre negatives. D) They were also presented as percentages of the total number of cells per 
image. E) The percentages were standardised to the O4+ values of the Cre negatives. Representative images 
present astrocytes from Cre negative (F, H) or Cre positive mice (G, I). Experiments were repeated three 
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times. The error bars represent ± standard error of the mean. One-way repeated measures ANOVA test was 
applied to the results to detect any possible significance. Scale bar represents 50 µm for F&G and 25 µm for 
H&I. Avg: average; DIV: days in vitro; FBS: foetal bovine serum; GFAP: glial fibrillary acidic protein; KO: 
knockout; PLL: poly-L-lysine; WT; wild type. 
 
Mouse myelinating cultures were also set up by plating down dissociated spinal cords 
from Cre- and Cre+ transgenic mouse embryos on top of PLL-coated glass coverslips 
without including any feeder astrocyte monolayers. A Cre- mouse and a Cre+ mouse 
were mated to obtain a litter that would consist of Cre- and Cre+ embryos with a 50% 
possibility of occurrence for each genotype (Fig 2.1). Therefore, the spinal cord from 
each embryo was treated separately to set up the myelinating cultures. The myelinating 
cultures from each embryo had its own control and its own CNTF treatments. The 
embryos were genotyped for Cre expression using tail DNA after the myelinating 
cultures were set up. Thus, the results obtained from Cre- and Cre+ embryos were later 
pulled down to obtain average values for myelination levels and neurite density at 
different conditions. This was considered as one experimental repeat because embryos 
were used from the same litter.  
Unfortunately, the analysis could only be done using Cre+ myelinating cultures (Cre+ 
spinal cords on PLL-coated coverslips) without being able to compare them with the 
Cre- myelinating cultures. The healthy myelinating cultures that could be maintained 
until 24 DIV and analysed successfully consisted of Cre+ samples only. The majority of 
the mouse litters (35 out of 44) contained more than 50% Cre+ embryos (Fig 6.6 A&B). 
There were even 10 litters, where all the embryos (100%) were found to be Cre+. The 
most likely explanation for this observation is that at least one of the GFAP-Cre+/- 
animals must have been mislabelled as GFAP-Cre-/- due the absence of a clear band in 
agarose gel electrophoresis possibly due to a failed PCR resulting from a degraded or 
contaminated DNA sample. Breeding GFAP-Cre+/- with another GFAP-Cre+/- due to 
mislabelling would result in 25% GFAP-Cre+/+, 50% GFAP-Cre+/-, and 25% GFAP-Cre-/- 
leading to a litter with 75% Cre+ genotype that can be seen for some litters in Fig 6.6 B. 
Crossing a GFAP-Cre+/+ animal with GFAP-Cre-/- would then result in litters with 100% 
Cre+ genotype. Some of the 44 litters, for which the details were presented in Fig 6.6 B, 
were used 1) to set up astrocyte monolayers, 2) to generate spinal cord myelinating 
cultures, 3) for optimisation purposes like identifying the best PLL solution that would 
help the spinal cord cultures stick better to the glass coverslips and thus generate 
healthier cultures, 4) to practise setting up myelinating cultures since working with such 
small mouse embryos required an adaptation period, during which the cultures did not 
appear healthy enough to be used for analyses. In addition, the spinal cords from the  
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Figure 6. 3 CNTF does not affect myelination levels in wild type or astrocytic-gp130 
knockout mouse spinal cord myelinating cultures                 
Wild type (GFAP-Cre-/-gp130fl/fl, Cre negative) and astrocytic-gp130 knockout (GFAP-Cre+/-gp130fl/fl, Cre 
positive) C57BL/6 mice were used to set up neurosphere-derived astrocyte cultures, plated on PLL-coated 
glass coverslips at a seeding density of 250 x 103 cells/ml. Dissociated spinal cords, obtained from wild type 
C57BL/6 mouse embryos, were plated on these astrocytes to form the spinal cord myelinating cultures. The 
myelinating cultures were treated with 0.5, 1, or 2 ng/ml of recombinant rat CNTF starting from 12 DIV 
onwards and they were immunostained at 24 DIV using the AA3 antibody to detect PLP and hence mature 
myelin and using SMI-31 to detect neurites. Images were captured using Olympus BX51fluorescent 
microscope and Image-Pro imaging software. Myelin percentages and neurite densities were quantified using 
“myelin.cp” pipeline in Cell Profiler. A&B) Myelination percentage is shown as standardised to untreated wild 
type cultures. CNTF does not appear to affect myelination levels or neurite densities in the Cre negative or 
Cre positive mouse spinal cord myelinating cultures significantly. The myelination levels and neurite density 
between the wild type and knockout mouse myelinating cultures do not differ significantly, either. C&D) Wild 
type and knockout mouse spinal cord myelinating cultures were also treated with 1 ng/ml of CNTF and 2 µg/ml 
of rat anti-CNTF neutralising antibody, which did not show any significant effects on the myelin levels or the 
neurite density. All experiments were repeated three times. One-way repeated measures ANOVA test was 
applied to the results to detect any possible significance. The error bars represent ± standard error of the 
mean. CNTF: ciliary neurotrophic factor; DIV: days in vitro; PLL: poly-L-lysine; PLP: proteolipid protein. 
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few Cre- embryos in some litters did not reveal a high cell yield probably due to only 
dissecting out smaller pieces of tissue and therefore, the cell suspension was not dense 
enough to generate enough number of coverslips to complete the experiments. 
Consequently, there were only three litters that could be used to present the effect of 
CNTF in embryonic mouse myelinating cultures, consisting of transgenic spinal cords on 
top of PLL-coated coverslips, and these cultures did not contain any samples from Cre- 
embryos, which would be the controls for the experiments (Fig 6.6 C&D). CNTF 
treatments did not show any significant changes on myelination levels in these 
astrocytic Gp130 deficient mouse cultures. The average myelination level was found to 
be 3.8% in these cultures, which is not very different from 4.7% that was the average 
myelination percentage in the mouse myelinating cultures, which were set up using wild 
type spinal cords on top of transgenic astrocytes (Fig 6.5 A&B). On the other hand, CNTF 
treatments appeared to increase the neurite density in the Cre+ spinal cord myelinating 
cultures on PLL-coverslips (Fig 6.6 D). 
In conclusion, the inactivation of the Gp130 gene using the Cre/loxP system under the 
control of the GFAP promoter in astrocytes of C57BL/6 mice did not affect 1) the 
morphology of the astrocyte cultures based on their GFAP expressions detected by 
immunocytochemistry, and the amount of contaminating type-2 astrocytes, 2) the 
potency of these astrocyte cultures to promote myelination. The myelinating cultures 
consisting of transgenic spinal cords on PLL-coated coverslips could only be analysed 
using Cre+ samples, which showed that neurite density increased upon CNTF treatments 
despite the inhibition of astrocytic CNTF signaling via GP130 receptor, but presented no 
difference in myelination levels. 
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Figure 6. 4 CNTF titration in astrocytic-gp130 knockout mouse spinal cord cultures does not 
show a significant effect on myelination level.                       
The mouse embryos from the mating of GFAP-Cre-/-gp130fl/fl   (Cre negative) and GFAP-Cre+/-gp130fl/fl  (Cre 
positive) transgenic strains were used to obtain dissociated spinal cords that were plated on PLL-coated glass 
coverslips. The embryonic tissue was later used for genotyping the mouse litters. A) The number of Cre 
positive and negative transgenic mouse pups were expressed as percentages within each litter. When 44 
litters were analysed, the percentage of Cre positive pups was found to be significantly higher than the 
percentage of Cre negative pups (**** P≤0.0001). The statistical significance was detected using paired 
Student’s t-test. B) In 10 litters with varying litter sizes, all of the mouse pups were Cre positive. C&D) Spinal 
cord myelinating cultures obtained from three litters provided healthy cultures to analyse myelination. The 
cultures were treated with 0.5, 1, or 2 ng/ml of rat recombinant CNTF starting from 12 DIV onwards and the 
cultures were immunostained at 24 DIV using the AA3 antibody to detect PLP and hence mature myelin and 
using SMI-31 to detect neurites. Images were captured using Olympus BX51 fluorescent microscope and 
Image-Pro imaging software. Myelination percentages and neurite density were quantified using “myelin.cp” 
pipeline in Cell Profiler. Myelination percentage is shown as standardised to the value of untreated cultures. 
CNTF did not affect myelination levels significantly in Cre positive transgenic mouse spinal cord cultures. 
However, it appeared to increase neurite density significantly compared to the untreated cultures (* P<0.05, ** 
P<0.01). One-way repeated measures ANOVA test was applied to the results to detect any possible 
significance. The error bars represent ± standard error of the mean. CNTF: ciliary neurotrophic factor; DIV: 
days in vitro; PLL: poly-L-lysine; PLP: proteolipid protein. 
 
 
 
 
 
 
 
187 
 
6.3.4 The possible transcription factors that could play a role in 
CNTF signaling in rat spinal cord myelinating cultures 
A microarray gene expression profiling was carried out previously to identify the 
transcriptional changes between untreated or CNTF-treated embryonic rat spinal cord 
cultures plated on either PLL- or TnC-astrocytes (Array 2, Chapter 3). To further analyse 
the possible roles of CNTF in myelinating cultures, the data obtained from Array 2 were 
used to form a list of putative transcription factors (TFs) involved in CNTF-signaling. The 
transcripts, which were differentially regulated upon CNTF treatment 4 and 24 hours 
later, were entered into a web-based program called oPOSSUM 3.0 that detects over-
represented conserved transcription factor binding sites (TFBSs) in the cis-regulatory 
regions (non-coding DNA) of a set of human, mouse, fly, worm and yeast genes (Kwon et 
al., 2012). This process has been named as Single Site Analysis (SSA) in the program and 
the JASPAR database has been used as the source of DNA-binding profiles (Portales-
Casamar et al., 2010). Because mouse is the closest species to the rat among the 
alternatives provided in the program, SSA was carried out on mouse genes.  
The up-regulated and down-regulated transcripts between two conditions were analysed 
separately as presented in Table 6.1. The TFBS hits were searched maximum 10,000 bp 
upstream/downstream from the Ensembl-annotated transcription start sites since this 
sequence length was adjusted by the developers of the program to reflect the 
intergenic distances. The analysis was carried out for all six DNA sequence distances 
available in the program; namely, 2000/0, 2000/2000, 5000/2000, 5000/5000, 
10000/5000, and 10000/1000 bp (Table 6.1). The TFs, whose DNA-binding sites were 
detected in the genes analysed at high enough levels to be statistically significant, are 
presented in Table 6.1 separately for each DNA sequence length. These results were 
based on the values with Z-score≥10 and Fisher score≥7 (Kwon et al., 2012).  Z-score 
and Fisher score reflect 1) the change in the relative number of TFBS motifs and 2) the 
number of genes with the TFBS motifs, respectively, in the foreground set vs. the 
background set. The results in Table 6.1 are significant in terms of both of the scoring 
methods and hence comparisons.   
The transcripts that were differentially regulated upon CNTF treatment in PLL-
myelinating cultures did not reveal any possible TFs involved with their differential 
expression (Table 6.1). In contrast, the analysis of down-regulated transcripts 4 hour 
after CNTF treatment in TnC-myelinating cultures presented CTCF, E2F1, INSM1, KLF4, 
MZF1_1-4, RREB1, SP1, SRF, STAT3, TCFCP2L1, and the protein complexes PPARG::RXRA 
and TLX1::NFIC as putative TFs that could be responsible for the CNTF-associated 
changes in these cultures (Table 6.1). These TFs contain different types of DNA-binding 
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domains such as zinc coordinating (CTCF, INSM1, KLF4, MZF1, PPARγ:RXRα, RREB1, SP1), 
basic helix-loop-helix (E2F1), helix-turn-helix (TLX1::NFIC), alpha-helix (SRF), beta-
scaffold (STAT3), and TCFCP2L1. Most of these transcription factors have been 
associated with different functions in the CNS including neurogenesis, neuronal survival, 
neuronal and/or glial differentiation, and regulation of cell apoptosis in health and 
pathology as summarised in Table 6.2.   
Table 6. 1 Possible transcription factors that are triggered by CNTF treatment in embryonic 
rat spinal cord myelinating cultures. 
	  	   PLL-­‐CNTF	  4	  h	  vs	  PLL-­‐Con	  4	  h	   PLL-­‐CNTF	  24	  h	  vs	  PLL-­‐Con	  24	  h	  
Sequence	  
Length	   Up	   Down	   Up	   Down	  
All	   -­‐	   -­‐	   -­‐	   -­‐	  
	  	  	  	   TnC-­‐CNTF	  4	  h	  vs	  TnC-­‐Con	  4	  h	   TnC-­‐CNTF	  24	  h	  vs	  TnC-­‐Con	  24	  h	  
Sequence	  
Length	   Up	   Down	   Up	   Down	  
2000/0	   	  -­‐	   INSM1,	  KLF4,	  SP1,	  SRF	   	  -­‐	   -­‐	  	  
2000/2000	   	  -­‐	   CTCF,	  KLF4,	  MZF1_1-­‐4,	  RREB1,	  SP1,	  
TCFCP2L1	  
	  -­‐	   	  -­‐	  
5000/2000	   	  -­‐	   CTCF,	  INSM1,	  KLF4,	  SP1	   	  -­‐	   	  -­‐	  
5000/5000	   	  -­‐	   CTCF,	  E2F1,	  INSM1,	  KLF4,	  SP1,	  TCFCP2L1	   	  -­‐	   	  -­‐	  
10000/5000	  	   	  -­‐	   E2F1,	  PPARγ::RXRα,	  SP1,	  TLX1::NFIC	   	  -­‐	   	  -­‐	  
10000/10000	   	  -­‐	   CTCF,	  E2F1,	  INSM1,	  PPARγ::RXRα,	  SP1,	  
STAT3	  
	  -­‐	   	  -­‐	  
Common	   -­‐	   SP1	   -­‐	   -­‐	  
All	   -­‐	   CTCF,	  E2F1,	  INSM1,	  KLF4,	  MZF1_1-­‐4,	  
PPARγ::RXRα,	  RREB1,	  SP1,	  SRF,	  STAT3,	  
TCFCP2L1,	  TLX1::NFIC	  
-­‐	   -­‐	  
Microarray gene expression profiling analysis (Array 2) was carried out using embryonic rat myelinating spinal 
cord cultures that were set up using neurosphere-derived rat astrocytes, plated on PLL- or TnC-coated glass 
coverslips. The cultures were either untreated (control, con) or treated with rat recombinant CNTF for 4 h or 24 
h. The transcripts that were differentially expressed between the untreated and CNTF-treated cultures were 
entered into the web-based program called oPOSSUM 3.0 for single site analysis that detects over-
represented conserved transcription factor binding sites in a set of mouse genes. The conservation cut off 
value was left as 0.4 and matrix score threshold as 85%. The analysis was run for all the possible 
upstream/downstream sequence lengths. The results with Z-score≥10 and Fisher score≥7 are shown in the 
table. The transcription factors detected from the analysis of the up- and down-regulated transcripts in CNTF-
treated cultures compared to control cultures are shown in the table under the columns named “Up” and 
“Down”, respectively. CNTF: ciliary neurotrophic factor; CTCF: CCCTC-binding factor; Hand1: heart and 
neural crest derivatives expressed 1: INSM1: insulinoma-associated 1; Klf4: Kruppel-like factor 4; MZF1: 
myeloid zing finger 1; PLL: poly-L-lysine; Tcfe2a: transcription factor E2a; TnC: tenascin C. 
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Table 6. 2 Previously reported functions of the putative transcription factors that could be 
playing role in CNTF-signaling in rat embryonic TnC-myelinating cultures. 
TF	   Reported	  functions	  related	  to	  CNS	  
CTCF	   • Ubiquitous	  deletion	  of	  Ctcf	  in	  the	  mouse	  leads	  to	  lethality	  before	  embryonic	  day	  
3.5	  (E3.5).	  
• Important	  for	  functional	  neural	  networks	  and	  regulation	  of	  neuronal	  diversity	  in	  
the	  brain.	  
• Conditional	   knockout	   of	   Ctcf	   in	   anterior	   retina	   and	   forebrain	   caused	   extensive	  
apoptosis	  at	  E8.5	  resulting	  in	  profound	  loss	  of	  telenchephalic	  and	  anterior	  retina	  
tissue	  by	  E13.5.	  	  
• Early	   neuroepithelial	   cells	   are	   more	   sensitive	   to	   CTCF	   loss	   than	   the	  
neuroprogenitors	  present	  slightly	  later	  in	  development.	  	  
• A	  transcription	  factor-­‐binding	  site	  was	  found	  in	  the	  regulatory	  region	  of	  golli-­‐Mbp	  
gene,	  expressed	  in	  the	  CNS.	  
• De	   novo	   mutations	   were	   identified	   in	   Ctcf	   in	   individuals	   with	   intellectual	  
disability,	  microcephaly,	  and	  growth	  retardation.	  
• References:	   	   Baruch	   et	   al.,	   2009;	   Hirayama	   et	   al.,	   2012;	   Gregor	   et	   al.,	   2013;	  
Watson	  et	  al.,	  2014	  
E2F1	   • Is	  involved	  in	  neurogenesis.	  E2f1-­‐deficient	  adolescent	  mice	  show	  decreased	  stem	  
cell	  and	  progenitor	  division,	  and	  reduced	  production	  of	  newborn	  neurons	  in	  their	  
proliferative	  brain	  zones.	  	  
• Plays	  a	  role	   in	  the	  generation	  of	  granule	  cells	   in	  the	  postnatal	  and	  adult	  CNS	  by	  
affecting	  proliferation	  and	  cell	  death.	  	  
• Modulates	   neuronal	   apoptosis	   in	   vitro.	   Cortical	   neuronal	   cultures	   from	   E2f1-­‐
deficient	   mice	   are	   resistant	   to	   induced	   apoptosis.	   Overexpression	   of	   E2f1	   in	  
cortical	  neuron	  cultures	  leads	  to	  neuronal	  cell	  apoptosis.	  	  	  
• Nuclear	   E2F1	   levels	   decrease	   during	   differentiation	   of	   rodent	   OPCs	   into	  
oligodendrocytes	  in	  developing	  rat	  white	  matter	  tracts	  and	  in	  cultured	  cells.	  
• E2F1	  might	  have	  novel	   roles	   in	  neuronal	  apoptosis	  of	  neurons	   in	   temporal	   lobe	  
epilepsy	  due	  to	  its	  abnormal	  location	  in	  neuronal	  cytoplasm.	  	  
• Apoptotic	  neuronal	  cell	  death	  in	  hippocampus	  is	  reduced	  in	  E2f1	  knockout	  mice	  
with	  acute	  pneumococcal	  meningitis	  compared	  to	  in	  wild	  types.	  
• Affects	   neuronal	   apoptosis,	   neuronal	   death	   and	   axonal	   damage	   in	   cerebral	  
ischemia.	  E2f1	  knockout	  mice	  show	  smaller	  infarcts	  and	  less	  neuronal	  damage.	  
• E2F1	   expression	   increases	   in	   cortex	   of	   adult	   rats	   with	   traumatic	   brain	   injury,	  
which	  also	  leads	  to	  neuronal	  loss,	  and	  microglial	  and	  astrocyte	  activation.	  	  
• Increases	  transiently	  1	  day	  after	  spinal	  cord	  injury	  in	  mouse	  hippocampus.	  
• E2f1	  levels	  decrease	  in	  NGF-­‐induced	  differentiating	  PC12	  cells.	  
• E2F1	   up-­‐regulation	   is	   associated	   with	   VEGF-­‐induced	   neuroproliferation	   and	  
dopamine-­‐induced	  apoptosis	  in	  rat	  cortical	  cultures.	  	  
• References:	  Hou	  et	  al.,	  2000;	  Hou	  et	  al.,	  2001;	  Cooper	  et	  al.,	  2002;	  MacManus	  et	  
al.,	  2003;	  Zhu	  et	  al.,	  2003;	  Jiang	  et	  al.,	  2007;	  Braun	  et	  al.,	  2008;	  Zhou	  et	  al.,	  2008;	  
Suzuki	  et	  al.,	  2011;	  Fiala	  et	  al.,	  2013;	  Kabadi	  et	  al.,	  2014;	  Magri	  et	  al.,	  2014;	  Wu	  et	  
al.,	  2014	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INSM1	   • Is	  expressed	  in	  developing	  mouse	  brain.	  
• INSM1	   is	   suggested	   to	   be	   expressed	   transiently	   during	   terminal	   neurogenic	  
divisions,	   from	   late	   progenitors	   to	   nascent	   neurons,	   and	   particularly	   during	  
symmetric	  neurogenic	  divisions.	  Insm1	  expression	  is	  lower	  in	  adult	  CNS.	  	  
• It	   is	   suggested	   that	   transient	   expression	   of	   INSM1	   at	   the	   appropriate	  
developmental	   window	   functions	   as	   a	   differentiation	   factor	   by	   facilitating	   cell	  
cycle	  exit	  and	  entrance	  into	  normal	  neuroendocrine	  cell	  differentiation.	  	  
• Promotes	   the	   transition	   of	   progenitors	   from	   apical	   and	   proliferative	   to	   basal,	  
terminal	  and	  neuronogenic	  state.	  
• Regulates	  the	  synthesis	  of	  monoaminergic	  neurotransmitters.	  
• References:	  Beslin	  et	  al.,	  2003;	  Duggan	  et	  al.,	  2008;	  Jacob	  et	  al.,	  2009;	  Lan	  et	  al.,	  
2009;	  Rosenbaum	  et	  al.,	  2011	  
KLF4	   • Plays	  role	  in	  reprogramming	  of	  pluripotent	  stem	  cells.	  
• The	   precise	   regulation	   of	   KLF4	   expression	   is	   critical	   to	   neuronal	   differentiation	  
and	  migration	  during	  the	  formation	  of	  cerebral	  cortex.	  	  
• Regulates	   axon	   regeneration.	   KLF4	   is	   suggested	   as	   a	   suppressor	   for	   neurite	  
outgrowth.	  
• Klf4	  is	  down-­‐regulated	  in	  porcine	  neural	  progenitor	  cells	  when	  treated	  with	  CNTF,	  
which	   stimulates	   the	   proliferation	   and	   differentiation	   of	   these	   cells	   into	   a	  
oligodendrocyte-­‐like	  morphology.	  	  
• Plays	   role	   in	   transient	   forebrain	   ischemia,	   where	   its	   expression	   increases	   in	  
reactive	  astrocytes	  in	  adult	  rat	  brains.	  
• Plays	   role	   in	   microglial	   activation	   and	   subsequent	   release	   of	   pro-­‐inflammatory	  
cytokines	  in	  vitro	  and	  in	  vivo.	  It	  can	  also	  suppress	  the	  anti-­‐inflammatory	  action	  of	  
drugs.	  
• An	  association	  has	  been	  found	  between	  high	  levels	  of	  KLF4	  and	  shorter	  survival	  in	  
high-­‐grade	  astrocytomas.	  	  
• References:	  Moore	  et	  al.,	  2009;	  Kaushik	  et	  al.,	  2010;	  Nori	  et	  al.,	  2011;	  Kaushik	  et	  
al.,	  2012;	  Qin	  et	  al.,	  2012;	  Shimojima	  et	  al.,	  2012;	  Yang	  et	  al.,	  2012b;	  Elsir	  et	  al.,	  
2013;	  Park	  et	  al.,	  2014	  
MZF1	   • Regulates	   the	  expression	  of	   an	  APP-­‐cleaving	  enzyme	   that	   is	   responsible	   for	   the	  
generation	  of	  beta-­‐amyloid	  peptides	  in	  Alzheimer’s	  disease	  and	  of	  a	  brain	  kinase.	  
• It	   is	   suggested	   to	   play	   role	   in	   drug-­‐stimulated	   FGF-­‐2	   expression	   in	   striatal	   rat	  
astrocytes.	  
• References:	  Nomato	  et	  al.	  1999;	  Lange-­‐Dohna	  et	  al.,	  2003;	  Luo	  et	  al.,	  2009	  
PPARγ::	  
RXRα	  	  	  	  
	  
	  
PPARγ::	  
• PPARγ:	  
• PPARs	  have	  been	  detected	  in	  brain	  and	  spinal	  cord.	  They	  have	  been	  shown	  to	  be	  
expressed	  in	  neurons,	  astrocytes	  and	  oligodendrocytes.	  	  
• Administration	   of	   PPARγ	   agonists	   before	   and	   at	   the	   time	   of	   cerebral	   infarction	  
reduces	  infarction	  volume	  and	  improves	  neurological	  function	  following	  ischemic	  
injury	  in	  rats.	  PPARγ	  is	  suggested	  to	  provide	  these	  positive	  effects	  by	  i)	  decreasing	  
the	   cerebral	   oxidative	   stress,	   ii)	   inhibiting	   ischemia-­‐induced	   inflammatory	  
markers,	   and	   iii)	   preventing	   ischemia-­‐induced	   vascular	   expression	   of	   adhesion	  
molecules	  and	  metalloproteinases.	  	  
• PPARγ	   agonists	   reduce	   glial	   activation	   and	   show	   a	   neuroprotective	   effect	   in	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RXRα	  	  
(cont’d)	  
animal	  models	  of	  Alzheimer’s	  disease	  and	  Parkinson’s	  disease.	  	  
• Activation	   of	   PPARγ	   signaling	   reduces	   the	   severity	   of	   motor	   symptoms	   in	   EAE	  
possibly	  through	  the	  regulation	  of	  the	  inflammatory	  pathway	  and	  modulation	  of	  
the	  maturation	  and	  differentiation	  of	  oligodendrocytes.	  
• RXRα:	  
• RXRα	  is	  expressed	  in	  various	  cells	  of	  brain	  tissue.	  
• RXRγ	  is	  suggested	  as	  a	  positive	  regulator	  of	  endogenous	  OPC	  differentiation	  and	  
remyelinaton	  in	  rats.	  	  
• RXRα	  agonists	  are	  suggested	  to	  have	  beneficial	  roles	  in	  ameliorating	  Alzheimer’s	  
disease	  pathogenesis.	  	  
• PPARγ::	  RXRα:	  
• PPARγ	  and	  RXRα	  form	  heterodimers	  to	  regulate	  target	  gene	  expression.	  
• The	   PPARγ-­‐RXRα	   heterodimer	   can	   be	   activated	   by	   the	   ligands	   of	   PPARγ	   or	   of	  
RXRα.	  The	  maximal	  receptor	  activity	  is	  provided	  by	  the	  binding	  of	  both.	  	  
• Co-­‐treatment	  of	  primary	  cortical	  neuron	  cultures	  with	  the	  combination	  of	  PPARγ	  
and	   RXRα	   ligands	   protects	   the	   cells	   from	   oxygen	   depravation-­‐induced	   damage	  
more	  robustly	  than	  each	  of	  the	  ligands	  alone.	  
• Primary	   rat	   microglia	   demonstrate	   a	   higher	   phagocytosis	   efficacy	   toward	  
erythrocytes	  in	  response	  to	  combined	  PPARγ	  activator	  and	  RXRα	  activator.	  
• Combinatorial	   administration	   of	   PPARγ	   and	   RXRα	   ligands	   provides	   a	   higher	  
reduction	  in	  behavioural	  dysfunction	  in	  EAE.	  	  
• References:	  PPARγ:	  Cullingford	  et	  al.,	  1998;	  Feinstein	  et	  al.,	  2002;	  Breidert	  et	  al.,	  
2002;	  Kielian	  et	  al.,	  2003;	  Moreno	  et	  al.,	  2004;	  Heneka	  et	  al.,	  2005;	  Pereira	  et	  al.,	  
2005;	   Shimazu	   et	   al.,	   2005;	   Sundararajan	   et	   al.,	   2005;	   Zhao	   et	   al.,	   2005a;	  
reviewed	  in	  Bordet	  et	  al.,	  2006;	  Lin	  et	  al.,	  2006a;	  Schintu	  et	  al.,	  2009	  /	  RXRα:	  Kojo	  
et	  al.,	  2004;	  Huang	  et	  al.,	  2011;	  Kawahara	  et	  al.,	  2014;	  Zhao	  et	  al.,	  2014	  /	  PPARγ::	  
RXRα:	   Leblanc	   et	   al.,	   1995;	   Mangelsdorf	   et	   al.,	   1995;	   Mukherjee	   et	   al.,	   1997;	  
Tontonoz	  et	  al.,	  1997;	  Diab	  et	  al.,	  2004	  
RREB1	   • RREB1	  has	  been	  shown	  to	  play	  role	  in	  pancreatic,	  prostate	  and	  thyroid	  cancers,	  in	  
tumoral	  calcinosis,	  in	  DNA	  damage	  repair	  through	  regulation	  of	  p53	  transcription,	  
and	  to	  repress	  HLA-­‐G	  expression.	  However,	  it	  has	  not	  been	  reported	  to	  play	  role	  
in	  the	  CNS	  in	  a	  direct	  way.	  	  
• References:	  Thiagalingam	  et	  al.,	  1996;	  Flajollet	  et	  al.,	  2009;	  Liu	  et	  al.,	  2009;	  Milon	  
et	  ak.,	  2010;	  Jiang	  et	  al.,	  2011;	  Franklin	  et	  al.,	  2014	  
SP1	   • Is	   suggested	   to	   play	   role	   in	   development	   due	   to	   increased	   expression	   in	  
differentiating	  cells.	  
• SP1	   is	   associated	   with	   MBP	   and	   PLP	   expressions	   in	   rat	   brain.	   Increased	   SP1	  
expression	  is	  associated	  with	  enhanced	  activation	  of	  MBP.	  The	  binding	  of	  SP1	  to	  
a	  regulatory	  region	  activates	  Mbp	  promoter.	  
• Its	   phosphorylation	   is	   important	   for	   MBP	   transcription	   and	   oligodendrocyte	  
differentiation	  in	  vitro.	  	  
• SP1	  plays	  role	  in	  TGFβ-­‐modulated	  OPC	  cell	  cycle	  withdrawal	  and	  differentiation.	  
• Primary	   astrocytes	   treated	   with	   ammonium	   chloride	   showed	   decreased	  mRNA	  
and	  protein	  levels	  of	  both	  CNTF	  and	  SP1.	  	  
• References:	  Tamura	  et	  al.,	  1988;	  Saffer	  et	  al.,	  1991;	  Zawia	  et	  al.,	  1998;	  Tretiakova	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et	  al.,	  1999;	  Wei	  et	  al.,	  2003;	  Wei	  et	  al.,	  2004;	  Wei	  et	  al.,	  2005;	  Paez	  et	  al.,	  2006;	  
Bodega	  et	  al.,	  2007;	  Calatayud	  et	  al.,	  2009;	  Guo	  et	  al.,	  2010;	  Palazuelos	  et	  al	  2014	  
SRF	   • Plays	  role	  in	  neuronal	  development,	  plasticity,	  learning	  and	  memory.	  
• Suggested	  to	  be	  important	  for	  early	  post-­‐natal	  development	  of	  the	  CNS	  based	  on	  
its	  progressive	  increased	  expression	  in	  neurons	  of	  the	  rat	  cerebral	  and	  cerebellar	  
cortices	  and	  in	  selective	  subcortical	  regions	  from	  birth	  through	  post-­‐natal	  day	  28.	  
• Regulates	   astrocyte	   and	   oligodendrocyte	   specification	   in	   neural	   precursor	   cells	  
(NPCs)	   in	   vitro	   and	   in	   vivo.	   Srf-­‐deficient	   NPCs	   generate	   fewer	   astrocytes	   and	  
oligodendrocytes	  in	  response	  to	  lineage-­‐specific	  differentiation	  factors.	  	  
• Neuronal	  Srf-­‐deficient	  mouse	  brains	  present	  lower	  expressions	  of	  several	  myelin	  
genes,	   reduced	   myelination,	   pathological	   axonal	   morphology,	   and	   increased	  
numbers	  of	  astrocytes.	  	  
• OPCs	  derived	  from	  neuronal	  Srf-­‐deficient	  mice	  have	  been	  shown	  to	  produce	  no	  
oligodendrocytes	  unlike	  those	  from	  wild	  type	  mice.	  Hippocampal	  mixed	  cultures	  
generated	   using	   these	   conditional	   Srf-­‐deficient	   mice	   also	   present	   reduced	  
oligodendrocyte	  maturation.	  	  
• Mediates	  the	  immediate	  early	  response	  and	  actin	  cytoskeletal	  gene	  transcription	  
in	  primary	  mouse	  CNS	  neurons,	  stimulated	  with	  several	  axon	  growth	  inhibitors.	  
• References:	   	  Stringer	  et	  al.,	  2002;	  Knoll	  and	  Nordheim,	  2009;	  Stritt	  et	  al.,	  2009;	  
Johnson	  et	  al.,	  2011;	  Lu	  et	  al.,	  2012;	  Stern	  and	  Knoll,	  2014	  
STAT3	   • Is	   involved	   in	   neuroprotection,	   promotion	   of	   axon	   growth,	   and	   optic	   nerve	  
regeneration	  upon	  inflammatory	  stimulation	  in	  rodents.	  
• Its	   phosphorylation	   increases	   upon	   CNTF	   treatment,	   which	   presents	  
neuroprotective	  effects	  in	  a	  rat	  model	  of	  multiple	  sclerosis.	  
• CNTF-­‐responsive	  elements	  are	  present	  within	  the	  Gfap	  gene	  promoter.	  
• 	  S-­‐nitrosoglutahtione-­‐induced-­‐astrocytes	   secrete	   higher	   levels	   of	   CNTF	   that	  
increases	  their	  GFAP	  expression	  via	  STAT3	  activation.	  
• Phosphorylated	  STAT3	  levels	  increase	  during	  spinal	  cord	  injury	  in	  precursor	  cells,	  
oligodendrocytes	  and	  astrocytes	  of	  rats.	  
• CNTF	   treatment	   promotes	   neuroepithelial	   stem	   cells	   to	   differentiate	   into	  
astrocytes	  in	  the	  presence	  of	  increased	  STAT3	  activation.	  
• References:	  	  Kahn	  et	  al.,	  1997;	  Rajan	  et	  al.,	  1998;	  Maier	  et	  al.,	  2004;	  Muller	  et	  al.,	  
2007;	  Tripathi	  et	  al.,	  2008;	  Leibinger	  et	  al.,	  2013;	  Paintlia	  et	  al.,	  2013	  
TCFCP2L1	   • Is	   important	   for	   establishing	   and	  maintaining	   pluripotent	   cell	   identity	   and	   self-­‐
renewal	  in	  embryonic	  stem	  cells.	  
• References:	  Pelton	  et	  al.,	  2001;	  van	  den	  Berg	  et	  al.,	  2010;	  Ye	  et	  al.,	  2013	  
TLX1::NFIC	  
	  
TLX1::NFIC	  
(cont’d)	  
• TLX1:	  
• Expressed	  by	  neural	  stem/progenitor	  cells	  in	  the	  adult	  brain.	  
	  
• Plays	  role	  in	  neurogenesis	  and	  differentiation	  of	  neurons	  in	  mouse	  brain.	  It	  is	  an	  
intrinsic	  regulator	  in	  the	  decision	  to	  proliferate	  or	  differentiate.	  
• Mediates	  proliferation	  and	  pluripotency	  of	  neural	  progenitors	  upon	  hypoxia.	  
• Determines	  excitatory	  neurotransmission	  over	  inhibitory	  one	  in	  embryonic	  dorsal	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A microarray gene expression profiling analysis was carried out using samples from rat embryonic spinal cord 
myelinating cultures (Array 2). The down-regulated transcripts upon CNTF treatment in myelinating cultures 
plated on rat astrocytes on TnC-coated coverslips were analysed in oPOSSUM 3.0 to detect over-represented 
conserved transcription factor binding sites. The conservation cut off value was left as 0.4 and matrix score 
threshold as 85%. The results with Z-score≥10 and Fisher score≥7 are shown in the table together with their 
previously reported functions in the central nervous system (CNS) or in vitro that could be related to CNS, as 
well. CNTF: ciliary neurotrophic factor; cont’d: continued; CTCF: CCCTC-binding factor; EAE: experimental 
autoimmune encephalomyelitis; GFAP: glial fibrillary acidic protein; HLA-G: major histocompatibility complex, 
class I, G; INSM1: insulinoma-associated 1; KLF4: Kruppel-like factor 4; MBP: myelin basic protein; MZF1: 
myeloid zinc finger 1; NFI: Nuclear factor I; OPC: oligodendrocyte precursor cell; PPAR: peroxisome 
proliferator-activated receptor; RREB1: ras responsive element binding protein 1; RXR: retinoid X receptor; 
SP1: specificity protein 1; SRF: serum response factor; STAT3: signal transducer and activator of transcription 
3; TCFCP2L1: transcription factor CP2-like 1; TGF: transforming growth factor; TLX: tailless; TnC: tenascin C; 
VEGF: vascular endothelial growth factor 
 
The results from the analysis of the down-regulated transcripts upon CNTF treatment in 
TnC-myelinating cultures were also presented as scatter plots, where the x and y 
coordinate planes represented Z-score and Fisher score values, respectively. Each graph 
is divided into four quadrants as seen in Fig 6.7 A. Quadrant II represents the TFBSs, for 
which the enrichment is due to a majority of DNA regions carrying a TFBS but at a low 
frequency per sequence (Fischer score high rank, Z-score low rank). Quadrant IV 
represents the TFs, for which the enrichment is due to a high frequency of TFBSs in 
some of the sequences and absence in others (Z-score high rank, Fisher score low rank). 
On the other hand, Quadrant III shows the TFBSs, which were not found to be enriched 
in the genes analysed. We were interested in Quadrant I, where Z-score and Fisher 
score of TFBS hits were both equal or higher than the significance threshold values (10 
and 7, respectively), showing that the significant enrichment of the binding sites of the 
mouse	  spinal	  cord.	  	  
• Represses	   cell	   cycle	   and	   glial	   differentiation	   but	   activates	   neuronal	   lineage	  
commitment	  in	  adult	  rat	  hippocampus-­‐derived	  progenitors.	  
• NFIC:	  
• NFI	  proteins	  bind	  to	  target	  sequences	  as	  either	  hetero-­‐	  or	  homodimers.	  
• Relatively	   low	  NFIC	   levels	   are	   present	   in	   the	   brain	   compared	   to	   those	   of	  NFIA,	  
NFIB,	   and	   NFIX,	   in	   the	   absence	   of	   which	   the	   mice	   present	   aberrant	   brain	  
development.	  Nfic-­‐deficient	  mice	  show	  mainly	  abnormal	  root	  (tooth)	  formation.	  
• NFIC	  binds	  to	  and	  regulates	  the	  expression	  of	  GFAP	  in	  vitro.	  
• NFIC	   regulates	   the	   expression	   of	   the	   human	   secretin	   (a	   neuropeptide)	   gene	   in	  
response	  to	  retinoic	  acid	  treatment	  in	  vitro.	  
• References:	  	  TLX1:	  Roy	  et	  al.,	  2002;	  Land	  et	  al.,	  2003;	  Stenman	  et	  al.,	  2003;	  Cheng	  
et	   al.,	   2004;	  Miyawaki	   et	   al.,	   2004;	   Roy	   et	   al.,	   2004;	   Shi	   et	   al.,	   2004;	   Li	   et	   al.,	  
2008b;	   Liu	   et	   al.,	   2008a;	   Zhang	   et	   al.,	   2008;	   Elmi	   et	   al.,	   2010;	   Qu	   et	   al.,	   2010;	  
Chavali	  et	  al.,	  2011;	  Ryan	  et	  al.,	  2013;	  Murai	  et	  al.,	  2014	  NFIC:	  Kruse	  et	  al.,	  1994:	  
Chaudhry	  et	  al.,	  1997;	  das	  Neves	  et	  al.,	  1999;	  Shu	  et	  al.,	  2003;	  Steele-­‐Perkins	  et	  
al.,	  2003;	  Lee	  et	  al.,	  2005;	  Steele-­‐Perkins	  et	  al.,	  2005;	  Driller	  et	  al.,	  2007;	  Campbell	  
et	  al.,	  2008;	  Braun	  et	  al.,	  2009	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suggested TFs is due to both facts explained above for quadrants II and IV (Kwon et al., 
2012). TFBS for SP1 (specificity protein 1) appeared to have the highest Z-score for most 
of the sequence lengths scanned (Fig 6.7 A, C-F) and the highest Fisher score for half of 
them (Fig 6.7 A-C, F). It was also the only common TF detected at all sequence lengths.  
SP1 has been previously shown to posses binding sites for some genes, which also 
contain recognition sites for CTCF (CCCTC-binding factor) or MZF1 (myeloid zinc finger 
protein 1) in a way that their recognition sequences do not interfere with that of each 
other (Yang et al., 1999; Yin et al., 1999; Hikichi et al., 2003; Lange-dohna et al., 
2003). These observations are in accordance with our findings, which suggest that all of 
the above-mentioned TFs contain conserved binding sites for shared genes (Table 6.3). 
For example, at the end of the analysis of the 2000/2000 bp regulatory DNA region, 
both SP1 and CTCF appeared to contain TFBSs for the genes of Col5a1, Cyp1b1, Ngfr, 
Pdlim7, Lox, Megf6, and Wif1; whereas, the genes that were likely to be regulated by 
both SP1 and MZF1 seemed to be Col5a1, Cyp1b1, Ngfr, Pdlim7, Fstl1, Lox, Megf6, and 
Wif1 (Table 6.3). Such similarities were also seen for other TFs. 
The microarray gene expression profiling analysis (Array 2) also revealed differentially 
expressed transcripts between spinal cord myelinating cultures at two time points (4 hr 
and 24 hr) and between cultures on different substrates (PLL or TnC). The up- and 
down-regulated transcripts between these two sets of different conditions were also 
analysed in oPOSSUM 3.0 (Tables 6.4 and 6.5). The TFs that appeared to be responsible 
for down-regulated transcripts over time in PLL-myelinating cultures were CREB1, NFKB, 
NFKB1, REL, RELA, SRF, USF1; while, the protein complex RXR::RAR_DR5 was detected 
as the TF associated with the down-regulations over time in TnC-myelinating cultures 
(Table 6.4). The TFs, which were detected in the analysis of the up-regulation of the 
transcripts in PLL-myelinating cultures compared to TnC-myelinating cultures at 4 hr, 
were CREB1, GFI, HLF, MZF1_5-13, NFKB1, REL, REST, SPIB, SRF, STAT1, TBP, and USF1; 
and at 24 hr were MZF1_1-4, MZF1_5-13, REST, TBP. In addition to being detected for 
the down-regulated transcripts upon CNTF-treatment in TnC-myelinating cultures, SRF 
appeared to play a role in the intracellular signaling pathways associated with the 
change of time from 4 hr to 24 hr and with the use of different coverslips-coating 
substrates (Table 6.4, 6.5), and MZF1 emerged as a putative TF to take part in the up-
regulations of transcripts in PLL-myelinating cultures compared to TnC-myelinating 
cultures (Table 6.5).  
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Figure 6. 7 Several transcription factors were suggested to play a role in CNTF-signaling in 
rat embryonic spinal cord myelinating cultures on TnC-astrocytes.                
A microarray gene expression profiling analysis (Array 2) was carried out using RNA samples from embryonic 
rat spinal cord myelinating cultures, which were plated on rat astrocytes on TnC-coated glass coverslips. After 
12 DIV, samples were collected 4 hours after treatment with CNTF to be used for a rat Illumina array. False 
discovery rate was designated as 5% and a list of up- and down-regulated transcripts upon CNTF was 
generated using Rank Products statistical analysis. The down-regulated transcripts upon CNTF treatment 
were entered into the web-based software, named oPOSSUM 3.0 to detect the highly conserved transcription 
factor-binding sites in those genes. The conservation cut off value was left at 0.40 and matrix score threshold 
as 85% as suggested by the developers of the program. Analysis was carried out for each DNA sequence 
length (2000/0, 2000/2000, 5000/2000, 5000/5000, 10000/5000, and 10000/10000 bp), provided in the 
program. The results were presented as Fisher score vs Z-score scatter plots using Microsoft Excel for each 
sequence length as seen above. The values with Z-score≥10 and Fisher score≥7 were considered statistically 
significant as directed by the developers of the program. These values for the binding sites are shown in red in 
Quadrant I with the corresponding transcription factor names next to them. CNTF: ciliary neurotrophic factor; 
DIV: days in vitro; TnC: tenascin C. 
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Table 6. 3 The genes that appeared to be enriched with the transcription factor binding sites 
for the transcription factors detected at the end of the analysis using oPOSSUM 3.0. 
A microarray gene expression profiling (Array 2) was carried out using embryonic rat spinal cord myelinating 
cultures on astrocytes, plated on PLL or TnC-coated coverslips. The analysis revealed a number of 
differentially regulated transcripts upon CNTF treatment. The down-regulated transcripts upon CNTF 
treatment in TnC-myelinating cultures were entered into oPOSSUM 3.0, a web-based program that detects 
over-represented conserved transcription factor binding sites (TFBSs) in the regulatory DNA regions of mouse 
genes. TFBS hits were searched at different base pair (bp) distances upstream and downstream from the 
Ensembl-annotated transcription start sites. Examples are given from the sequence lengths of 2000/0, 
2000/2000, 10000/5000, 10000/10000 to cover all the TFBS hits detected for this set of genes. Transcription 
factors (TFs) for the TFBS hits with values of Z-score≥10 and Fisher score≥7 for each sequence length are 
presented in bold above. These TFBS hits appear to be present in the regulatory regions of the genes shown 
in the table. PLL: poly-l-lysine; TnC: tenascin C.  
Seq.	  
Length	   The	  genes	  enriched	  with	  TFBSs	  for	  the	  TFs	  shown	  in	  bold	  
2000/	  	  	  0	  	  	  	  	  	  	  	  
bp	  
INSM1:	  Cd248,	  Igf2,	  Nfatc4,	  Colec12,	  Col5a1,	  Cyp1b1,	  Pdlim7,	  Fstl1,	  Fbn2,	  Col18a1,	  Msx1	  
KLF4:	  Cd248,	  Igf2,	  Nfatc4,	  Loxl2,	  Colec12,	  Emp1,	  Col5a1,	  Cyp1b1,	  Ngfr,	  Pdlim7,	  Fstl1,	  Fbn2,	  
Igfbp2,	  Slc14a2,	  Loxl1,	  Wif1,	  Col18a1,	  Msx1	  	  
SP1:	  Cd248,	  Igf2,	  Nfatc4,	  Loxl2,	  Thbs2,	  Colec12,	  Col5a1,	  Cyp1b1,	  Ngfr,	  Pdlim7,	  Lox,	  Fbn2,	  
Igfbp2,	  Slc14a2,	  Megf6,	  Loxl1,	  Wif1,	  Col18a1,	  Msx1	  
SRF:	  Cd248,	  Igf2,	  Pdlim7,	  Msx1	  
2000/	  
2000	  	  bp	  
CTCF:	  Col5a1,	  Cyp1b1,	  Ngfr,	  Pdlim7,	  Fstl1,	  Lox,	  Megf6,	  Wif1	  
KLF4:	  Cd248,	  Igf2,	  Nfatc4,	  Loxl2,	  Colec12,	  Emp1,	  Col5a1,	  Cyp1b1,	  Ngfr,	  Pdlim7,	  Fstl1,	  Lox,	  Fbn2,	  
Boc,	  Igfbp2,	  Slc14a2,	  Megf6,	  Loxl1,	  Wif1,	  Fmod,	  Col18a1,	  Msx1	  
MZF1:	  Cd248,	   Igf2,	  Nfatc4,	  Loxl2,	  Thbs2,	  Colec12,	  Emp1,	  Col5a1,	  Cyp1b1,	  Ngfr,	  Pdlim7,	  Fstl1,	  
Lox,	  Fbn2,	  Boc,	  Igfbp2,	  Slc14a2,	  Megf6,	  Col3a1,	  Loxl1,	  Wif1,	  Fmod,	  Col18a1,	  Msx1	  
RREB1:	  Igf2,	  Nfatc4,	  Pdlim7,	  Boc,	  Igfbp2,	  Col18a1	  
SP1:	   Cd248,	   Igf2,	   Nfatc4,	   Loxl2,	   Thbs2,	   Colec12,	   Col5a1,	   Cyp1b1,	   Ngfr,	   Pdlim7,	   Lox,	   Fbn2,	  
Igfbp2,	  Slc14a2,	  Megf6,	  Loxl1,	  Wif1,	  Col18a1,	  Msx1	  
TCFCP2L1:	   Cd248,	   Igf2,	   Nfatc4,	   Loxl2,	   Colec12,	   Emp1,	   Col5a1,	   Pdlim7,	   Fbn2,	   Boc,	   Igfbp2,	  
Megf6,	  Col3a1,	  Loxl1,	  Fmod,	  Col18a1,	  Msx1	  
10000/5
000	  	  bp	  
E2F1:	  Cd248,	   Igf2,	  Nfatc4,	   Loxl2,	  Colec12,	  Emp1,	  Cyp1b1,	  Ngfr,	  Pdlim7,	  Fstl1,	   Lox,	  Fbn2,	  Boc,	  
Slc14a2,	  Col3a1,	  Loxl1,	  Wif1,	  Col18a1,	  Msx1,	  Cckar	  
PPARG::RXRA:	   	   Cd248,	   Igf2,	   Nfatc4,	   Emp1,	   col5a1,	   Ngfr,	   Pdlim7,	   Fstl1,	   Fbn2,	   Boc,	   Igfbp2,	  
Slc14a2,	  Loxl1,	  Fmod,	  Col18a1,	  Msx1,	  Cckar	  
SP1:	  Cd248,	  Igf2,	  Nfatc4,	  Loxl2,	  Thbs2,	  Colec12,	  Emp1,	  Col5a1,	  Cyp1b1,	  Ngfr,	  Pdlim7,	  Fstl1,	  Lox,	  
Fbn2,	  Boc,	  Igfbp2,	  Slc14a2,	  Megf6,	  Col3a1,	  Loxl1,	  Wif1,	  Fmod,	  Col18a1,	  Msx1	  
TLX1::NFIC:	  Igf2,	  Col5a1,	  Pdlim7,	  Boc,	  Igfbp2,	  Col3a1,	  Col18a1	  
10000/1
0000	  bp	  
CTCF:	  Nfatc4,	  Emp1,	  Col5a1,	  Cyp1b1,	  Ngfr,	  Pdlim7,	  Fstl1,	  Lox,	  Megf6,	  Col3a1,	  Wif1,	  Fmod	  
E2F1:	  Cd248,	   Igf2,	  Nfatc4,	   Loxl2,	  Colec12,	  Emp1,	  Cyp1b1,	  Ngfr,	  Pdlim7,	  Fstl1,	   Lox,	   Fbn2,	  Boc,	  
Slc14a2,	  Col3a1,	  Loxl1,	  Wif1,	  Col18a1,	  Msx1,	  Cckar	  
INSM1:	  Cd248,	   Igf2,	  Nfatc4,	  Loxl2,	  Thbs2,	  Colec12,	  Col5a1,	  Cyp1b1,	  Ngfr,	  Pdlim7,	  Fstl1,	  Fbn2,	  
Boc,	  Igfbp2,	  Slc14a2,	  Col13a1,	  Wif1,	  Col18a1,	  Msx1	  
PPARG::RXRA:	   	   Cd248,	   Igf2,	   Nfatc4,	   Loxl2,	   Emp1,	   Col5a1,	   	   Ngfr,	   Pdlim7,	   Fstl1,	   	   Fbn2,	   Boc,	  
Igfbp2,	  Slc14a2,	  Loxl1,,Fmod,	  	  Col18a1,	  Msx1,	  Cckar	  
SP1:	  Cd248,	  Igf2,	  Nfatc4,	  Loxl2,	  Thbs2,	  Colec12,	  Emp1,	  Col5a1,	  Cyp1b1,	  Ngfr,	  Pdlim7,	  Fstl1,	  Lox,	  
Fbn2,	  Boc,	  Igfbp2,	  Slc14a2,	  Megf6,	  Col3a1,	  Loxl1,	  Wif1,	  Fmod,	  Col18a1,	  Msx1	  
STAT3:	   Cd248,	   Igf2,	   Nfatc4,	   Loxl2,	   Colec12,	   Emp1,	   Col5a1,	   Cyp1b1,	   Ngfr,	   Pdlim7,	   Fstl1,	   Lox,	  
Fbn2,	  Boc,	  Igfbp2,	  Slc14a2,	  Megf6,	  Col3a1,	  Loxl1,	  Wif1,	  Fmod,	  Col18a1,	  Msx1	  
 
 
197 
 
Table 6. 4 Possible transcription factors that are stimulated over time in untreated and 
CNTF-treated embryonic rat spinal cord myelinating cultures. 
	  	   PLL-­‐Con	  24	  h	  vs	  PLL-­‐Con	  4	  h	   PLL-­‐CNTF	  24	  h	  vs	  PLL-­‐CNTF	  4	  h	  
Sequence	  
Length	   Up	   Down	   Up	   Down	  
2000/0	   -­‐	   CREB1,	  NFKB,	  REL,	  RELA,	  SRF,	  USF1	   -­‐	   SRF	  
2000/2000	   -­‐	   CREB1,	  NFKB,	  NFKB1,	  REL,	  RELA,	  SRF	   -­‐	   -­‐	  
5000/2000	   -­‐	   MEF2A,	  NFKB,	  NFKB1,	  REL,	  RELA,	  SRF	   -­‐	   -­‐	  
5000/5000	   -­‐	   NFKB,	  NFKB1,	  REL,	  RELA,	  SRF	   -­‐	   -­‐	  
10000/5000	  	   -­‐	   NFKB1,	  RELA	   -­‐	   -­‐	  
10000/10000	   -­‐	   NFKB1	   -­‐	   -­‐	  
Common	   	   NFKB	   -­‐	   -­‐	  
All	   -­‐	   CREB1,	  NFKB,	  NFKB1,	  REL,	  RELA,	  SRF,	  
USF1	  
-­‐	   SRF	  
	  	  	  	   TnC-­‐Con	  24	  h	  vs	  TnC-­‐Con	  4	  h	   TnC-­‐CNTF	  24	  h	  vs	  TnC-­‐CNTF	  4	  h	  
Sequence	  
Length	   Up	   Down	   Up	   Down	  
2000/0	   -­‐	   RXR::RAR_DR5	   -­‐	   -­‐	  
2000/2000	   -­‐	   RXR::RAR_DR5	   -­‐	   -­‐	  
5000/2000	   -­‐	   -­‐	   -­‐	   -­‐	  
5000/5000	   -­‐	   -­‐	   -­‐	   -­‐	  
10000/5000	  	   -­‐	   -­‐	   -­‐	   -­‐	  
10000/10000	   -­‐	   -­‐	   -­‐	   -­‐	  
All	   -­‐	   RXR::RAR_DR5	   -­‐	   -­‐	  
Microarray gene expression profiling analysis (Array 2) was carried out using embryonic rat myelinating spinal 
cord cultures that were set up using neurosphere-derived rat astrocytes, plated on PLL- or TnC-coated glass 
coverslips. The cultures were either untreated (control, con) or treated with rat recombinant CNTF for 4 h or 24 
h. The transcripts that were differentially expressed over time (24 h versus 4 h) in control and CNTF-treated 
cultures were entered into the web-based program called oPOSSUM 3.0 for single site analysis that detects 
over-represented conserved transcription factor binding sites in a set of mouse genes. The conservation cut 
off value was left as 0.4 and matrix score threshold as 85%. The analysis was run for all the possible 
upstream/downstream sequence lengths. The results with Z-score≥10 and Fisher score≥7 are shown in the 
table. The transcription factors detected from the analysis of the up- and down-regulated transcripts in 24 h 
samples compared to 4 h samples are shown in the table under the columns named “Up” and “Down”, 
respectively. Ar: androgen receptor; CNTF: ciliary neurotrophic factor; CREB1: cyclic AMP-responsive 
element-binding protein 1; NFKB1: nuclear factor kappa B 1; PLL: poly-L-lysine; REL: reticuloendotheliosis 
oncogene; REST: RE1-silencing transcription factor; RAR: retinoic acid receptor; RXR: retinoic X receptor; 
SRF: serum response factor; TnC: tenascin C.  
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Table 6. 5 Possible transcription factors that could take part in the cellular mechanisms 
stimulated by the substrates, on which embryonic rat spinal cord myelinating cultures are 
plated. 
	  	   PLL-­‐Con	  4	  h	  vs	  TnC-­‐Con	  4	  h	   PLL	  Con	  24	  h	  vs	  TnC	  Con	  24	  h	  
Sequence	  
Length	   Up	   Down	   Up	   Down	  
2000/0	   CREB1,	  GFI,	  MZF1_5-­‐13,	  REL,	  
SPIB,	  TBP,	  USF1	  	  
-­‐	   -­‐	   -­‐	  
2000/2000	   CREB1,	  HLF,	  NFKB1,	  REL,	  REST,	  
SPIB,	  STAT1	  
-­‐	   REST,	  TBP	   -­‐	  
5000/2000	   GFI,	  REST,	  SPIB,	  SRF,	  TBP	   -­‐	   MZF1_1-­‐4,	  MZF1_5-­‐13,	  REST	   -­‐	  
5000/5000	   REST,	  SRF,	  STAT1,	  TBP,	  USF1	   -­‐	   MZF1_1-­‐4,	  MZF1_5-­‐13,	  REST	   -­‐	  
10000/5000	  	   REL,	  REST	   -­‐	   MZF1_5-­‐13,	  REST	   -­‐	  
10000/10000	   REL	   -­‐	   MZF1_5-­‐13,	  REST	   -­‐	  
Common	   -­‐	   -­‐	   -­‐	   -­‐	  
All	   CREB1,	  GFI,	  HLF,	  MZF1_5-­‐13,	  
NFKB1,	  REL,	  REST,	  SPIB,	  SRF,	  
STAT1,	  TBP,	  USF1	  
-­‐	  
	  
MZF1_1-­‐4,	  MZF1_5-­‐13,	  
REST,	  TBP	  
-­‐	  
	  
Microarray gene expression profiling analysis (Array 2) was carried out using embryonic rat myelinating spinal 
cord cultures that were set up using neurosphere-derived rat astrocytes, plated on PLL- or TnC-coated glass 
coverslips. The transcripts that were differentially expressed between the PLL- and TnC-cultures were entered 
into the web-based program called oPOSSUM 3.0 for single site analysis that detects over-represented 
conserved transcription factor binding sites in a set of mouse genes. The conservation cut off value was left as 
0.4 and matrix score threshold as 85%. The analysis was run for all the possible upstream/downstream 
sequence lengths. The results with Z-score≥10 and Fisher score≥7 are shown in the table. The transcription 
factors detected from the analysis of the up- and down-regulated transcripts in PLL-cultures compared to TnC-
cultures are shown in the table under the columns named “Up” and “Down”, respectively. CNTF: ciliary 
neurotrophic factor; CREB1: cyclic AMP-responsive element-binding protein 1; PLL: poly-L-lysine; REL: 
reticuloendotheliosis oncogene; REST: RE1-silencing transcription factor; SRF: serum response factor; 
STAT1: signal transducer and activator of transcription 1; TBP: TATA box binding protein; TnC: tenascin C. 
 
6.3.5 Metabolomics of CNTF signaling in embryonic rat spinal 
cord myelinating cultures 
Further experiments were carried out to understand the pathways CNTF triggers in 
neurosphere-derived rat astrocyte cultures. Metabolite samples were collected from 
untreated and CNTF-treated PLL- and TnC-astrocytes to be analysed by Glasgow 
University Metabolomics Facility. Metabolite levels in spent culture medium (secreted 
metabolites) and those contained in cells were both compared between above-
mentioned culture conditions. Q-Exactive Hybrid Quadrupole-Orbitrap mass 
spectrometer (Q-Exactive MS) was used to process the samples for the purposes of lipid 
chromatography tandem mass spectrometry (LC-MS/MS). Quality control (QC) pooled 
standards, which are the aliquots of the total mixture of all the untreated and CNTF-
treated culture samples, were also run in between the culture samples so that the data 
could be normalised after the run to correct the drift in the measured signal based on 
the assumption that all QC samples should be identical (Dunne et al., 2011).  
Thermo MetQuest metabolic stability screening application was used to process high-
resolution accurate mass data gathered from Q-Exactive MS and to produce “.raw” files 
that were converted to “mzXML” files to present positive and negative total ion current 
(TIC) chromatograms. These TIC plots present signal intensities against retention times 
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in the three biological repeats for each astrocyte culture condition (Appendix VI). 
Consistency of the signal intensity values at the same retention times between the 
biological replicates is interpreted as a successful sample preparation with little or no 
technical variance and this is observed by the overlay of three colours in TIC plots. Our 
results showed such high consistency between the biological replicates for all of the 
samples (Appendix VI).  
The data collected from Q-Exactive MS were condensed in an IDEOM file, which is a 
Microsoft Excel template with a collection of macros that enable automated data 
processing of mass spectrometry data (Creek et al., 2012). The signal intensities 
detected at each retention time for each biological replicate were used to obtain the 
average signal intensity for each culture condition. The average intensities of control 
(untreated) and CNTF-treated conditions were compared to generate fold changes 
(FCs), for which unpaired t-test was applied to detect the significance in binary 
comparisons. The results for CNTF-treated PLL- and TnC-cells and -cell medium were 
compared to those of control ones. The putative metabolites, for which the FCs were 
found to be statistically significant, are shown in Tables 6.6, 6,7, 6.8, and 6.9 from the 
highest to the lowest FC. The metabolites highlighted in yellow with a bold font were 
the ones identified with authentic standards; whereas, the other metabolites were 
putatively identified from the database based on accurate mass to charge ratio (m/z 
value) but predicted retention times. Those metabolites with matching values to the 
authentic standards were inosine and dGMP in astrocyte cells on PLL (PLL-As, Table 
6.6), and phthalate and l-lysine in the medium of PLL-As (Table 6.7). There were no 
such metabolites detected in spent medium from PLL- or TnC-As (Tables 6.7 & 6.9). 
Inosine and dGMP levels increased significantly in PLL-astrocytes upon CNTF treatment 
(Table 6.6); whereas, the treatment decreased the levels of phthalate and l-lysine in 
TnC-astrocytes. 
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Table 6. 6 Putative metabolites that were produced at different levels upon CNTF treatment 
in neurosphere-derived rat astrocytes on PLL. 
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192	   9.0	   C6H12N2O5	   1	   Ser-­‐Ser	   5	   Peptide-­‐di	  	   1.0	   5.9	  
226	   4.0	   C14H26O2	   12	   (9Z)-­‐Tetradecenoic	  acid	   5	   Lipids:	  F.	  A.	  	   1.0	   1.9	  
341	   3.9	   C19H35NO4	   1	   trans-­‐2-­‐Dodecenoylcarnitine	   5	   0	   1.0	   1.7	  
224	   6.5	   C15H12O2	   7	   (2S)-­‐Flavanone	   7	   0	   1.0	   1.5	  
338	   3.9	   C18H26O6	   2	   Pinolidoxin	   5	   0	   1.0	   1.5	  
268	   9.0	   C10H12N4O5	   3	   Inosine	   10	   Nucl.	   1.0	   1.5	  
689	   4.2	   C38H77N2O6P	   1	  
[SP	  (18:0/14:0)]	  N-­‐(octade	  
canoyl)-­‐tetradecasphing-­‐4-­‐en	  
ine-­‐1-­‐phosphoethanolamine	  
5	   Lipids:	  Sph.	   1.0	   1.4	  
182	   3.5	   C14H14	   1	   1,2-­‐Dihydrostilbene	   5	   0	   1.0	   1.3	  
347	   9.2	   C10H14N5O7P	   7	   dGMP	   10	   Nucl.	   1.0	   1.2	  
332	   3.6	   C20H28O4	   20	  
[FA	  oxo,hydroxy(4:0)]	  9-­‐oxo-­‐
15S-­‐hydroxy-­‐5Z,10Z,13E,17Z-­‐
prostatetraenoic	  acid	  
5	   Lipids:	  F.	  A.	  	   1.0	   1.2	  
208	   5.0	   C15H12O	   2	   Chalcone	   7	   0	   1.0	   1.2	  
387	   3.8	   C56H86O	   1	   2-­‐decaprenylphenol	   7	   Cof.	  &	  Vit.	  	   1.0	   1.2	  
247	   9.0	   C10H17NO6	   2	   Linamarin	   5	   0	   1.0	   1.1	  
729	   4.2	   C41H81N2O6P	   2	   SM(d18:1/18:1(9Z))	   5	   Lipids:	  Sph.	   1.0	   1.1	  
283	   4.2	   C15H25NO4	   2	   Amabiline	   7	   0	   1.0	   0.9	  
99	   5.0	   C5H9NO	   3	   N-­‐Methyl-­‐2-­‐pyrrolidinone	   7	   0	   1.0	   0.9	  
408	   4.3	   C23H36O6	   2	  
[FA	  methyl,oxo,hydroxy(2:0)]	  
methyl	  9-­‐oxo-­‐11R-­‐hydroxy-­‐15R-­‐
acetoxy-­‐5Z,13E-­‐prostadienoate	  
5	   Lipids:	  F.	  A.	  	   1.0	   0.8	  
192	   4.3	   C11H12O3	   6	   Carpacin	   5	   0	   1.0	   0.8	  
766	   3.9	   C43H76NO8P	   28	   PE(20:2(11Z,14Z)/18:3(6Z,9Z,12Z)	   5	  
Lipids:	  
Gly.	   1.0	   0.7	  
133	   7.2	   C4H7NO2S	   1	   L-­‐thiazolidine-­‐4-­‐carboxylate	   5	   0	   1.0	   0.7	  
399	   4.5	   C23H45NO4	   1	   [FA]	  O-­‐Palmitoyl-­‐R-­‐carnitine	   8	   Lipids:	  F.	  A.	  	   1.0	   0.6	  
788	   4.0	   C44H86NO8P	   24	  
[PC	  (18:0/18:1)]	  1-­‐octade	  
canoyl-­‐2-­‐(9Z-­‐octadecenoyl)-­‐sn-­‐
glycero-­‐3-­‐phosphocholine	  
5	   Lipids:	  Gly.	   1.0	   0.6	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241	   4.5	   C12H19NO4	   2	   N-­‐(3-­‐Oxooctanoyl)	  homoserine	  lactone	   5	  
Lipids:	  
F.	  A.	  	   1.0	   0.4	  
Confluent neurosphere-derived rat astrocyte monolayers plated on PLL-coated glass coverslips were washed 
with PBS and lysed with a mixture of chloroform/methanol/water at 9 DIV. The lysates were centrifuged and 
the supernatant was sent to Glasgow University Metabolomics Facility for the analysis using a Q-Exactive 
Hybrid Quadrupole-Orbitrap mass spectrometer. Using a Microsoft Excel interface named IDEOM, R statistical 
packages XCMS and Mzmatch were run to detect peaks, combine data and annotate related peaks. The fold 
changes (FCs) between the signal intensities of metabolites detected in untreated PLL-astrocytes (PLL Con) 
and CNTF-treated PLL-astrocytes (PLL CNTF) were calculated and unpaired t-test was used to detect the 
significance between these FCs in IDEOM. Presented in bold are the statistically significant (p≤0.05) 
increased (highlighted in red) and reduced (highlighted in blue) fold changes in “PLL CNTF” astrocytes. The 
putative metabolites highlighted in yellow (Inosine and dGMP) were matched within 3 ppm of the mass and 
5% of the retention time of an authentic standard, run prior to every batch of samples. Confidence scores of 8 
or lower are identifications based on accurate mass but predicted retention time. The isomers column shows 
the number of different compounds that have identical chemical formulas, but different structures. Mass is the 
accurate monoisotropic mass and RT is the chromatographic retention time (RT) of the compound.  Masses 
are highlighted according to the polarity mode of detection (red, blue, and white for positive, negative, and 
both types of ionisation, respectively). CNTF: ciliary neurotrophic factor; Cof. & Vit.: cofactors and vitamins; 
DIV: day in vitro; F.A.: fatty acyls; Gly.: glycerophospholipids;  Nucl.: nucleotide; PLL: poly-L-lysine; ppm: parts 
per million; Sph.: sphingolipids 
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Table 6. 7 Putative metabolites that were secreted at different levels upon CNTF treatment 
by the neurosphere-derived rat astrocytes on PLL. 
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196	   7.2	   C8H12N4O2	   1	  
3,5-­‐dihydro-­‐5-­‐methyl	  idene-­‐4H-­‐
imidazol-­‐4-­‐one	   5	   0	   1.0	   1.78	  
521	   4.6	   C26H52NO
7P	  
11	   1-­‐Oleoylglycero	  phosphocholine	   5	   0	   1.0	   1.46	  
84	   9.4	   HO3Cl	   1	   Chlorate	   5	   0	   1.0	   1.41	  
316	   3.8	   C19H24O4	   6	   3,4-­‐Dihydroxy-­‐9,10-­‐secoandrosta-­‐1,3,5(10)-­‐triene-­‐9,17-­‐dione	   5	  
Lipids:	  
Sterol	  
lipids	  
1.0	   1.35	  
246	   8.7	   C9H14N2O6	   2	   5-­‐6-­‐Dihydrouridine	   5	   0	   1.0	   1.34	  
271	   4.0	   C15H29NO3	   1	   Tridecanoylglycine	   7	   0	   1.0	   1.27	  
224	   6.5	   C15H12O2	   7	   (2S)-­‐Flavanone	   7	   0	   1.0	   1.26	  
523	   4.5	   C26H54NO7P	   9	  
[PC	  (18:0)]	  1-­‐octadecano	  yl-­‐sn-­‐
glycero-­‐3-­‐phosphocholine	   5	   Lipids:	  Gly.	   1.0	   1.24	  
151	   7.3	   C6H9N5	   1	   N3-­‐Metyladenine	   5	   0	   1.0	   1.19	  
101	   8.0	   C4H7NO2	   5	   Diacetylmonoxime	   7	   0	   1.0	   1.19	  
195	   10.4	   C6H13NO4S	   1	   MES	   7	   M.C.	   1.0	   1.19	  
184	   4.2	   C10H16O3	   9	   4,5-­‐dihydro-­‐5,5-­‐dimethyl	  -­‐4-­‐(3-­‐oxobutyl)furan-­‐2(3H)-­‐one	   5	   0	   1.0	   0.94	  
166	   9.6	   C8H6O4	   7	   Phthalate	   9	   Xenobiotic	  	   1.0	   0.89	  
262	   4.0	   C16H22O3	   2	   3''-­‐hydroxy-­‐geranylhydroquinone	   5	   0	   1.0	   0.84	  
238	   4.5	   C16H14O2	   1	   [Fv	  Methox]	  4'-­‐Methoxychalcone	   5	   Lipids:	  Polyketide	   1.0	   0.81	  
146	   18.4	   C6H14N2O2	   8	   L-­‐Lysine	   10	   A.	  A.	   1.0	   0.80	  
238	   3.8	   C15H26O2	   9	   [FA	  (15:0)]	  3-­‐pentadecynoic	  acid	   5	   Lipids:	  F.	  A.	   1.0	   0.66	  
248	   3.8	   C15H20O3	   20	   Tomentosin	   5	   0	   1.0	   0.63	  
133	   7.2	   C4H7NO2S	   1	   L-­‐thiazolidine-­‐4-­‐carboxylate	   5	   0	   1.0	   0.39	  
103	   10.7	   C4H9NO2	   14	   N,N-­‐Dimethylglycine	   8	   A.	  A.	   1.0	   0.34	  
Spent medium was collected from confluent neurosphere-derived rat astrocyte monolayers, plated on PLL-
coated glass coverslips, into a mixture of chloroform/methanol/water at 9 DIV. The samples were sent to 
Glasgow University Metabolomics Facility for the analysis using a Q-Exactive Hybrid Quadrupole-Orbitrap 
mass spectrometer. Using a Microsoft Excel interface named IDEOM, R statistical packages XCMS and 
Mzmatch were run to detect peaks, combine data and annotate related peaks. The fold changes (FCs) 
between the signal intensities of secreted metabolites from untreated PLL-astrocytes (PLL Con) and CNTF-
treated PLL-astrocytes (PLL CNTF) were calculated and unpaired t-test was used to detect the significance 
between these FCs in IDEOM. Presented in bold are the statistically significant (p≤0.05) increased 
(highlighted in red) and reduced (highlighted in blue) fold changes of the intensities of secreted metabolites 
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from “PLL CNTF” astrocytes. The putative metabolites highlighted in yellow (phthalate and l-lysine) were 
matched within 3 ppm of the mass and 5% of the retention time of an authentic standard, run prior to every 
batch of samples. Confidence scores of 8 or lower are identifications based on accurate mass but predicted 
retention time. The isomers column shows the number of different compounds that have identical chemical 
formulas, but different structures. Mass is the accurate monoisotropic mass and RT is the chromatographic 
retention time (RT) of the compound. Masses are highlighted according to the polarity mode of detection (red, 
blue, and white for positive, negative, and both types of ionisation, respectively). A.A.: amino acid; CNTF: 
ciliary neurotrophic factor; DIV: day in vitro; F.A.: fatty acyls; Gly.: glycerophospholipids; M.C.: medium 
component; PLL: poly-L-lysine; ppm: parts per million. 
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Table 6. 8 Putative metabolites that were produced at different levels upon CNTF treatment 
in neurosphere-derived rat astrocytes on TnC. 
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165	   9.5	   C9H11NO2	   7	   D-­‐Phenylalanine	   8	   A.	  A.	   1.00	   2.35	  
159	   10.1	   C8H17NO2	   4	   DL-­‐2-­‐Aminooctanoicacid	   5	   0	   1.00	   0.87	  
122	   7.3	   C6H6N2O	   4	   Picolinamide	   7	   0	   1.00	   0.84	  
101	   8.0	   C4H7NO2	   5	   Diacetylmonoxime	   7	   0	   1.00	   0.82	  
300	   3.8	   C20H28O2	   25	   [PR]	  Tretinoin/All-­‐Trans	  Retinoic	  Acid	   5	  
Lipids:	  
Prenols	   1.00	   0.82	  
131	   11.1	   C4H9N3O2	   2	   Creatine	   8	   A.	  A.	   1.00	   0.82	  
314	   3.6	   C18H34O4	   12	  
[FA	  hydroxy(18:1)]	  9,10-­‐
dihydroxy-­‐12Z-­‐octadecenoic	  
acid	  
5	   Lipids:	  F.	  A.	   1.00	   0.81	  
106	   7.3	   C4H10O3	   1	   Diethylene	  glycol	   5	   0	   1.00	   0.78	  
226	   7.2	   C12H22N2O2	   1	   1,8-­‐Diazacyclotetradecane-­‐2,9-­‐dione	   5	   0	   1.00	   0.78	  
133	   10.4	   C5H11NO3	   4	   1-­‐deoxyxylonojirimycin	   7	   0	   1.00	   0.77	  
176	   4.8	   C8H16O4	   2	   [FA	  hydroxy(8:0)]	  6,8-­‐dihydroxy-­‐octanoic	  acid	   7	   Lipids:	  F.	  A.	   1.00	   0.77	  
363	   4.0	   C19H29N3O4	   1	   Phe-­‐Val-­‐Val	   5	   Peptide	  tri	   1.00	   0.77	  
158	   8.3	   C6H10N2O3	   2	   4-­‐Methylene-­‐L-­‐glutamine	   8	   Carb.	   1.00	   0.73	  
191	   8.1	   C7H13NO3S	   1	   N-­‐Acetylmethionine	   7	   0	   1.00	   0.68	  
152	   9.7	   C9H12O2	   4	   3-­‐Isopropylcatechol	   7	   0	   1.00	   0.66	  
175	   7.3	   C10H9NO2	   12	   Indole-­‐3-­‐acetate	   6	   A.	  A.	   1.00	   0.66	  
302	   11.7	   C11H22N6O4	   2	   Ala-­‐Gly-­‐Arg	   5	   Peptide	  tri	   1.00	   0.66	  
216	   10.1	   C10H20N2O3	   1	   Val-­‐Val	   5	   Peptide	  di	   1.00	   0.65	  
247	   8.5	   C9H17N3O5	   3	   Ala-­‐Ala-­‐Ser	   7	   Peptide	  tri	   1.00	   0.64	  
146	   10.6	   C4H6N2O2S	   1	   ZAPA	   5	   0	   1.00	   0.64	  
140	   7.7	   C6H8N2O2	   7	   Methylimidazoleacetic	  acid	   8	   A.	  A.	   1.00	   0.64	  
116	   4.7	   C6H12O2	   16	   Hexanoic	  acid	   5	   Lipids:	  F.	  A.	   1.00	   0.55	  
133	   7.2	   C4H7NO2S	   1	   L-­‐thiazolidine-­‐4-­‐carboxylate	   5	   0	   1.00	   0.46	  
Confluent neurosphere-derived rat astrocyte monolayers plated on TnC-coated glass coverslips were washed 
with PBS and lysed with a mixture of chloroform/methanol/water at 9 DIV. The lysates were centrifuged and 
the supernatant was sent to Glasgow University Metabolomics Facility for the analysis using a Q-Exactive 
Hybrid Quadrupole-Orbitrap mass spectrometer. Using a Microsoft Excel interface named IDEOM, R statistical 
packages XCMS and Mzmatch were run to detect peaks, combine data and annotate related peaks. The fold 
changes (FCs) between the signal intensities of the metabolites detected in untreated TnC -astrocytes (TnC 
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Con) and CNTF-treated TnC -astrocytes (TnC CNTF) were calculated and unpaired t-test was used to detect 
the significance between these FCs in IDEOM. Presented in bold are the statistically significant (p≤0.05) 
increased (highlighted in red) and reduced (highlighted in blue) fold changes in “PLL CNTF” astrocytes. 
Confidence scores of 8 or lower are identifications based on accurate mass but predicted retention time. The 
isomers column shows the number of different compounds that have identical chemical formulas, but different 
structures. Mass is the accurate monoisotropic mass and RT is the chromatographic retention time (RT) of the 
compound. Masses are highlighted according to the polarity mode of detection (red, blue, and white for 
positive, negative, and both types of ionisation, respectively).  A.A.: amino acids; Carb.: carbohydrate; CNTF: 
ciliary neurotrophic factor; DIV: day in vitro; F.A.: fatty acyls; ppm: parts per million; TnC: tenascin C. 
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Table 6. 9 Putative metabolites that were secreted at different levels upon CNTF treatment 
by the neurosphere-derived rat astrocytes on TnC. 
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299	   5.3	   C18H37NO2	   7	   [SP]	  3-­‐dehydrosphinganine	   5	   Lipids:	  Sph.	  	   1.00	   4.79	  
103	   10.7	   C4H9NO2	   14	   N,N-­‐Dimethylglycine	   8	   A.	  A.	   1.00	   2.57	  
146	   4.9	   C6H10O4	   16	   [FA	  oxo,hydroxy(6:0)]	  2-­‐oxo-­‐4-­‐hydroxy-­‐hexanoic	  acid	   5	  
Lipids:	  	  
F.	  A.	  	   1.00	   1.42	  
141	   7.3	   C7H11NO2	   3	   L-­‐Hypoglycin	   7	   0	   1.00	   1.34	  
192	   4.3	   C11H12O3	   6	   Carpacin	   5	   0	   1.00	   1.23	  
411	   3.3	   C23H41NO5	   1	   3-­‐Hydroxyhexadecadienoylcarnitine	   5	   0	   1.00	   1.20	  
346	   3.6	   C20H26O5	   8	   Microhelenin	  C	   5	   0	   1.00	   0.85	  
238	   4.5	   C16H14O2	   1	   [Fv	  Methox]	  4'-­‐Methoxychalcone	   5	  
Lipids:	  
Polyketi
des	  
1.00	   0.82	  
171	   7.7	   C7H9NO4	   3	   2,3,4,5-­‐Tetrahydrodipicolinate	   8	   A.	  A.	   1.00	   0.75	  
188	   7.8	   C7H12N2O4	   2	   L-­‐glycyl-­‐L-­‐hydroxyproline	   7	   Peptide	   1.00	   0.71	  
191	   10.7	   C6H9NO4S	   1	   a	  Cysteine	  adduct	   7	   M.	  C.	   1.00	   0.70	  
283	   8.9	   C11H17N5O4	   2	   Ala-­‐Gly-­‐His	   5	   Peptide	  tri	   1.00	   0.61	  
240	   3.8	   C15H28O2	   5	   [FA	  dimethyl(13:0)]	  2,5-­‐dimethyl-­‐2E-­‐tridecenoic	  acid	   7	  
Lipids:	  	  
F.	  A.	  	   1.00	   0.59	  
189	   7.6	   C6H11N3O4	   3	   Asn-­‐Gly	   5	   Peptide	  di	   1.00	   0.53	  
Spent medium was collected from confluent neurosphere-derived rat astrocyte monolayers, which were plated 
on PLL-coated glass coverslips, into a mixture of chloroform/methanol/water at 9 DIV. The samples were sent 
to Glasgow University Metabolomics Facility for the analysis using a Q-Exactive Hybrid Quadrupole-Orbitrap 
mass spectrometer. Using a Microsoft Excel interface named IDEOM, R statistical packages XCMS and 
Mzmatch were run to detect peaks, combine data and annotate related peaks. The fold changes (FCs) 
between the signal intensities of the secreted metabolites from untreated TnC-astrocytes (TnC Con) and 
CNTF-treated TnC -astrocytes (TnC CNTF) were calculated and unpaired t-test was used to detect the 
significance between these FCs in IDEOM. Presented in bold are the statistically significant (p≤0.05) 
increased (highlighted in red) and reduced (highlighted in blue) fold changes of the intensities of secreted 
metabolites from “TnC CNTF” astrocytes. Confidence scores of 8 or lower are identifications based on 
accurate mass but predicted retention time. The isomers column shows the number of different compounds 
that have identical chemical formulas, but different structures. Mass is the accurate monoisotropic mass and 
RT is the chromatographic retention time (RT) of the compound. Masses are highlighted according to the 
polarity mode of detection (red, blue, and white for positive, negative, and both types of ionisation, 
respectively). A.A.: amino acid; CNTF: ciliary neurotrophic factor; DIV: day in vitro; F.A.: fatty acyls; M.C.: 
medium component; ppm: parts per million; Sph.: sphingolipids; TnC: tenascin C.  
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The putative metabolites that were produced in or secreted by PLL- and TnC-astrocytes 
at different levels upon CNTF treatment (Tables 6.6-6.9) appeared to be mostly 
involved in lipid metabolisms. Among the subtypes of lipid metabolism were the 
metabolisms of fatty acyls, glycerophospholipids, sphingolipids, sterol lipids, 
polyketides and prenols. Fatty acyl metabolism was the only common one between all 
four comparisons (Tables 6.6-6.9). The other groups of metabolites appeared to be 
involved in the metabolisms of amino acids, nucleotides, peptides, cofactors and 
vitamins, and xenobiotics. N,N-Dimethylglycine was the only common putative 
metabolite that was found to be secreted at significantly different levels upon CNTF 
treatment by both PLL- and TnC-astrocytes (Tables 6.7, 6.9). On the other hand, CNTF 
treatment lowered the levels of	   L-thiazolidine-4-carboxylate in both PLL- and TnC- 
astrocyte cells (Tables 6.6, 6.8). L-thiazolidine-4-carboxylate and (2S)-flavanone were 
detected at lower levels in the presence of exogenous CNTF in both PLL-astrocyte cells 
and spent medium (Tables 6.6, 6.7); whereas, such a common metabolite was not seen 
between the cells and spent medium of TnC-astrocytes.  
All the putative metabolites that were presented in the IDEOM file after the mass 
spectrometry analysis were also used to generate volcano plots to narrow down the list 
to those presenting the highest fold changes (≥2) and significance values (≤0.05) when 
CNTF-treatment and control conditions were compared (Fig 6.8). According to these 
plots, CNTF treatment seemed to increase the production of the dipeptide ser-ser 
(serinyl-serine) and the amino acid D-phenylalanine (DPh) in PLL- and TnC-astrocytes, 
respectively (Fig 6.8 A&B). On the other hand, CNTF treatment reduced the levels of N-
(3-Oxooctanoyl) homoserine lactone (N3OHL) and L-thiazolidine-4-carboxylate (LT4C) 
in PLL- and TnC-astrocytes, respectively (Fig 6.8 A&B). In addition, L4TC levels were 
decreased upon CNTF treatment also in the PLL-astrocyte medium. Conversely, the 
level of the amino acid derivative N,N-Dimethylglycine (NNDG) was reduced in the 
spent medium of PLL-astrocytes even though it was increased in that of TnC-astrocytes 
(Fig 6.8 C&D). Therefore, CNTF treatment could affect the levels of the same 
metabolites in the opposite way based on the substrate the rat astrocytes were plated 
on. Lastly, the sphingolipid 3-dehydrosphinganine (3DS) levels were increased upon 
CNTF treatment in TnC-astrocyte medium (Fig 6.8D). These changes in the signal 
intensities could be seen more clearly in the column bars in Fig 6.9, where the levels of 
the metabolites could also be compared between the cells and the spent cell medium 
(dark and light gray bars, respectively). The majority of serinyl-serine produced by 
astrocyte cultures appeared to be secreted into the culture medium (Fig 6.9 B); while, 
the opposite was seen for NNDG and 3DS (Fig 6.9 E&F).    
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Figure 6. 8 Volcano plots presented several putative metabolites that could be important for 
CNTF signaling in rat astrocyte cultures.                        
Metabolite samples extracted from untreated and CNTF-treated neurosphere-derived rat astrocyte cells and 
spent culture medium were analysed using Q-Exactive Hybrid Quadrupole-Orbitrap mass spectrometer. The 
signal intensities for each metabolite was measured over 1400 seconds of a period of retention time. The 
results were presented in an IDEOM file, where volcano plots were generated. Presented in the y-axis are the 
statistical significance values (unpaired t-test) and in the x-axis are the fold changes (FCs) between the 
average values of the signal intensities of three biological repeats for different culture conditions. The points 
with a fold change of ≥ 2 and with a P value of ≤ 0.05 were labelled. The results are presented as compared to 
different controls. Each control was compared to two other conditions within each volcano plot (shown boxed 
on top left corners). A) N3OHL was decreased and Ser-Ser was increased upon CNTF treatment in astrocyte 
cells, plated on PLL-coated coverslips (PLL-As). B) L4TC was decreased and DPh was increased upon CNTF 
treatment in TnC-As. C) NNDG and LT4C were both decreased after CNTF treatment in the spent medium 
from PLL-As; whereas NNDG and 3DS were both increased with the addition of CNTF in the spent medium of 
TnC-As. The metabolites that showed the highest fold changes when their levels were compared between 
untreated PLL- and TnC- cultures are also shown in the graphs in green (A) and blue (B-D). 2,7AANAA: 2,7-
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Anhydro-alpha-N-acetylneuraminic acid; 3DS: [SP] 3-dehydrosphinganine; CNTF: ciliary neurotrophic factor; 
DPh: D-Phenylalanine; LT4C: L-thiazolidine-4-carboxylate; N3OHL: N-(3-Oxooctanoyl)homoserine lactone; 
NEG: N-Ethylglycocyamine; NNDG: N,N-Dimethylglycine; OPRC: [FA] O-Palmitoyl-R-carnitine; PLL: poly-L-
lysine; SC: stearoylcarnitine; T2DDC: trans-2-dodecenoylcarnitine; TDC: tetradecanoylcarnitine; TnC: tenascin 
C.   
 
The volcano plots also showed the metabolites with the highest fold changes when their 
levels were compared between the untreated PLL- and TnC-cultures (Fig 6.8). The level 
of trans-2-dodecenoylcarnitine (T2DDC) was increased and the levels of N-3-
oxooctanoyl-homoserine lactone (N3OHL), o-palmitoyl-r-carnitine (OPRC), 
stearoylcarnitine (SC), and tetradecanoylcarnitine (TDC) were decreased in untreated 
TnC-astrocytes compared to their levels in PLL-astrocytes, which can also be seen in 
Table 6.10. The secreted metabolites that were detected in TnC-culture spent medium 
in higher levels were 2,7-Anhydro-alpha-N-acetylneuraminic acid (2,7AANAA) and N-
ethylglycocyamine (NEG); while, the level of N,N-dimethylglycine (NNDG) was higher 
in PLL-culture spent medium (Fig 6.8, Table 6.11). 
In conclusion, the mass spectrometry analysis identified a list of putative metabolites 
that could be involved in CNTF-signaling in neurosphere-derived rat astrocyte cultures, 
plated on PLL- or TnC-coated coverslips. Those that showed the highest signal 
intensities upon CNTF treatment compared to control levels were serinyl-serine in PLL-
astrocyte cultures and 3-dehydrosphinganine, D-phenylalanine, N,N-Dimethylglycine 
(NNDG) in TnC-astrocyte cultures; whereas, the levels of NNDG and N-(3-Oxooctanoyl) 
homoserine lactone decreased after conditioning with CNTF in PLL-As cultures and the 
level of L-thiazolidine-4-carboxylate was reduced in both types of astrocyte cultures.  
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Figure 6. 9 Signal intensities of the putative metabolites that were previously identified to be 
possibly involved in CNTF-signaling using volcano plots.                          
Metabolite samples extracted from untreated and CNTF-treated neurosphere-derived rat astrocyte cells and 
spent culture medium were analysed using Q-Exactive Hybrid Quadrupole-Orbitrap mass spectrometer. The 
signal intensities for each metabolite was measured over 1400 seconds of a period of retention time. The 
results were presented in an IDEOM file, where volcano plots were generated showing P value of significance 
test (unpaired t-test) vs fold change between the average values of the signal intensities of three biological 
repeats. The points with a fold change of ≥ 2 and with a P value of ≤ 0.05 were labelled. The signal intensities 
of putative metabolites (PMs) that were found to be produced at different levels upon CNTF treatment are 
shown in arbitrary units. The PMs that showed different levels upon CNTF treatment in the cells of astrocyte 
cultures on PLL (A&B) and on TnC (C&D) and in the spent medium of astrocyte cultures on PLL (C&E) and 
on TnC (E&F) are presented above. * P ≤0.05, ** P ≤0.01, *** P ≤0.001. CNTF: ciliary neurotrophic factor; 
PLL: poly-L-lysine; TnC: tenascin C. 
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Table 6. 10 Putative metabolites that were produced at different levels in neurosphere-
derived rat astrocytes on TnC compared to those on PLL. 
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341	   3.9	   C19H35NO4	   1	  
trans-­‐2-­‐
Dodecenoylcarnitine	   5	   0	   1.0	   2.1	  
338	   3.9	   C18H26O6	   2	   Pinolidoxin	   5	   0	   1.0	   1.8	  
226	   4.0	   C14H26O2	   12	   (9Z)-­‐Tetradecenoic	  acid	   5	  
Lipids:	  
F.A.	   1.0	   1.7	  
155	   10.0	   C3H10NO4P	   3	  
N-­‐Methylethanolamine	  
phosphate	   8	   Lipid	  	   1.0	   1.4	  
159	   7.3	   C7H13NO3	   10	  
N-­‐&alpha;-­‐acetyl-­‐DL-­‐
norvaline	   5	   0	   1.0	   1.1	  
332	  
3.6	   C20H28O4	   20	  
[FA	  oxo,hydroxy(4:0)]	  9-­‐
oxo-­‐15S-­‐hydroxy	  5Z,	  	  	  
10Z,13E,17Z-­‐
prostatetraenoic	  acid	  
5	   Lipids:	  	  	  	  F.	  A.	  	   1.0	   1.1	  
97	   7.4	   C4H7N3	   1	   Deoxycytosine	   5	   0	   1.0	   0.9	  
182	   7.3	   C10H14O3	   8	   5-­‐Oxo-­‐1,2-­‐campholide	   5	   0	   1.0	   0.9	  
310	   4.1	   C20H22O3	   4	   [Fv]	  Dihydrocordoin	   5	  
Lipids:	  
Polyke.	   1.0	   0.9	  
509	  
4.6	   C25H52NO7P	   8	   LysoPC(17:0)	   5	   Lipids:	  Gly.	   1.0	   0.9	  
240	  
3.8	   C15H28O2	   5	  
[FA	  dimethyl(13:0)]	  2,5-­‐
dimethyl-­‐2E-­‐tridecenoic	  
acid	  
7	   Lipids:	  F.A.	   1.0	   0.8	  
282	  
3.5	   C17H30O3	   4	  
[FA	  hydroxy(17:0)]	  12S-­‐
hydroxy-­‐16-­‐heptadecynoic	  
acid	  
5	   Lipids:	  F.A.	   1.0	   0.8	  
292	  
4.0	   C19H32O2	   17	  
[FA	  hydroxy(18:1)]	  8-­‐
hydroxy-­‐11E-­‐octadecen-­‐9-­‐
ynoic	  acid	  
5	   Lipids:	  F.A.	   1.0	   0.8	  
315	   3.7	   C17H33NO4	   2	  
[FA	  (10:0)]	  O-­‐decanoyl-­‐R-­‐
carnitine	   5	  
Lipids:	  
F.A.	   1.0	   0.8	  
193	   8.2	   C6H11NO4S	   1	  
&gamma;-­‐thiomethyl	  
glutamate	   5	   0	   1.0	   0.8	  
192	   4.3	   C11H12O3	   6	   Carpacin	   5	   0	   1.0	   0.7	  
146	  
10.0	   C6H10O4	   16	   (R)-­‐3-­‐Hydroxy-­‐3-­‐methyl-­‐2-­‐oxopentanoate	   8	   A.	  A.	   1.0	   0.5	  
427	   4.4	   C25H49NO4	   1	   Stearoylcarnitine	   7	   0	   1.0	   0.5	  
241	   4.5	   C12H19NO4	   2	  
N-­‐(3-­‐Oxooctanoyl)	  
homoserine	  lactone	   5	  
Lipids:	  
F.A.	   1.0	   0.5	  
399	   4.5	   C23H45NO4	   1	  
[FA]	  O-­‐Palmitoyl-­‐R-­‐
carnitine	   8	  
Lipids:	  
F.A.	   1.0	   0.5	  
371	   4.7	   C21H41NO4	   1	   Tetradecanoylcarnitine	   5	   0	   1.0	   0.4	  
Confluent neurosphere-derived rat astrocyte monolayers, which were plated on PLL- or TnC-coated glass 
coverslips were washed with PBS and lysed with a mixture of chloroform/methanol/ water at 9 DIV. The 
lysates were centrifuged and the supernatant was sent to Glasgow University Metabolomics Facility for the 
analysis using a Q-Exactive Hybrid Quadrupole-Orbitrap mass spectrometer. Using a Microsoft Excel interface 
named IDEOM, R statistical packages XCMS and Mzmatch were run to detect peaks, combine data and 
annotate related peaks. The fold changes (FCs) between the signal intensities of the metabolites detected in 
PLL-astrocytes (PLL Con) and TnC-astrocytes (TnC Con) were calculated and unpaired t-test was used to 
detect the significance between these FCs in IDEOM. Presented in bold are the statistically significant 
(p≤0.05) increased (highlighted in red) and reduced (highlighted in blue) fold changes in “TnC Con” astrocytes. 
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Confidence scores of 8 or lower are identifications based on accurate mass but predicted retention time. The 
isomers column shows the number of different compounds that have identical chemical formulas, but different 
structures. Mass is the accurate monoisotropic mass and RT is the chromatographic retention time (RT) of the 
compound.  Masses are highlighted according to the polarity mode of detection (red, blue, and white for 
positive, negative, and both types of ionisation, respectively). A.A.: amino acid metabolism; Carb.: 
carbohydrate; DIV: day in vitro; F.A.: fatty acyls; Gly.: glycerophospholipids; PLL: poly-L-lysine; ppm: parts per 
million; Polyke.: polyketides; TnC: tenascin C.  
 
Table 6. 11 Putative metabolites that were secreted at different levels by the neurosphere-
derived rat astrocytes on TnC compared to those on PLL. 
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207	   7.3	   C8H17NO5	   3	   N-­‐Ethylglycocyamine	   5	   0	   1.0	   7.5	  
291	   9.6	   C11H17NO8	   3	  
2,7-­‐Anhydro-­‐alpha-­‐N-­‐
acetylneuraminic	  acid	   7	   0	   1.0	   3.1	  
278	  
3.8	   C17H26O3	   4	  
[FA	  hydroxy(17:2)]	  7-­‐hydroxy-­‐
10E,16-­‐heptadecadien-­‐8-­‐ynoic	  
acid	  
5	   Lipids:	  F.A.	   1.0	   1.6	  
82	   9.4	   H3O3P	   1	   Phosphonate	   5	   0	   1.0	   1.6	  
116	   7.9	   C4H4O4	   3	   Maleic	  acid	   10	   Carb.	   1.0	   1.4	  
268	   3.9	   C26H32O12	   1	  
[Fv	  Hydroxy,methoxy(5:0/9:1)]	  
5-­‐Hydroxy-­‐6,7,3',4',5'-­‐
pentamethoxyflavanone	  5-­‐O-­‐
rhamnoside	  
7	  
Lipids:	  
Polyket
ides	  
1.0	   1.3	  
308	   3.8	   C20H36O2	   12	   Icosadienoic	  acid	   6	   Lipid	  	   1.0	   1.2	  
154	  
4.2	   C9H14O2	   11	   [FA	  (9:2)]	  2,6-­‐nonadienoic	  acid	   5	   Lipids:	  F.A.	   1.0	   1.1	  
132	   9.8	   C3H8N4O2	   1	   Methylenediurea	   5	   0	   1.0	   0.8	  
136	   7.2	   C7H8N2O	   3	   Pralidoxime	   5	   0	   1.0	   0.6	  
103	  
10.7	   C4H9NO2	   14	   N,N-­‐Dimethylglycine	   8	   A.	  A.	   1.0	   0.4	  
Spent medium was collected from confluent neurosphere-derived rat astrocyte monolayers, which were plated 
on PLL- or TnC-coated glass coverslips, into a mixture of chloroform/methanol/water at 9 DIV. The samples 
were centrifuged and the supernatant was sent to Glasgow University Metabolomics Facility for the analysis 
using a Q-Exactive Hybrid Quadrupole-Orbitrap mass spectrometer. Using a Microsoft Excel interface named 
IDEOM, R statistical packages XCMS and Mzmatch were run to detect peaks, combine data and annotate 
related peaks. The fold changes (FCs) between the signal intensities of secreted metabolites from PLL-
astrocytes (mPLL Con) and TnC-astrocytes (mTnC Con) were calculated and unpaired t-test was used to 
detect the significance between these FCs in IDEOM. Presented in bold are the statistically significant 
(p≤0.05) increased (highlighted in red) and reduced (highlighted in blue) fold changes of the intensities of 
secreted metabolites from “TnC Con” astrocytes. Confidence scores of 8 or lower are identifications based on 
accurate mass but predicted retention time. The isomers column shows the number of different compounds 
that have identical chemical formulas, but different structures. Mass is the accurate monoisotropic mass and 
RT is the chromatographic retention time (RT) of the compound.  Masses are highlighted according to the 
polarity mode of detection (red and blue for positive and negative type of ionisation, respectively). A.A.: amino 
acid metabolism; Carb.: carbohydrate metabolism; DIV: day in vitro; F.A.: fatty acyls; PLL: poly-L-lysine; ppm: 
parts per million; Polyke.: polyketides; TnC: tenascin C.  
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6.4 General conclusions and discussion 
The cytokine CNTF has previously been reported to play a stimulatory role in 
myelination as explained above. Even though exogenous recombinant rat CNTF has been 
demonstrated to increase the myelination levels in embryonic rat spinal cord 
myelinating cultures, plated on neurosphere-derived astrocytes on PLL-coated 
coverslips (Nash et al., 2011b), my experiments did not show any significant effect of 
CNTF treatment on myelination levels in these cultures. CNTF titrations in PLL-
myelinating cultures using astrocyte monolayers at different seeding densities did not 
present a significantly different effect, either. Therefore, it is likely that the difference 
observed between the two studies is due to the methods followed to quantify 
myelination levels. In addition, because the fold changes of increased myelination levels 
were not very high in the other study, either (Nash et al., 2011b), it is also possible that 
biological variation observed in these rat spinal cord myelinating cultures requires a 
much higher number of samples to be analysed and failing that makes it more difficult 
to observe a change in myelination levels upon CNTF treatment. However, my results 
also showed that pre-treatment of astrocyte cultures with CNTF before using them for 
PLL-myelinating cultures did increase the myelination levels, which suggests the 
importance of the activation of astrocytes by CNTF to be able to increase their ability 
to support myelination. Despite the fact that CNTF treatment did not change the GFAP 
or nestin fluorescence signal intensities of the PLL- or TnC-astrocytes in my 
experiments, the positive role of astrocytes on myelination upon increased CNTF levels 
is in agreement with the other examples in the literature (Albrecht et al., 2003; 
Reviewed in Liberto et al., 2004; Ye et al., 2004; Albrecht et al., 2007; Escartin et al., 
2007; Bechstein et al., 2012; Modi et al., 2013).  
Treatments of embryonic mouse spinal cord PLL-myelinating cultures with CNTF from 12 
DIV onwards did not affect myelination levels significantly. Considering the fact that 
CNTF could be playing a role in myelination as explained above, transgenic mice were 
also used to demonstrate the effects of the inhibition of the signaling of CNTF together 
with the other IL-6 family cytokines on myelination. GFAP-Cre+/-gp130fl/fl mice 
contained the gene for Cre recombinase with an expression under the control of Gfap 
promoter, allowing the conditional knockout of Gp130 gene in their astrocytes 
(Drogemuller et al., 2008). Despite the previous findings showing increased levels of 
demyelination accompanied by more severe disease course in GFAP-Cre+/-gp130fl/fl mice 
with EAE (Haroon et al., 2011), no significant difference was observed between the 
myelination levels of the spinal cord PLL-myelinating cultures, generated using Cre 
negative or Cre positive mice. In addition, the treatment with neither recombinant 
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CNTF nor the neutralising antibody anti-CNTF showed an effect in these Cre+ or Cre- 
myelinating cultures. This could be due to the differences between in vitro and in vivo 
systems since primary cultures do not always parallel the results observed in vivo 
(Reviewed in Reichardt and Gunzer, 2006; in Yin and Chen, 2008; in LeRoux et al., 
2009). Alternatively, the stimulatory effect of CNTF signaling on myelination could be 
more prominent in the presence of demyelination as seen in EAE (Haroon et al., 2011) 
compared to that in normal conditions. It would be interesting to observe how Cre+ 
myelinating cultures would behave compared to Cre-myelinating cultures in an in vitro 
model of CNS pathology. One example could be the model developed by Boomkamp et 
al., (2012) that mimics spinal cord injury in spinal cord myelinating cultures, where a 
cut is made across using a razor blade manually to generate the lesion, around which 
myelination levels stay lower than the controls till the end of the cultural period. 
Embryonic rat spinal cord cultures were also used to identify potential transcription 
factors (TFs) that could be involved in CNTF signaling mechanisms. The data obtained 
from the microarray gene expression profiling analysis (Array 2, Chapter 3) were 
analysed online using a program that detects the over-representative conserved TF 
binding sites (TFBSs). The analysis of the differentially regulated transcripts in the 
presence of exogenous CNTF in PLL-myelinating cultures did not reveal any significant 
results possibly due to the small number of transcripts available. Significant results 
were seen only for the list of down-regulated transcripts 4 hr after CNTF treatment in 
TnC-myelinating cultures. The analysis was run for each length of regulatory DNA region 
separately and the results obtained from all of the runs were put together to present a 
general picture. The putative TFs that could be responsible for the repression of certain 
genes upon CNTF treatment in these cultures were identified to be CTCF, E2F1, INSM1, 
KLF4, MZF1_1-4, RREB1, SP1, SRF, STAT3, TCFCP2L1, TLX1::NFIC.  
Among these TFs, SRF and MZF1 were also suggested to play a role in non-CNTF-related 
mechanisms such as gene expression regulations between cultures on different 
substrates (PLL vs TnC) and/or regulations over time. SRF could be a repressor of the 
genes that were down-regulated over time in PLL-myelinating cultures (Table 6.4); 
however, it could be a transcriptional activator of the genes that were up-regulated in 
PLL-myelinating cultures compared to TnC-myelinating cultures or a transcriptional 
repressor of the genes that were down-regulated in TnC- cultures compared to PLL-
cultures (Table 6.5). Similarly, MZF1 was detected as a putative transcriptional factor 
when the transcripts that were up-regulated in PLL-myelinating cultures compared to 
TnC-myelinating cultures were analysed (Table 6.5) 
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SP1 (specificity protein 1) was the common TF detected for all the sequence lengths 
analysed. Some genes have previously been shown to posses separate binding sites for 
SP1 and CTCF, and others for SP1 and MZF1 (Yang et al., 1999; Yin et al., 1999; Hikichi 
et al., 2003; Lange-dohna et al., 2003). Some of these TFs, SP1 and KLF4, have also 
been reported to be associated with CNTF-signaling. For example, SP1 mRNA and 
protein levels have been shown to decrease in primary rat astrocyte cultures, where the 
reduction of CNTF levels was induced by an exogenous reagent (Bodega et al., 2007). In 
addition, SP1 has been shown to play a role in the expressional regulations that are 
induced by GP130 family cytokines other than CNTF such as leptin and oncostatin M 
(Botelho et al., 1998; Lin et al., 2012). Another such cytokine, LIF, has also been shown 
to up-regulate Klf4 expression in neural precursor cultures (Buono et al., 2012) and to 
contain DNA-binding motifs for SP1 in the regulatory regions of its gene (Chambers et 
al., 1997). These observations are in accordance with our findings and therefore they 
strengthen the possibility of these TFs being involved in CNTF-signaling in spinal cord 
myelinating cultures. 
As another attempt to gain insights into the CNTF-signaling, samples from the cells and 
the spent medium of neurosphere-derived PLL- and TnC-astrocyte cultures were 
analysed by lipid chromatography tandem mass spectrometry (LC-MS/MS). The analysis 
suggested the following putative metabolites to be important for CNTF-signaling in 
astrocyte cultures: serinyl-serine, 3-dehydrosphinganine (3DS), D-phenylalanine (DPh), 
N,N-Dimethylglycine (NNDG), N-(3-Oxooctanoyl) homoserine lactone (N3OHL), L-
thiazolidine-4-carboxylate (LT4C). The direction of change upon CNTF treatment for 
each of these metabolites in the astrocyte cultures is presented in Table 6.10.  
Interestingly, CNTF appears to regulate NNDG in opposite directions in astrocyte 
cultures on PLL or TnC. This may not be surprising considering that NNDG has been 
associated with both positive and negative roles in the CNS. A synthetic derivative of 
NNDG has reduced neurologic dysfunction and brain edema in mice suffering from 
glioblastoma (Jones-Bolin et al., 2006) and therapeutic effects of NNDG in combined 
treatments of seizure disorders have also been reported (Jones-Bolin et al., 2006). 
Conversely, a case report has presented abnormal peripheral nervous system 
myelination in addition to abnormally slow myelination and atrophy in white matter of 
an infant male with a mutation in a hydrolase gene, which also has resulted in elevated 
levels of NNDG in plasma (Baric et al., 2004). Therefore, it is possible that the different 
signaling pathways regulated by CNTF in PLL- and TnC-astrocytes (as also suggested by 
Array 2, Chapter 3) change the levels of production/hydrolysis of NNDG in opposite 
ways. 
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Table 6. 12 The putative metabolites that showed the highest fold changes upon CNTF 
treatment in neurosphere-derived rat astrocyte cultures. 
Changes	  in	  the	  levels	  of	  the	  metabolites	  upon	  CNTF	  treatment	  
in	  PLL-­‐astrocyte	  cultures	   in	  TnC-­‐astrocyte	  cultures	  
In	  cells	   In	  spent	  medium	   In	  cells	   In	  spent	  medium	  
serinyl-serine é	   NNDG	  ê	   DPh	  é	   NNDG	  é	  
N3OHL ê LT4C	  ê	   LT4C	  ê	   3DS	  é	  
3DS: [SP] 3-dehydrosphinganine; CNTF: ciliary neurotrophic factor; DPh: D-Phenylalanine; LT4C: L-
thiazolidine-4-carboxylate; N3OHL: N-(3-Oxooctanoyl)homoserine lactone; NNDG: N,N-Dimethylglycine; PLL: 
poly-L-lysine; TnC: tenascin C.   
 
LT4C was the other common metabolite that was shown to present lower levels upon 
CNTF treatment in both PLL- and TnC-astrocyte cultures. Its levels were reduced in both 
the cells and the spent medium of both types of cultures even though the significance 
was detected for some of them (Fig 6.9, Table 6.10). LT4C is a brain metabolite that 
has been reported to have in vivo antioxidant effects and to improve the immune 
response in aged mice (De la Fuente et al., 1998). LT4C-supplemented diet has also 
presented decrease of the age-dependent oxidative damage in brain and liver 
mitochondria of adult mice followed by improved neurological functions (Navarro et al., 
2007). In addition, it has been demonstrated to be a therapeutic agent for some 
tumours and a scavenging agent for reactive nitrosamines (Deutch et al., 1992). 
Considering these positive effects of LT4C in vivo, it appears that CNTF would be 
generating an environment with increased oxidative stress by decreasing the levels of 
LT4C in the astrocyte cultures. However, over dosage of LT4C has also been observed to 
be neurotoxic, leading to convulsions in children (Garnier et al., 1982; Wlodek et al., 
1993). CNTF might be preventing the accumulation of LT4C and hence the 
neurotoxicity, which could be associated with the neuroprotective roles of CNTF (Barbin 
et al., 1984; Hagg and Varon, 1993; Naumann et al., 2003; Krady et al, 2008). LT4C 
could be a metabolite, via which CNTF regulates the homeostasis of the environment to 
provide less cell toxicity.  
The levels of the metabolites secreted by astrocytes with and without CNTF treatment 
were compared in attempt to identify astrocytic regulators that could contribute to the 
elevated myelination levels in spinal cord myelinating cultures. Even though CNTF was 
suggested to stimulate myelination in both PLL- and TnC-myelinating cultures (Nash et 
al., 2011b), I could show the stimulatory effects only for the PLL-astrocytes that were 
pre-treated before they were used as feeder monolayers for the spinal cord myelinating 
cultures (Fig 6.2). No such effect was observed with TnC-astrocytes. Nevertheless, the 
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secreted metabolites that presented significantly different levels upon CNTF treatment 
in both types of astrocyte cultures (Tables 6.7, 6.9) could be investigated further in 
future studies in an attempt to identify any potential metabolites or metabolic 
pathways involved in previously-shown CNTF roles such as neuroprotection, stimulation 
of the OPC proliferation and maturation, and myelination, as explained above. For 
example, the increase of 3-dehydrosphinganine (3DS) levels after CNTF treatment in 
TnC-astrocyte cultures (Table 6.10) is very interesting since 3DS takes place in the first 
step of the sphingolipid biosynthesis (Mandon et al., 1992), which eventually leads to 
the production of sphingomyelin (Fig 6.10). Because sphingomyelin is particularly found 
in the myelin sheaths (reviewed in O’Brien, 1965; in Jana and Pahan, 2010), the 
increase in the levels of 3DS due to CNTF treatment suggests another association 
between CNTF and stimulation of myelination.  
In summary, recombinant rat CNTF treatment triggered different metabolic changes 
compared to untreated astrocyte monolayers, which were less supportive for 
myelination but were not different in terms of fluorescent expression of GFAP. A list of 
putative transcription factors that were associated with CNTF signaling in TnC-
myelinating cultures was also identified. 
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Figure 6. 10 KEGG map showing the pathways involved in sphingolipid metabolism.  
Samples extracted from neurosphere-derived rat astrocyte cultures, plated on TnC-coated glass coverslips, 
were analysed by means of lipid chromatography tandem mass spectrometry. Q-Exactive Hybrid Quadrupole-
Orbitrap was used for the analysis. The signal intensity (abundance)  was found to be increased upon CNTF 
treatment for the metabolite 3-dehydrosphinganine, which was identified putatively based on accurate m/z but 
a predicted retention time. The isomer 3-dehydrosphinganine and sphingosin, which is another possible 
isomer with the same chemical formula, are both shown in blue in the map above. The map was obtained from 
the web-based software named Pathos (Burgess et al., 2011, http://motif.gla.ac.uk/Pathos/). Sphingomyelin, 
which is a sphingolipid found particularly in the myelin sheaths, is highlighted in a box with pink borders. 
CNTF: ciliary neurotrophic factor; KEGG: Kyoto Encyclopedia of Genes and Genomes; m/z: mass to charge 
ratio; TnC: tenascin C. 
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Differences were observed by means of microarray analysis in terms of gene expression 
between spinal cord myelinating cultures under different conditions; conditions that 
were previously shown by Nash et al. (2011) to induce distinct levels of myelination. 
The candidates selected from those lists of differentially regulated genes (Ccl2, Ccl7, 
and Serpinb2) could not be validated to affect myelination when the myelinating 
cultures were treated with recombinant proteins. Our hypothesis was not supported, in 
that up-regulated genes in cultures that were previously shown to be more supportive 
for myelination did not enhance myelination in myelinating cultures. Therefore, it is 
likely that the differential regulation of these transcripts is not associated with 
myelination but with another difference between these cultures such as astrocyte 
reactivity. Some of the transcripts that were associated with elevated astrocyte 
reactivity in vivo in the presence of LPS-induced neuroinflammation or a mouse model 
of ischemia (Zamanian et al., 2012) were found to be differentially expressed between 
PLL- and TnC-myelinating cultures, and between untreated and CNTF-treated cultures 
in a way that suggested that TnC-astrocytes might not be as “quiescent” as previously 
suggested (Holley et al., 2005). TnC-astrocytes were categorised as “quiescent” based 
on their lowered nestin expression compared to PLL-astrocytes . However our results 
suggest that nestin expression is not a highly reliable method to identify astrocyte 
reactivity since spinal cord mixed cells on TnC-astrocytes expressed higher levels of 
Cxcl10 and Lcn2, which were shown to be elevated in both above-mentioned models of 
in vivo injury (Zamanian et al., 2012). 
This thesis also provides a list of transcription factors (CTCF, E2F1, INSM1, KLF4, 
MZF1_1-4, PPARγ::RXRα, RREB1, SP1, SRF, STAT3, TCFCP2L1, TLX1::NFIC) that could be 
involved in CNTF signalling in myelinating cultures, which could be responsible for the 
previously reported stimulatory roles of CNTF on neuronal survival, oligodendrocyte 
proliferation and maturation, and myelination (Barbin et al., 1984; Barres et al., 1996; 
Albrecht et al., Messersmith et al., 2000; 2003; Krady et al., 2008; Cao et al., 2010) 
and/or for its role in activating astrocytes (Winter et al., 1995; Levison et al., 1996; 
1998; Hudgins and Levison, 1998). 
Lastly, we detected several metabolites produced by astrocytes that were previously 
shown to be supportive for myelination at varying degrees. Those metabolites found in 
increased levels in PLL-astrocyte cultures compared to TnC-astrocytes, and in CNTF-
treated astrocytes compared to untreated cultures may therefore be stimulatory for 
myelination and/or astrocyte reactivity. Among these metabolites, 3-
dehydrosphinganine stands out as a strong candidate to be stimulatory for myelination 
based on the fact that it takes place in sphingolipid biosynthesis (Mandon et al., 1992) 
leading to the production of sphingomyelin, which is particularly found in the myelin 
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sheaths (reviewed in O’Brien, 1965; in Jana and Pahan, 2010). Further analysis is 
required to validate this hypothesis in the future. However, the list of metabolites 
presented in this thesis provides a basis to inspire future studies to identify different 
metabolic roles of astrocytes. 
7.1 Advantages and disadvantages of the techniques 
used in this thesis 
7.1.1 Embryonic rat spinal cord myelinating cultures 
The embryos obtained from one pregnant female rat allow the generation of 
myelinating cultures at a number enough to be treated, in duplicate, with up to 
approximately 15 different factors in one experiment. Therefore, the number of animals 
to be used for three experimental repeats is reduced compared to in vivo studies. The 
spinal cord myelinating cultures are advantageous compared to DRG/OPC co-cultures 
since they mimic the in vivo situation more closely due to the fact that they contain all 
the major cell types of the CNS. They are also easy to manipulate once generated, and 
unlike organotypic slice cultures, do not require the use of tissue choppers to initiate 
the cultures. On the other hand, these cultures appear to be variable in terms of 
myelination levels observed, which could be due to technical variations and/or 
biological variation of the animals that provide the tissue for the cultures although the 
latter is minimised by using in-bred animals. However, standardising the data to control 
levels solves this problem in terms of myelination levels. As for mRNA expression levels 
detected by qRT-PCR, normalising the data does not always appear to be enough to 
overcome the problem of variation in these cultures as also seen in this thesis. 
7.1.2 Microarray gene expression analysis and qRT-PCR 
Microarray gene expression profiling analysis allows comparison between the expression 
of over 22,000 genes between myelinating cultures under different conditions in one 
experiment, carried out with three biological repeats. However, using mixed neural 
cultures as samples makes it more difficult to identify which cells are responsible for 
the differential regulation detected in the microarray analysis. Moreover, it is also 
possible that the differential regulation of some genes in certain cell types will be 
masked by the expression of those genes by other cell types at much higher levels under 
all culture conditions tested. Using purified astrocytes (Array 1, Nash et al., 2011), 
oligodendrocytes, or microglia alone for microarray analysis could overcome this 
problem but this method will lose the complex crosstalk between the different CNS cell 
types provided in spinal cord myelinating cultures. Microarray also needs to be validated 
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by other studies because the statistics become more complicated and the possibility of 
false positives increases in microarray experiments due to the very high numbers of 
variables. 
To validate microarrays, usually qRT-PCR experiments are conducted and because the 
comparative expression of one gene is measured in one experiment, the statistics 
involved in the experiment are less complicated and less prone to false positives. 
However, qRT-PCR can lead to large differences between biological replicates (Willems 
et al., 2008), which was also seen in this thesis. Using a strict test such as repeated 
measures one-way ANOVA followed by Bonferroni correction to obtain statistical 
significance still ensures that the data are more reliable. 
7.1.3 Immunocytochemistry 
Immunocytochemistry (ICC) allowed the visualisation of GFAP and nestin proteins in 
astrocyte cultures in this thesis, which was compared in an attempt to observe 
differences in astrocyte reactivity. This method is not only easy and fast to carry out 
but also allows the observation of general astrocyte cell morphology in the cultures. As 
GFAP staining can sometimes fail to detect astrocytes that express lower levels of this 
protein (Bushong et al., 2002; Cahoy et al., 2008), western blotting might be a more 
advantageous technique to compare levels of GFAP protein between cultures under 
different conditions. However, western blotting does not allow the detection of GFAP 
protein level expressed per cell unlike ICC. ICC performed in this thesis was also used to 
visualise myelinated axons in spinal cord myelinating cultures in a way where 
specifically myelin sheaths that wrap around axons could be quantified rather than all 
membrane detected by PLP antibody. This antibody provides a very strong signal in ICC 
and thus makes the visualisation and quantification processes easier. However, other 
myelin markers such as MOG or MBP that would provide a more specific localisation to 
myelin sheaths could also be used.  
7.1.4 Cell Profiler to quantify myelination level 
The software Cell Profiler was used to quantify myelination level present in spinal cord 
myelinating cultures in this thesis. It provides an unbiased quantification of myelination 
compared to manual quantification such as where myelin sheaths are manually drawn 
over in Adobe Photoshop (Nash et al., 2011; Lamond et al; 2013) but sometimes includes 
cell bodies in the analysis. Despite this disadvantage, Cell Profiler has recently been 
shown to be a technique sensitive enough to detect significant differences in 
myelination level in spinal cord myelinating cultures under different conditions (Lindner 
 
 
223 
 
et al., 2015). In addition, carrying out the ICC using an antibody against MOG (myelin 
oligodendrocyte glycoprotein), which is expressed at later stages in oligodendrocyte 
maturation and stains the cell bodies far less than PLP antibody does (Lindner et al., 
2015) can provide a stronger method to quantify myelination more precisely. Cell 
Profiler also facilitates the quantification process highly, both compared to Adobe 
Photoshop manual quantification and to methods where myelin sheaths are observed 
using electron microscopy. 
7.1.5 Cre-loxP transgenic mice 
The Cre-loxP system facilitates the generation of conditional knockout animals 
especially when ubiquitous knockouts do not live long enough to obtain tissue for 
experimental procedures. As Gp130 knockout mice die in early embryonic stages 
(Yoshida et al., 1996), astrocytic Gp130 knockout mice provide a tool to study Gp130 
deficiency and hence CNTF and other IL-6 family cytokine signalling in astrocytes of 
these animals. However, the major handicap in using these animals is that there is no 
PCR product in the absence of a transgene, and a homozygous Cre transgene is 
indistinguishable from the hemizygous Cre transgene. Since a failed PCR produces the 
same outcome as an absent transgene, the newborn GFAP-Cre+/-gp130fl/fl pups to 
continue the colony can be mislabelled as GFAP-Cre-/-gp130fl/fl, which eventually can 
lead to the generation of GFAP-Cre+/+gp130fl/fl since the colony is maintained by 
breeding GFAP-Cre+/-gp130fl/fl with GFAP-Cre-/-gp130fl/fl genotype. Crossing GFAP-
Cre+/+gp130fl/fl with GFAP-Cre+/-gp130fl/fl will then lead to litters with 100% Cre+ 
genotype, which will not be able to be used due to absence of a Cre- control sample. 
7.2 Future Experiments 
In order to further elucidate CNTF mechanisms on myelination, the astrocytic 
metabolites detected upon CNTF treatment (Chapter 6) could be used as a basis for 
future experiments, which might identify enzymes and metabolic steps crucial and 
specific for CNTF signalling in these astrocyte cultures and hence myelination. These 
experiments could even identify metabolic markers to be used for the diagnosis of 
demyelinating neurodegenerative diseases (Francis et al., 2012; Blasco et al., 2013). 
The involvement of CNTFaR-mediated signalling could also be investigated in these 
cultures as suggested above to clarify whether astrocytic CNTFaR levels are enough to 
initiate the transcriptional and metabolic changes that would lead to increased 
myelination levels or whether these levels are minimal and would require the crosstalk 
between astrocytes and other neural cells to become elevated. The presence of CNTFaR 
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could be shown using a series of experiments including immunocytochemistry, western 
blotting, and qRT-PCR using astrocyte cells and also samples from their spent medium 
to detect the soluble form of the receptor. 
The microarray analysis (Array 2) was carried out using samples from myelinating 
cultures at 12 days in vitro (DIV), which is usually considered to be the time point when 
oligodendrocyte processes begin to interact with axons (Sorensen et al., 2008; Nash B, 
2010). However, it is not until 15-18 DIV that myelin sheaths around axons form in these 
cultures (Sorensen et al., 2008; Nash B, 2010). As eight different culture conditions 
(8x3=24 samples) were used in Array 2, it was not practical to conduct a study with a 
higher number of time points. Nevertheless, later time points such as 15 DIV, 18 DIV, 
and 21 DIV, where myelination appears to be more active, could also be analysed in the 
future to gain more insight into the CNTF effect on myelination. On the other hand, the 
results in this thesis showed that CNTF enhanced myelination only when astrocytes were 
pre-treated 4-5 days before they were used as monolayers for spinal cord myelinating 
cultures but did not show an effect when the myelinating cultures were treated starting 
from 12 DIV onwards. This suggests that CNTF effect might be stronger at early time 
points such as 6-8 DIV, which could also be included in the microarray analysis. To make 
the experiment more manageable by reducing the number of samples, the experiment 
could be performed using TnC-astrocytes alone since TnC is found in the CNS unlike PLL, 
which is a bacterial product. This thesis showed a much higher percentage of type-2 
astrocytes, when neurospheres were plated on PLL. However, type 2-astrocytes have 
not been detected in vivo (Skoff, 1990; Fulton et al., 1992; Franklin and Blakemore, 
1995; Franklin, 2002; Noble et al., 2004). Therefore, TnC-astrocytes appear to reflect in 
vivo better and could be chosen over PLL-astrocytes when required. The microarray 
analysis could also be repeated using purified oligodendrocyte cultures or microglia 
cultures alone to overcome the problem of higher expression levels by other cell types 
in the mixed neural cultures that could mask the differential changes occurring in 
specific cell types with lower expression levels. 
The transcription factors and metabolites identified in this thesis could be investigated 
further in the future to understand the roles of CNTF in myelinating cultures especially 
on myelination. Transgenic animals overexpressing or knockout for one or more of the 
transcription factors or key enzymes that are found in the astrocytic pathways of 
production of those metabolites identified here could provide tools for such studies. 
Similarly, transgenic animals could also be used to investigate the role of GP130 further 
by conducting the same myelination studies performed here on transgenic mice that 
lack oligodendroglial Gp130 expression, provided by Cre-loxP system, where the 
expression of Cre is driven by a mature oligodendroglial gene promoter such as PLP, 
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MBP, or MOG. This will provide a tool to observe the importance of oligodendroglial 
CNTF signalling on myelination. Analysis of myelination could also be undertaken in 
tissue samples taken from these transgenic mice. 
7.3 Astrocyte diversity: subtypes and reactivity states/ 
phenotypes 
Astrocytes are mainly divided into two subgroups, namely protoplasmic and fibrous 
(Cajal, 1909), and have been visualised generally using antibodies against the 
cytoskeletal protein GFAP for more than four decades (Eng et al., 1970). This widely 
used astrocyte marker has later been shown to be absent from some astrocyte 
populations, which have been detected by other astrocytic markers, discovered more 
recently (Cahoy et al., 2008). The discovery of the fact that astrocytes originate in the 
CNS as different subpopulations, which present distinct expressions of transcription 
factors also suggests that there might be various astrocyte subtypes that are still 
awaiting to be explored (Hochstim et al., 2008; Garcia-Marques and Lopez-Mascaraque, 
2013). Differences observed in the developmental origin, morphology, and location of 
the protoplasmic and fibrous astrocyte subtypes and newly emerged pial astrocytes 
have been interpreted as each subgroup playing different roles during development and 
mostly likely in adulthood (Molofsky et al., 2014; reviewed in Bayraktar, et al., 2015). 
Considering the possible variability of astrocyte subclasses and hence of their numerous 
vital functions in the CNS during homeostasis and in reaction to pathologies, the 
identification of the differences between the astrocyte subtypes appears crucial.   
The diversity of astrocytes in the CNS can increase even more when these cells go 
through activation upon CNS pathology, which will generate astrocytes with different 
reactive phenotypes with distinct cell morphology and proliferation rate, and 
cytokine/chemokine expression profiles (reviewed in Sofroniew and Vinters, 2010). We 
have used an in vitro model that allows the comparison of relatively “quiescent” 
astrocytes on tenascin C (TnC) with more “activated” ones on poly-L-lysine (PLL, Holley 
et al., 2005; Nash et al., 2011b), their reactivity being based on the increased 
immunofluorescence detected for nestin protein expression. I showed that these 
astrocyte cultures consist primarily of type-1 astrocytes, which have been associated 
with protoplasmic astrocytes found mainly in the grey matter (Raff et al., 1983; Peters 
et al., 1991). Even though multiple sclerosis (MS) is generally considered as a disease 
affecting the white matter, demyelination in grey matter and specifically within the 
cerebral cortex has been shown to be extensive particularly in patients with progressive 
disease (Kidd et al., 1999; Peterson et al., 2001; reviewed in Kutzelnigg and Lassmann, 
2014). Therefore these PLL- and TnC-astrocyte cultures might represent grey matter 
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astrocytes in vivo and also provide an in vitro model to study the effects of grey matter 
astrocytes on the myelination of i) white matter neural cells such as embryonic spinal 
cord mixed cells (Thomson et al., 2006, 2008; Sorensen et al., 2008) or ii) grey matter 
neural cells like cortical cells if methods could be developed in the future to generate 
and maintain healthy cortical myelinating cultures.  
It is likely that type-1 astrocytes in neurosphere-derived astrocyte cultures secrete 
factors to stimulate the generation of type-2 astrocytes in the same cultures in much 
smaller numbers as also suggested by other studies (Lillien et al., 1988). Type-2 
astrocytes were shown to develop from oligodendrocyte precursor cells (OPCs) and were 
associated with in vivo fibrous astrocytes by Raff et al. (1983) but it has so far not 
proved possible to identify cells with the antigenic phenotype of type-2 astrocytes in 
vivo (Skoff, 1990; Fulton et al., 1992; Franklin and Blakemore, 1995; Franklin, 2002; 
Noble et al., 2004). The substrate on which neurosphere-derived astrocytes are plated 
appears to affect their ability to generate type-2 astrocytes. As the density at which the 
striatum-derived neurospheres are seeded on PLL-coated glass coverslips increases, the 
percentage of type-2 astrocytes formed is also elevated as shown in this thesis (Chapter 
5) probably due to raised concentrations of stimulatory factors secreted by type-1 
astrocytes. However, the percentage of type-2 astrocytes in TnC-astrocyte cultures is 
not affected by the increasing seeding density of neurospheres and hence by the total 
cell number in these cultures, which suggests that TnC-astrocytes might exhibit a 
negative feedback for type-2 astrocyte stimulatory factors and keep their 
concentrations at a constant level possibly to provide homeostasis as it would be 
expected from their “quiescent” phenotype. Identification of such factors, which can 
stimulate the generation of type-2 astrocytes, can give more insight into the regulation 
of differentiation of astrocytes in vitro, which might be later linked to in vivo. Members 
of the BMP (bone morphogenetic protein) family other than BMP4, which is already used 
in serum-free medium to stimulate the differentiation of both types of astrocytes in 
vitro (Chen et al., 2012; Hu et al., 2012; Fan et al., 2014), and/or smaller CNTF-like 
proteins (Lillien et al., 1988) could be among such factors. Even though cells with 
similar antigenic profiles to type-2 astrocytes have not been detected so far in vivo, the 
fact that OPCs can give rise to astrocyte-like glia (pituicytes) during development of rat 
neurihypophysis, a CNS structure located at the base of the brain (Virard et al., 2006), 
suggests that type-2 astrocytes might have similarities with some in vivo glial cells to 
some extent.   
Astrocytes were in general thought to be reactive and play negative roles in CNS 
pathology but later they were also presented to have stimulatory effects that can 
contribute to recovery (Williams et al., 2007). The emerging view suggests that there is 
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a continuum of astrocyte reactive phenotypes present (Sofroniew and Vinters, 2010; 
Nash et al., 2011a) suggesting greater astrocyte diversity in the CNS than previously 
anticipated. Therefore, identifying a range of factors to manipulate the astrocyte 
cultures to mimic in vivo astrocytes in different stages of various CNS pathologies allows 
the distinct astrocyte reactivity profiles to be studied. This simple in vitro model can be 
diversified by changing the factors such as the substrate on which astrocyte cultures are 
plated and the treatment of cultures with relevant cytokines/chemokines or other 
secreted factors not yet identified. Using this system, we have compared TnC-
astrocytes with PLL-astrocytes, which were previously shown to exhibit “quiescent” and 
more reactive phenotypes, respectively (Holley et al., 2005). Even though their GFAP 
and nestin expressions, detected by immunocytochemistry, did not differ in our 
experiments, unlike other reported studies (Holley et al., 2005; Nash et al., 2011b), 
differences have been observed between PLL- and TnC-astrocytes in other ways, which 
could also be associated with their reactive phenotypes. GFAP or nestin expression 
might not always be appropriate markers to detect the changes in astrocyte reactivity if 
for example astrocytes obtain an activated phenotype closer to quiescence than to high 
reactivity, in which case other markers will gain importance. In addition to previously 
conducted transcriptomics analyses (Cahoy et al., 2008; Nash et al., 2011b; Zamanian et 
al., 2012), we showed for the first time that lipid chromatography tandem mass 
spectrometry (LC-MS/MS) could be an adequate method to identify metabolites that 
might be used as markers for specific astrocyte phenotypes in the future and provide 
insights into differences between their metabolisms. PLL- and TnC-astrocytes showed 
differences mainly in lipid metabolism, which were altered even more after treatment 
with CNTF. The changes observed for secreted metabolites suggest that astrocytes with 
presumably distinct reactive phenotypes can alter the composition of the medium they 
are cultured in principally in terms of lipid content, which in turn can affect the 
functions of other neural cells plated on top of these astrocyte monolayers as seen in 
spinal cord myelinating cultures (Nash et al., 2011b).  
7.4 How do in vitro astrocytes reflect in vivo astrocytes? 
PLL is a modified amino acid that is widely used in tissue culturing due to its adhesive 
properties allowing the attachment, proliferation, and maintenance of cells from 
different tissue sources (Mazia et al., 1975; Gebicke-Harter et al., 1981). Even though 
the majority of cells in PLL-astrocyte cultures appear similar to protoplasmic astrocytes 
as shown in Chapter 5, the absence of PLL in eukaryotes makes it difficult to estimate 
what state of reactivity astrocytes will gain on this substrate. Attempts have been made 
to generate astrocyte cultures that do not display a reactive phenotype and thus 
resemble the in vivo quiescent phenotype more closely compared to conventional PLL-
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astrocytes. These attempts have revealed the coverslip-coating molecule TnC as a 
substrate that leads to decreased expression of reactive markers in neurosphere-derived 
astrocyte monolayers compared to those plated on PLL (Holley et al., 2005; Nash et al., 
2011b). However, despite their seemingly “quiescent” phenotype, TnC-astrocytes are 
likely to contain a denser extracellular matrix (ECM) environment, which they continue 
to provide when they are used as supporting monolayers for mixed neural cells. In 
addition to the up-regulation of ECM molecules such as Col6a1 (collagen), Omd 
(osteomodulin, a keratan sulphate proteoglycan), Ltbp2 (latent TGF-β1 binding protein 
2), and Mfap5 (microfibrillar associated protein 5, involved in elastic fibre formation) in 
TnC-astrocytes (Array 1, Nash et al., 2011b); the ECM components of collagen (Col1a2), 
and ficolin (Fcnb) were also up-regulated in mixed neural cells supported by TnC-
astrocytes, where an ECM-modifying protease Mmp3 was down-regulated compared to 
PLL-cultures (Array 2, Chapter 3). Interestingly, expressions of several structural 
proteins were also promoted in mixed neural cells on TnC-astrocytes as presented in 
Chapter 3.  
The detection of elevated levels for other glial scar markers in cultures on TnC also 
supports the suggestion that TnC-astrocytes might not be as “quiescent” as originally 
thought. The increased mRNA expression of the ECM glycoprotein fibronectin 1 (Fn1) in 
TnC-astrocytes and in mixed neural cells, supported by these astrocytes, suggests that 
TnC-astrocytes could be creating an inhibitory environment such as seen in lesions of MS 
and EAE, where FN1 protein specifically localises in areas of demyelination and inhibits 
oligodendrocyte differentiation and remyelination (Stoffels et al., 2013). FN1 is 
proposed to play a role in the formation of the glial scar due to its increased expression 
in microglia /macrophages and reactive astrocytes of injured CNS (Camand et al., 2004; 
Stenzel et al., 2011; Kim et al., 2013) similar to transgelin (Tagln) that presents 
increased expression after spinal cord injury in rats (Lin et al., 2005) and was detected 
also to be up-regulated in astrocytes and mixed neural cultures on TnC as shown in 
Chapter 3. Therefore, it is likely that the three glial scar markers (eNCAM, EGFR, bFGF) 
used by Holley et al. (2005) to compare the reactivity of astrocytes on different 
substrates are not enough to provide a general profile for distinct astrocyte reactive 
phenotypes. 
Considering the likelihood of a wide spectrum of astrocyte reactive states, a more 
comprehensive study should be carried out, where immunocytochemistry and western 
blotting analysis for various glial scar/CNS injury markers can be used to differentiate 
astrocytes on TnC from those plated on PLL or other coating substrates. It is possible 
that some of these markers will present raised levels in TnC-astrocytes while others will 
be lowered, such as seen for Serpinb2 (Dietzmann et al., 2000) in this thesis. 
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Therefore, to be able to refer to one in vitro astrocyte phenotype as more reactive than 
another one with more certainty, a panel of reactivity markers should be graded 
according to the associated CNS disease/pathology severity, after which levels of these 
markers can be compared between two astrocyte phenotypes and those that express 
markers of higher reactivity could be termed more “reactive”. Such an extensive 
investigation can also reveal reactivity markers that can be grouped together based on 
their similar spatial and temporal expressions upon various CNS pathologies and common 
association with pathology severity, which might reduce the large list of markers into 
several basic groups to allow higher practicality when carrying out the future 
experiments.  
Zamanian et al. (2012) have carried out such an extensive study, where they compared 
transcriptional changes in reactive astrocytes upon two different injury models in mice. 
Transient ischemia and neuroinflammation were induced by occluding the middle 
cerebral artery (MCAO) and by a single intraperitoneal injection of the bacterial 
endotoxin LPS, respectively. Both injury models presented increased mRNA expression 
for astrocyte reactivity markers GFAP and vimentin by 1 day; whereas, nestin expression 
was induced only in MCAO astrocytes. The increase in the expression of these markers 
resolved gradually over time, measured up to 7 days. Having established that they had 
isolated purified populations of reactive astrocytes from injured animals in addition to 
less reactive (“quiescent”) astrocytes from sham-operated and saline-injected control 
animals, they carried out a gene expression profiling microarray analysis to compare 
“quiescent” astrocytes with reactive astrocytes within each injury scenario. They 
showed that reactive astrocyte transcriptome could depend on the nature of the 
inducing stimulus. Some of the transcripts that were up-regulated specifically upon the 
type of injury were also detected in the myelinating cultures (Table 7.1). Zamanian et 
al. (2012) suggested that reactive astrocytes in ischemia could be beneficial due to 
their increased expression of neurotrophic factors and cytokines; while, LPS reactive 
astrocytes could be detrimental with their up-regulated expression of complement 
factors. It is difficult to predict which type of in vivo reactive astrocytes PLL- and TnC 
astrocytes might be reflecting since some ischemia-associated transcripts (Anxa3 and 
Icam1) were up-regulated in TnC-cultures; while others were up-regulated in PLL-
cultures (Hmox1, Ptgs2, Vgf). Therefore, both PLL- and TnC-astrocytes might be 
reactive to some extent, which would require another in vitro phenotype to mimic in 
vivo “quiescent” astrocytes more closely.  
Zamanian et al. (2012) also identified common transcripts that were up-regulated in 
reactive astrocytes from both injuries (Cxcl10, Lcn2, and Serpina3n), which we found to 
be expressed in embryonic rat spinal cord myelinating cultures (Table 7.1) that were set  
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Table 7. 1 Possible astrocyte reactivity markers that were detected both in vivo and in vitro. 
In	  vivo	  
markers	  
The	  
injury	  
model	  
Astrocyte	  
cultures	  	  	  	  	  	  	  	  	  
(no	  CNTF)	  
Array	  1	  
Mixed	  
neural	  
cells	  	  	  	  	  
(no	  CNTF)	  
Mixed	  
neural	  
cells	  	  	  	  	  	  	  	  	  
(+	  CNTF)	  
Differential	  expression	  of	  markers	  
in	  mixed	  neural	  cells	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
a)	  on	  a	  different	  substrate,	  b)	  
upon	  treatment,	  c)	  over	  time	  
Anxa3	   MCAO	   -­‐	   TnC	   TnC	   a)	  PLL-­‐Con-­‐4	  vs	  TnC-­‐Con-­‐4	  é	  
a)	  PLL-­‐CNTF-­‐24	  vs	  TnC-­‐CNTF-­‐	  24	  é	  
Chi3l1	   LPS	   -­‐	   -­‐	   PLL	   a)éPLL-­‐CNTF-­‐24	  vs	  TnC-­‐CNTF-­‐24	  	  
Ctgf	   MCAO	   TnC	   -­‐	   TnC	   a)	  PLL-­‐CNTF-­‐24	  vs	  TnC-­‐CNTF-­‐24	  é 
b)	  éTnC-­‐CNTF-­‐24	  vs	  TnC-­‐Con-­‐24	  
Cxcl1	   LPS	   -­‐	   -­‐	   PLL	   a)	  éPLL-­‐CNTF-­‐4	  vs	  TnC-­‐CNTF-­‐4	  
c)	  PLL-­‐CNTF-­‐24	  vs	  PLL-­‐CNTF-­‐4	  é	  
Cxcl10	   LPS,	  
MCAO	  
TnC	   TnC	   -­‐	   a)	  PLL-­‐Con-­‐4	  vs	  TnC-­‐Con-­‐4	  é	  
Emp1	   MCAO	   -­‐	   -­‐	   TnC	   a)	  PLL-­‐CNTF-­‐24	  vs	  TnC-­‐CNTF-­‐24	  é	  	  
b)	  TnC-­‐CNTF-­‐4	  vs	  TnC-­‐Con-­‐4	  é 
c)	  PLL-­‐CNTF-­‐24	  vs	  PLL-­‐CNTF-­‐4	  é 
c)	  TnC-­‐Con-­‐24	  vs	  TnC-­‐Con-­‐4	  é	  
Hmox1	   MCAO	   -­‐	   PLL	   -­‐	   a)	  éPLL-­‐Con-­‐4	  vs	  TnC-­‐Con-­‐4	  
c)	  PLL-­‐Con-­‐24	  vs	  PLL-­‐Con-­‐4	  é	  
c)	  TnC-­‐CNTF-­‐24	  vs	  TnC-­‐CNTF-­‐4	  é	  
Icam1	   MCAO	   	  -­‐	   TnC	   -­‐	   a)	  PLL-­‐Con-­‐4	  vs	  TnC-­‐Con-­‐4	  é	  
Lcn2	   LPS,	  
MCAO	  
-­‐	   TnC	  	  
	  
PLL	   a)	  PLL-­‐Con-­‐4	  vs	  TnC-­‐Con-­‐4	  é	  
a)	  éPLL-­‐CNTF-­‐24	  vs	  TnC-­‐CNTF-­‐24	  
b)	  éPLL-­‐CNTF-­‐24	  vs	  PLL-­‐Con-­‐24	  
c)	  PLL-­‐Con-­‐24	  vs	  PLL-­‐Con-­‐4	  é	  
c)	  PLL-­‐CNTF	  24	  vs	  PLL-­‐CNTF-­‐4	  é	  
c)	  TnC-­‐Con-­‐24	  vs	  TnC-­‐Con-­‐4	  é	  
Ptgs2	   MCAO	   -­‐	   PLL	   PLL	   a)	  éPLL-­‐Con-­‐4	  vs	  TnC-­‐Con-­‐4	  
a)	  éPLL-­‐CNTF-­‐4	  vs	  TnC-­‐CNTF-­‐4	  
c)	  PLL-­‐Con-­‐24	  vs	  PLL-­‐Con-­‐4	  é	  
c)	  PLL-­‐CNTF-­‐24	  vs	  PLL-­‐CNTF-­‐4	  é	  
Serpina3n	   LPS,	  
MCAO	  
-­‐	   -­‐	   PLL	   a)é	  PLL-­‐CNTF-­‐4	  vs	  TnC-­‐CNTF-­‐4	  
Vgf	   MCAO	   -­‐	   PLL	   PLL	   a)é	  PLL-­‐Con-­‐4	  vs	  TnC-­‐Con-­‐4	  
a)	  éPLL-­‐Con-­‐24	  vs	  TnC-­‐Con-­‐24	  
a)	  éPLL-­‐CNTF-­‐24	  vs	  TnC-­‐CNTF-­‐24	  
Astrocytic transcripts that were shown to be up-regulated in an animal model of ischemia and 
neuroinflammation (Zamanian et al., 2012) were compared with i) transcripts that were differentially regulated 
between neurosphere-derived astrocyte monolayers plated on PLL or TnC and ii) transcripts that were 
differentially regulated in embryonic rat mixed spinal cord cultures (mixed neural cells) at different conditions. 
Zamanin et al. (2012) identified several transcripts (in vivo markers) that could be associated with astrocytic 
reactivity due to their up-regulation in neuroinflammation, induced by intraperitoneal injection of LPS, and 
ischemia, which was initiated by occluding the middle cerebral artery (MCAO). Markers that were up-regulated 
in both injury models are shown as highlighted in yellow. The coverslip-coating substrates (PLL or TnC) on 
which astrocytes (Array 1, Nash et al., 2011b) and mixed neural cells showed increased expression for in vivo 
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markers with or without the presence of CNTF treatment are presented in the table. Binary comparisons, 
where in vivo markers present up-regulated expression in one of two conditions (underlined and shown with 
é), are also shown above. Expressions were compared in mixed neural cells between cultures a) on PLL and 
TnC, b) untreated or treated with CNTF, c) over time (4 hr vs 24 hr). Anxa3: annexin A3; Chi3l1: chitinase 3-
like 1; CNTF: ciliary neurotrophic factor; Ctgf: connective tissue growth factor; Cxcl1: chemokine (C-X-C motif) 
ligand 1; Cxcl10: chemokine (C-X-C motif) ligand 10; Emp1: epithelial membrane protein 1; Hmox1: heme 
oxygenase 1; Icam1: intercellular adhesion molecule 1; Lcn2: lipocalin2; PLL: poly-L-lysine; Ptgfs2: 
prostaglandin-endoperoxide synthase 2; Serpina3n: serine (or cysteine) peptidase inhibitor, clade A, member 
3 NTnC: tenascin C; Vgf: VGF nerve growth factor. 
 
up using PLL- or TnC-astrocytes. Cxcl10 and Lcn2 were detected to be up-regulated in 
TnC-myelinating cultures compared to PLL-myelinating cultures, which would parallel 
the discussion above that TnC-cultures could be more reactive despite their reduced 
nestin expression (Holley et al., 2005). CNTF treatment, on the other hand, increased 
Lcn2 expression in PLL-myelinating cultures, which suggests that CNTF could make PLL-
astrocytes more reactive through signaling cascades involving Lcn2 while the same 
signaling pathway will not be activated in TnC-astrocytes. This is not surprising as our 
microarray analysis (Array 2) proposed that CNTF shows its pro-myelinating effects in 
PLL- and TnC-myelinating cultures through different transcriptional changes (Chapter 
3). Serpina3n was also up-regulated in PLL-cultures in the presence of CNTF treatment 
compared to TnC-cultures; however, it is difficult to interpret this change due to the 
absence of any other significant transcriptional changes detected between untreated 
PLL- and TnC-cultures, or between untreated and CNTF-treated cultures. Because 
astrocyte reactivity can be present not only to different degrees (based on their 
expression of reactivity markers) but also with opposing roles on CNS biology (positive vs 
negative), CNTF-induced reactivity in PLL-astrocytes could be of a kind that is 
beneficial as evidenced by its stimulatory effect on myelination levels (Chapter 3, Nash 
et al., 2011b). In contrast, TnC-astrocytes could be more reactive compared to PLL-
astrocytes in a different way, where they actively suppress myelination rather than just 
being quiescent as suggested earlier (Holley et al., 2005). 
The inhibitory roles of TnC-astrocytes on myelination in mixed embryonic spinal cord 
myelinating cultures (Nash et al., 2011b) could be due to their more compact ECM that 
physically and chemically can hinder axonal ensheathment process (Mohan et al., 2010) 
and increased levels of other suppressing cues such as markers of reactivity as explained 
above and possibly due to increased immunological signaling as evidenced by the 
microarray analysis (Chapter 3). The interaction of astrocytes with TnC in vitro might be 
stimulating intrinsic mechanisms in astrocytes to prepare a denser ECM and a more 
reactive environment to some extent, possibly with the help of other neural cells plated 
on top, in an attempt to patch a hypothetical scar, stop inflammation and initiate other 
repair mechanisms before re/myelination can take place. Despite this comparatively 
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reactive environment, astrocytes might not be reactive enough to increase their GFAP 
expression due to lack of activating signals that can be provided by macrophages and/or 
other peripheral leukocytes that can infiltrate into the CNS upon demyelination-
inducing signals even in the presence of an intact blood brain barrier (Kondo et al., 
1987; Hiremath et al., 1981; McMahon et al., 2002). Therefore, culturing astrocytes 
with activated macrophages might lead to a much higher increase in GFAP expression on 
TnC compared to that on PLL due to potentially more reactive environment present in 
TnC-astrocyte cultures.  
The previously detected down-regulation of nestin in TnC-astrocytes (Holley et al., 
2005; Nash et al., 2011b) could be associated with the differentiation stage of 
astrocytes rather than their reactive state especially considering the fact that both PLL- 
and TnC-astrocytes present similar levels of GFAP (Holley et al., 2005), a widely used 
astrocyte marker of reactivity (Axelsson et al., 2011) as mentioned above. A lower 
nestin expression might represent the presence of more mature astrocytes (Frederiksen 
and McKay, 1988; Lendahl et al., 1990) on TnC. Astrocytes on TnC might reduce their 
nestin expression while increasing GFAP levels as they mature, which would be similar 
to their differentiation during in vivo CNS development (Wiese et al., 2012). On the 
other hand, PLL-astrocytes might be able to initiate GFAP expression as they become 
more differentiated without lowering their nestin expression first, which would 
probably create mature astrocytes with some properties of immature astrocytes. This 
could be an artefact of the interaction between astrocytes and PLL that is not found in 
the CNS. The up-regulation of several developmental proteins in mixed neural cells on 
PLL-astrocytes such as Arc, Ascl1, Dlx1, and Gadd45g (Array 2, Chapter 3) also 
supports this suggestion. The increased capacity of PLL-astrocytes to support 
myelination could thus also be related to their more regenerative environment possibly 
allowing the development and the process of oligodendrocyte differentiation more 
efficiently as also evidenced by their up-regulated levels of tenascin R (TnR), which has 
been shown to promote oligodendrocyte differentiation in vitro as opposed to TnC 
(Czopka et al., 2009). 
Future experiments can be conducted to investigate cell differentiation and astrocyte 
reactivity on PLL- and TnC-astrocytes by comparing these cultures to astrocyte 
monolayers on tenascin R (TnR)-coated coverslips (Czopka et al., 2009) or neural ECM 
(nECM)-coated coverslips that are covered with a mixture of ECM molecules (laminin, 
collagen IV, entacin, and heparin sulphate proteoglycan, Garcia-Parra et al., 2012), 
which could be more similar to in vivo conditions. Moreover, coverslips coated with 
nECM have been shown to increase neuronal survival and neuronal differentiation of rat 
hippocampal cells compared to that seen in cultures on PLL-coverslips (Garcia-Parra et 
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al., 2013). Astrocytes isolated from adult animals could also be used to obtain a 
“quiescent” phenotype that resembles the in vivo adult quiescence more closely 
compared to astrocyte cultures generated using neonatal tissue (Wu et al., 1998). In my 
opinion, neurosphere-derived astrocytes on TnC reflect adult astrocytes, which would 
be in contact with the reactive ECM environment in vivo in the absence of activating 
signals from macrophages, as explained above. Because TnC levels increase upon CNS 
pathology in vivo possibly to contribute to the recovery of the injury (Chen et al., 2010; 
reviewed in Jakovcevski et al., 2013), it is not surprising that mature astrocytes will 
have intrinsic mechanisms triggered by TnC to initiate repair mechanisms rather than 
giving the priority to generating an environment to promote axonal ensheathment. 
However, further experiments are required to elucidate this hypothesis. Embryonic 
spinal cord myelinating cultures on PLL- and TnC could be compared, for example, in 
terms of the way they will react to a single cut made using a razor blade manually to 
mimic spinal cord injury (Boomkamp et al., 2012). If TnC-astrocytes are indeed 
programmed to initiate recovery at a higher level than PLL-astrocytes, they will most 
likely patch the cut faster and more efficiently. It would also be interesting to observe 
these changes in the presence of activated macrophages that can provide signals to 
activate astrocytes as proposed above.  
7.5 Crosstalk between neural cells and astrocytes 
We have used astrocyte cultures as supporting monolayers for embryonic mixed spinal 
cord cells, where it is possible to follow neuronal survival, neurite outgrowth, 
oligodendrocyte precursor cell proliferation and extension of their processes to 
myelinate axons. The astrocytic lipids detected after the LC-MS/MS analysis could be 
sources of energy for highly active neurons or possibly monomers for lipid-rich 
myelinogenesis process in oligodendrocytes as suggested by previous studies showing 
that astrocytes play an important role in supplying fatty acids to neurons and other cells 
(Moore et al., 1991, 2001; Bernoud et al., 1998). These lipids could be secreted with 
apolipoproteins to provide intercellular trafficking of fatty acids from astrocytes to 
other neural cells (Innis and Dyer, 2002) or transported to axonal mitochondria via 
“carnitine-transporters” from astrocytic peroxisomes as hypothesised for the transfer of 
fatty acids from oligodendrocytes to neurons (reviewed in Kassmann, 2014). Astrocytic 
peroxisomes perform β-oxidation of especially very long chain fatty acids (VLCFAs) and 
thereby may provide the monomer acetyl-CoA for de novo fatty acid and cholesterol 
synthesis in the brain, which might be important for remyelination and the maintenance 
of the myelin structure in the CNS (Morita et al., 2012). Consequently, the metabolic 
changes observed in astrocyte monolayers could be important for the regulation of 
myelination in embryonic spinal cord myelinating cultures.  
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Nash et al. (2011b) have suggested that the reason why only two transcripts were 
differentially expressed upon CNTF treatment in PLL-astrocytes, detected by microarray 
analysis (Array 1), could be the lack of the crosstalk between astrocytes and other 
neural cells. This suggestion was in parallel with the previous observations showing that 
intracranial CNTF injection can induce astrogliotic response in neonatal rat brains, 
where CNTF-alpha receptor (CNTF-αR, Fig 1.6) mRNA and protein expression was 
detected in neurons but not in S100α-expressing astrocytes (Kahn et al., 1997). Despite 
the lack of neurons in the astrocyte cultures I have used, CNTF treatment did change 
the levels of various metabolites in these PLL- and TnC-astrocyte monolayers, where 
CNTF-αR might have been expressed by astrocytes and allowed the CNTF signaling that 
would lead to those metabolic changes. Another possibility is that CNTF signals through 
currently unknown receptors/receptor complexes that do not involve CNTF-αR, which 
can be confirmed in the future through a series of experiments involving 
immunocytochemistry, qRT-PCR, and/or western blotting by using the astrocyte 
cultures. It is also possible that astrocytes express CNTF-αR subunit at low levels that 
might be enough to initiate CNTF signaling and thereby a few transcriptional changes, 
which might be involved in complex signaling pathways and lead to various metabolic 
changes.  
The CNTF effect observed in the metabolomics analysis might also be attributed to 
possible mechanisms allowing CNTF to regulate the activity of enzymes in the astrocyte 
cultures without directly involving transcriptional changes. One example is that CNTF 
has recently been shown to stimulate enzyme activity of tyrosine hydroxylase in rat and 
mouse neuronal cultures, where CNTF was suggested to alter the phosphorylation state 
of the enzyme during post-translation modification (Shi et al., 2012). CNTF was 
proposed to activate ERK 1/2 (Dziennis and Habecker, 2003), which would 
phosphorylate the enzyme at a specific serine residue that would allow increased 
enzymatic activity; whereas, the phosphorylation observed at another serine residue 
upon CNTF treatment was associated with targeting of the enzyme for proteasomal 
degradation (Shi et al., 2012). CNTF might therefore be leading to metabolic changes in 
astrocyte cultures by activating the phosphorylation of different amino acid residues of 
potentially distinct enzymes through possibly GP130 receptor signalling (Fig 1.6, Shi and 
Habecker, 2012), where the binding of CNTF to astrocytic CNTF-αR is a prerequisite or 
other receptors are involved in the initiation of CNTF signalling.  
The crosstalk between astrocyte monolayers and neural mixed cells in cocultures on PLL 
revealed increased numbers of transcripts that were differentially regulated upon CNTF 
treatment possibly due to the elevated CNTF-αR levels, secreted by neurons, as Nash et 
al. (2011b) have predicted and as explained above. Interestingly, even in the presence 
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of the crosstalk, 13 transcriptional changes were detected after CNTF treatment in PLL-
myelinating cultures (Array 2) as opposed to 2 changes detected previously in PLL-
astrocytes (Array 1). On the other hand, 43 transcripts were differentially regulated 
upon CNTF treatment in mixed neural cells on TnC. It might be that higher levels of 
CNTF-αR will lead to a higher number of transcriptional changes, in which case CNTF-αR 
would need to be present in mixed neural cells on TnC at elevated levels compared to 
those on PLL, which was not detected in Array 2. Another explanation could be that 
CNTF-αR levels are not directly associated with the number of transcriptional changes 
CNTF will stimulate in myelinating cultures. The stimulation of CNTF on myelination 
levels appears to be more efficient in mixed neural cells on TnC compared to those on 
PLL (Nash et al., 2011b). This higher increase in myelination levels in TnC-cultures 
might be due to a more complex CNTF signaling that triggers a higher number of 
transcriptional changes rather than due to increased levels of CNTF-αR. However, to 
speculate about the importance of CNTF-αR levels on the transcriptional changes in 
these cultures, TnC-astrocytes should also be compared before and after the CNTF 
treatment by means of microarray (not carried out in Array 1). If CNTF differentially 
regulates a high number of transcripts in TnC-astrocytes and if these transcripts show 
similarities with those detected in mixed neural cells on TnC, it could be concluded that 
CNTF signalling is almost as efficient in astrocyte monolayers as it could be in mixed 
neural cells. Otherwise, the production of CNTF-αR subunit by other neural cells might 
be considered important.     
7.6 CNTF effect on neural cultures 
Myelination levels were increased in spinal cord mixed neural cultures seeded on 
astrocytes that were pretreated with CNTF (Chapter 6) as also shown by others (Nash et 
al., 2011b). Despite stimulating different signaling pathways in mixed neural cultures on 
PLL and TnC as discussed in Chapter 3, CNTF appears to regulate ECM in both of these 
myelinating cultures in the same direction. The expressions of several ECM proteins 
were down-regulated while the expression of an ECM-modifying protease was up-
regulated upon CNTF treatment in both PLL- and TnC-cultures (Array 2, Chapter 3). 
Therefore, its stimulating role on myelination could involve mechanisms that create a 
more permissive environment for oligodendrocyte process extension and axon 
ensheathment. Furthermore, metabolomics studies showed that CNTF increased the 
levels of several fatty acids and sphingolipids that might be important for 
myelinogenesis as explained in Chapter 6. Thus, CNTF may be included in disease-
modifying combination therapies in the future to treat neurodegenerative diseases such 
as multiple sclerosis, where it could help to constrain the excessive enlargement of glial 
scar and facilitate recovery (Fang et al., 2013).  
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The failure to show increased myelination levels in neural mixed cells on TnC-astrocytes 
upon CNTF treatment in this thesis could be related to the timing of the treatments. 
Neither pre-conditioning astrocyte monolayers with CNTF nor treatments initiated 12 
DIV after neural mixed cells were plated on astrocyte monolayers presented a 
significant change on axonal ensheathment (Chapter 6) unlike previous observations 
(Nash et al., 2011b). Considering the possible “adult phenotype” of TnC-astrocytes as 
discussed above, conditioning astrocyte monolayers and continuing with the CNTF 
treatment once spinal cord mixed cells are plated on top could provide a more efficient 
strategy to alter the myelination-inhibitory conditions in TnC-cultures. I might have 
missed the critical time frame for CNTF to initiate its positive effects by depriving the 
cultures from CNTF treatment during 12 DIV after they had been set up, which might 
not have made a difference in the other study (Nash et al., 2011b) maybe due to the 
differentiation stage of the astrocytes used. Because TnC-astrocytes might constitute a 
relatively non-permissive environment with their increased levels of ECM proteins as 
discussed above, neural mixed cells on these astrocytes might require more time and 
energy to down-regulate those ECM molecules and then stimulate processes leading to 
myelination such as oligodendrocyte proliferation, maturation, and process extension. 
One of the ways to save energy upon CNTF treatment could be halting myelination-
related processes temporarily as can be evidenced by the down-regulation of a tight 
junction protein, Claudin 11 (Chapter 3), which promotes the proliferation and 
migration of oligodendrocytes and takes place on myelin sheaths (Morita et al., 1999; 
Bronstein et al., 2000a, 2000b; Tiwari-Woodruff et al., 2001). This transcript was up-
regulated over time (4 hr vs 24 hr) in untreated mixed neural cultures on TnC (Chapter 
3), which suggests that CNTF inhibits such an increase rather than reducing Cldn11 
expression continuing until then. Resuming and facilitating the myelination-promoting 
functions could be very sensitive and prone to errors unless the very right conditions are 
provided, which is why high variations were observed for myelination levels in 
TnC+CNTF myelinating cultures even in the original study that did present significant 
increase in axonal ensheathment (Nash et al., 2011b).      
7.7 General conclusions  
Astrocytes not only constitute the majority of cells in the CNS but also take part in 
various vital functions to maintain homeostasis in normal conditions and to repair 
damaged tissue upon distinct pathologies as explained earlier in Chapter 1. The 
potential of reactive astrocytes to exert both beneficial and detrimental effects in CNS 
disorders (Williams et al., 2007) underlines the importance of the necessity to identify 
different activated astrocyte phenotypes and conditions required to generate them. 
This identification might allow the manipulation of astrocytes in a way to stimulate 
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their favourable roles to be exploited in therapies for numerous neurodegenerative 
diseases (Buffo et al., 2010; Hamby and Sofroniew, 2010), including multiple sclerosis, 
Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (Holley 
et al., 2003; Rothstein et al., 2005; Mena and de Yebenes, 2008; Fuller et al., 2009). 
This thesis provides examples for different in vitro astrocyte phenotypes, which were 
associated with in vivo astrocyte subtypes and phenotypes as discussed above, and also 
presents specific transcriptional and metabolic changes associated with their roles on 
myelination. Similar studies comparing other astrocyte phenotypes, possibly generated 
by being plated on different coverslip-coating reagents or stimulated by distinct 
cytokines/chemokines, can provide further insights into astrocytic roles that could be 
employed in modifying current treatments or in developing new therapies for 
neurodegenerative diseases.  
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 Appendix I  
 
Figure I. I Electropherograms and RIN values, obtained using the Agilent 2100 Bioanalyser, 
for total RNA samples, used for microarray gene expression profiling analysis.                   
Only 4 hr samples are presented. 
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Figure I. II Electropherograms and RIN values, obtained using the Agilent 2100 Bioanalyser, 
for total RNA samples, used for microarray gene expression profiling analysis.           
Only 24 hr samples are presented. 
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Appendix II 
 
Figure II. I Electropherograms, obtained using the Agilent 2100 Bioanalyser, for cRNA 
samples, used for microarray gene expression profiling analysis.             
Only 4 hr samples are presented. 1: PLL-control-n1; 2: PLL-CNTF-n1; 3:TnC-control-n1; 4:TnC-CNTF-n1; 5: 
PLL-control-n2; 6: PLL-CNTF-n2; 7:TnC-control-n2; 8:TnC-CNTF-n2; 9: PLL-control-n3; 10: PLL-CNTF-n3; 
11:TnC-control-n3; 12:TnC-CNTF-n3. 
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Figure II. II Details of the electropherograms, obtained using the Agilent 2100 Bioanalyser, 
for cRNA samples, used for microarray gene expression profiling analysis.             
Only 4 hr samples are presented. 1: PLL-control-n1; 2: PLL-CNTF-n1; 3:TnC-control-n1; 4:TnC-CNTF-n1; 5: 
PLL-control-n2; 6: PLL-CNTF-n2. 
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Figure II. III Details of the electropherograms, obtained using the Agilent 2100 Bioanalyser, 
for cRNA samples, used for microarray gene expression profiling analysis.           
Only 4 hr samples are presented. 7:TnC-control-n2; 8:TnC-CNTF-n2; 9: PLL-control-n3; 10: PLL-CNTF-n3; 
11:TnC-control-n3; 12:TnC-CNTF-n3. 
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Figure II. IV Electropherograms, obtained using the Agilent 2100 Bioanalyser, for cRNA 
samples, used for microarray gene expression profiling analysis.               
Only 24 hr samples are presented. 13: PLL-control-n1; 14: PLL-CNTF-n1; 15:TnC-control-n1; 16:TnC-CNTF-
n1; 17: PLL-control-n2; 18: PLL-CNTF-n2; 19:TnC-control-n2; 20:TnC-CNTF-n2; 21: PLL-control-n3; 22: PLL-
CNTF-n3; 23:TnC-control-n3; 24:TnC-CNTF-n3. 
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Figure II. V Details of the electropherograms, obtained using the Agilent 2100 Bioanalyser, 
for cRNA samples, used for microarray gene expression profiling analysis.         
Only 24 hr samples are presented. 13: PLL-control-n1; 14: PLL-CNTF-n1; 15:TnC-control-n1; 16:TnC-CNTF-
n1; 17: PLL-control-n2; 18: PLL-CNTF-n2. 
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Figure II. VI Details of the electropherograms, obtained using the Agilent 2100 Bioanalyser, 
for cRNA samples, used for microarray gene expression profiling analysis.            
Only 24 hr samples are presented. 19:TnC-control-n2; 20:TnC-CNTF-n2; 21: PLL-control-n3; 22: PLL-CNTF-
n3; 23:TnC-control-n3; 24:TnC-CNTF-n3. 
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Figure II. VII Details of the electropherograms, obtained using the  Agilent 2100 Bioanalyser, 
for cRNA sample of #8.                    
The electropherograms were obtained either before (A) or after (B) the samples were centrifuged at high-
speed vacuum centrifuge. #8 sample is TnC-CNTF-n2.  
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Appendix III 
Table III. I The concentrations of biotinylated RNA samples, which were used for microarray 
gene expression profiling, before and after they were concentrated using a high-speed 
vacuum centrifuge. 
 
Sample	  
#	  
Sample	  	  
Name	  
Time	  
point	   n	  	  
Concentration	  
(ng/μl)	  
Concentration	  
(ng/μl)	  
	  	   	  	   	  	   	  	   	  	  
after	  
centrifugation	  
1	   PLL	  Control	   4	  hours	   1	   144	   640	  
2	   PLL	  +	  CNTF	   4	  hours	   1	   153	   595	  
3	   TnC	  Control	   4	  hours	   1	   88	   461	  
4	   TnC	  +	  CNTF	   4	  hours	   1	   128	   415	  
5	   PLL	  Control	   4	  hours	   2	   117	   442	  
6	   PLL	  +	  CNTF	   4	  hours	   2	   92	   343	  
7	   TnC	  Control	   4	  hours	   2	   130	   557	  
8	   TnC	  +	  CNTF	   4	  hours	   2	   13/	  75	   261	  
9	   PLL	  Control	   4	  hours	   3	   129	   732	  
10	   PLL	  +	  CNTF	   4	  hours	   3	   117	   417	  
11	   TnC	  Control	   4	  hours	   3	   117	   434	  
12	   TnC	  +	  CNTF	   4	  hours	   3	   195	   409	  
	  	   	  	   	  	   	  	   	  	   	  	  
13	   PLL	  Control	   24	  hours	   1	   171	   452	  
14	   PLL	  +	  CNTF	   24	  hours	   1	   141	   392	  
15	   TnC	  Control	   24	  hours	   1	   119	   418	  
16	   TnC	  +	  CNTF	   24	  hours	   1	   128	   358	  
17	   PLL	  Control	   24	  hours	   2	   214	   595	  
18	   PLL	  +	  CNTF	   24	  hours	   2	   120	   352	  
19	   TnC	  Control	   24	  hours	   2	   162	   422	  
20	   TnC	  +	  CNTF	   24	  hours	   2	   186	   413	  
21	   PLL	  Control	   24	  hours	   3	   140	   438	  
22	   PLL	  +	  CNTF	   24	  hours	   3	   159	   417	  
23	   TnC	  Control	   24	  hours	   3	   127	   189	  
24	   TnC	  +	  CNTF	   24	  hours	   3	   90	   231	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Appendix IV
 
Figure IV. I The effcts of different treatments on the maturation of oligodendrocytes. 
Oligodendrocyte precursor cells (OPC) were purified from the rat cerebral cortical astrocyte cultures. They 
were initially maintained in medium containing the growth factors (GF) PDGF and FGF2, known mitogens that 
inhibit oligodendrocyte maturation. After 4-5 DIV, the cultures were treated with CCL2, CCL7 or SERPINB2 
(SB2) at 1 ng/ml or 10 ng/ml. GF+ control cultures were always fed with medium containing PDGF and FGF2; 
whereas, GF- control cultures were fed with standard oligodendrocyte medium without GFs after the initial 
period of 4-5 DIV to allow the maturation of OPCs. The cultures were stained using the O4 and anti-PLP 
antibodies together with DAPI at 8-10 DIV to detect the number of mature oligodendrocytes. The cells were 
counted in Image J using 15-20 images per coverslip from fluorescent microscopy. Total number of cells were 
quantified using “dapi.cp” pipeline in Cell Profiler. PLP positive cells were expressed as a percentage of the 
total number of cells per coverslip. All PLP+ cells were also positive for the O4 antibody. Two coverslips were 
used per condition. The averages shown here are from two experimental repeats. The error bars present the 
±standard deviation. Statistical analysis could not be carried on the data due to the lack of the minimum 
required number of experimental repeats. DIV: days in vitro; FGF2: fibroblast growth factor 2; GF: growth 
factor; PDGF: platelet-derived growth factor; PLP: proteolipid protein.    
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Table IV. I Percentage of PLP positive mature oligodendrocytes upon treatments with CCL2, 
CCL7 or SERPINB2 
Percentage	  of	  PLP+	  cells	  
	  	  
GF-­‐	   GF+	  	   CCL2	  	  
1	  ng/ml	  
CCL2	  
	  10	  ng/ml	  
CCL7	  
1	  ng/ml	  
CCL7	  	  
10	  	  ng/ml	  
SB2	  	  	  	  	  	  	  	  	  
1	  ng/ml	  
SB2	  	  	  	  	  	  
10	  ng/ml	  
n=1	   4.9	   0.0	   9.0	   1.3	   6.2	   0.3	   0.3	   5.7	  
n=2	   2.2	   0.0	   0.8	   0.8	   1.4	   5.2	   0.4	   3.8	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
Avg.	   3.6	   0.0	   4.9	   1.0	   3.8	   2.8	   0.3	   4.8	  
SD	   1.9	   0.0	   5.8	   0.3	   3.4	   3.4	   0.1	   1.4	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  Percentage	  of	  PLP+	  cells,	  standardised	  to	  control	  within	  each	  biological	  
replicate.	   	  	  
	  	  
GF-­‐	   GF+	  	   CCL2	  
1	  ng/ml	  
CCL2	  
10	  ng/ml	  
CCL7	  	  
1	  ng/ml	  
CCL7	  	  	  	  	  	  	  	  
10	  	  ng/ml	  
SB2	  	  	  	  	  	  	  
1	  ng/ml	  
SB2	  	  	  	  	  	  
10	  ng/ml	  
n=1	   1.0	   0.0	   1.9	   0.3	   1.3	   0.1	   0.1	   1.2	  
n=2	   1.0	   0.0	   0.4	   0.4	   0.6	   2.3	   0.2	   1.7	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
Avg.	   1.0	   0.0	   1.1	   0.3	   0.9	   1.2	   0.1	   1.4	  
SD	   0.0	   0.0	   1.1	   0.1	   0.5	   1.6	   0.1	   0.4	  
Purified rat oligodendrocyte precursor cells (OPCs) were treated with 1 ng/ml or 10 ng/ml of CCL2, CCL7 or 
SERPINB2 (SB2). Control cultures consisted of GF+ cultures that were always fed with medium containing the 
growth factors (GF) PDGF and FGF2; whereas, GF- control cultures were fed with standard oligodendrocyte 
medium without GFs after the initial period of 4-5 DIV to allow the maturation of OPCs. The number of PLP 
positive (+) cells are expressed as a percentage of the total number of cells per coverslips. Two coverslips 
were used per condition. The averages presented in the table are from two experimental repeats. These 
averages are also shown as values standardised to GF- controls within each experimental repeat (biological 
replicate). Avg: average; GF: growth factor; SD: standard deviation.  
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Figure IV. II Representative images from the 1st experimental repeat of the effects of 
different treatments on oligodendrocyte maturation.                
Purified rat oligodendrocyte precursor cells were initially maintained in medium containing the growth factors 
(GF) PDGF and FGF2, known mitogens that inhibit oligodendrocyte maturation. After 4-5 DIV, the cultures 
were treated with CCL2, CCL7 or SERPINB2 (SB2) at 1 ng/ml or 10 ng/ml. GF+ control cultures were always 
maintained in medium with GFs; whereas GFs were not added to the GF- control cultures after 4-5 DIV to 
allow oligodendrocyte maturation. The cultures were stained using the O4 and anti-PLP antibodies together 
with DAPI at 8-10 DIV to detect the number of mature oligodendrocytes. The O4 antibody, PLP and DAPI are 
shown in red, green and blue, respectively. All scale bars represent 50 µm. DIV: days in vitro; FGF2: fibroblast 
growth factor 2; GF: growth factor; PDGF: platelet-derived growth factor; PLP: proteolipid protein.    
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Figure IV. III Representative images from the 2nd experimental repeat of the effects of 
different treatments on oligodendrocyte maturation.                 
Purified rat oligodendrocyte precursor cells were initially maintained in medium containing the growth factors 
(GF) PDGF and FGF2, known mitogens that inhibit oligodendrocyte maturation. After 4-5 DIV, the cultures 
were treated with CCL2, CCL7 or SERPINB2 (SB2) at 1 ng/ml or 10 ng/ml. GF+ control cultures were always 
maintained in medium with GFs; whereas GFs were not added to the GF- control cultures after 4-5 DIV to 
allow oligodendrocyte maturation. The cultures were stained using the O4 and anti-PLP antibodies together 
with DAPI at 8-10 DIV to detect the number of mature oligodendrocytes. The O4 antibody, PLP and DAPI are 
shown in red, green and blue, respectively. All scale bars represent 50 µm. DIV: days in vitro; FGF2: fibroblast 
growth factor 2; GF: growth factor; PDGF: platelet-derived growth factor; PLP: proteolipid protein.    
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Appendix V
 
Figure V. I Treatment of cut myelinating cultures with SERPINB2, CCL2 or CCL7       
Embryonic rat spinal cord myelinating cultures, set up using PLL-astrocytes, were cut manually using a razor 
blade at 23 DIV to initiate an in vitro model of CNS pathology. They were treated with 10 ng/ml of recombinant 
SERPINB2, CCL2 or CCL7 at the time points of 24, 26 and 28 DIV and were immunostained at 29 DIV. In 
each experimental repeat, there was also a batch of cells that were not cut (uncut) but treated with the same 
reagents at the same time points. The areas adjacent to cut lesions were used for the quantification of 
myelination in cut cultures. Myelination was presented as standardised to untreated uncut cultures. The 
experiment was repeated three times. One-way repeated measures ANOVA test was applied to the results to 
detect any possible significance. The error bars represent ± standard error of the mean. *P<0.05; **P<0.01; 
***P<0.001. CNS: central nervous system; DIV: days in vitro; PLL: poly-L-lysine. 
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Appendix VI 
 
Figure VI. I Positive and negative total ion current (TIC) chromatograms of control and 
CNTF-treated PLL-astrocyte samples.                                                                                       
The samples extracted from confluent astrocytes, which were plated on PLL-coated coverslips, were analysed 
by Q-Exactive Hybrid Quadrupole-Orbitrap mass spectrometry. Y-axis presents the signal intensity in billions 
(G) as arbitrary units and x-axis presents the retention time in seconds. TIC plot for each biological replicate is 
shown in a different colour: blue, black, or green. 
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Figure VI. II Positive and negative total ion current (TIC) chromatograms of control and 
CNTF-treated TnC-astrocyte samples.                    
The samples extracted from confluent astrocytes, which were plated on TnC-coated coverslips, were analysed 
by Q-Exactive Hybrid Quadrupole-Orbitrap mass spectrometry. Y-axis presents the signal intensity in billions 
(G) as arbitrary units and x-axis presents the retention time in seconds. TIC plot for each biological replicate is 
shown in a different colour: blue, black, or green. 
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Figure VI. III Positive and negative total ion current (TIC) chromatograms of control and 
CNTF-treated PLL-astrocyte culture medium samples.                          
The samples extracted from the spent medium of confluent astrocytes, plated on PLL-coated coverslips, were 
analysed by Q-Exactive Hybrid Quadrupole-Orbitrap mass spectrometry. Y-axis presents the signal intensity 
in billions (G) as arbitrary units and x-axis presents the retention time in seconds. TIC plot for each biological 
replicate is shown in a different colour: blue, black, or green. 
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Figure VI. IV Positive and negative total ion current (TIC) chromatograms of control and 
CNTF-treated TnC-astrocyte culture medium samples.                                                   
The samples extracted from the spent medium of confluent astrocytes, plated on TnC-coated coverslips, were 
analysed by Q-Exactive Hybrid Quadrupole-Orbitrap mass spectrometry. Y-axis presents the signal intensity 
in billions (G) as arbitrary units and x-axis presents the retention time in seconds. TIC plot for each biological 
replicate is shown in a different colour: blue, black, or green. 
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Appendix VII 
List of genes detected in Array 2 
Ace2 Angiotensin-converting enzyme 2 
Acot1 acyl-CoA thioesterase 1 
Acsbg1 acyl-CoA synthetase bubblegum family member 1 
Adamts1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 
Adcy8 adenylate cyclase 8 
Adcyap1 adenylate cyclase activating polypeptide 1 
Adora2a Adenosine receptor A2a 
Aff4 AF4/FMR2 family, member 4 (Predicted) 
Agpat7 lysophosphatidylcholine acyltransferase 4 
Agt angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 
Agtr1a Type-1A angiotensin II receptor 
Aif1 allograft inflammatory factor 1 
Aldh1a1 aldehyde dehydrogenase 1 family, member A1 
Alk anaplastic lymphoma receptor tyrosine kinase 
Anxa3 annexin A3 
AP-1 activator protein-1 
APOC1 Apolipoprotein C-I 
Arc activity-regulated cytoskeleton-associated protein 
Arhgdib Rho, GDP dissociation inhibitor (GDI) beta 
Arhgef19 Rho guanine nucleotide exchange factor (GEF) 19 
Ascl1 Achaete-scute homolog 1 
Asgr1 Asialoglycoprotein receptor 1 
Atp1a2 Sodium/potassium-transporting ATPase subunit alpha-2 
Axl Axl receptor tyrosine kinase 
Baalc brain and acute leukemia, cytoplasmic 
BAMBI BMP and activin membrane-bound inhibitor homolog 
Bcl2a1d BCL2-related protein A1 
Bdnf   brain-derived neurotrophic factor 
Boc  BOC cell adhesion associated, oncogene regulated 
Brunol6 Bruno-like 6, RNA binding protein (Drosophila) (Predicted)  
Bub1 budding uninhibited by benzimidazoles 1 homolog 
Cartptp CART prepropeptide 
Casp1 Caspase-1, Interleukin-1 beta convertase 
Cbs cystathionine beta synthase  
Ccdc67 Coiled-coil domain-containing protein 67 
Cckar   cholecystokinin A receptor 
Ccl chemokine (C-C motif) ligand 
Ccna2 Ccna2 protein 
Ccr1 chemokine (C-C motif) receptor 1 
Cd248 CD248 molecule, endosialin  
Cd37 CD37 antigen 
CD53 Leukocyte surface antigen CD53 
Cd68 CD68 antigen 
Cd93 CD93 antigen 
Ch25h cholesterol 25-hydroxylase 
Chgb chromogranin B (secretogranin 1) 
Chi3l1 Chitinase-3-like protein 1 
Cldn11 claudin 11 
Col16a1 collagen, type XVI, alpha 1  
Col18a1 collagen, type XVIII, alpha 1 
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Col1a2 collagen, type I, alpha 2  
Col3a1 collagen, type III, alpha 1  
Col5a1 collagen, type V, alpha 1 
Colec12 collectin sub-family member 12  
Coq10b coenzyme Q10 homolog B 
Creb cAMP responsive element binding protein  
Crem cAMP responsive element modulator  
Crh      corticotropin releasing hormone 
Cryab crystallin, alpha B 
CSC2 CRISPR-associated protein Csc2                      
Ctgf connective tissue growth factor 
Cth cystathionine gamma-lyase 
Cxcl chemokine (C-X-C motif) ligand 
Cxcr chemokine (C-X-C motif) receptor 
Cyp1b1 cytochrome P450, family 1, subfamily B, polypeptide 1 
Cyr61 cysteine-rich, angiogenic inducer, 61 
Dclk1 Serine/threonine-protein kinase DCLK1 
Ddit4l DNA-damage-inducible transcript 4-like  
Dlx1 distal-less homeobox 1 
Dlx2  distal-less homeobox 2 
Dusp1 dual specificity phosphatase 1  
Dynlrb2 Dynein light chain roadblock-type 2  
Egr1 early growth response 1  
Ell2 elongation factor, RNA polymerase II, 2 
Emd emerin 
Emp1   epithelial membrane protein 1 
Entpd5 Ectonucleoside triphosphate diphosphohydrolase 5 
Fabp4 fatty acid binding protein 4, adipocyte 
Fbn2    fibrillin 2 
Fcgr3 Fc receptor, IgG, low affinity III 
Fcnb ficolin B 
Fn1 fibronectin 1 
Fmod   fibromodulin 
Fos FBJ osteosarcoma oncogene  
Fstl1  follistatin-like 1 
G0S2 G0/G1 switch protein 2 
Gadd45g growth arrest and DNA-damage-inducible, gamma 
Gapdh glyceraldehyde-3-phosphate dehydrogenase 
Gda Guanine deaminase 
Gdf15 growth differentiation factor 15 
Gem GTP binding protein overexpressed in skeletal muscle 
Gldc glycine dehydrogenase 
Glipr1 GLI pathogenesis-related 1 
Gp130 glycoprotein 130  
Gpr103 pyroglutamylated RFamide peptide receptor  
GPR37L1 Endothelin B receptor-like protein 2, G protein-coupled receptor 37-like 1, isoform 
CRA_a 
GPC4 Glypican 4 
Gstm1 glutathione S-transferase mu 1  
Gstm7 glutathione S-transferase mu 7 
GSTP2 Glutathione S-transferase P 2 
H19 H19, imprinted maternally expressed transcript 
Hbb hemoglobin, beta 
Hbegf    heparin-binding EGF-like growth factor 
Hcrt hypocretin 
HLA-DMB Major histocompatibility complex, class II, DM beta, isoform CRA_a  
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Hmox1 heme oxygenase (decycling) 1  
HTRA1 Serine protease HTRA1 
Icam1 intercellular adhesion molecule 1 
ICER inducible cAMP early repressor 
Igf2     insulin-like growth factor 2 
Igfbp2   insulin-like growth factor binding protein 2 
Inpp5d Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 
Irf5 interferon regulatory factor 5 
Irf7 interferon regulatory factor 7  
Isg12(b)  interferon, alpha-inducible protein 27 
Kcnc2 Potassium voltage-gated channel subfamily C member 2 
Kcnn4 potassium intermediate/small conductance calcium-activated channel, subfamily 
N, member 4  
Kif11 kinesin family member 11  
Klf4 Kruppel-like factor 4 
Krt19 keratin 19 
Laptm5 lysosomal protein transmembrane 5 
Lcn2 lipocalin 2 
Lcp1 lymphocyte cytosolic protein 1  
Lipa lipase A, lysosomal acid, cholesterol esterase  
Lgi2 leucine-rich repeat LGI family, member 2  
Lgi4 leucine-rich repeat LGI family, member 4  
Loxl    lysyl oxidase-like 
Lpl lipoprotein lipase  
LY86 Lymphocyte antigen 86 (Predicted) 
Maff v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog F  
Map1b Microtubule-associated protein 1B 
Mat2a methionine adenosyltransferase II, alpha 
Megf6   multiple EGF-like-domains 6 
Mfhas1 
Malignant fibrous histiocytoma amplified sequence 1 (Predicted), isoform CRA_a 
Mmd2 Monocyte to macrophage differentiation-associated 2  
Mmp matrix metalloproteinase  
Mrc1 mannose receptor, C type 1 
Mrps10 28S ribosomal protein S10, mitochondrial 
Msr2 myosuppressin receptor 2 
Msx1 Msh homeobox 1 
Mt1a Metallothionein-1 
Mx1 MX dynamin-like GTPase 1 
Negr1 Neuronal growth regulator 1 
Nfatc4 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 
Nfil3 nuclear factor, interleukin 3, regulated 
Nfkbia 
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha  
Ngfr nerve growth factor receptor  
Nmbr neuromedin B receptor  
Nmu Neuromedin-U 
Npas4 neuronal PAS domain protein 4 
Nptx2 neuronal pentraxin II 
Npy Pro-neuropeptide Y 
Nr4a2 nuclear receptor subfamily 4, group A, member 2 
Nr4a3 nuclear receptor subfamily 4, group A, member 3 
Nqo1 NAD(P)H dehydrogenase, quinone 1  
NTS Neurotensin/neuromedin N 
Oas1a 2'-5' oligoadenylate synthetase 1A 
Ocil C-type lectin domain family 2 member D5 
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Ogn Mimecan, Osteoglycin 
Omd osteomodulin 
Osgin1 oxidative stress induced growth inhibitor 1  
Oxnad1 oxidoreductase NAD-binding domain containing 1  
P2ry12 P2Y purinoceptor 12 
P2ry14 purinergic receptor P2Y, G-protein coupled, 14 
Pax3 paired box 3 
PBS phosphate-buffered saline 
Pdlim7 PDZ and LIM domain 7 
Penk1   proenkephalin 
Per1 period circadian clock 1  
PIk3ap1 phosphoinositide-3-kinase adaptor protein 1  
Pkm2 pyruvate kinase, muscle 
Plagl1 pleiomorphic adenoma gene-like 1  
Plcd4 phospholipase C, delta 4 
Plec1 Plectin-1 
Plek pleckstrin 
Pnoc Prepronociceptin 
Porf1   preoptic regulatory factor 1 
Postn periostin, osteoblast specific factor  
Ppp1r1b protein phosphatase 1, regulatory (inhibitor) subunit 1B  
Pqlc1 PQ-loop repeat-containing protein 1 
Prph1 peripherin 
Ptgs2 prostaglandin-endoperoxide synthase 2  
Ptp4a1 protein tyrosine phosphatase type IVA, member 1 
Ptpn6 Tyrosine-protein phosphatase non-receptor type 6, Protein-tyrosine phosphatase 
SHP-1 
Ptprn protein tyrosine phosphatase, receptor type, N 
Rab27b RAB27B, member RAS oncogene family 
Rac2 RAS-related C3 botulinum substrate 2 
Rasd1 RAS, dexamethasone-induced 1  
Rbm3 RNA binding motif protein 3 
RBP1 Retinol-binding protein 1 
Reg3b  regenerating islet-derived 3 beta 
Rgs4 Regulator of G-protein signaling 4 
Rib43a coiled-coil protein associated with protofilament ribbons 
Ribc2 RIB43A domain with coiled-coils 2  
Rilp Rab interacting lysosomal protein 
Rom1 retinal outer segment membrane protein 1 
Rpe65 retinal pigment epithelium 65 
S100A11 S100 calcium-binding protein A11 
S100a13 S100 calcium binding protein A13  
S100a3 S100 calcium binding protein A3 
Scd1 Acyl-CoA desaturase 1 
Scg2 secretogranin II 
Serpina3n Serine protease inhibitor A3N 
Serpinb2   serpin peptidase inhibitor 
Serpinf1 serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium 
derived factor), member 1 
Sfxn5 Sideroflexin-5 
Slamf9 SLAM family member 9 [ 
SLC  solute carrier 
Slc14a2   urea transporter member 2 
Slc2a5 solute carrier family 2 (facilitated glucose transporter), member 5 
Slc38a1 solute carrier family 38, member 1  
Slc7A5 Large neutral amino acids transporter small subunit 1 
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Slc7A11 solute carrier family 7 (anionic amino acid transporter light chain, xc- system), 
member 11  
Slco1c1 solute carrier organic anion transporter family, member 1c1  
Slco2b1 solute carrier organic anion transporter family, member 2b1 
Snap25 Synaptosomal-associated protein 25 
Snf1lk salt-inducible kinase 1 
Sorl1 Protein Sorl1 
Sostdc1 sclerostin domain containing 1 
Spag4 sperm associated antigen 4  
Spbc24 Kinetochore protein Spc25 
Spp1 Osteopontin 
Srrm2  serine/arginine repetitive matrix 2  
Ssg1 steroid sensitive gene 1  
Stc1 stanniocalcin 1 
Sult1a1 Sulfotransferase 1A1 
Tagln transgelin 
Tbc1d17 TBC1 domain family, member 17 
Tbx15 T-box 15 
Th1 T helper cell type 1 
Thbs2    thrombospondin 2 
Thrsp thyroid hormone responsive  
Tlr toll-like receptor 
Tmem37 Voltage-dependent calcium channel gamma-like subunit, Transmembrane protein 
37 
Tnnc2 troponin C2, fast  
Tpm4 Tropomyosin alpha-4 chain 
Traf4af1 kinetochore-localized astrin/SPAG5 binding protein 
Trem2 triggering receptor expressed on myeloid cells 2 
Tsp2   thrombospondin 2 
Ttk Ttk protein kinase (Predicted) 
Ube1c ubiquitin-like modifier activating enzyme 3  
Usp2    ubiquitin specific peptidase 2 
Vgf similar to viral growth factor, nerve growth factor inducible  
Vif Vif protein 
Vip vasoactive intestinal polypeptide 
Vmp Vacuole membrane protein 1 
Wif1   WNT inhibitory factor 1 
Ypel4 yippee-like 4  
Zbp1 Z-DNA binding protein 1 
Zdhhc20 zinc finger, DHHC-type containing 20  
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